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Abstract 
 
Heart muscle contraction is regulated via the β adrenergic response that results to 
phosphorylation of Protein Kinase A (PKA), which in turn decreases the Ca2+ 
sensitivity of the cardiac myofilament, which is very important for the heart muscle to 
relax. Mutations in the thin filament that cause Dilated Cardiomyopathy (DCM) and 
some that cause Hypertrophic Cardiomyopathy (HCM) abolish this relationship, so 
that the Ca2+ sensitivity becomes independent of Troponin I (TnI) phosphorylation 
(uncoupling). The aim of the thesis is to unravel the molecular mechanism of the 
uncoupling phenomenon. It is known that there is a specific interaction between the 
phosphorylatable TnI N terminal peptide and the Ca2+ binding site on TnC, that is 
weakened by phosphorylation and we hypothesize that it is disrupted in case of a 
DCM or HCM mutation, giving rise to the uncoupling phenomenon. Ca2+ sensitisers 
and desensitisers change the Ca2+ sensitivity of the cardiac muscle like mutations do 
but their relationship with TnI phosphorylation has never been studied before.  
Using the in vitro motility assay I showed that the Ca2+ sensitisers EMD 57033 and 
Bepridil increased the Ca2+ sensitivity of donor thin filaments and additionally they 
uncoupled the Ca2+ sensitivity from the TnI phosphorylation. Epigallocatechin-3-
gallate (EGCG) decreased the Ca2+ sensitivity of donor thin filaments whilst retaining 
the coupling. On the other hand, EGCG reduced the Ca2+ sensitivity of 
phosphorylated but not dephosphorylated mutant thin filaments restoring the Ca2+ 
sensitivity change to TnI phosphorylation. EGCG re-coupled 5 DCM (TPM1 E54K 
and E40K, TNNI3 K36Q, TNNC1 G159D, ACTC E361G) mutants and 3 HCM 
(TPM1 E180G, TNNT2 K280N, ACTC E99K) mutants which were originally 
uncoupled.  
We were given 30 analogue compounds structurally similar to EGCG and nine of 
them were able to re-couple uncoupled TPM1 E180G HCM mutant thin filaments. 
The working compounds re-coupled DCM mutation TPM1 E54K and HCM mutation 
ACTC E99K.  
I show for the first time that it is possible to mimic and reverse the effect of DCM and 
HCM mutations on troponin pharmacologically. EGCG and its analogue compounds 
might have significant implications for the effective treatment of thin filament 
cardiomyopathies that uncouple the Ca2+ sensitivity from TnI phosphorylation.   
 3 
In a separate study I investigated 11 mutations in skeletal muscle tropomyosin 
associated with various myopathies. I found that 7 mutations cause a gain of function 
that could be accounted for at the molecular level due to destabilising specific actin-
tropomyosin interactions. Gain of function at the molecular level correlates with a 
hypercontractile phenotype in patients.  
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1 Introduction 
 
1.1 General Introduction 
 
The main subject studied in this thesis is the “uncoupling” of troponin I (TnI) 
phosphorylation to the calcium (Ca2+) sensitivity in the heart muscle and its 
importance in health and disease. Heart muscle contraction allows for the heart to 
successfully pump blood around the human body. This is achieved in the molecular 
level by thick filaments in the sarcomere composing mainly of myosin to slide along 
thin filaments composing of actin, tropomyosin and troponin. The contraction is 
initiated through intracellular Ca2+ concentration, which is released inside the muscle 
cells and binds to troponin C (TnC), the calcium-sensing component of the troponin/ 
tropomyosin switch. This allows for structural changes to occur and actin can now 
bind to myosin so contraction can occur (Kobayashi and Solaro, 2005).  
As opposed to the skeletal muscle contraction, which is modulated through the nerve 
impulses, cardiac contraction is modulated by the effect of two hormones, adrenaline 
and noradrenaline. The response of the heart muscle to adrenaline is regulated via the 
β adrenergic signaling, which leads to phosphorylation of Protein Kinase A (PKA) 
that acts on many proteins, which in turn regulate heart muscle contraction. One of 
these proteins is TnI and when it gets phosphorylated by the PKA, the Ca2+ sensitivity 
of the sarcomere decreases, meaning that the rate of Ca2+ dissociation from TnC is 
higher, and the muscle can then relax.  
The response of the heart to adrenaline has been found to be disrupted in heart 
diseases (El- Armouche and Eschenhagen, 2009). For example, in inherited 
cardiomyopathies Dilated Cardiomyopathy (DCM) and Hypertrophic 
Cardiomyopathy (HCM), which I am studying, it has been recently discovered that 
Ca2+ sensitivity does not change upon TnI phosphorylation, and we have named this 
phenomenon “uncoupling” (Memo et al., 2013, Bayliss et al., 2012, Messer and 
Marston, 2014).  
Opposing to the structural mechanism of regulation of the heart muscle by Ca2+, 
which has been elucidated mainly due to crystallographic studies (Takeda et al., 
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2003), the structural mechanism of the regulation of Ca2+ sensitivity upon 
phosphorylation still remains unknown, mainly de to the fact that the structure of the 
part of the TnI peptide that gets phosphorylated still remains unresolved (Hwang et 
al., 2014). This brings us difficulties in unraveling the mechanism behind the 
uncoupling phenomenon and how the different mutations in any of the sarcomeric 
proteins can lead to uncoupling of the Ca2+ sensitivity to TnI phosphorylation. The 
aim of the thesis is to shed light upon the uncoupling phenomenon and its importance; 
in a structural, physiological and clinical perspective.  
1.2 Muscle structure 
 
There are three types of muscles in the human body: smooth muscle, skeletal muscle 
and cardiac muscle. Skeletal muscle is anchored to the skeleton of an organism and 
cardiac muscle is analogous to the skeletal muscle but it is only found in the heart. 
Cardiac and skeletal muscles are structurally very similar but they have many 
differences in contractile protein isoforms and regulatory proteins, which will be 
described later on in the chapter. 
1.2.1 The skeletal muscle 
 
The primary function of the skeletal muscle is to support and move the skeleton of an 
organism. The skeletal muscle also supports soft tissue, maintains body temperature 
and guards body entrances and exits. Usually it is attached to bones through tendons, 
which are made of collagen and has the ability to contract and this produces 
movement. The skeletal muscle is a voluntary muscle and it is under the control of the 
central nervous system. Skeletal muscle contains neurons, blood vessels, connective 
tissue and specialized muscle cells called myocytes. A diagram of the structure of the 
skeletal muscle is shown in Error! Reference source not found.. The skeletal 
muscle is separated from the surrounding organs through a layer of collagen fibres 
called the epimysium. The skeletal muscle is organised in bundles of muscle fibres 
called fascicles, which are separated from each other by the perimysium containing 
blood vesicles and nerves. Each fascicle is itself constructed by single muscle fibres, 
separated by endomysium. Throughout single fibres specialized cells called satellite 
cells are found, which are skeletal muscle precursor cells that differentiate to 
myocytes in case of injury.  
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Skeletal muscle fibres are massive single cells that contain many nuclei inside the 
same cell membrane called the sarcolemma. The sarcolemma contains structures 
called the transverse tubules (T-tubules) that contain many ion channels, important for 
the membrane potential depolarization that initiates contraction (See Section 1.3.2). 
The main organelle of the myocytes is the sarcoplasmic reticulum, which releases 
Ca2+ ions important for contraction (See Section 1.3.3). Inside the muscle fibres 
hundreds to thousands myofibrils are located, that are themselves composed of thin 
and thick filaments (See Section 1.2.3). Different genetic diseases of the skeletal 
muscle can occur in case of a mutation in any of the skeletal muscle genes. These will 
be discussed more in Chapter 3.  
 
Figure 1-1: Skeletal muscle structure 
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Figure 1.11: Structure of the skeletal muscle 
 
Taken from http://www.shoppingtrolley.net/skeletal%20muscle.shtml 
 
1.1.5 The Cardiovascular System and the Heart 
The cardiovascular system is a necessary transport system for the delivery of oxygen and 
nutrients, hormones and heat to different districts of the body and at the same time the 
removal of carbon dioxide and excretory products. This system is composed of two major 
Structure of the skeletal muscle and its different components. Taken from 
http://www.shoppingtrolley.net/skeletal%20muscle.shtml 
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1.2.2 The heart muscle and the cardiovascular system 
 
The function of the heart muscle is to pump blood around the human body for the 
delivery of oxygen and nutrients and also for the excretion of CO2. The 
cardiovascular system consists of two circulatory systems: the pulmonary system 
which pumps blood from the right side of the heart to the lungs and then back to the 
left side of the heart and the systemic system which pumps blood from the left side of 
the heart to the rest of the body and then back to the right side of the heart. The first 
person that described in detail the anatomy of the heart was William Harvey (1578-
1657).  
1.2.2.1 The structure of the heart 
 
The heart can be divided into four chambers. Left and right side of the heart consist of 
a mechanical pump, which is called the ventricle and the atrium, which is located 
above the ventricle and is responsible for filling the ventricle.  The heart is divided 
into the upper chamber (containing the atria) and the lower chamber (containing the 
ventricles) separated by the septum. Atria and ventricles are separated by the mitral 
valves, which carry the blood from the atria to the ventricles only one way preventing 
backflow. The valve on the right side is called the tricuspid valve and the one on the 
left side is called the mitral valve. The semilunar valves are located between the 
arteries that carry the blood away from the heart and the ventricles. The semilunar 
valve on the right side of the heart is called pulmonary valve and the semilunar valve 
on the left side of the heart is called aortic valve. Figure 1-2 shows the structure of the 
heart.  
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Figure 1-2: The anatomical structure of the heart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main type of cells in the heart are the cardiomyocytes, which are the muscle cells 
that contain the contractile apparatus and are responsible for the beating of the heart 
(see Section 1.2.3). Other heart cell types found in the heart are cardiac pacemaker 
cells and cells of the vasculature such as fibroblasts, smooth muscle cells, pericytes, 
epithelial cells, endothelial cells and other connective tissue cell types, that make up 
70% of the heart cells (Katz, 2006). The cardiomyocytes are found in the 
myocardium, which is the muscle layer of the heart and are arranged in fibres 
consisting of four to six myocytes separated from each other by collagen (LeGrice et 
al., 1995).  
 
 
 
 
Anatomy of the human heart with its different components. Arrows indicate the blood 
flow in the heart.  Taken from http://www.colorado.edu/intphys/Class/IPHY3430-
200/image/14-7.jpg  
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Figure 1.12: Anatomy of the heart 
 
 
Taken from http://www.colorado.edu/intphys/Class/IPHY3430-200/image/14-7.jpg 
 
 
The mass of the heart is mainly made up of cardiomyocytes, which are the specialised cells 
containing the contractile apparatus required for the contraction and therefore pumping of 
blood. But 70% of the total number of cells of the heart consists of fibroblasts, smooth 
muscle cells, epithelial and endothelial cells (Katz, 2006). 
The heart is contained within the pericardial sac, which consists of an outer fibrous layer and 
the serous pericardium. The serous pericardium consists of two layers separated by the 
pericardial cavity, which contains a small amount of lubricating fluid. These two layers are 
the parietal layer, which is associated to the fibrous outer layer, and the visceral layer, which 
is part of the epicardium and is made of connective tissue covered by epithelium and protects 
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1.2.3 The sarcomere 
 
Skeletal muscle and cardiac muscle are also called striated muscles, because they 
have striations when they are looked at under the phase contrast microscope. Striated 
muscle contains sarcomeres, which is the basic unit of contraction. Sarcomeres are 
composed of parallel thick and thin filaments. Contraction of the muscle occurs 
through the sliding of thin filaments upon the thick filaments. Sarcomeres are 
repeated in series to form a myofibril, which in turn is repeated in parallel to form a 
myocyte, which is the muscle cell. The myocytes, apart from myofibrils also contain 
cell nuclei, mitochondria to provide energy and other organelles.  
A sarcomere is defined as the section between two Z lines. Actin thin filaments are 
anchored in the Z lines with opposite polarity either side. The thick filaments are also 
bipolar with a bare zone in the centre with no cross-bridges. The M line is located in 
the middle of the thick filament that contains the protein myomesin, which holds the 
thick filaments together. The area where the thick filaments are present is called 
anisotropic or A band from its appearance in the phase contrast microscope. Within 
this region there is the C zone, which is the area where the C protein is present and 
where the thick filaments interact with the thin filaments. The region that contains 
only thick filaments is called the H zone. The isotropic or I band is the region 
whereby only thin filaments are found. Upon contraction, the I band shortens, while 
the A band remains constant.  
Thin filaments are composed of actin, troponin and tropomyosin, which will be 
described in detail later on. Thick filaments are composed mainly of myosin (see 
section 1.2.4), myosin binding protein C (MyBP-C) that is found in the C zone and 
titin, which is the largest protein in the human body. Other sarcomeric proteins 
include nebulin, obscurin, and tropomodulin that play a role in assembly of the 
sarcomere. Figure 1-3 B shows the structure of a sarcomere.  
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Figure 1-3: The structure of a sarcomere 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) A cardiac myocyte is composed of repeated myofibrils, which in turn consist of 
repeated sarcomeres. B) Structure of one sarcomere: Thin filaments are composed of 
actin (white spheres), troponin (red spheres) and tropomyosin (orange strands). Thick 
filaments are composed of myosin (purple rectangles) and MyBP-C (red rectangles). 
Titin is also shown in green. Adapted from Morimoto (Morimoto, 2008).  
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1.2.4 The thick filament 
 
The thick filament is composed mainly of the motor protein myosin, and also of 
myosin associated proteins such as MyBP-C and titin. Titin is a giant protein that 
spans the whole sarcomere and is responsible for controlling the passive tension 
(Neiva-Sousa et al., 2015). The role of MyBP-C is not yet fully understood but it is 
essential for the sarcomeric organisation and for the actin-myosin cross-bridges to 
occur (Moss et al., 2015).  
Myosin is encoded by thirteen classes of genes in total. There are different types of 
myosin, such as myosin I, II and V. Myosin II is involved in muscle contraction and it 
consists of two heavy chains and four light chains, the heavy chain being 200 kDa 
each and the light chains being 17-25 kDa (Gordon et al., 2000). Different genes 
encode myosin heavy chains in skeletal and cardiac muscle. Skeletal muscle myosin 
heavy chain is encoded by six genes in mammals (MYH-1, -2, -3, -4, -8, -13). Cardiac 
myosin is encoded by two genes, MYH-6 and -7 that encode the two isoforms of 
cardiac myosin heavy chains, α and β (Jaenicke et al., 1990). The ratio between the 
two isoforms change during development and the β isoform is the predominant 
ventricular form in human adult (Lompre et al., 1984). The light chains are 
themselves subdivided into two categories, regulatory (RLC) and essential (ELC) and 
each heavy chain is associated with one of each of the light chains. A myosin heavy 
chain contains a myosin head called Subfragment 1 (or S1), which contains an actin 
binding site and an ATP binding site, essential for muscle contraction. The rest of the 
myosin heavy chains form a dimeric coiled-coil structure, which forms the filament 
and is called the myosin rod. The rod is connected to the SI via the hinge region. A 
pair of each of the light chains binds to the hinge region. Treatment of myosin II with 
α-chymotrypsin leads to a cleavage in the hinge region, separating the myosin head 
from the rods. The myosin head together with the hinge region and the light chains is 
called the heavy meromyosin (HMM) fragment and the other fragment, containing 
just the myosin rod is called light meromyosin (LMM) (Weeds and Taylor, 1975). 
Figure 1-4 shows the structure of myosin. HMM and S1 are soluble and are 
commonly used for in vitro studies, including the main method used in this thesis, the 
in vitro motility assay (IVMA).  
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Figure 1-4: Structure of myosin II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.5 The thin filament 
 
The thin filament consists of actin, tropomyosin and troponin. A complex is formed 
by actin polymerisation to form a long filamentous structure (Figure 1-5).  
 
Figure 1-5: Thin filament structure 
 
 
 
 
 
1.2.5.1 Actin  
 
Myosin structure and its domains. ECL essential light chain, RLC regulatory light 
chain, S1 subfragment 1, HMM heavy meromyosin, LMM light meromyosin.  
Adapted from Alberts et al (Alberts et al., 2002) 
The structure of the thin filament consisting of actin, troponin and tropomyosin. Taken 
from http://www.mechanobio.info/topics/cytoskeleton-dynamics  
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Actin is the major component of the thin filament, because it is the molecule that 
makes the contractile interaction by interacting with myosin. There are two forms of 
actin, globular (G-actin) and filamentous (F-actin). A G-actin monomer consists of a 
single polypeptide chain with 375 amino acid that folds into two domains. The large 
(inner domain) and the small (outer domain) are linked together by two loops and as a 
result, two clefts are formed between the domains. The upper cleft contains the 
nucleotide site where ATP binds and a divalent ion binding site where Ca2+ and Mg2+ 
bind (Dominguez and Holmes, 2011). G-actin polymerises to form the F-actin by a 
small re-arrangement of the domains with the aid of ATP hydrolysis (dos-Remedios 
and Moens, 1995). The F-actin is stabilised together by hydrophobic and electrostatic 
interactions between the actin monomers. The DNase 1 binding loop (D loop) plays a 
major role in the formation of these interactions and also for the polymerisation of G-
actin to F-actin (von der Ecken et al., 2015). The structure of actin has been resolved 
by electron microscopy (EM) and has been shown to be a double helix with 13 actin 
molecules per half turn (Holmes et al., 1990). Figure 1-6 shows the structure of actin.  
 
Figure 1-6: Structure of actin 
 
 
 
 
 
 
 
 
 
A) Structure of G actin monomer, showing the inner domain (3 and 4) and the outer domain 
(1 and 2). B) Structure of the F actin C) structure of actin thin filament a) actin monomers 
presented as green and blue spheres to form the double helix and b) the shape of the F actin 
as discovered by EM. Adapted from Hodgkinson (Hodgkinson, 2000). 
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1.2.5.2 Tropomyosin 
 
Tropomyosin is the second component of the thin filament and its role is to regulate 
contraction. It is a dimer, consisting of two tropomyosin molecules of around 33 kDa 
each. Tropomyosin is encoded by four genes, TPM1, TPM2, TPM3 and TPM4 and all 
of them have alternatively spliced variants that result in many tropomyosin isoforms. 
The splicing of each gene can produce up to 40 different mRNA variants (Vindin and 
Gunning, 2013). Because of great variety of tropomyosin variants, the naming of the 
variants has led to confusion. Recently, Geeves et al have devised a new system for 
tropomyosin nomenclature which takes into account the gene and exon structure 
(Geeves et al., 2015). This new nomenclature has been adapted from all the major 
labs working with tropomyosin and should be used globally (Marston, 2015).  
Different isoforms of tropomyosin are found in different types of muscle and in 
different combinations. The most predominant form in the heart muscle is the 
Tpm1.1, at 97-99%. In skeletal muscle Tpm1.1, Tpm2.2 and Tpm3.12 are all 
expressed in both slow and fast fibres, but in different proportions depending on the 
muscle type. When Tpm2.2 and Tpm1.1 or Tpm3.12 are found in the same tissue, 
then tropomyosin prefers to form heterodimers (for example Tpm1.1 with Tpm2.2 or 
Tpm2.2 with Tpm3.12). Tpm1.1 is expressed in higher levels in fast twitch type 2 
fibres and less in slow switch type 1 fibres. Tpm3.12 is only expressed in slow switch 
type 1 fibres but Tpm2.2 is expressed in all skeletal muscles (Perry, 2001).  
The key function of tropomyosin is to regulate muscle contraction in a co-operative 
manner. This is successfully achieved by tropomyosin’s structure and its 
incorporation into the thin filament. Tropomyosin dimers form a semi- rigid curved 
coiled coil that fits itself around the actin helix. Each tropomyosin dimer forms head 
to tail interactions with another tropomyosin dimer in order to form a long continuous 
polymer along the F-actin. N terminal acetylation of tropomyosin is crucial for 
binding of the two monomers together as well as for the formation of complex with 
troponin T (Palm et al., 2003).  
Recently the 3D structure of F-actin in complex with tropomyosin was determined 
using cryo-electron microscopy at a resolution of 6.5 Å. Tropomyosin is negatively 
charged and can interact with a positively charged group in F-actin (von der Ecken et 
al., 2015). One tropomyosin dimer interacts with seven actin monomers and 
tropomyosin contains seven pseudo-repeating units at the site of interaction with actin 
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(Hitchcock DeGregori and Varnell, 1990). Tropomyosin has an organization of seven 
structural motifs of 40 amino acids each, that are found at the place where 
tropomyosin interacts with the seven actin molecules. The structural motif at the site 
of interaction with actin can be divided in two regions, the α band (consisting of 20 
amino acids) and the β band (consisting of the rest 20 amino acids). The α band is 
thought to be involved in the actin-tropomyosin interaction in the “closed ” state 
whereas the β band is thought to be involved in the actin-tropomyosin interaction in 
the “open” state (Holthauzen et al., 2004) although this is challenged by recent 
structural analysis (von der Ecken et al., 2015). There is a specific amino acid motif in 
tropomyosin at the site of interaction with actin, with two basic or acidic amino acids 
next to each other that make contact with actin. The actin-tropomyosin contacts are 
very important in health and disease, because a series of mutations in this interface in 
Tpm2.2 and Tpm3.12 has been found that cause a hypercontractile phenotype in 
patients, and can be explained on a basis of disrupting this structure (Memo and 
Marston, 2013). This structure-function relationship will be examined in Chapter 3.   
The affinity by which tropomyosin interacts with one actin monomer is relatively 
weak, (Kd 0.1-1 mM) because the majority of the interactions between actin and 
tropomyosin are mainly electrostatic (Lehman and Craig, 2008). The total sum of 
weak interactions between actin and tropomyosin justifies the strong interaction 
between the two proteins. The weak interactions allow for the flexibility of 
tropomyosin binding to actin that is important for the muscle contraction (Li et al., 
2010). As will be described in Section 1.3.4, tropomyosin sterically blocks 
actin/myosin interaction in the absence of Ca2+. In the presence of Ca2+ the position of 
tropomyosin on the actin filament changes, allowing for the interaction of actin with 
myosin to occur. The mechanism by which tropomyosin moves over actin is 
uncertain, but a sliding mechanism has been proposed (Lehman and Craig, 2008). The 
tropomyosin polymer is relatively rigid, which is important for the formation of the 
thin filament and also for the transduction of the Ca2+ signal to the thin filaments (Li 
et al., 2010). Figure 1-7 shows the structure of tropomyosin and actin complex.  
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Figure 1-7: Structure of tropomyosin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.5.3 Troponin  
 
Troponin is the regulatory protein of the thin filament and it is the mediator for the 
different signals (for example Ca2+ binding and phosphorylation in the case of the 
cardiac muscle) to regulate muscle contraction. Troponin forms a complex of three 
different subunits. These are Troponin T (TnT), Troponin I (TnI) and Troponin C 
(TnC). For each of the subunits there are multiple isoforms that are expressed 
according to different tissue types and also different developmental stages. There are 
three genes that encode for TnI, three genes that encode for TnT and two that encode 
A) Ribbon showing the dimer coil coiled structure of tropomyosin. The numbers 
indicate the seven positions of actin binding and actin binding sites are shown in 
cyan. (Hitchcock- DeGregori and Singh, 2010) B) a) Cryo-electron microscopy of 
F-actin interacting with tropomyosin. Actin subunits are in grey with five of them 
in green and one in cyan. Tropomyosin in yellow. b) close view of the actin-
tropomyosin interactions. (Von der Ecken et al., 2015)  
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for TnC (Barton et al., 1997). Figure 1-8 shows the structure of the troponin complex 
with the different subunits.  
 
Figure 1-8: Structure of troponin 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.5.3.1 Troponin C 
 
Troponin C (TnC) is around 18 kDa and is encoded by two genes: TNNC1 which 
encodes the TnC subunit in the fast skeletal muscle and TNNC2 which encodes the 
TnC subunit in the slow skeletal and the heart muscle (Townsend et al., 1997b, 
Townsend et al., 1997a). TnC forms the core of the troponin complex and it is a 
dumb-bell shape composed of two globular regions at the N terminal and the C 
terminal respectively that are linked together by a link chain consisting of 
hydrophobic amino acids (Herzberg and James, 1985). The linker chain forms a stable 
α helix in the crystal structure form, but in solution it can adopt different structures 
Figure showing the structure of cardiac troponin as determined by Molecular Dynamics 
(MD) simulations using the crystal structure of Takeda (Takeda et al., 2003) and modeling 
the missing peptides. Blue represents TnC, red represents TnI and green represents TnT. 
A) Ribbon diagram of troponin and its different subunits. Catalytic and structural Ca2+ are 
shown, and also the inhibitory and the switch peptide of TnI (see Section 1.2.5.3.2). B) 
Troponin surface rendering in a water molecule box. Images were kindly provided by Mr 
Juan Eiros Zamora as part of the MD project.  
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(Li and Hwang, 2015). The function of the TnC subunit is the binding of Ca2+, which 
regulates muscle contraction. Apart from Ca2+, the divalent cation Mg2+ also binds to 
TnC. The divalent cations can bind to either of the two globular regions at an EF hand 
motif (Kawasaki et al., 1998). Two of the sites, III and IV have high affinity for Ca2+ 
(KCa ~ 107 M-1) and these two sites are called structural sites, because almost always 
divalent cations are bound there. Sites I and II are selective to Ca2+ but with a lower 
affinity for Ca2+ (KCa ~ 105 M-1). They are called regulatory sites because they are 
responsible for the regulation of the muscle to Ca2+. In the cardiac muscle there is 
only one regulatory site, which is site II (Gordon et al., 2000). Comparison of the two 
domains of TnC showed that skeletal TnC N terminus was in a closed state while 
skeletal TnC C terminus was in an open state, suggesting that binding of Ca2+ in TnC 
N terminus results in a “closed” to “open” transition exposing a hydrophobic cleft. In 
the case of cardiac TnC, both Ca2+ occupation at site II and the presence of TnI are 
required for the “open” conformation of TnC, having implications for the regulation 
of the cardiac muscle (see Section 1.3.7).   
 
Figure 1-9: Structure of TnC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) a) Secondary structure of TnC. Cylinders represent helices and arrows represent β strands. 
Ca2+ in a circle represents the regulatory Ca2+ site and the circles without designation represents 
structural site. Proteins of the thin filament that interact with TnC are also indicated (Katrukha, 
2013) b) Domain structure of the TnC. B) Structure of skeletal TnC. Ca2+ is represented by 
green spheres C) Structure of cardiac TnC. Ca2+ is represented by cyan spheres (Li and Hwang, 
2015) 
 39 
1.2.5.3.2 Troponin I 
 
Troponin I (TnI) is the inhibitory subunit of troponin and is around 24 kDa in size. 
There are three isoforms of TnI that are expressed in different tissues. The slow 
skeletal isoform is encoded by TNNI1 gene, fast skeletal isoform is encoded by 
TNNI2 gene and the cardiac specific isoform of TnI is encoded by TNNI3 gene. The 
structure of the different isoforms is highly conserved, the only difference being the 
cardiac specific isoform that contains an extra N terminal peptide (Barton et al., 
1997). In the cardiac muscle, TnI isoform switching occurs during development. Slow 
skeletal TnI is the predominant form during foetal development. The levels of slow 
skeletal TnI start declining at birth and have completely switched to cardiac specific 
TnI isoform 9 months after birth (Marston and Redwood, 2003).  
TnI has six regions, each of them has a specific function: 1) an N terminal extension, 
unique to the cardiac TnI, 2) the region binding to the C terminal lobe of TnC 3) a 
region that binds TnT in the C Terminus 4) the first region that binds to actin that 
includes the inhibitory peptide 5) a switch region and 6) a second actin binding region 
(Kobayashi and Solaro, 2005).  
The main function of TnI is to bind to actin and inhibit its interaction with myosin. In 
the absence of tropomyosin and the other troponin subunits, TnI is able to inhibit 
ATPase activity. The region that is responsible for the inhibitory action of TnI is 
called the inhibitory peptide and it involves the residues 96-116 in rabbit skeletal 
muscle. The inhibitory region alone can inhibit myosin ATPase activity and can bind 
to actin in vitro (Perry, 1999).The second inhibitory region is also important for the 
Ca2+ regulation of the muscle, as it was shown from the first crystal structure of 
cardiac TnI (Takeda et al., 2003).  
Most of the functional domains of troponin can be found in the crystal structure apart 
from the N terminal extension of the cardiac TnI (TnI1-31). This is a very important 
region of the TnI, because it contains the phosphorylatable Serines 22 and 23. These 
are the only phosphorylatable sites on troponin and are phosphorylated by PKA under 
physiological conditions (Ayaz-Guner et al., 2009). The function of the 
phosphorylation of Serines 22 and 23 is a decrease in the Ca2+ sensitivity of the thin 
filament, which ultimately modulates the response of the thin filament to adrenaline 
(Solaro et al., 2008). When TnI gets phosphorylated, the rate of Ca2+ dissociation 
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from TnC increases by 2-3 fold (Robertson et al., 1982). More information about the 
regulation of the cardiac muscle by phosphorylation can be found in Section 1.3.7 
Howarth et al have proposed the structural changes occurring in the TnI-TnC that lead 
to a change in Ca2+ dissociation upon TnI phosphorylation in the N terminal 
extension. This model suggests that when TnI is dephosphorylated the N terminal 
extension is in contact with the TnC region where Ca2+ binds and this increases the 
affinity of Ca2+ to TnC. Phosphorylation of the Serines 22 and 23 results in the N 
terminal extension moving away from the TnC and that affects Ca2+ binding 
(Howarth et al., 2007). This model has now been updated with more recent findings 
using molecular dynamics simulations of whole troponin showing that the changes 
that occur upon phosphorylation of TnI are subtle (Cheng et al., 2014). Figure 1-10 
shows a simplified model of cardiac TnI with its different regions and how it interacts 
with its neighbouring proteins.  
 
 Figure 1-10: Cartoon structure of cTnI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
studies inasmuch as it is naturally expressed in the embry-
onic/neonatal period. Hearts of TG-ssTnI mice had slower
relaxation kinetics, depressed eﬀects of b-adrenergic stimu-
lation [8], and protection against acidosis [9,10] and ische-
mia/reperfusion injury [11]. All of these properties are
properties of preparations from neonatal rat hearts, and
indicated that the special cardiac function in the neonatal
period is importantly controlled by the isoform of TnI.
More recent studies using mutant forms of cTnI with either
pseudo-phosphorylated PKA sites (cTnI-S23D, S24D) or
non-phosphorylatable mutant cTnI-S23A, S24A strongly
support a critical role of cTnI phosphorylation in the con-
trol of cardiac contractility. Yasuda et al. [12] concluded
from their studies of hearts of mice expressing these mutant
forms of cTnI that phosphorylation of cTnI is a significant
factor in cardiac relaxation with an importance similar to
that of phospholamban phosphorylation. Takimoto et al.
[13] also reported that hearts of mice expressing cTnI-
S23D/S24D had a constitutive enhancement of rate-depen-
dent increases in systolic and diastolic function in vivo.
Along these lines, Varian and Janssen [14] reported a fre-
quency dependent decrease in myofilament sensitivity to
Ca2+ associated with increasing heart rates and most likely
attributable to cTnI phosphorylation. The role of cTnI
phosphorylation in the relaxant eﬀect of adrenergic stimu-
lation has also been emphasized in work reported by Stel-
zer et al. [15] in studies of mice expressing cTnI-S23D/
S24D against a cTnI and myosin binding protein C null
background. These studies together with others provide
compelling evidence for a prominent role of cTnI phos-
phorylation in the maintenance of power and frequency
response in ejecting ventricles [13,16–19]. Apart from their
significant eﬀects on cardiac dynamics, cTnI phosphoryla-
tion at the PKA sites aﬀects length dependence of activa-
tion (LDA) [20]. Cooperative mechanisms involving
feedback eﬀects of strongly bound cross-bridges are impor-
tant for LDA and are also sensitive to isoform specific
structure in cardiac TnI [21].
Sites of phosphorylation on cTnI distinct from the PKA
sites have diﬀerent eﬀects on cardiac dynamics and myofil-
ament sensitivity to Ca2+ and thus have led to the concept
of ‘‘yin-yang’’ regulation of the function of cTnI dependent
on the relative balance of phosphorylation of these sites
[22,23]. Sites at Ser-42, and Ser-44 are substrates mainly
for protein kinase C, and when phosphorylated induce a
depression in maximum tension, and a decrease in cross-
bridge kinetics [24–26], as reflected in a depression of thin
filament sliding in the motility assay and ATPase rate.
On the other hand, it is apparent that phosphorylation of
Thr-143 induces an increase in sensitivity to Ca2+ [27]
and an apparent depression in cross-bridge kinetics [25].
As reviewed elsewhere, phosphorylation of sites at Ser-42,
Ser-44, and Thr-143 may be considered maladaptive, when
and if they predominate as may occur in disorders of
the heart [28]. cTnI-Ser-150, a highly conserved and
strategically located amino acid, is also a substrate for
phosphorylation by P21 activated kinase [29], and when
phosphorylated induces an increase in Ca2+-sensitivity.
However, at this time the physiological significance of
cTnI-S150 phosphorylation is poorly understood.
Molecular mechanisms of cTnI function in Ca2+ and cross-
bridge dependent activation of cardiac sarcomeres
Structure–function analysis of cTnI reveals mechanisms
of the ability of this single protein to control and modulate
sarcomeric activation and dynamics [2,3]. As illustrated in
Fig. 1, cTnI is a rod-like and flexible protein with the fol-
lowing distinct regions: a cardiac specific N-terminal exten-
sion region, an IT-arm region, the inhibitory region (Ip),
the switch region (H3), and the C-terminal mobile domain.
The IT-arm region consists of two a-helices that interact
with the C-lobe of cTnC and the a-helix of the C-terminal
domain of TnT (T2). Apart from IT-arm region, the rest of
TnI molecule appears flexible and, as described below, the
Fig. 1. Model illustrating interactions of troponin (Tn) components in the
diastolic state and with phosphorylation of Ser-23, Ser-24 in the unique N-
terminal extension containing a phosphorylation helix, a proline helix
linker and an acidic region. Tm, tropomyosin, cTnI, cardiac troponin I,
cTnT, cardiac TnT, H3, the switch peptide that binds to a hydrophobic
patch on cTnC as indicated, Ip, a basic inhibitory peptide. cTnC is
illustrated in apo state and indicates the N-lobe regulatory Ca-binding
domain (II) and C-lobe slowly exchanging Ca/Mg sites in the mobile C-
domain demonstrates a second actin binding site. The model emphasizes
the potential for the phosphorylated N-extension of cTnI to interact with
the inhibitory peptide. See text and Ref. [47] for details.
R.J. Solaro et al. / Biochemical and Biophysical Rese rch Communications 369 (2008) 82–87 83
Cartoon diagram showing the structure of TnI and its interaction with actin (purple), 
tropomyosin (light blue) and TnC (red) in the presence of Ca2+. The Ip region is the 
inhibitory regio  and H3 indicates t e switch peptide that binds to a hydrophobic 
patch on TnC. The structural and regulatory Ca2+ sites on TnC are also shown (Solaro 
et al., 2008) 
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1.2.5.3.3 Troponin T  
 
Troponin T (TnT) is 35 kDa and it is important to anchor the troponin complex onto 
the actin filament. It has been described as the glue that holds the regulatory system 
together (Tobacman, 1996). TnT is encoded by the genes TNNT1, TNNT2 and 
TNNT3. Different genes express TnT according to the tissue type. The cardiac 
specific form of TnT is encoded by TNNT2 and the gene is alternatively spliced to 
produce different isoforms (Marston and Redwood, 2003). Fast skeletal TnT is 
expressed by TNNT3 and slow skeletal TnT is expressed by TNNT1. There are no 
cardiac isoforms of TnT present in the skeletal muscle and the different isoforms are 
expressed in different stages of development.  
Only a small part at the C terminus is present in the first crystal structure of troponin 
(Takeda et al., 2003) and the other parts of the molecule have been gathered by the 
structure of fragments. TnT can be subdivided into two regions after enzymatic 
cleavage, TNT1 (N terminal) and TNT2 (C terminal). TNT1 binds to tropomyosin 
and its association is not sensitive to Ca2+. This region, which is not found in the 
crystal structure, is very important for the regulation of the thin filament together. A 
study by Manning et al has shown that the flexibility of this region is correlated to the 
Ca2+ sensitivity by studying different mutants in this region (Manning et al., 2012b). 
A crystal structure containing the N terminus and C terminus of tropomyosin together 
with a small fraction of cardiac TNT1 showed the formation of a four helix bundle 
containing two tropomyosin C terminal chains, one tropomyosin N terminal chain and 
one of TnT (Murakami et al., 2008). The integration of cTnT into the thin filament is 
shown in Figure 1-11. The TNT2 region of TnT anchors the TnT to TnC/TnI complex 
through interaction with the N terminus of TnI in a Ca2+ independent manner (Malnic 
et al., 1998). The integration of TnT in the rest of the thin filament is of particular 
importance, as the function of TnT is to co-ordinate muscle contraction.  
 
Figure 1-11: The integration of cTnT into the thin filament
tein dynamics and to eventually characterize the downstream
effects of altered cTnT flexibility on troponin complex
function.
From our earlier work, we observed that the effected flexible
hinge region identified from the molecular dynamics (MD)
simulations of cTnTFHCmutations is!18 angstroms from the
point mutation at Arg-92 and lies between residues 104–110
(3), an unexpected result. Understanding how a single amino
acid substitution in cTnT causes such a distant effect was
addressed by characterizing the dynamics of WT and mutant
cTnT segments using MD. Our results demonstrated that the
removal of a charged residue in R92L and R92Wmutants is the
central modulator of dynamics in the region of residues 104–
110 of cTnT (6). These findings provided valuable clues to the
link between cTnT structure and function in the context of the
TNT1 N-terminal tail domain of cTnT (4, 7). TNT1 is a mod-
ulator in the formation of a TnT-Tm-Tm complex involving
the N and C terminus overlap region of Tm (1, 7–9).
A concern with the application of the previous concepts is
that flexibility is not in and of itself a rigorously defined math-
ematical quantity, which can be used to assess and predict bio-
logical function. To directly address this limitation, we now
calculate forces acting on a bending coordinate within a model
of cTnT residues 70–170 and correlate these data with results
generated in R-IVM functional studies. We have found that
the in silico parameter for flexibility and the in vitro param-
eter for cooperativity of calcium activation were correlated
statistically, whereas others were not. A primary sequence
analysis was performed and showed the highest degree of
conservation of charged residues is found in TNT1, provid-
ing further support for the hypothesis that this region is
crucial in the normal function of the thin filament and a hot
spot for FHC-related mutations. Thus, we have now demon-
strated that a strong correlation between molecular flexibil-
ity as quantified by a force constant can be linked to clinically
relevant changes in thin filament function, a finding that sets
the stage for eventual approaches to predict pathogenicity of
novel TNT1 mutations in this complex disorder.
EXPERIMENTAL PROCEDURES
Development of in Silico Model—MD simulations were con-
ducted as described previously (3, 6). !-Helical models of resi-
dues 70–170 of murine cTnT sequences for the WT protein,
R92L, R92W, and R92K were made using the commercial soft-
ware INSIGHTII (Accelrys, Inc., San Diego, CA). To simulate
the protein environment, charged residues were assigned par-
tial charges corresponding to physiological conditions. Mini-
mization, equilibration, and production runs of MD were per-
formed using CHARMM29 macromolecular simulation
package with a classical potential for all atoms (10, 11). The
nonbonded interaction cutoff was set to 12 angstroms and
smoothed to zero between 12 and 14 angstroms. Starting struc-
tures were created byminimizing each cTnT segment using the
steepest descent method with a step size of 200 fs for 20,000
cycles or until the gradient of the energy converged (11). For the
remaining phases of the simulation, we used the SHAKE algo-
rithm to constrain all bonds involving hydrogen atoms and an
integration time step of 1 fs. We slowly increased the tempera-
ture to 300 K over 10 ps, at which point, we allowed the systems
to equilibrate for 50 ps prior to proceeding with the production
run. Initial velocities were assigned from a Boltzmann distribu-
tion at a low temperature and rescaled every 100 steps during
the heating phase. During the production run, the dynamics
were simulated for an additional 300 ps. We monitored the
coordinates and system properties every five fs for the WT,
R92L, R92W, and R92K models, using Visual Molecular
Dynamics (VMD) to create movies of the production run
dynamics (30).
Our earlier work demonstrated that this model maintained
thermodynamic and structural equilibrium for 100 ps (3). Thus,
300 ps is more than adequate to explore changes in average
structure and dynamics. The advantage to the study of frag-
ments of large protein assemblages is not that you can run them
for long periods of time but rather that short periods of time
suffice to answer questions. Furthermore, we performed four
separate simulations for each variant with different initial con-
ditions to ensure that the phenomena we observed were not
merely due to inadequate sampling of conformation space. It is
well known that multiple short simulations are far superior to
single long ones for exploring conformation space. The results
we obtained were qualitatively invariant to initial conditions.
As was done previously, a means of characterizing structural
change in the helix was by identifying changes in distance
between !-carbons four amino acids apart (or simply n" (n#
4) distance, where n is the ! carbon residue number) along the
helices throughout the MD production run. We designate a
shortening in n " (n # 4) distance as a compaction; and a
lengthening in this distance is designated as an expansion, or
helical opening.
To determine the bending force throughout the hinge
region, we defined an intrinsic bending coordinate, ". " defines
an internal coordinate system along the backbone of a protein
based on relative positions of three contiguous !-carbons as
shown in Fig. 2. From the chain rule, we can introduce the
coordinate ".
FIGURE 1.Orientation to TNT1with respect to the thin filament. Yellow, cTnTwith TNT1 thickened; blue, cTnI; red, cTnC; cyan, calcium; light/dark gray, actin;
green, two overlapping Tm associated with top cTn; orange, two overlapping Tm associated with bottom cTn.
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The orientation of cTnT to the thin filament: TnT is in yellow with TNT1 thickened, cTnI is in 
blue, cTnC in red, actin in light/dark grey, tropomyosin in green and orange (Manning et al., 
2012a) 
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1.3 Muscle contraction 
1.3.1 The cardiac cycle 
 
The cardiac cycle is the series of events that occurs in the whole heart for it to beat 
and be able to circulate blood around the body (Figure 1-12). The cardiac cycle has an 
average duration of 0.9 sec (67 beats per min). It contains two phases: systole, which 
occurs when the ventricles contract, and diastole, which occurs when the ventricles 
relax. One cardiac cycle can be described as a “Pressure and Volume” loop (PV loop). 
It consists of four phases: Ventricular filling (D), Isovolumetric contraction (A), 
Ejection (B), Isovolumetric relaxation (C). Ventricular filling is the initial phase of 
the cycle in which blood flows from the atria to the ventricles. Ventricular pressure 
then begins to rise, and in order to further fill the ventricles the atria contract. As soon 
as the ventricular pressure rises above atrial pressure, atrioventricular valves close and 
the ventricle becomes a closed chamber. This results in a steep rise in the pressure but 
the volume remains the same. The next step is the ejection phase, which occurs when 
ventricular pressure exceeds arterial pressure. Then, the outflow valves are open and 
ejection can initiate. The pressure then begins to decline as cardiac muscle begins to 
relax. A period of isovolumetric relaxation occurs then, whereby the pulmonary 
valves close and the ventricles become again a closed chamber. The pressure falls 
very quickly and when ventricular pressure falls below the levels of the atrial pressure 
the atrioventricular valves open and blood can flood through from the atria, which has 
now been refilled during ventricular systole.  
 
Figure 1-12: The cardiac cycle 
 
 
 
 
 
 
 
 
A) The stages of the cardiac cycle. B) Left ventricular pressure- volume loop (PV loop) 
for one cardiac cycle. The loop has an anti-clockwise direction (Levick, 2000). 
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1.3.2 The action potential  
 
The signal that triggers muscle contraction is the action potential. Both skeletal and 
cardiac muscles undergo a reversal of the membrane potential from -60 mV to +30 
mV.  
The action potential is initiated from adjacent cells: in the case of skeletal muscle, the 
action potential comes from the axon of a motor neuron, which then reaches the 
synapsis of the neuron and the neurotransmitter acetylcholine gets released. 
Acetylcholine binds to receptors in the membrane of the muscle fibres called 
sarcolemma, which cause an influx of Na+ ions that depolarize the membrane 
potential of the sarcolemma.  
In case of the cardiac muscle, the action potential initiates from the cardiac 
pacemaker, the sinoatrial (SA) node that is located at the top of the right atrium. The 
SA node initiates a membrane depolarization that spreads along the heart. The action 
potential passes from the atrial cells to the ventricular cells through the 
atrioventricular (AV) node that is located posterior of the atrial septum. Without the 
AV node the action potential cannot pass through to the ventricular myocytes. The 
AV node is responsible for the delay of the depolarization in the cardiac muscle, 
which allows the blood present in the atrial to have enough time to move into the 
ventricles. Connected to the AV node are fibres known as the bundle of His that pass 
through the septum into the ventricles. Purkinje fibres are located at the termini of the 
His bundles which are responsible for transmitting the wave of polarization to the 
ventricles (Levick, 2009). Figure 1-13 shows the action potential propagation in the 
heart.  
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Figure 1-13: The action potential propagation in the heart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.3 The excitation-contraction coupling 
 
The action potential propagation is linked to muscle contraction through Ca2+ in a 
process called excitation-contraction coupling (EC coupling). The EC coupling has 
been shown to be very similar between skeletal and cardiac muscle, although the 
dynamics of the process has differences because of the different isoforms of the 
proteins involved in the process.  
The arrival of the action potential causes a change in the Ca2+ concentration in the 
sarcoplasm from 0.1 µM to around 2 µM. The rise in free Ca2+ concentration comes 
from the release of Ca2+ from the store of Ca2+ of the myocyte, the sarcoplasmic 
reticulum (SR) and from the plateau current, iCa. The action potential spreads over the 
sarcolemma membrane, and this induces L type Ca2+ channels which are located on 
the surface of the membrane to open and this cause an increase of the intracellular 
Ca2+ concentration, mainly close to the membrane. This is called the plateau current 
iCa. The slight increase in intracellular Ca2+ concentration induces the opening of 
This figure shows the action potential depolarization across the heart, starting from the 
SA node and reaching the ventricles (Cunningham, 2002). 
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channels on the SR, called the ryanodine receptors to open by a process called 
calcium- induced calcium release (CICR). The Ca2+ concentration within the myocyte 
rises within 10 milliseconds. This sudden increase in the intracellular Ca2+ 
concentration triggers muscle contraction. L type channels are negatively regulated by 
Ca2+ by binding to calmodulin, which then binds to the L type channel inducing its 
closure. Ca2+ is actively pumped again back to the sarcoplasmic reticulum by an 
ATPase called SERCA (Sarco- Endoplasmic Reticulum Ca2+ ATPase). An additional 
10 % of Ca2+ is exported out of the myocyte by sarcolemmal transporters such as 
NCX (Na+ Ca2+ exchanger) (Bers, 2002) (Figure 1-14). 
Ca2+ binds to troponin, the Ca2+ sensing component of the myofilament, which then 
regulates its contraction, making the Ca2+ important for the muscle function. Any 
change of the ability of troponin to sense Ca2+, or Ca2+ irregulation in the myocyte is 
therefore important for the development of diseases.  
 
Figure 1-14: Ca2+ cycle in the cardiomyocyte 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The major components of the Ca2+ contraction system in the cardiomyocyte is shown. 
Ca2+ enters via the L type Ca2+ channels and via the Ryanodine Receptor (RyR) from 
the SR. It is uptaken by SERCA ATPase, which is regulated by phospholamban (PLB) 
NCX channel (Na+ Ca2+ exchanger) removes the Ca2+ ions in exchange with Na+. The 
diagram also shows a time course of the EC coupling (Bers, 2002).  
 46 
1.3.4 The sliding filament theory and the cross-bridge cycle 
 
In order for the muscle to contract, thin and thick filaments make contact with each 
other and the thin filament slides along the thick filament. In the sarcomere thin and 
thick filaments are in parallel to each other and when they slide past each other, their 
length does not change but the length of the sarcomere in total changes. It has been 
proposed that the force of the myofibrils is proportional to the amount of filaments 
that overlap. This is because when thin and thick filaments overlap they form cross-
bridges that are responsible for the production of force. These cross-bridges are in fact 
myosin heads that overhang from the thick filament.  
The detail of the cross-bridge mechanism derived mostly from X-ray crystallography. 
The theory of the cross-bridge cycle was developed from Huxley in 1957 and explains 
muscle contraction through the formation of these cross-bridges that generate tension 
(Huxley, 1957). The structure was linked to the enzymatic cycle by Lymn and Taylor 
who described how myosin also acts as an enzyme and uses ATP hydrolysis to drive 
the cross-bridge cycle (Lymn and Taylor, 1971). Myosin has ATPase activity, which 
provides the energy for contraction. The ATPase activity is activated by actin and 
inhibited by ADP and Pi. Through the cross-bridge cycle, ATP binds to the ATPase 
site on myosin, and gets hydrolysed to ADP and Pi. This energy is used to change the 
position of the myosin head to create power stroke.  
The myosin head can exist in two different conformations, 90° (“up” position of the 
lever arm) and 45° (“down” position of the lever arm). In the beginning of the cycle, 
the myosin head is in the down position binding to actin. When ATP binds to the 
ATPase site, induces a dissociation of the actin molecule and also a conformational 
change, which changes the position of the myosin head from down to up. In the next 
step, ATP gets hydrolysed into ADP and Pi and myosin/ADP/Pi will rebind to actin. 
This rebinding of actin leads to the release of ADP and Pi from myosin. As the Pi is 
released the myosin head returns to its original down position, and this moves the 
actin along by ~10 nm. In the last step, ADP is also released and the cycle can start 
again (Spudich, 2001). Therefore, one cross-bridge cycle breaks down one molecule 
of ATP. The position of the myosin head depends on the existence of a kink on the 
relay helix which leads to a rotation of 60° and the structural changes in myosin in 
going through the different steps of the power stroke involve two switches (switch 1 
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and 2) and a β sheet (Geeves and Holmes, 2005). Figure 1-15 shows the cross-bridge 
cycle and also the structural changes that occur upon the cycle.  
The total force of the muscle depends on the amount of cross-bridges formed in the 
sarcomere and their attached lifetimes. 
 
Figure 1-15: The cross-bridge cycle  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Schematic diagram showing the cross-bridge cycle. A) Different states of actin/myosin 
interactions are shown (weak/strong/unbound) and different nucleotide species (ATP. 
ADP and Pi) and the conformation of the myosin head during the different steps of the 
cross-bridge cycle.  B) The structural changes that occur throughout the cross-bridge cycle 
(Geeves and Holmes, 2005).  
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1.3.5 Thin filament switch 
 
The troponin complex has a specific 3D structure, which switches the filament 
between activated and inactivated states. The different components of troponin are 
responsible for different functions and can modulate muscle contraction. The 
functional properties of the switch are clear but the structural basis is not fully 
understood. In the last few decades, attempts have been made to build a model and the 
Takeda structure has helped to understand the mechanism of the filament switch to a 
large extent.   
The troponin complex is divided into two regions: The troponin core domain and the 
extended structure of TnI (Figure 1-16). The core domain contains part of the TnC 
anchored to a W shaped TnT-TnI arm and the regulatory sequence of TnI that 
undergoes conformational changes according to Ca2+. The TnI regulatory domain 
comprises of residues 137-210 (Takeda et al., 2003). The TnI/TnT arm make contact 
with tropomyosin through a tropomyosin binding site in TnT (Perry, 1998).  
 
Figure 1-16: The structure of the core domain of the troponin complex 
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Figure 1.17: The core domain of the troponin complex 
 
Ribbon model of the crystal structure of the troponin complex when Ca2+-saturated. TnC in orange; TnT in blue; 
TnI in green. (Kobayashi and Solaro, 2005) 
 
 
The proposed activation model wants the C-terminal regulatory sequence of TnI, which is 
composed of two actin binding sites separated by a "switch segment", to be able to bind actin 
in the absence of Ca2+, thus blocking the access to the actin binding sites to myosin. When 
The core domain of the TnC when it is Ca2+ saturated. TnC is coloured red, TnT in 
blue and TnI in green. The regulatory head and the IT arm are shown (Kobayashi 
and Solaro, 2005). 
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 In the absence of Ca2+, the inhibitory region of TnI binds to actin, thus inhibiting its 
interaction with myosin and blocking contraction. The regulatory region consists of 
two actin binding sites (TnI135-147 and TnI160-209) and the “switch peptide” in the 
middle (TnI148-158). The switch peptide is able to switch position when Ca2+ binds to 
the N terminal lobe of TnC and can bind to a hydrophobic pocket on TnC. This 
removes the actin blockage and allows it to interact with myosin. Furthermore, 
tropomyosin changes position relative to the actin groove and co-operatively releases 
the steric blockage allowing further cross-bridges to form. Figure 1-17 shows the 
structural changes that occur upon the thin filament switch. The thin filament switch 
model was first proposed by Malnic and the model states the two different 
interactions of troponin with actin/tropomyosin and how these interchange upon Ca2+ 
binding (Malnic et al., 1998). The first crystal structure of troponin by Takeda et al 
provided structural evidence for the Malnic model because it showed that the switch 
in the presence of Ca2+ is bound to TnC and this position inhibits contraction (Takeda 
et al., 2003).  
 
Figure 1-17: The thin filament switch 
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Ca2+ binds to the N-terminal lobe of TnC, these EF-hands will open a hydrop obic cavity 
where the switch segment can bind (Figure 1.18), removing the block from the actin surface 
(Mercier et al., 2003). When this happens it seems also that the conformational changes 
induced by Ca2+ binding get transduced through TnT to tropomyosin, triggering its 
movement to a different sterical position on the actin's groove (see 1.3.1.2), and giving 
coop rativity to the system (Xu et al., 1999, Maytum et al., 1999). 
 
Figure 1.18: The proposed thin filament switch 
 
In the proposed model of thin filament activation, TnI acts as the thin filament's switch. Its regulatory C-
terminal region can either interact directly with actin, inhibiting the cross-bridge cycle, or interact with TnC 
when Ca2+ binds it. In the detail square is represented the structure of the N-lobe of TnC with and without Ca2+ 
bound. When Ca2+ binds it triggers a conformational change that opens a hydrophobic pocket on TnC where the 
regulatory region of TnI can bind (in green). (Takeda et al., 2003, Kobayashi and Solaro, 2005) 
 
This figure shows the thin filament sw tch i  respon e to Ca2+. TnI acts as the regulatory 
switch, where in the absence of Ca2+ interacts with actin preventing contraction. Ca2+ 
binds to a pocket in TnC and this causes a conformational change opening a hydrophobic 
pocket in TnC where the regulatory domain of TnI can bind, no longer inhibiting the 
actin/myosin interaction (Li et al., 2004) 
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1.3.6 The three state model 
 
Muscle contraction can also be explained by the three state model of the 
troponin/tropomyosin/actin complex that oscillates between different states according 
to myosin and Ca2+ binding. The concept of the three state model was developed in 
the early 80s where it was proposed that the thin filaments can exist in two different 
conformations: a closed state and an open state.  
In the 90s the two state model was further developed according to new kinetic studies. 
Instead, the three state model was proposed, where thin filaments can be found in 
three conformational states, (“open”, “closed” and “blocked”) (McKillop and Geeves, 
1993).  
Actin on its own will always be active (in the “open” state), but in the presence of 
tropomyosin and troponin the three states would be possible. Actin and tropomyosin 
in the absence of troponin would only have two conformations, “open” and “closed”. 
Myosin S1 can bind to actin in two different ways, weak (attached or “A state”) and 
in this way the thin filament is found in the “closed” state, and strong (rigor or “R 
state”) where the thin filament is found in the “open” state. Only when S1 binds in the 
R position can there be ATPase activity and thus the cross-bridge cycle can start. In 
the presence of Ca2+ the equilibrium change between the “closed” and the “open” 
state and this is S1 dependent. In both states myosin binds first weakly (K1), and this 
drives the equilibrium towards the “open” state (this step is regulated by KT). Then 
thin filament is able to reach the R state (this step is regulated by K2) and thus the 
cross-bridge cycle can complete. The third state is the “blocked” state, which only 
occurs when Ca2+ is not present. The equilibrium constant that drives the equilibrium 
from the “blocked” to the “closed” state is Ka and is Ca2+ dependent. Due to the 
inhibitory action of troponin, the tropomyosin and actin are found in a constrained 
position, being impossible for myosin to bind. The “blocked” and “closed” states are 
both called “B state” and the “open” state is called “M state”. Only in the “M state” 
can the cross-bridge cycle initiate. The three state model is illustrated in Figure 1-18 
A.  
Tropomyosin plays a central role in the blockage of contraction in absence of Ca2+. In 
resting muscle tropomyosin is located in a position at the actin filament that would 
physically block the attachment of strong myosin cross-bridges to actin. When Ca2+ 
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binds to troponin, tropomyosin gets into the grooves between the actin strands and the 
steric block is removed (see Figure 1-18 B) 
 
 
Figure 1-18: The three state model and the tropomyosin block 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Diagram showing the three state model of thin filament activation. Actin is 
represented in circles, tropomyosin is represented by the solid line and myosin S1 is 
represented by the triangle. The equilibria between the states are also shown (Maytum et 
al., 1999). B) Model of regulation of muscle contraction showing the tropomyosin 
movement from B to M state. Actin is shown in light purple, myosin in beige, 
tropomyosin in the B state in yellow and in the M state in blue a) pseudo-atomic model 
of tropomyosin/actin complex showing tropomyosin in the M state b) tropomyosin in 
the B state c) the rotation of tropomyosin to reach the M state location d) tropomyosin is 
locked in the M state (Lehman et al., 2013) 
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1.3.7 The regulation of the cardiac muscle 
 
The regulation of the skeletal and cardiac muscle is under the control of Ca2+ and it 
occurs through the thin filament switch, as described before. The cardiac muscle has 
an additional modulation in order to increase the cardiac output to meet the demands 
of the human body. The modulation of the cardiac muscle is under the sympathetic 
nervous system. The sympathetic nerves release the neurotransmitter adrenaline 
(epinephrine) or noradrenaline (norepinephrine) which have similar effects. These 
hormones lead to an increase in the heart rate (chronotropy), the force by which the 
cardiac muscle contracts (inotropy) and the rate of relaxation (lusitropy). Adrenaline 
and noradrenaline work by binding to β1 adrenergic receptors (G coupled receptors), 
found on the plasma membrane of the cardiomyocytes. Binding of the agonists to the 
receptors stimulates the GS α-subunit of the receptor to activate adenylyl cyclase. 
Adenylyl cyclase is an enzyme that catalyses the conversion of ATP to cAMP. cAMP 
creates a signalling pathway which has different effects to regulate heart beating.  
The chronotropic effect occurs by an increase of the pacemaker potential rate taking 
less time to reach the threshold. This is due to the direct effect of the cAMP on the 
pacemaker current (iF) and the calcium current (iCa). The inotropic effect arises from 
the action of Protein Kinase A (PKA), which is activated through cAMP. PKA 
phosphorylates many different targets for cardiac muscle contraction and relaxation 
(El-Armouche and Eschenhagen, 2009). Some of targets of PKA phosphorylation are 
proteins that control the E-C coupling, such as L-type Ca2+ channel, Ryanodine 
Receptors and Phospholamban (PLB).  PLB is a protein that binds to SERCA and 
inhibits its action. When intracellular Ca2+ is increased, Ca2+ binds to SERCA and 
removes PLB from its binding site. However, if PLB is phosphorylated it forms 
polymers in its dissociated form and thus is no longer able to inhibit SERCA and Ca2+ 
ions will be moved out of the cytosol faster (MacLennan and Kranias, 2003).Another 
target of the PKA are the Ryanodine Receptors which is believed that their 
phosphorylation increases the probability of opening and releasing Ca2+ into the 
cytoplasm (Bers, 2002). PKA also phosphorylates MyBP-C that allows its integration 
into the cardiac cycle by dissociating it from the myosin head (Flashman et al., 2004). 
Finally, another important target of the PKA is TnI. The result of TnI phosphorylation 
is a decrease in the Ca2+ sensitivity of the myofilament and this is one of the most 
important aspects in this thesis. This is important because Ca2+ would dissociate faster 
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from the myofilament and the cardiac muscle can relax. TnI phosphorylation by the 
PKA thus leads to a positive lusitropic response (Solaro et al., 2008). The β 
adrenergic response and the proteins involved in the process are shown in Figure 
1-19. In cardiomyopathies and heart failure, many of the downstream effectors of the 
β adrenergic response are compromised (El-Armouche and Eschenhagen, 2009). One 
example is the inability of Ca2+ sensitivity to change upon TnI phosphorylation, the 
phenomenon of which I will be studying extensively in this thesis and will be 
described in detail later on.  
TnI gets phosphorylated by PKA upon β adrenergic stimulation (Solaro et al., 1976) 
and the phosphorylation of TnI happens in Serines 22 and 23 of the N terminal 
extension of cardiac TnI (Mittmann et al., 1990). Studies have demonstrated the 
effects of TnI phosphorylation and have shown that it reduces myofilament Ca2+ 
sensitivity and increase the cross-bridge cycle kinetics at high Ca2+ concentrations 
(Ray and England, 1976, Bailin, 1979, Mope et al., 1980). It has been suggested that 
TnI phosphorylation by PKA leads to a decrease of the Ca2+ sensitivity because of the 
higher dissociation rate of Ca2+ from TnC (Robertson et al., 1982, Zhang et al., 1995, 
Dong et al., 2007). In all cases the Ca2+ sensitivity change upon phosphorylation is 2-
3 fold compared to the native. Ca2+ sensitivity change upon phosphorylation has been 
also observed in donor cardiomyocytes as shown in a study by Kooij et al, where the 
Ca2+ sensitivity of force development was reduced in cardiomyocytes treated with the 
catalytic subunit of PKA (Kooij et al., 2010). Similarly, Messer et al observed an 
increase in Ca2+ sensitivity of reconstituted donor thin filaments upon 
dephosphorylation of TnI using in vitro motility assay (Messer et al., 2007).  
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Figure 1-19: β adrenergic response of the cardiac muscle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The β adrenergic response of the cardiac muscle and the different targets of PKA 
phosphorylation upon β adrenergic stimulation are shown. PKA (protein kinase A) is shown 
in a green box and all its targets are indicated with arrows.  AR adrenergic receptor, 
which is a G protein coupled receptor, and in black circles its subunits. AC adenylyl, 
cyclase, L-type VOCC L-type Ca2+ channel, SR sarcoplasmic reticulum, RyR ryanodine 
receptor, SERCA sarco/endoplasmic reticulum Ca2+ ATPase, TnI troponin I, MBPC 
myosin-binding protein C.  
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1.4 Primary cardiomyopathies  
 
Cardiomyopathies can be subdivided into different types: Dilated Cardiomyopathy 
(DCM), Hypertrophic Cardiomyopathy (HCM), restrictive cardiomyopathy and 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), all having different 
clinical characteristics. In this thesis I will investigate only two types of 
cardiomyopathies, DCM and HCM so they will be described in more detail.  
Cardiomyopathies can be either primary or secondary. Primary cardiomyopathies 
occur when the heart is the primary organ affected and secondary cardiomyopathies 
occur as a result of other systemic disorders (Alves et al., 2010) 
In this thesis I will concentrate on primary cardiomyopathies and more specifically 
genetic cardiomyopathies, whereby the cause of the disease is a genetic mutation.  
The most described causes of cardiomyopathy are mutations in genes that express 
proteins of the cardiomyocyte. So far more than 900 different mutations of genes have 
been found expressed in the cardiomyocyte that lead to cardiomyopathies, more than 
400 of them being in sarcomeric genes (including thin filament mutations which we 
study; actin, tropomyosin and troponin) (Harvey and Leinwand, 2011). 
1.4.1  Dilated Cardiomyopathy (DCM) 
 
DCM affects 36.5 in 100,000 individuals and is characterized by left ventricular 
dilation, enlargement of the ventricular chamber and thinning of the ventricular walls 
(Figure 1-20). This leads to systolic dysfunction with a reduced ejection fraction. 
Usually DCM is prevalent in individuals around 30-60 years old, but can also occur in 
infants and young adults. DCM can lead to sudden death and 50% of patients die 
within five years after the symptoms begin to occur (Harvey and Leinwand, 2011). 
The most successful treatment so far is heart transplant.  
Histological examination of DCM hearts has shown that the cardiomyocytes are 
increased in length and also become polyploid because of an increase in DNA 
synthesis. Moreover, the number of contractile myofibrils in the cardiomyocytes 
decreases so they appear empty and hollow in histological sections (Davies, 2000). 
Death of cardiomyocytes also occurs through apoptosis and necrosis. This results in 
an increase in interstitial fibrosis at the space between the cardiomyocytes. Fibrosis 
attracts immune cells such as macrophages and T lymphocytes at the interstitial space 
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and it has been found a Th1 type of immune response in DCM patients. Th1 helper T 
cells play a major role in inflammation and healing process. (Efthimiadis et al., 2011).  
 
Figure 1-20: Section of a DCM vs donor heart 
 
 
 
 
 
 
 
 
 
 
 
DCM can have many causes. Many times DCM occurs as a secondary pathology of 
other diseases, such as coronary artery disease, thyroid disease, viral myocarditis, 
immunological diseases or alcohol. This is why the term DCM is imprecise, because 
it is based on the morphology of the left ventricle, regardless of the cause of the 
disease. Based on that, DCM can be divided into “ischemic” and “non-ischemic”. 
Most of the times, the primary cause remains unknown and the disease is called 
“idiopathic” and in that case DCM is not associated with another systemic cause. 
From the “idiopathic” DCM in about one third of the cases the disease is thought to 
be of genetic origin because it has been found in the family history. In that case it is 
called “familial DCM” (fDCM) (Hershberger et al., 2013). 
About one third of the familial DCM patients have been associated with a specific 
mutation and mutations in more than 40 genes have been found. Most of the 
mutations are autosomal dominant but a few are found to be X linked and recessive 
(Hershberger and Siegfried, 2011). 
These include genes that encode proteins in the sarcomere, the Z disk, ion channels, 
mitochondria, cytoskeleton or nuclear envelope. DCM mutations are usually 
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1.4 Dilated Cardiomyopathy (DCM) 
Dilated cardiomyopathy (DCM) is a disease clinically characterised mainly by left ventricular 
dilation, and systolic dysfunction, with a reduction of the ejection fraction (< 50%). It is 
estimated to affect 36.5 in 100,000 individuals (Cohn et al., 1997). 
 
Figure 1.22: Normal v DCM heart 
 
A) A section of a normal heart. B) A section of a DCM heart. Adapted from Seidman and Seidman (2001). 
 
 
The ventricular wall thickness is normal or reduced, which could mask an increase in its 
mass, but the ventricular cavity increases in size (Figure 1.22), creating more space for the 
blood to clot at the apices adding the risk of thrombus and in the worst case a potential 
thromboembolic event. DCM can lead to heart failure, sudden death and only 50% of the 
patients survive 5 years after initial diagnosis. So far, only heart transplantation has been 
successful enough in prolonging the life expectancy of the patients. 
Histologically the myocytes increase their length and the nuclear size, because of DNA 
synthesis. They can become polyploid and the number of myofibrils can decrease. They 
A) Section of a healthy donor heart B) Section of a heart from a DCM patient 
(Seidman and Seidm n, 2001) 
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nonsynonymous missense (they create a protein with a different amino acid sequence 
than the wild type). However, deletions, nonsense and frameshift mutations have also 
been reported (Hershberger et al., 2013). The first gene mutation that was identified 
as cause of DCM was a mutation in dystrophin, which is a membrane-associated 
protein of the cytoskeleton (Muntoni et al., 1993) while the first mutation coding a 
sarcomeric protein was in ACTC encoding for actin (Olson et al., 1998). Recently titin 
truncating mutations have been found to be a major cause of fDCM (Herman et al., 
2012). For the purpose of this thesis, I will focus on the mutations in the sarcomeric 
genes. In this thesis I will look at 5 DCM mutations in genes encoding proteins of the 
sarcomere: ACTC E361G, TNNI K36Q, TNNC G159D, and TPM1 E54K and E40K 
based on the study by Memo et al (Memo et al., 2013). It is noted that mutations in 
thin and thick filament proteins that cause DCM are associated with DCM on its own, 
without additional phenotypes (Kamisago et al., 2000, Mogensen et al., 2004b).  
1.4.2 Hypertrophic Cardiomyopathy (HCM) 
 
HCM is the most common inherited cardiac disease, with a prevalence of 1 in 500 
individuals. HCM affects men more than women and has an age related phenotype; 
with symptoms occurring after adolescence and sometimes is asymptomatic (Maron 
et al., 1995, Maron et al., 1984). HCM is characterized by enlargement of the heart 
and asymmetric hypertrophy of the left or the right ventricle. Typically, 
the hypertrophy leads to a decrease in the ventricular volume.  
Histologically HCM is characterized by cardiomyocyte hypertrophy and also myocyte 
disarray (disorientation of the enlarged cardiomyocytes). Cardiomyocytes of an HCM 
heart also undergo premature death that leads to increased interstitial fibrosis. The 
area affected by the disease and also the degree of myocyte hypertrophy varies among 
HCM patients (Wigle et al., 1985). 
Patients with HCM can be asymptomatic while others might suffer shortness of breath 
and mild to moderate chest pain (Spirito et al., 1997). The disease can lead to heart 
failure or even sudden cardiac death (SCD). SCD is defined as “unexpected sudden 
collapse occurring <1 hour from the onset of symptoms in patients who had 
previously experienced a relatively stable and uneventful clinical course” (Maron et 
al., 2000) and occurs especially in athletes (Maron and Pelliccia, 2006). The 
prevalence of SCD is 1-2 % per year (Elliott and McKenna, 2004). 25% of the HCM 
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patients develop an obstruction to the ejection of blood from the left ventricle during 
systole, and these are called Hypertrophic Obstructive Cardiomyopathy (HOCM) 
patients. The obstruction is clinically characterized as Left Ventricular Outflow Tract 
Obstruction (LVOTO). The presence of LVOTO increases the probability of the 
patients developing heart failure and death (Maron et al., 2003). 
 
Figure 1-21: Heart from an HCM patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCM was the first cardiomyopathy that was linked to genetic mutations (Geisterfer-
Lowrance et al., 1990) and about 50% of HCM cases are due to mutations. In contrast 
to DCM, the majority of the mutations are found mainly in genes that encode 
sarcomeric proteins. For this reason HCM is called “the disease of the sarcomere” 
(Thierfelder et al., 1994). Over 600 mutations in 12 different genes have been 
associated with the disease and HCM patients carrying a mutation in any of the 
sarcomeric genes show a more severe phenotype with greater hypertrophy than HCM 
patients with no known mutations (Van Driest et al., 2005). The HCM mutations are 
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Figure 1.29: Heart from a HCM patient 
 
 Heart sectioned in a cross-sectional plane demonstrating asymmetrical left ventricular wall thickening 
Labelled region are: left atrium (LA), aorta (Ao), right ventricle (RV), left ventricular free wall (FW) 
and ventricular septum (VS) (Maron, 1997) 
 
1.5.1.2 Diagnosis and prognosis of HCM patients 
The diagnosis of HCM is most commonly confirmed with two-dimensional 
echocardiography used to measure the size of left ventricular wall thickness. Sudden 
cardiac death may occur in HCM patients as the first sign of the disease without any 
previous symptoms. Sudden cardiac death is defined by Maron et al as ‘unexpected 
sudden collapse occurring <1 hour from the onset of symptoms in patients who had 
previously experienced a relatively stable and uneventful clinical course’(Maron et al., 
2000). However the majority of HCM patients will be non-symptomatic for the 
majority of their lives and 25% will achieve a normal longevity with an overall 
mortality rate of ~1% (Maron et al., 2003a). 
 
 
Heart from an HCM patient from a cross sectional plane. Ao represents the aorta, LA 
is the left atrium, RV is the right ventricle, FW is the left ventricular free wall and VS 
is the ventricular septum (Maron, 1997). It is clearly shown the enlargement of the 
heart and asymmetric hypertrophy.  
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usually autosomal dominant and a few patients carry more than one mutation (Ingles 
et al., 2005)  
The first HCM mutation identified was β myosin heavy chain (MYH7) (Geisterfer-
Lowrance, Kass et al. 1990) followed by mutations in myosin regulatory (MYL2) and 
essential light chain (MYL3), Myosin Binding Protein C (MYBPC3), cardiac Troponin 
T (TNNT2) and cardiac Troponin I (TNNTI3) (Redwood et al., 1999) but have 
received little mechanistic study to date. Mutations in cardiac actin (ACTC) and 
tropomyosin (TPM1) have also been found. Out of all the mutations causing HCM, 
the most frequent are mutations in genes encoding cardiac MyBP-C and βMHC (Xu 
et al., 2010). In this thesis three HCM mutations will be studied, E99K in ACTC 
(Olson et al.), E180G in TPM1  (Thierfelder et al., 1994) and K280N in TNNT2 
(Bayliss, 2012, Ferrara et al., 2015).  
Figure 1-22: The distribution of sarcomeric mutations in HCM 
 
 
 
 
 
 
 
 
 
 
 
 
and may cause outflow tract obstruction that, along with
impaired relaxation, can lead to whole heart failure. HCM
is also associated with sudden cardiac death due to
arrhythmias especially in young active adults. The overall
risk of fatal complications of HCM is 1–2% per year.
Although hypertrophy and sudden cardiac death are both
caused by HCM mutations, the connection between them is
unclear. The mutant protein in HCM is expressed from birth
but is compensated for in almost all cases until adolescence,
and sometimes, symptoms never develop. This variable
penetrance indicates that genetic background is significant
to the outcome of HCM mutations.
Idiopathic DCM is a common cause of heart failure,
especially in the young. The disease is characterised by an
unexplained left ventricular dilation and impaired systolic
function and is believed to be caused by mutations in up to
50% of cases. Typical diagnostic criteria are left ventricular
end diastolic diameter >117% of expected for age and body
weight and fractional shortening <25%. Mutations in
sarcomeric proteins seem to be associated with a ‘pure’
DCM phenotype without any additional symptoms [4, 5].
The primary criterion for establishing a genetic disease
is, of course, the pattern of inheritance and genetic linkage.
This was essential for initial studies, but subsequent studies
have usually used a candidate gene approach, testing for
inherited mutations in the genes coding for sarcomeric
proteins and sometimes limited to the more frequently
occurring ones. In the case of HCM, about 40% of cases are
never linked to a mutation: this may be a false negative due
to incomplete genetic investigation or it may be due to
other diseases that cause hypertrophy, such as Noonan's
syndrome or Pompe's disease. The most common mutated
genes are MYBPC3 coding for myosin-binding protein-C
(MyBP-C) and MYH7 coding for β-myosin heavy chain,
which make up over 80% of recorded mutations (Fig. 1).
In DCM, a much smaller proportion of cases have been
linked to a specific mutation. Ideally, a mutation is
established via genetic linkage to the disease over several
generations; however, this is difficult and expensive, and
many mutations (including de novo ones) are established
on the basis of a mutation being found in a sarcomeric
protein that is not found in a large population of matching
normal patients. This has potential for a false positive due
to a rare polymorphism; it is also possible that the true
mutation may be missed or that the patient may harbour
two disease-causing mutations, both of which are required
for the phenotype. Some mutations are associated with
mixed HCM/DCM phenotypes [6, 7].
If we restrict ourselves to the study of the mutations in
the contractile proteins of the sarcomere that clearly fit the
criteria for causing of HCM or DCM, we are still
confronted with a formidable scientific problem in linking
mutation with phenotype. Many different mutations in one
protein (for instance, over 200 different MYBPC3 mutations
cause HCM) and in different proteins (mutations in at least
eight genes cause HCM) can cause the same disease
phenotype. Conversely, different mutations in any one
protein can cause either DCM or HCM (compare Tables 2
and 3). The question to be addressed, therefore, is do all
mutations that cause one phenotype cause the same
functional abnormality at the myofilament level, and if so,
how does the abnormality of sarcomere function lead to the
disease phenotype?
To understand how mutations in individual heart muscle
proteins lead to the distinctive disease phenotypes of HCM
and DCM, it is necessary to examine heart muscle over a
broad range of levels of organization, from single mole-
cules through intact tissue, using multiple techniques. Our
experience of these investigations has shown that in order
to obtain meaningful results, it is essential to study heart
muscle in as near native conditions as possible. Animal
models alone are often inadequate representations of human
disease, whilst investigation of human tissue has practical
limitations, and the state of tissue examined may not be
physiological. Nevertheless, by applying a common range
of advanced experimental techniques to both animal and
human heart, resolution of these problems becomes more
likely.
A problem for the direct investigation of the effect of
HCM mutations in human heart tissue is that the samples
usually studied are from myectomy operations to relieve
left ventricular outflow tract obstruction (LVOTO). LVOTO
MYBPC3 MYH7
TNNT2
TNNI3MYL2
MYL3
   TPM1
     ACTC
Fig. 1 Pie chart showing the distribution of HCM-causing mutations
in contractile protein genes; based on data of Richard et al. [84].
MYH7 β-myosin heavy chain, MYBPC3 myosin-binding protein C,
TNNT2, troponin T, TNNI3 troponin I, MYL2 myosin light chain 2,
ACTC cardiac α-actin, TPM1 α-tropomyosin, MYL3 ventricular
myosin light chain 1
246 J. of Cardiovasc. Trans. Res. (2011) 4:245–255
A pie chart showing the distribution f mutations i  thick and thin filament 
proteins that cause HCM. MYH7 β myosin heavy chain, MYBPC3 myosin-binding 
protein C, TNNT2 cardiac troponin T, TNNI3 cardiac troponin I, MYL2 myosin 
light chain 2, ACTC cardiac actin, TPM1 Tpm1.1, MYL3 ventricular myosin light 
chain 1. Taken from Marston, 2011.  
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1.4.3 Methodology to study familial cardiomyopathies 
 
fDCM and fHCM are the two major familial cardiomyopathies in human, and thus 
there is a demand to study these diseases and the molecular mechanisms that are 
responsible for them. Different models in different levels have been developed in the 
recent years to study familial cardiomyopathies and all of them give us important 
insights about mechanisms of cardiomyopathies. In this section I will briefly describe 
some of these methodologies that others and us use and are relative to this thesis.  
In order to study thin filament mutations (investigated in this thesis) that cause DCM 
or HCM in detail and be able to establish structure-function relationships, the in vitro 
motility assay (IVMA) is often used and is the main methodology used in this thesis. 
The IVMA was firstly developed in our lab by Dr Ian Frazer and Prof Steve Marston 
(Fraser and Marston, 1995b). In this technique, thin filaments can be reconstituted by 
proteins extracted from tissue (troponin, tropomyosin and actin) and slide along a bed 
of immobilised HMM in a Ca2+ dependent manner. In IVMA the movement of 
filaments can be studied, and the Ca2+ sensitivity of the thin filaments can be 
measured. Because the proteins can be extracted from different sources, different 
mutations in the thin filaments can be easily studied. Furthermore, the proteins can be 
easily manipulated in the post-translation level (such as phosphorylation) using 
biochemical methods (Messer et al., 2007, Bayliss et al., 2012, Memo et al., 2013), 
making IVMA a good model to study mutations in the filament level. Similarly to 
IVMA, the actomyosin S1 fragment ATPase activity can be measured using the 
ATPase assay to study the regulatory properties of thin filaments (Deng et al., 2001). 
However, an important limitation of the IVMA is the fact that the assay is unloaded 
and force cannot be measured. A complementary methodology to the IVMA to study 
mutations in the myofilament level is the myofibrilar assay. Such an assay was 
developed in our lab by Dr Petr Vikhorev. This apparatus can measure contractility of 
skinned myofibrils; force of contraction, kinetics of contraction and relaxation, and 
rates of Ca2+ activation (Vikhorev et al., 2014). While in IVMA thin filaments are 
reconstituted from proteins from different sources, in the myofibrilar assay all 
structural elements and contractile proteins are retained, representing better the 
physiological situation. 
On the whole organism level, the most usual methodology to study DCM and HCM is 
through mouse models (Zaragoza et al., 2011). Over the last decades, several DCM 
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and HCM mouse models have been developed that incorporate mutations found in 
human and most of the times recapitulate many of the same characteristics of the 
human disease. A DCM mouse model has been developed in Steve Marston’s lab 
with the E361G mutation in ACTC gene encoding for actin (Song et al., 2010, 
Wilkinson et al., 2015) and similarly an HCM mouse model was also developed with 
the ACTC E99K mutation (Song et al., 2011, Song et al., 2013). These two mouse 
models enabled us to study DCM and HCM and compare their mechanism of action 
in the molecular level, and will also be investigated in this thesis. Another mutation 
that is being studied in this thesis is the HCM-causing mutation E180G. A mouse 
model with this mutation has been developed by Alves et al (Alves et al., 2014) and 
showed many characteristics of HCM in human. Although mouse models can provide 
very insightful information about mechanisms of disease in the whole organism level, 
being able to link specific mutations with phenotype and disease progression, mouse 
models cannot represent the human situation 100%. 
To overcome this problem, cardiovascular research recently has recently turned to the 
use of patient specific induced pluripotent stem cells (i-PSCs) derived cardiomyocytes 
for the study of DCM and HCM (Sun et al., 2012). These patient specific cells can be 
used study the diseases in the tissue level and not only the cellular, through 
Engineered Heart Tissue (EHT) or microtissue. EHT is a hydrogel based 3D muscle-
like tissue whereby cells beat in synchrony and produce contractile force, a situation 
closely resembling that of intact heart tissue (Eschenhagen et al., 1997). Titin 
mutations causing DCM have been successfully modelled and studied using cardiac 
microtissue engineered from human iPSC (Hinson et al., 2015). In Figure 1-23 the 
different models and levels to study DCM and HCM are shown.  
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Figure 1-23: Methodology used to study HCM and DCM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.4 The molecular mechanisms of DCM and HCM mutations 
 
It has been a mystery for many years how mutations in any of the sarcomeric proteins 
can lead to cardiomyopathies and still there has been a lot of research going on to 
elucidate the mechanisms behind the diseases. 
It is important to establish that fDCM and familial HCM (fHCM) are two distinctive 
genetic diseases and do not overlap. For example, DCM can never develop to HCM 
but HCM can lead to heart failure after a long time and after the symptoms of HCM 
have been developed. fDCM and fHCM have also distinct molecular mechanisms.  
HCM has been associated with a hypercontractility demonstrated by an increased 
Ca2+ sensitivity. Initially, studies performed in in vitro models of HCM, mostly 
looking at mutations in the thin filament using recombinant proteins. These studies 
showed a higher Ca2+ sensitivity and increased Ca2+ affinity in mutant proteins, as 
Methodology used in research to study DCM and HCM. iPSC induced pluripotent stem 
cells, IVMA in vitro motility assay, EHT engineered heart tissue.  
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well as increased cross-bridge kinetics and incomplete relaxation (Marston, 2011). A 
study by Sequeira et al looking at human cardiomyocytes with HCM mutations in the 
thick and thin filament showed that in all cases HCM caused an increase of the 
myofilament Ca2+ sensitivity and impaired length-dependent activation (Sequeira et 
al., 2013).  
It has been demonstrated that increased Ca2+ sensitivity is associated with higher risk 
of arrhythmias contributing to the phenotype of HCM. Increased Ca2+ sensitivity 
alone is sufficient to cause the HCM phenotype ex vivo, as it has been demonstrated 
by treating papillary muscles of wild type mice with the Ca2+ sensitiser EMD 57033 
(Baudenbacher et al., 2008). However, the mechanisms by which increased Ca2+ 
sensitivity induces the histological changes observed in HCM are less clear. Sudden 
cardiac death correlates with increased Ca2+ sensitivity in vitro (Haim et al., 2007) but 
does not correlate with hypertrophy (Varnava et al., 2001), suggesting two separate 
mechanisms.   
Early studies with recombinant proteins causing DCM have shown that DCM is 
linked to a decrease in Ca2+ sensitivity, decreased Ca2+ affinity for TnC and decreased 
cross-bridge cycle kinetics (Robinson et al., 2002, Mirza, 2005). However, studies 
from human and transgenic mice in Prof Steve Marston’s laboratory and other studies 
have shown that DCM mutations can lead to either a decrease or an increased Ca2+ 
sensitivity (Marston, 2011, Messer and Marston, 2014). For example, in vitro motility 
assay studies with the DCM mutation E361G in actin showed similar Ca2+ sensitivity 
compared to normal. This led to the need to find a common mechanism for DCM 
mutations.  
In a study by Memo et al, seven thin filament mutations leading to DCM were studied 
using IVMA. Phosphorylated and dephosphorylated thin filaments were compared 
and the Ca2+ sensitivity was independent of TnI phosphorylation (uncoupled) in all 
the DCM causing mutations, leading to the hypothesis that uncoupling is the common 
molecular mechanism of DCM (Memo et al., 2013). 
Can uncoupling be a common molecular defect both HCM and DCM? The next 
section will cover the aspects of the uncoupling phenomenon and its importance in the 
field of cardiomyopathies.  
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1.5 The uncoupling of Ca2+ sensitivity to TnI phosphorylation and its 
importance 
 
1.5.1 TnI phosphorylation by PKA 
 
The phosphorylation of TnI and its effects have important implications in health and 
disease (Zhang et al., 2011). End-stage failing hearts have reduced TnI 
phosphorylation levels and this leads to an increase of the Ca2+ sensitivity seen in 
these hearts. (Wolff et al., 1995, Bodor et al., 1997, van der Velden et al., 2003). A 
study by Messer et al using IVMA has shown that phosphorylation changes in 
troponin alone can lead to contractile abnormalities in failing hearts (Messer et al., 
2007). Failing hearts had a decreased level of TnI phosphorylation and this correlated 
with an increased Ca2+ sensitivity. When the TnI of the failing hearts was replaced 
with TnI treated with PKA the Ca2+ sensitivity was restored to the normal levels. In a 
study by Yasuda et al, phosphomimetic mutants S23/24D had no difference in 
isoproterenol stimulation relative to controls, whereas when cardiomyocytes were 
transfected with either non-phosphorylatable TnI or sTnI blunted the response to 
isoproterenol (Yasuda et al., 2007). It is noted that phosphomimetic mutants can 
represent TnI phosphorylation by PKA and the physiological implications. Transgenic 
(TG) mice with a mutated TnI lacking phosphorylation sites showed similar results, 
lacking lusitropic response to Isoproterenol (Pi et al., 2002). These studies highlight 
the importance of the TnI phosphorylation as well as the Ca2+ sensitivity in biology 
and disease.  
1.5.2 The discovery of the uncoupling phenomenon 
 
 In the first investigations of the molecular mechanisms of cardiomyopathies, the 
effect of TnI phosphorylation was not considered. The first group to discover the 
uncoupling phenomenon was a study by Deng et al, whereby the Ca2+ sensitivity of 
the HCM causing mutation R145G in TnI was independent of phosphorylation (Deng 
et al., 2001). A few further independent studies have shown Ca2+ sensitivity 
uncoupled from TnI phosphorylation. For example, the mutation L29Q in TnC that 
causes HCM shows uncoupling, as measured by IVMA and also actomyosin ATPase 
activity (Schmidtmann et al., 2005). 
 65 
 Dong et al looked at another mutation that also showed uncoupling, G159D. This 
mutation in TnC is a DCM causing mutation and is one of the best clinically 
characterised mutations (Mogensen et al., 2004a 2007, Kaski et al., 2007). For this 
reason, the G159D mutation has been intensively investigated in our lab and in others. 
Myofilaments containing the G159D mutation showed Ca2+ sensitivity independency 
to the change of TnI phosphorylation status (Biesiadecki et al., 2007). Dyer et al from 
Steve Marston’s laboratory looked at Tn extracted from the human sample containing 
the G159D mutation and found that Ca2+ sensitivity of thin filaments reconstituted 
with the mutant troponin was not sensitive to TnI phosphorylation using IVMA (Dyer 
et al., 2009).  
 
1.5.3 Uncoupling as a mechanism of cardiomyopathies with thin filament 
mutations 
 
The first complete study of the uncoupling phenomenon was by Memo et al, where 
seven different mutations causing DCM were studied, and the mutations were not 
only limited to mutations in troponin. The mutations studied were E40K, E54K and 
D230N in Tpm1.1, R141W and ΔΚ210 in TnT, K36Q in TnI and E361G in actin. 
Using the IVMA in reconstituted thin filaments and comparing phosphorylated and 
dephosphorylated troponin it was clear that the Ca2+ sensitivity was independent from 
TnI phosphorylation (Memo et al., 2013). It is interesting to note that when the mutant 
thin filaments were compared to normal the Ca2+ sensitivity was increased, decreased 
or remained the same.  
This led to the hypothesis that the molecular phenotype of DCM is uncoupling of 
Ca2+ sensitivity to TnI phosphorylation making the heart unresponsive to the β 
adrenergic response. The uncoupling phenomenon in DCM was confirmed by another 
study looking at rare TnC variants leading to DCM (Pinto et al., 2011).  
The uncoupling phenomenon has also been demonstrated in some HCM mutations as 
well. For example, the Ca2+ sensitivity of mice carrying the HCM mutation R92W in 
TnT was uncoupled to TnI phosphorylation at 2 months of age (Guinto et al., 2009). 
Uncoupling has also been demonstrated in thin filaments reconstituted with the HCM 
mutation K280N in TnT (Messer et al., 2012) and also in thin filaments reconstituted 
with E99K mutant actin from transgenic mice (Song et al., 2011). However, the 
situation is less clear in permeabilised muscle. Sequeira et al found that some HCM 
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mutations uncouple and others partially uncouple Ca2+ sensitivity to TnI 
phosphorylation (Sequeira et al., 2013). DCM and HCM mutations where uncoupling 
has been observed are summarised in Table 1-1.  
Unexpectedly, uncoupling of the Ca2+ sensitivity to TnI phosphorylation has also 
been observed as a secondary effect in myectomy samples independently of 
mutations.  The purpose of myectomy operation is to relieve left ventricular outflow 
tract obstruction (LVOTO), which is causing pressure overload in HOCM patients. 
Several defects have been found in HOCM samples, including abnormal 
phosphorylation levels of TnI and MyBP-C (Messer et al., 2009) (Copeland et al., 
2010) and actin isoform expression (Copeland et al., 2010). Myectomy samples with 
mutations in MYBPC3, MYH7, TNNT2 and unknown mutations also showed 
uncoupling in IVMA when the phosphorylation levels were manipulated using 
standard biochemical methods (Bayliss et al., 2012b). Subunit exchange experiments 
were carried out to investigate which molecule was responsible for uncoupling and it 
was found to be in TnT. However, no post-translational modifications in TnT subunit 
were found to account for this abnormality. Figure 1-24 shows the uncoupling 
phenomenon in different situations measured by the IVMA by members of the 
Marston’s laboratory. 
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 Figure 1-24: The uncoupling phenomenon in DCM and HCM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage motility of reconstituted thin filaments in response to different Ca2+ 
concentrations. Phosphorylated (solid lines) and dephosphorylated thin filaments (dotted 
lines) were compared. DCM mutations are represented in red, HCM mutations are 
represented in purple and non failing (donor) thin filaments are represented in blue. A) 
D230N tropomyosin. B) Thin filaments were reconstituted with human heart troponin 
with exchanged recombinant TnT K280N subunit C) Thin filaments were reconstituted 
from HOCM troponin or PKA treated HOCM troponin. D) Ca2+ regulation of 
phosphorylated or dephosphorylated donor thin filaments E) EC50 ratio of 
phosphorylated to dephosphorylated thin filaments containing different DCM (red) or 
HCM mutations (purple). Non failing (donor) thin filaments are represented in blue. 
Picture adapted from Messer and Marston, 2014.  
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Table 1-1: Examples of the uncoupling phenomenon in DCM and HCM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.4 The physiological importance of the uncoupling phenomenon 
 
The implications of uncoupling of the Ca2+ sensitivity to the TnI phosphorylation in 
diseased heart is that even when TnI gets phosphorylated the Ca2+ sensitivity would 
not decrease, making the diseased heart unresponsive to part of the β adrenergic 
response. This would lead to a blunting of the lusitropic response, predisposing the 
heart to failure.  
The physiological relevance of uncoupling has been demonstrated with DCM 
transgenic animals carrying the E361G mutation in ACTC. This mouse showed 
blunting of the lusitropic and inotropic response to adrenaline in vivo and ex vivo, as a 
result of uncoupling the Ca2+ sensitivity to TnI phosphorylation (Wilkinson et al., 
2015). Furthermore, the HCM E99K transgenic mice showed blunted response to 
dobutamine (a drug which stimulates β1 adrenergic receptors), which would occur as 
Mutation( Effect(on(Ca2+(
sensitivity(
Measurement(
method(
Publication(
DCM$ $ $ $
ACTC$E361G$ No$difference$ IVMA$ Song$et$al,$2010,$Memo$et$al,$2013$
TPM1$E54K$ No$difference$ IVMA$ Memo$et$al,$2013$
TPM1$E40K$ Decrease$ IVMA$ Memo$et$al,$2013$
TPM1$D230N$ Increase$ IVMA$ Memo$et$al,$2013$
TNNC1$G159D$ Increase$ IVMA,$Ca$binding$ Biesiadecki$et$al,$2007,$Dong$et$al,$
2008,$Dyer$et$al,$2009,$Memo$et$al,$
2013$
TNNC1$Y5H$ Decrease$ Skinned$fiber$ Pinto$et$al,$2011$
TNNC1$M103I$ Decrease$ Skinned$fiber$ Pinto$et$al,$2011$
TNNC1$I148V$ Decrease$ Skinned$fiber$ Pinto$et$al,$2011$
TNNT2$∆K210$ Decrease$ IVMA,$Skinned$fiber$ Du$et$al,$2007,$Memo$et$al,$2013$
TNNT2$R141W$ Decrease$ IVMA$ Memo$et$al,$2013$
TNNI3$K36Q$ Decrease$ IVMA,$ATPase$ Carballo$et$al,$2009,$Memo$et$al,$2013$
HCM$ $ $ $
ACTC$E99K$ Increase$ IVMA$ Song$et$al,$2011$
TNNC1$L29Q$ Increase$ Ca$binding,$ATPase$ Schmidtmann$et$al,$2005,$Dong$et$al,$
2008,$Li$et$al,$2013$
TNNT2$K280N$ Increase$ IVMA$ Bayliss$et$al,$2012$
TNNI3$R145G$ Increase$ IVMA,$ATPase$ Deng$et$al,$2001$
TNNI3$R21C$ Increase$ Skinned$fiber$ Gomes$et$al,$2005,$Wang$et$al,$2011$
TNNI3$G203S$ Increase$ IVMA,$ATPase$ Deng$et$al,$2013$
TNNI3$K206Q$ Increase$ IVMA,$ATPase$ Deng$et$al,$2013$
TNNT2$R92W$ Increase$ Cardiac$myocytes$ Guinto$et$al,$2009$!
Adapted from Messer and Marston, 2014 
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a result of uncoupling (Song et al., 2013). TnI G203S transgenic mice did not respond 
to chronic swimming exercise, which correlates with lack of response to β adrenergic 
stimulation. It is noteworthy that loss of one part of the system seems to lead to a loss 
of the whole. For example, PLB KO mice showed a blunted lusitropic and inotropic 
response to Isoproterenol, analogous to TG mice with the ACTC mutation E361G that 
uncouples TnI phosphorylation to Ca2+ sensitivity showing blunted response to 
dobutamine (Li et al., 2000a).  
E361G TG mice did not show any phenotype of the disease unless under stress. This 
has been observed in other DCM mouse models such as TnT ∆K210, MyBP-C 
knockout and titin knock-in (Messer and Marston, 2014). This is also well-matched 
with the lack of response to adrenergic stimulation which would not be observable at 
rest. Targeting the uncoupling phenomenon pharmacologically might be therefore a 
way to treat cardiomyopathies.  
The role of uncoupling in HCM is less clear. In all cases of HCM there is increased 
Ca2+ sensitivity and this might be the primary effect that causes the HCM phenotype 
and it dominates over the uncoupling phenomenon. The recent view for the case of 
HCM is that the common mechanism is increased force, and not increased Ca2+ 
sensitivity (Spudich, 2014). In any case, it will be interesting to investigate whether 
increasing Ca2+ sensitivity would also lead to uncoupling or Ca2+ sensitivity and 
uncoupling act via separate mechanisms. In this thesis this will be investigated, as 
well as the structural mechanisms that lead to uncoupling.  
1.6 Aims 
 
The uncoupling phenomenon has been shown to play a very important role in the 
development of cardiomyopathies. In this thesis I will investigate some the aspects of 
the uncoupling phenomenon, its molecular mechanism, its correlation to Ca2+ 
sensitivity, and the potential to induce it or reverse it using pharmacological agents. 
The main method used in the thesis was the in vitro motility assay (IVMA). The 
advantage of this technique is that is a simple technique to screen functional 
properties of the contractile proteins in vitro. Subunits of the thin filaments can be 
purified separately and from different sources, the Ca2+ sensitivity can be easily 
measured as a function of movement of the filaments in relationship to Ca2+ and the 
phosphorylation of the different proteins can be manipulated easily by biochemical 
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methods. Thus this method is very appropriate for the extensive study of the 
uncoupling phenomenon. 
In order to familiarise myself with the IVMA, I also got involved in a small project 
concerning skeletal muscle myopathies. I studied 7 mutations in Tpm2.2 or Tpm3.12 
that lead to various skeletal muscle diseases and evaluated whether there is a common 
molecular behaviour in terms of the location of the mutation. The aim of this study 
was to elucidate a structure-function mechanism for tropomyosin mutations that 
would lead to future predictions. For the purpose of the thesis, this project is included 
as an entire different chapter, with its own introduction and discussion separate from 
the rest of the thesis, which investigates the uncoupling phenomenon in 
cardiomyopathies.  
The study by Memo et al showed that uncoupling of TnI phosphorylation to Ca2+ 
sensitivity is the molecular mechanism behind DCM. In this study mutations in all the 
components of the thin filament were studied (actin, troponin, tropomyosin) and in all 
cases TnI phosphorylation was uncoupled to Ca2+ sensitivity. How is it possible for a 
mutation in any component of the thin filament to cause perturbations in troponin and 
thus cause uncoupling?   
As suggested by recent studies, troponin can have two conformations depending on 
the phosphorylation level and there is a specific interaction between TnC and TnI that 
occurs when TnI is phosphorylated and accounts for the change in Ca2+ sensitivity 
that makes the myofilament respond to β adrenergic response.  
We propose that this interaction between TnC and TnI is destabilised or change if 
there is a perturbation (for example a mutation) in any of the components of the thin 
filament that causes the uncoupling phenomenon to occur. To test this hypothesis, I 
used small molecules, which increase or decrease the Ca2+ sensitivity by binding to 
TnC and are though to affect this interaction. The hypothesis is that the small 
molecules will cause perturbations in the TnC-TnI interaction and might induce 
uncoupling. This will give insights about the mechanisms of the uncoupling 
phenomenon. The most surprising and important finding results I got was that the 
Ca2+ desensitiser EGCG could reverse the uncoupling in mutant thin filaments.  
As part of my PhD I initiated a collaboration with Dr Ian Gould from the Department 
of Chemistry and he performed molecular dynamics (MD) simulations in troponin to 
observe the structural differences upon phosphorylation. 
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2 MATERIALS AND METHODS 
 
2.1 Sources of sample proteins  
2.1.1 Sources of human heart samples 
2.1.1.1 Sources of donor heart samples 
 
All donor heart samples were provided by Prof Cristobal Dos Remedios, University 
of Sydney, Sydney, Australia. Ethical approval for usage of the samples was obtained 
from the Brompton, Harefield & NHLI, London and from St Vincent’s Hospital, 
Sydney. Non-failing adult myocardium was obtained from patients who were first 
assigned as donors but no suitable recipient was found or the heart was considered 
unusable for other reasons. The donors had no history of cardiac disease, had a 
normal cardiac examination, a normal admission ECG and normal ventricular 
function on transthoracic echocardiography as performed within 24 hours of heart 
explantation. Immediately after explantation of the heart, the ventricular wall was cut 
into 1g pieces and stored in liquid nitrogen. The clinical details of the donors are 
shown in Table 2-1.  
2.1.1.2 Sources of Dilated Cardiomyopathy  
 
Two samples were obtained from patients diagnosed with DCM undergoing heart 
transplant. An explanted heart sample with the missense mutation Lys36Gly (K36Q) 
in Troponin I (TNNI) that causes DCM was used (Carballo et al., 2009). The heart 
sample carrying this mutation was kindly provided by Prof Cristobal Dos Remedios 
from University of Sydney, Sydney, Australia. The other sample of DCM mutation 
used in this study was from a patient carrying the missense mutation Gly159Asp 
(G159D) in Troponin C (TNNC). A sample from a transplanted heart from the patient 
was collected by Dr Adam Jacques from the Great Ormond Street Hospital, London 
(Dyer et al., 2009). Ethical approval for usage of the samples was obtained from the 
Brompton, Harefield & NHLI, London and from St Vincent’s Hospital, Sydney. Both 
samples were stored in liquid nitrogen at all times. The clinical characteristics of both 
DCM mutations are summarised in Table 2-1.  
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2.1.1.3 Sources of Hypertrophic Cardiomyopathy  
 
For this study, a sample from a patient diagnosed with HCM and carrying the 
missense mutation Lys280Asp (K280N) on Troponin T (TNNT2) was donated by Prof 
Cristobal Dos Remedios, University of Sydney, Sydney, Australia. Ethical approval 
for usage of the sample was obtained from the Brompton, Harefield & NHLI, London 
and from St Vincent’s Hospital, Sydney The mutation was identified by Prof Van der 
Velden (Bayliss et al., 2012a).  
 
Table 2-1: Table of human heart samples used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2  Sources of mouse heart samples  
2.1.2.1 The Dilated Cardiomyopathy mouse model  
 
A DCM mouse model was developed in our lab by Dr Weihua Song carrying the 
mutation Glu361Gly (E361G) on actin (ACTC) which is correlated with DCM (Song 
et al., 2010, Wilkinson et al., 2015). Whole hearts from the transgenic mice were 
extracted and frozen in liquid nitrogen.  
Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Subarachnoid 
Haemorrhage  (SAH), Middle Cerebral Artery (MCA), Left Ventricular Ejection Fraction 
(LVEF), Echocardiography (ECO) 
stored in liquid nitrogen at all times. The clinical characteristics of both DCM mutations are 
summarised in Table 2.1.  
 
2.1.1.3 Sources of Hypertrophic Cardiomyopathy  
!
For this study, a sample from a patient diagnosed with HCM and carrying the missense 
mutation Lys280Asp (K280N) on Troponin T (TTNT2) was donated by Prof Cristobal Dos 
Remedios, University of Sydney, Australia. 
Table&2.1:&Table&of&samples&used&in&this&study&
!
Sample& Diagnosis& Gender& Age& LVEF&on&ECO&&
Donor! NH! SAH! Female! 48! !
! NJ! SAH! Female! 55! !
! NK! Cardioplegia! Male! 45! !
! NL! SAH/Aneurism! Female! 42! 65%!
! NN! Right!MCA!infarct! Male! 40! !
! NS! Family!of!hypertension! Female! 55! !
DCM& G159D! DCM! ! 3! 20%!
! K36Q! DCM! Male! 15! 15M20%!
HCM& K280N! HCM! Male! 26! !
 
 
 
2.1.2 Sources of mouse heart samples  
2.1.2.1 The Dilated Cardiomyopathy mouse model  
!
A DCM mouse model w s developed in our lab by Dr Weihua Song carrying the mutation 
Glu361Gly (E361G) on actin (ACTC) which is correlated with DCM (Song et al 2010, 
Hypertrophic!Crdiomyopathy!(HCM),!Dilated!Cardiomyopathy!(DCM),!Subarachnoid!Haemorrhage!!
(SAH),!Medal!Cerebral!Artery!(MCA),!Left!Ventricular!Ejection!Fraction!(LVEF),!Ecocardiography!(ECO)!
!
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2.1.2.2 The Hypertrophic Cardiomyopathy mouse model  
 
An HCM mouse model overexpressing the mutation Glu99Lys (E99K) on actin 
(ACTC) was developed in our laboratory by Dr Weihua Song (Song et al., 
2011)Whole hearts from the transgenic mice were extracted from these mice and 
frozen in liquid nitrogen.  
2.1.3 Tropomyosin samples 
2.1.3.1 TPM1 mutants causing cardiomyopathy 
 
Two mutations in a tropomyosin that cause DCM have been used in this study: 
Glu40Lys (E40K) and Glu54Lys (E54K), both in TPM1. These two mutations were 
identified as a cause of DCM by a study on two families by Olson et al (Olson et al., 
2001). Purified recombinant AS α tropomyosins E40K and E54K and wild type (WT) 
were provided by Dr Charles Redwood, University of Oxford, Oxford, UK. 
Furthermore, a tropomyosin mutation that causes HCM and has been characterised in 
this lab (Bing et al., 2000) is a mutation in TPM1 Glu180Gly (E180G). Purified 
recombinant AS α tropomyosin E180G was provided by Dr Charles Redwood, 
University of Oxford, Oxford, UK. The recombinant proteins were expressed in 
baculovirus/sf9 insect cells.  
2.1.3.2 TPM2 mutants causing skeletal muscle myopathy  
 
Mutations in TPM2 that cause skeletal muscle diseases were studied in this thesis. 
Briefly, mutations were introduced into TPM2 cDNA by site-directed mutagenesis. 
The wild type and also the mutant tropomyosins were cloned into sf9 insect cells and 
recombinant proteins were isolated using the protocol of Akkari et al 
(Akkari et al., 2002). These cells are able to keep the post–translational modifications 
of the eukaryotic system including the N terminal acetylation. Purified WT 
tropomyosin was also provided. Mutant Tpm2.2 proteins included in this study are: a 
deletion in Lys49 (ΔK49), which is associated with Cap disease (Ohlsson et al., 
2008), Arg91Gly (R91G), associated with distal arthrogryposis (Sung et al., 2003) 
and a deletion in Glu139 (ΔE139) found in a patient with Cap disease (Clarke et al., 
2009).  Baculovirus/sf9 pellets with the mutations ∆K49 and R91G Tpm2.2 mutants 
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were supplied by Dr Kristen Nowak and Dr Elyshia McNamara. ∆E139 mutant pellets 
were provided by Mintu Martilla, University of Helsinki, Helsinki, Finland. WT 
purified Tpm2.2 was provided by Dr Mohammed El-Mezgueldi, University of 
Leicester, Leicester, UK.  
2.1.3.3 TPM3 mutants that cause skeletal muscle myopathy  
 
Baculovirus/sf9 pellets from recombinant Tpm3.12 mutants Lys168Glu (K168E), 
deletion in E139 (ΔE139), Arg167His (R167H) and Arg244Gly (R244G) were 
provided by Dr Kristen Nowak, Dr Elyshia McNamara and Royston Ong, University 
of Western Australia, Nedlands, Australia, The skeletal muscle diseases associated 
with theses mutations can be found in Table 2.2.  
Tpm3.12 218del (∆E218) and 224del (∆E224) were provided by Dr Kristen Nowak, 
Dr Elyshia McNamara and Royston Ong already purified from baculovirus/sf9 (see 
Section 2.1.3.2) in a lyophilised form. A summary of all the tropomyosin mutations 
used in this study can be found in Table 2-2. WT Tpm3.12 was supplied by Dr 
Mohamed El-Mezgueldi, University of Leicester, UK and Dr Kristen Nowak, 
University of Western Australia, Nedlands, Australia.  
 
Table 2-2: Summary of the Tropomyosin mutations used in this study 
   
Dilated Cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), Congenital 
Fibre type Disproportion (CTFD). Isoform description according to Geeves et al, 2014 
Muta%on( Disease( Gene( Isoform(
E40K% DCM% TPM1% Tpm1.1%
E54K% DCM% TPM1% Tpm1.1%
E180G% HCM% TPM1% Tpm1.1%
∆K49% Cap%disease% TPM2% Tpm2.2%
R91G% Distal%arthrogryposis% TPM2% Tpm2.2%
∆E139% Cap%disease% TPM2% Tpm2.2%
K168E% CFTD% TPM3% Tpm3.12%
R167H% Cangenital%myopathy% TPM3% Tpm3.12%
R244G% CFTD% TPM3% Tpm3.12%
∆E218% Severe%sIﬀ%myopathy% TPM3% Tpm3.12%
∆E224% Severe%sIﬀ%myopathy% TPM3% Tpm3.12%
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2.2 Protein preparation 
2.2.1 Purification of myosin from rabbit muscle   
 
Heavy Meromyosin (HMM) is a crucial motor protein for the IVMA. HMM is the 
soluble part of myosin thus myosin was firstly isolated from rabbit by Mr O’Neal 
Copeland as by the method of Margossian and Lowey (Margossian and Lowey, 
1982).  
Immediately after the rabbit was sacrificed, the back muscle was taken and cooled 
down on ice for one hour. The muscle was then skinned and diced before being 
minced two times in a pre-cooled meat grinder. The minced muscle was then 
weighed, on average around 300g of minced muscle was obtained from one rabbit. 
Myosin was extracted from the minced muscle in three volumes of myosin extraction 
buffer (300 mM KCl, 150 mM potassium phosphate (48 mM K2HPO4 / 102 mM 
KH2PO4), 20 mM EDTA, 5 mM MgCl2, 1 mM ATP and 5 mM DTT pH 6.5 and 
protease inhibitors: E-64, chymostatin, leupeptin & pepstatin A) for exactly 10 
minutes with continual stirring. The extract was centrifuged at 25,000 x g (13,000 
rpm, Sorvall Evolution RC, SLA-1500 rotor) for 5 minutes. The pellet was saved for 
F-actin preparation (see section 2.2.3). The supernatant was filtered through glass 
wool and diluted gradually with 12 volumes of cold distilled H2O. Myosin was 
allowed to precipitate overnight with no agitation. The next day, myosin was pelleted 
by centrifugation at 13,000 rpm (Sorvall Evolution RC, SLA-3000 rotor) for 6 
minutes. The resulting pellet was resuspended with 3 M KCl at the ratio of 220 ml per 
kg of starting muscle. Once dissolved, the myosin solution was dialysed overnight 
(600 mM KCl, 25 mM potassium phosphate (8 mM K2HPO4 / 17 mM KH2PO4), 10 
mM EDTA and 2 mM DTT, pH 6.5 and protease inhibitors: E-64, chymostatin, 
leupeptin & pepstatin A). 
The dialysate was gradually diluted two-fold with cold distilled H2O, stirred for 30 
minutes and then centrifuged at 50,000 x g (20,000 rpm Sorvall Evolution RC SS-34 
rotor) for 1 hour. This step was designed to remove any actomyosin still present. The 
resulting supernatant was diluted eight-fold with cold distilled H2O and left for 1 hour 
to allow the myosin to precipitate. The myosin was then pelleted by centrifugation at 
25,000 x g (13,000 rpm, Sorvall Evolution RC, SLA-1500 rotor) for 10 minutes. This 
pellet was resuspended in 1/4 volume of 4 M KCl. Finally the dissolved myosin was 
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centrifuged at 45,000 rpm (Sorvall Discovery 90SE, T-865 rotor) for 1 hour. After 
which the final product was preserved by dropping 100 µl aliquots directly into liquid 
nitrogen to form myosin pellets, which were then stored in liquid nitrogen for future 
use. The concentration of the myosin was determined by Lowry assay (see Section 
2.3.1.2) this was usually in the range of 30- 60 mg/ml. 
2.2.2 Preparation of Heavy meromyosin (HMM) 
 
HMM was prepared from the myosin pellets stored in liquid nitrogen. The preparation 
of myosin is based on the protocol of Okamoto (Okamoto and Sekine, 1985, Frazer 
and Marston, 1995). Two pellets of myosin per HMM sample were removed from 
liquid nitrogen and were put in an Eppendorf tube to thaw on ice. This was then 
diluted in HA buffer (0.1 mM NaCO3, 0.1 mM EGTA, 2 mM DTT, pH 7.4) to a final 
concentration of 1.9 mg/ml, mixed thoroughly and left on ice for 20 minutes. The 
myosin was centrifuged for ten minutes at 21,100 x g (14,800 rpm, Thermo Scientific 
Heraeus Fresco 21) at 4°C. The supernatant was discarded and the pellet was 
carefully mixed with 100 µl Buffer HB (20 mM imidazole, 1 M KCl, 4 mM MgCl2, 2 
mM DTT, pH 7 measured at 25°C) and left on ice for 10 minutes. The total volume 
was then made up to 200 µl with Buffer HA and incubated at 25°C for 10 minutes in 
an Eppendorf thermomixer. The myosin was then digested with 7.4 µl of 4 mg/ml 
TLCK α chymotrypsin (Sigma type VII, C-3142, UK) and incubated for 8 minutes at 
25°C. The digestion was stopped by adding the myosin to STOP solution (27000 µl 
Buffer HA with 3 mM MgCl2 and 0.1 mM phenylmethylsulfonyl fluoride (PMSF)) 
and leaving it on ice for one hour. It was then centrifuged at 33,7000 x g (100,000 
rpm, Sorvall MC-120 SE, S100-AT6 rotor) for 20 minutes at 4°C. The supernatant 
contained pure HMM, the concentration of which was determined by the Bradford 
assay (see Section 2.3.1.1). The usual concentration range of HMM obtained was 0.3-
0.7 mg/ml. HMM was stored at 4°C to be used for the IVMA and remained viable for 
5 days.  
2.2.3 Preparation of skeletal F-actin.  
2.2.3.1 Acetone powder preparation from skeletal muscle 
 
The preparation of F-actin from acetone powder is based on the method of Straub 
(Straub, 1942). The acetone powder preparation has the same starting material as the 
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myosin preparation from the rabbit muscle (see Section 2.2.1). Acetone powder was 
made by washing the myosin pellet obtained from the first centrifugation step of the 
myosin preparation (see Section 2.2.1) before being dried to form the acetone powder. 
The preparation of the acetone powder was carried out by Mr O’Neal Copeland. In 
each step, the muscle residue was dispersed by manual homogenising and then 
filtered through a nylon mesh and squeezed to drain liquid. The pellet was weighed 
and washed as follows: 
1. 3 washes with 10 volumes of cold dH2O for 5 minutes at 4°C 
2. 1 wash with 4 volumes of 0.4 NaHCO3 for 45 minutes at room temperature 
(stirring) 
3. 3 washes with 2 volumes of 1 M Tris-HCl pH 8.5 for 5 minutes at 4°C 
4. 5 washes with 4 volumes of acetone for 10 minutes at 4°C 
After the final acetone wash, the pellet was left to dry to form powder in the fume 
hood overnight. The following day it was stored at -20°C for future use.  
2.2.3.2 Preparation of F-actin from acetone powder 
 
F-actin was prepared from the acetone powder based on the method of Spudich and 
Watt (Spudich and Watt, 1971). A sample of around 2.5 g of acetone powder (see 
Section 2.2.3.1) was removed from -20°C storage and was left to thaw on ice. The 
acetone powder was dissolved in 50 ml of G-actin Buffer (2 mM Tris-HCl, 0.2 mM 
ATP, 0.1 mM CaCl2, 1 mM NaN3, 500 nM DTT, pH 8.0) and stirred for 30 minutes at 
4°C. The solution was centrifuged at 15,000 x g (18,000 rpm, Sorvall Evolution RC, 
SS-34 rotor) for 20 minutes at 4°C. The pellet was resuspended in an additional 15 ml 
of G-actin Buffer and was centrifuged as before. The supernatants were combined and 
filtered through glass wool into a measuring cylinder. G-actin polymerization was 
initiated by the addition of 0.1 volume of 10 x KME buffer, (0.5 M KCl, 100 mM 
Tris-HCl, 25 mM MgCl2, 10 mM EGTA, 10 mM NaN3, pH 8.0). The solution was 
gently mixed by sealing the measuring cylinder with parafilm TM and inverted slowly 
several times. It was then incubated in a water bath at 30°C for 45 minutes. The KCl 
concentration was adjusted to 0.8 M by the addition of 0.34 volumes of 3 M KCl. 
This solution was mixed at room temperature for 20 minutes by intermittent inversion 
of the resealed measuring cylinder. The F-actin was pelleted by centrifugation at 
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146,000 x g (45,000 rpm Sorvall Discovery 90SE, T-865 rotor) for 1.5 hours at 4°C. 
The supernatant was discarded, the pellets rinsed in distilled H2O and then dissolved 
in 12-13 ml of G-actin buffer. The dissolved actin was then resuspended before being 
dialysed against G-actin buffer for 48 hours. The actin was depolymerized due to the 
reduction in the concentration of KCl. The solution was centrifuged at 146,000 x g 
(45,000 rpm, Sorvall Discovery 90SE, T-865 rotor) for 1.5 hours at 4°C. 
The G-actin supernatant was filtered through glass wool and loaded onto a 2.5 x 90cm 
Sephacryl S300 gel filtration column, which had previously been equilibrated with 1.5 
L of G-actin buffer. It was run overnight at a flow rate of 50 ml/hour and fractions 
were collected every 6 minutes in a fraction collector (Frac 920, GE Healthcare, UK). 
A single peak was recorded on Pharmacia U.V. monitor II system. Fractions 
producing the peak were checked by measuring their optical density (absorbance) at 
290 nm in a quartz cuvette. Any fractions that gave reading of higher than 0.35 were 
pooled together. 
The G-actin was polymerized for the final time by the addition of 0.1 volumes of 
10xKME buffer at 30°C for 45 minutes and centrifuged at 146,000 x g (45,000 rpm, 
Sorvall Discovery 90SE, T-865 rotor) for 1.5 hours at 4°C as before. The supernatant 
was discarded and the F-actin pellets were dissolved in ATPase buffer (100 mM KCl, 
5 mM PIPES-K2, 2.5 mM MgCl2, 1 mM DTT, 10 mM NaN3, pH 7.3) at around 10 
mg/ml. This was stored for up to one month at 4°C for experimental use. For later 
experiments, F-actin was stored as100 µl aliquots to avoid cross-contamination.  
2.2.3.3 F-actin preparation from mouse heart  
 
F-actin was isolated from WT, E361G or E99K transgenic mice at 2-6 months of age 
(See section 2.1.2). The method of purification of actin from the mouse hearts was 
developed in the lab by Dr Emma Dyer (Song et al., 2010). One heart (50-100 mg) 
was pulverised and homogenised with 10 x volume of wash buffer (3.9 mM 
NaH2PO4, 0.1 mM Na2HPO4, 0.1 M NaCl, 5 mM MgCl2, 0.5 mM EGTA, 5 mM DTT 
and 2 mg/ml protease inhibitors chymostatin, leupeptin and pepstatin, pH 7.0) in an 
electric homogeniser. The samples were spun at 16,662 x g (13,400 rpm, Thermo 
Scientific Heraeus Fresco 21) for 3 minutes at 4°C. The wash step was repeated four 
times; 2 times with Triton x 100 (Sigma), 2 without. The supernatant was discarded, 
the pellet was extracted twice in 1.5 volume of thin filament extraction buffer (5 mM 
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ATP and 1.5 mM blebbistatin in wash buffer) and spun at 21,000 x g (13,400 rpm, 
Thermo Scientific Heraeus Fresco 21). The supernatants were combined and spun at 
466,800 x g (100,000 rpm, Sorvall RCM-120 SE, RCM-120 rotor) for 25 minutes at 
4°C. Thin filaments are sedimented and the pellets containing thin filaments were 
resuspended 3 times in 50 µl “actin resuspension buffer” (2.6 mM NaH2PO4, 17.4 
mM Na2HPO4, 0.1 M NaCl, 5 mM MgCl2, 5 mM DTT, 1 mM ATP, 3 mM 
blebbistatin, pH 6) and dialysed in the same buffer for 2 hours at 4°C. The samples 
were then spun at 16,662 x g (13,000 rpm, Thermo Scientific Heraeus Fresco) at 4°C 
for 2 minutes. 3 M KCl was added to the supernatant to a concentration of 0.8 M to 
dissociate actin from troponin-tropomyosin. 150 nM TRITC-phalloidin (Sigma, UK) 
was added to keep actin polymerised and stable. The actin was then spun at 446,800 x 
g (100,000 rpm, Sorvall MC-120 SE, S100-AT6 rotor) for 25 minutes at 25°C and the 
pellet containing the F-actin was resuspended in 50 µl of ACEX buffer (2 mM Tris-
HCl, 0.2 mM CaCl2, 0.2 mM ATP, 1 mM DTT, pH 8.0) overnight at 4°C. The actin 
was then labelled with TRITC-phalloidin and remained functional for IVMA for 10-
15 days. (See Section 2.5.2).  
2.2.4 Purification of the troponin complex 
 
Troponin was purified from human and mouse heart (See section 2.1.1 and 2.1.2) by a 
method developed by Messer (Messer et al., 2007). The sample was removed from 
liquid nitrogen. One mouse heart (50-100 mg) or 100-200 mg of human heart was 
pulverised in a percussion motor, which was cooled with liquid nitrogen. All steps of 
troponin preparation were performed at 4°C to ensure stability of the protein. The 
tissue sample was washed by homogenisation with 1.5 ml of wash buffer (5 mM 
NaH2PO4, 5 mM Na2HPO4, 0.1 M NaCl, 5 mM MgCl2, 0.5 mM EGTA, 0.1% Triton 
X-100, 5 mM DTT, 2 mg/ml of the protease inhibitors chymostatin, leupeptin and 
pepstatin A, pH 7.0) using a micropestle. The sample was then centrifuged at 21,000 
x g (14,800 rpm Thermo Scientific Heraeus Fresco 21) for 3 minutes at 4° C. The 
supernatant was discarded and the pellet was further washed three more times with 
the same procedure. After the last washing step, the supernatant was discarded and the 
pellet was homogenized with 5 x volume of extraction buffer (0.7 M LiCl, 25 mM 
Tris, 5 mM EGTA, 0.1 mM CaCl2, 5 mM DTT, 2 mg/ml of each protease inhibitor, 
pH 7.5) to extract the myofilament proteins from the tissue. The sample was then 
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mixed in a rotating wheel for 25 minutes at 4° C and afterwards was spun at 21,000 x 
g (14,800 rpm, Thermo Scientific Heraeus Fresco 21) for three minutes at 4°C. The 
supernatant was kept at 4°C and the pellet underwent three more extractions steps for 
20, 15 and 10 minutes respectively. All the supernatants from the extraction steps 
were kept and pooled together and centrifuged at 337,000 x g (100,000 rpm, Sorvall 
RCM-120 SE, S100-AT6 rotor) for 20 minutes at 4°C. The supernatant (spun extract) 
contained soluble myofilament proteins was kept at 4°C. Troponin was purified from 
the spun extract using affinity column chromatography consisting of 0.6 ml of CNBr 
Sepharose CL-4B conjugated with a monoclonal anti-troponin I antibody (14G5) gift 
from N. Gusev and A. Katrukha (Katrukha et al., 1995). The matrix was equilibrated 
in 4.5 ml of troponin extraction buffer prior to the addition of spun extract. The spun 
extract was added to the sepharose column and incubated for 15 minutes at 4° C on 
the rotating wheel to ensure that the troponin is bound to the antibody of the column. 
Eight 2 ml tubes were setup and labelled: 1 flow through (FT), 2 wash (W1 and W2), 
and 5 containing the elution fractions (E1-E5). After incubation, the column 
containing the spun extract was placed in the FT tube, and the soluble proteins such as 
actin, tropomyosin and myosin were run through. The column was then washed two 
times with 0.8 ml extraction buffer (tubes W1 and W2). Finally the troponin was 
eluted with 0.6 ml elution buffer (0.1 M glycine, 5 mM DTT and 2 mg/ml protease 
inhibitors, pH 2) in each elution tube (E1-E5). To neutralize the low pH of the elution 
buffer 100 µl of 1 M MOPS, pH 8 was added in each of the elution fractions during 
preparation of the tubes. A sample was taken from each step and run on an SDS 
PAGE gel (see 2.3.2.) to determine in which fraction the troponin was eluted (see 
Figure 2-1). The troponin was usually eluted in fraction E1 and some times in fraction 
E2. The fraction in which troponin was eluted was therefore dialysed in small dialysis 
tubing (BioDesignDilaysis Tubing D001, Fisher Scientific, UK) against dialysis 
buffer (1 M KCl, 10 mM MES, 0.1 mM CaCl2, 5 mM DTT, 2 mg/ml protease 
inhibitors, pH 6) overnight at 4°C with gentle stirring. The next day, troponin was 
centrifuged at 21,100 x g (18,400 rpm Thermo Scientific Heraeus Fresco 21) for 5 
minutes at 4°C to remove any insoluble material. The supernatant was kept and stored 
at 4°C for use with the IVMA. The final concentration was measured using the Lowry 
assay (see Section 2.3.1.2). The usual concentration obtained was 4-10 µM and the 
troponin remained stable for three days after extraction.  
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Figure 2-1: Troponin extraction steps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.5 Further manipulation of the troponin complex 
2.2.5.1 Phosphorylation of Human Cardiac Troponin  
 
For the purpose of the thesis, it was desirable to increase the phosphorylation levels of 
the mutant K280N and K36Q produced by the exchange method (see Section 2.2.5.3). 
Mutant troponin was taken after column elution (see Section 2.2.4) and was dialysed 
against “phosphorylation buffer P” (0.5 M KCl, 50 mM MOPS, 20 mM NaF, 1 mM 
DTT, 10 mM MgCl2, pH 7.0) for four hours at 4°C. The PKA catalytic subunit from 
bovine pancreas (Sigma, UK, P2645) was prepared to 200 units/ml solution in 
“phosphorylation buffer A” (same as “phosphorylation buffer P” without KCl). 300 µl 
of troponin (4-10 µM) was mixed together with 6.75 µl of Mg2+-ATP (100 mM), 24 
µl of Protein Kinase A (PKA) (200 units/ml) and 6.75 µl of “phosphorylation buffer 
Different troponin extraction steps are represented in each lane. M molecular weight 
marker, SE spun extract, FT flow through, W1 wash 1, W2 wash 2, E1 elution 1, E2 
elution 2, E3 elution 3, E4 elution 4, E5 elution 5. TnI troponin I, TnT troponin T, 
TnC troponin C. 
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P” in a 1.5 ml Eppendorf tube. The mixture was left to incubate overnight at 4°C on 
the rotating wheel. The next day, it was centrifuged at 21,000 x g (14,800 rpm, 
Thermo Scientific Heraeus Fresco 21) for 5 minutes at 4°C to remove any insoluble 
material. The supernatant contained phosphorylated troponin and was stored at 4°C.  
2.2.5.2 Dephosphorylation of Human Cardiac Troponin  
 
All the donor samples have been shown to have high phosphorylation levels so for the 
purpose of this study it was needed to completely dephosphorylate the troponin 
complex. TnI was dephosphorylated by incubating troponin with 90 U/ml Shrimp 
Alkaline Phosphatase (SAP) (Sigma, P9088, UK) after the column elution (see 
Section 2.2.4). The reaction mixture was then dialysed overnight with dialysis buffer 
at 4°C. The next day the sample was centrifuged at 21,000 x g (14,800 rpm, Thermo 
Scientific Heraeus Fresco 21) for 5 minutes at 4°C.  
2.2.5.3 Exchange of native troponin subunits with recombinant TnI or TnT 
 
Mutant troponin K820N and K36Q were produced by exchanging the native TnI from 
donor hearts with mutant recombinant TnI subunit (in the case of K36Q) or TnT with 
mutant recombinant TnT (in the case of K280N). All the recombinant subunits were 
provided by Dr Charles Redwood, University of Oxford, Oxford, UK. The exchange 
process was based on the troponin extraction protocol (see Section 2.2.4) with a 
further step as described by Bayliss et al (Bayliss et al., 2012b). After obtaining the 
“spun extract” from high speed centrifugation, the “spun extract” was dialysed in 
“denaturing buffer” (6 M Urea, 1 M KCl, 10 mM MES, 0.1 mM CaCl2, 5 mM DTT, 2 
mg/ml protease inhibitors, pH 6) for 6 hours at 4°C to denature the protein complexes 
instead of loading it onto the affinity column. A 10 fold excess of the mutant 
recombinant TnT or TnI subunit was added to the sample and the mix then was 
dialysed overnight at 4°C in dialysis buffer. The next day, the sample was centrifuged 
at 21,000 x g (14,800, Thermo Scientific Heraeus Fresco 21) for 20 minutes at 4°C. 
The samples were loaded into the affinity column and troponin was eluted. Different 
antibody columns were used dependent on the subunit exchanged. For example, when 
TnI was exchanged, an anti-TnT column was used (7F4, sepharose column donated 
by N. Gusev) whereas when TnT was exchanged an anti-TnI column was used 
(14G5). The fraction that contained troponin was dialysed in dialysis buffer at 4°C for 
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at least 4 hours. Finally the sample was centrifuged at 21,000 x g (14,800 rpm, 
Thermo Scientific Heraeus Fresco 21) for 5 minutes at 4°C. These exchanged 
troponins had a relatively short functional life and they remained viable for 2 days. A 
diagram for preparation of troponin (exchanged and native) is shown in Figure 2-2. 
Figure 2-2: Troponin extraction steps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Analysis of proteins  
2.3.1 Determination of protein concentration 
2.3.1.1 Bradford assay 
 
 The Bradford assay was used to determine the concentration of the HMM preparation 
(Bradford, 1976). 100 µl of HMM was mixed thoroughly with 1 ml Bradford reagent 
(Sigma, B6916, UK) and was left to incubate at room temperature for 5 minutes. The 
absorbance of the solution was measured at 595 nm (Ultrospec III, Pharmacia LKB). 
A diagram of the basic troponin extraction steps is shown in blue. The method for the 
subunit exchange is shown in green and the phosphorylation/dephosphorylation in red.  
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The concentration of each HMM sample was calculated using a previously 
established calibration curve (see Figure 2-3).  
 
Figure 2-3: The calibration curve for the Bradford assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.1.2 The Lowry assay  
 
In order to determine the concentration of actin, tropomyosin and troponin the Lowry 
assay was used (Lowry et al., 1951). Lowry solution A was prepared which consisted 
of 48 parts of 2% Na2CO3, 1 part of 0.5 CuSO4, 1 part of 1% NaK titrate. 5, 10 and 
15 ml of the protein were made up to 500µl of NaOH, to which 5 ml of solution A 
was added. The mixture was vortexed and incubated at room temperature for 10 
minutes. Then, 500 µl of Lowry solution B (1 part Folin’ s solution reagent (VWR) to 
1 part of water) was added. The solution was vortexed thoroughly and was left to 
incubate for 30 minutes at room temperature. Finally the absorbance was measured at 
595 nm and the protein concentration was calculated using a previously established 
calibration curve.  
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2.3 Analysis of proteins 
2.3.1 Determination of protein concentration 
2.3.1.1 The Bradford assay 
The Bradford assay was used to determine the concentration of the HMM preparation 
(Bradford, 1976). 100µl of HMM was mixed thoroughly and incubated with 1ml of Bradford 
reagent (Sigma, B6916) for 5 minutes at room temperature. A blank was also incubated for 
the same time which consisted of 1ml of Bradford reagent. The absorbance of the solution 
was measured at 595nm on (Ultrospec III, Pharmacia LKB) after zeroing the 
spectrophotometer using the blank. The concentration was determined using the previously 
established calibration curve (see Figure 2.9).  
 
Figure 2.9: Calibration curve for the Bradfor  assay 
 
Bradford assay was calibrated using rabbit skeletal HMM. 
2.3.1.2 The Lowry assay 
The Bradford assay was a useful tool to determine protein concentration in solutions where 
the protein content was relatively high. The Lowry assay was used for solutions where the 
protein concentration was relatively low (Lowry et al., 1951), for example to determine the 
The calibration curve for Bradford assay that was calculated using skeletal HMM.  
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2.3.2 Sodium Dodecylsulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
 
2.3.2.1 Sample preparation  
 
Protein solutions were diluted 1:1 (v/v) with 2 x SDS sample buffer (125 mM Tris-
HCl, 10% SDS, 130 mM DTT, 0.05 bromophenol blue, pH 6.8). The samples were 
heated at 98°C for five minutes.  
2.3.2.2 Criterion TGX gels 
 
Two types of precast SDS gels were used in this study: Criterion TGX gel and Mini 
Protean TGX gels. Gradient Criterion TGX 4-15% (Biorad Laboratories, US) was run 
at 200 V for 40 minutes in standard Laemmli running buffer (25 mM Tris-Base, 192 
mM Glycine, 0.1% SDS) (Laemmli, 1970)  
2.3.2.3  Mini-Protean TGX gels 
 
Mini-Protean TGX 4-15% (Biorad Laboratories, US) were run at 200 V for 30 
minutes in standard Laemmli running buffer (25 mM Tris-Base, 192 mM Glycine, 
0.1% SDS) (Laemmli, 1970).  
2.3.2.4 Phosphate affinity SDS-PAGE 
 
Phosphate affinity SDS-PAGE is a technique used to separate proteins according to 
their phosphorylation status (Kinoshita et al., 2006). This technique has been used to 
investigate the phosphorylation of cardiac TnI in human heart by Messer et al (Messer 
et al., 2009) . 50 µM of Phos-tag conjugated moieties (NARD Institute, Hyogo, 
Japan) were added into the resolving gel of the polyacrylamide gel. The 
polyacrylamide gel consisted of 10% resolving (including Phos-tag) and 4% stacker 
polyacrylamide gel. The gel was run in 100 V for 90 minutes and then a Western blot 
was performed (See section 2.3.4)  
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2.3.3 Protein staining  
2.3.3.1 Protein staining with Coomassie blue  
 
Coomassie blue staining solution (800 ml) was made up by Mr O’Neal Copeland 
from 2 PhastGelTMBlue R tablets (GE Healthcare, 17-0518-01) dissolved in 60% 
methanol for 30 minutes and then diluted 1:1 with 20% acetic acid. Upon completion 
of electrophoresis the gel was immersed in fixing solution (50% methanol, 10% acetic 
acid) for 5 minutes with agitation at room temperature. The gel was then immersed in 
~100 ml Coomassie Blue staining solution for 15 minutes with agitation at room 
temperature. The gel was then destained by immersion in ‘destain solution’ (25% 
methanol, 8% acetic acid) with agitation for 30 minutes or until satisfactorily 
destained at room temperature.  
2.3.4 Western Blot  
 
Western blot was performed to measure the phosphorylation status of TnI by blotting 
the Phosphate affinity SDS-PAGE (See section 2.3.2.4) and incubating it using a 
primary antibody against TnI. Proteins were separated using Phosphate affinity SDS 
PAGE (see Section 2.3.2.4) and then they were transferred to a Nitrocellulose 
Transfer membrane (Trans-Blot, 0.2 µm Nitrocellulose, Bio-Rad, UK) using the 
Trans-Blot Turbo (Bio-Rad, UK) system for 7 minutes at 25 V, 1.3 mA. The 
membrane was then blocked in 10 ml of 20% Sea-block blocking buffer (Thermo 
Scientific, UK) in PBS-Tween (PBS, 0.1% Tween-20) for one hour at room 
temperature with agitation to prevent non-specific binding of the antibody to the 
membrane. It was then probed with the primary antibody, a cardiac TnI specific 
antibody (P4-14G5, Abcam, UK) that was diluted in 10 ml 20% Sea-block in PBS-
Tween (1:1000). The membrane was incubated with the antibody overnight at 4° C 
with agitation.  
The following day the membrane was briefly rinsed 3 times and then washed 3 times 
for 5 minutes agitating with PBS-Tween. The secondary antibody (anti- mouse IgG, 
horseradish peroxidase linked whole antibody, GE Healthcare, UK) was diluted in 10 
ml 20% Sea-block in PBS-Tween (1:10,000). The membrane was incubated with the 
secondary antibody for one hour at room temperature with agitation. It was then 
rinsed 3 times and then washed 3 times for 5 minutes agitating with PBS-Tween. The 
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proteins were visualised using ECL Prime Western Blotting Detection reagent (GE 
Healthcare, UK) and the chemiluminescence was detected by a camera based gel 
imager (G:BOX Chemi XT16, Syngene)  (Figure 2-4). 
Figure 2-4: Phosphate affinity SDS PAGE showing phosphorylated and 
dephosphorylated troponin 
  
 
 
 
 
 
2.3.4.1 Densitometric Analysis  
 
Digital images of gels and Western blots were visualised with a CCD camera based 
gel imager (G:BOX Chemi XT16, Syngene) and GeneSnap (version 7.05, Synoptics 
Ltd) software. Exposure time for gels stained with Coomassie Blue was 80 
milliseconds and for Western blots it was 10 and 30 seconds, then 1, 2 and 5 minutes. 
Protein bands were analysed by scanning densitometry using GeneTools software 
(version 4.00, Synoptics Ltd, Figure 2-5) (Messer et al., 2009, Copeland et al., 2010).  
 
 
 
 
Representative western blot of phosphate affinity SDS-PAGE showing phosphorylated 
and dephosphorylated troponin extracted from donor sample. On the left the 
dephosphorylated troponin is shown (treated with shrimp alkaline phosphatase) and 
phosphorylated troponin is shown on the right with the three different phosphorylation 
levels (P2, P1 and P0).  
 88 
Figure 2-5: Densitometric analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Sources of drugs and compounds 
2.4.1 Ca2+ sensitisers 
 
EMD 57033 was kindly donated by E Merck KGaA, Darmstadt. Bepridil was 
purchased from Sigma (Bepridil Hydrochloride, Sigma B5016, UK). Both were 
diluted in motility buffer A, and for later experiments in DMSO (3 mM stock for 
EMD57033, 10 mM stock for Bepridil) and stored at -20° C.  
2.4.2 Ca2+ desensitisers  
 
Epigallocatechin-3-gallate (EGCG) (Minimum 95%, E4143, Sigma, UK) and Silybin 
(Minimum 98%, S0417, Sigma, UK) were dissolved in DMSO (10 mM) and stored at 
-20° C.  
2.4.3 EGCG analogue compounds 
 
EGCG and Silybin-like compounds originally developed as HSP90 inhibitors were 
kindly donated by Dr Brian Blagg, University of Kansas (Khandelwal et al., 2013a, 
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Figure 2.8: GeneTools densitometric analysis screenshot 
 
Example of a GeneTools screenshot with the analysis of a troponin purification gel stained with Coomassie 
Blue. In detail is the analysis of the three troponin bands. 
 
 
 
 
2.5 In Vitro Motility As ay 
2.5.1 Buffers for IVMA 
The  basic  buffer  for  IVMA  is  ‘motility  buffer  A’  (50  mM  KCl,  25  mM  imidazole,  4  mM  
MgCl2, 1 mM EDTA, 5 mM DTT, pH 7.4). Alongsi e motility buffer A, motility buffers B, 
C & D are required for the IVMA. Buff  B consists of 4 ml of buffer A and 12 Pl of 22.5% 
BSA. Buffer C consisted of 425 Pl of cold distilled H2O, 26 Pl of catalase (Sigma, C3515) 
stock (26 mg/ml), 26 Pl of glucose oxidase (Sigma, G6641) stock (19 mg/ml), 20 Pl of 
glucose stock (100 mg/ml), 3 Pl of 22.5% BSA and 500 Pl of 1% methylcellulose dissolved 
in motility buffer 2A. Buffer D was almost identical but contained 415 Pl of distilled H2O 
and an addition of 10 Pl of 100 mM Mg2+-ATP.  
Analysis of the troponin complex stained in Coomassie blue is shown. The 
analysis of the three protein bands is shown on the bottom.  
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Zhao et al., 2011). Their details are summarised in Table 2-3. The compounds were 
diluted in DMSO to make 10 mM stock and then stored in -20° C for use.  
 
Table 2-3: EGCG and Silybin analogues 
 
 
 
 
 
  
Table of the EGCG or Silybin analogue compounds donated by Dr Brian Blagg, 
showing their molecular weight and the quantity given. N/A: Not applicable (not 
given). Compounds 1-28 are EGCG analogues. S1 and S2 are Silybin analogues.  
2.4.2 Ca2+ desensitisers  
!
Epigallocatechin-3-gallate (Minimum 95%, E4143, Sigma, UK) and Silibinin (Minimum 
98%, S0417, Sigma, UK) were dissolved in DMSO (10 mM) and stored at -20° C 
2.4.3 EGCG analogue compounds 
EGCG- like compounds were kindly donated by Dr Brian Blagg, University of Kansas (Table 
2.2). They were diluted in DMSO to make 10 mM stock and then stored in -20° C for use.  
!
Vial%No% Molecular%weight% Quantity%
1! 482.49! 7.9!mg!
2! 406.43! 4.0!mg!
3! 314.34! 4.8!mg!
4! 300.31! 6.5!mg!
5! 394.42! 3.0!mg!
6! 270.33! 15.1!mg!
7! 344.36! 5.7!mg!
8! 440.49! 4.4!mg!
9! 300.31! 2.8!mg!
10! 510.54! 1.1!mg!
11! 420.46! 4.7!mg!
12! 302.28! 1.4!mg!
13! 328.37! 5.6!mg!
14! 480.56! 5.6!mg!
15! 606.67! 12.1!mg!
16! 358.39! 3.1!mg!
17! 316.31! 2.6!mg!
19! 374.39! 4.7!mg!
20! 393.39! 7.1!mg!
21! 498.53! 1.2!mg!
22! 367.41! 3.9!mg!
23! 286.28! 1.7!mg!
24! 304.34! 4.5!mg!
26! 304.34! 2.1!mg!
27! 515.61! 13.7!mg!
28! 420.46! 2.0!mg!
S01! 480.43! N/A!
S02! 482.44! 5.7!mg!
 
!
 
 
Table!of!the!EGCG!analogue!or!silybinin!compounds!donated!by!Dr!Brian!Blagg,!
showing!their!molecular!weight!and!the!quantity!given.!N/A:!Not!applicable!
(not!given).!Compounds!1028!are!EGCG!analogues.!S1!and!S2!are!Silibinin!
analogues!
 90 
2.5 The in vitro motility assay (IVMA) 
2.5.1 Buffers for IVMA 
 
The main buffer for the in vitro motility assay (IVMA) is motility buffer A (50 mM 
KCl, 25 mM Imidazole, 4 mM MgCl2, 1 mM EDTA, 5 mM DTT, pH 7.4). Apart 
from motility buffer A, motility buffer B, C and D are required for IVMA. Motility 
buffer B consists of 4 ml of motility buffer A and 12 µl of 22% BSA (Albumin from 
bovine serum, Ultra pure, Sigma, A3675, UK). Buffer C consisted of 850 µl of cold 
dH2O, 52 µl catalase (26 mg/ml stock, Sigma, C3515, UK), 52 µl glucose oxidase 
(100 mg/ml stock, Sigma, G6641, UK), 40 µl glucose (stock 100 mg/ml), 6 µl of 22% 
BSA and 1 ml of 1% methylcellulose dissolved in 2 x motility buffer A. Buffer D was 
identical to buffer C with an additional 40 µl of 100 nM Mg+2-ATP.  
2.5.2 Fluorescent labelling of F-actin 
 
F-actin was labelled with TRITC-phalloidin to visualise the filaments. 36 µl of 33 
mM TRITC-phalloidin was added in 438 µl of motility buffer A and mixed by 
vortexing. 20 µl of 1 mg/ml of F-actin was then carefully added to the solution, and 
was gently mixed. The tube was then wrapped in aluminium foil and incubated 
overnight at 4°C. Labelled actin (φ actin) was always stored at 4°C and was stable for 
4 weeks.  
2.5.3 Affinity precipitation of HMM 
 
Affinity precipitation of HMM is required for the IVMA, in order to remove the 
“rigor heads” (Fraser and Marston, 1995a). These bind irreversibly to the myosin 
even in the absence of ATP and hence lead to a low fraction of filaments moving. To 
minimise the presence of “rigor heads”, HMM obtained from rabbit myosin (see 
Section 2.2.2) was treated with F-actin in the presence of ATP (Frazer and Marston, 
1995). 200 mg/ml of HMM were mixed with 150 mg/ml of F-actin and 1 mM Mg2+-
ATP in the presence of motility buffer A, total of 1,500 µl. The sample was incubated 
on ice for 10 minutes and then it was centrifuged at 337,000 x g (100,000 rpm, 
Sorvall MC-120SE, S100- AT6 rotor) for 20 minutes at 4°C to pellet F-actin with the 
associated rigor heads (Figure 2-6). The supernatant which represents the functional 
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HMM was collected and was stored at 4°C. The functional HMM was used within 6 
hours.  
 
Figure 2-6: Affinity precipitation of HMM 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.4 Preparation of the flow cells 
 
Flow cells were constructed using microscope slides (Sigma, S8400, UK) and 
coverslips (VWR, 630125, UK) that were put together using silicon grease (BDH, 
6380 2B, UK). Each motility flow cell consisted of two flow chambers. Prior to the 
formation of the motility chambers, the coverslips were first siliconised by immersing 
for 30 seconds with agitation in a solution containing 40 ml of chloroform (Sigma, 
496189) and 0.2 % dichloromethylsilane (Fluka, 39909, UK). The purpose of this 
process was to create clean coverslips with a hydrophobic surface to which HMM 
could adhere. Following the coverslip preparation, the microscope slides were placed 
with the frosted side up and were layered with three parallel longitudinal rows of 
silicon grease at the top, middle and bottom of the slide. 2-3 cm of copper wire was 
then placed on the top and bottom layer of grease. Finally, the siliconised coverslip 
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Figure 2.1: Schematic representation of the affinity precipitation of HMM 
 
ATP represented by yellow dots; ADP+Pi represented by 3/4 of a yellow dot; actin represented by orange lines; 
HMM in green. 
 
 
2.2.2 Preparation of F-actin 
2.2.2.1 Acetone Powder Preparation from Rabbit Skeletal Muscle 
To prepare skeletal muscle F-actin, skeletal muscle acetone powder was made by treating the 
pellet obtained from the initial myosin extraction (section 2.2.1.1) with a series of washes, 
before being dri d to form the acet e powder. This protocol is based on the methods of 
Straub (1942). In each step, the muscle residue was dispersed by manual homogenising and 
then filtered through a nylon mesh and squeezed to drain liquid. The weighed pellet was 
washed as follows: 
1) 10 volumes of cold dH2O for 5 minutes at 4° C, repeated twice. 
2) 4 volumes of 0.4% NaHCO3, for 45 minutes at room temperature with stirring. 
3) 2 volumes of 1 mM Tris-HCl pH 8.5, for 5 minutes at 4° C, repeated twice. 
Here is shown the affinity precipitation of HMM. Full yellow dots represent ATP. ¾ of 
a yellow dot represent ADP+Pi. The orange lines represent the actin and myosin is 
shown in green.  
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was placed on top of the slide, covering all the layers of the grease (Figure 2-7). The 
motility chambers were prepared at least one day before performing the IVMA 
experiment. All solutions and motility chambers were kept dry by storage in a 
desiccator cabinet (Nalgene, 5317-0120, UK). 
 
Figure 2-7: Construction of the flow cells 
 
 
 
 
 
 
 
 
 
2.5.5 Reconstitution of the thin filaments  
 
Stock solutions of 2 µM of troponin and tropomyosin were made in motility buffer A 
and kept on ice. Thin filaments were constructed by adding together all the 
components (troponin, tropomyosin and actin) at 10 fold of the required 
concentration. Drugs dissolved in motility buffer A or DMSO (See Section 2.4) were 
also added in the mix at the appropriate concentration (Table 2-4). The φ actin was 
added lastly, and the solution was carefully mixed. The proteins (± drug) were 
incubated at 4°C for 15 minutes before 10 fold dilution with motility buffer A and 
addition to the flow motility cell. Actin and actin/tropomyosin were also analysed by 
this method. 
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volume of each channel of the flow cell is approximately 50 Pl. Flow cells were prepared at 
least one day b fore they were used in the IVMA experiments. 
 
Figure 2.9: Construction of flow cell 
 
 
2.5.4 Reconstitution of Thin Filaments 
Stock solutions of 2 PM tropomyosin and troponin were made up with motility buffer A and 
kept on ice with the TRITC-ph lloidin labelled actin (I -actin). Thin filam nt solutions were 
prepared with the appropriate components added at ten-fold the required concentration for 
IVMA analysis. The motility buffer A was added first, followed by tropomyosin and 
troponin. This was thoroughly mixed before the I- actin was added and mixed. These were 
incubated at 4° C for 15 minutes before ten-fold dilution in motility buffer A immediately 
before being loaded into the flow cells. Actin (plain actin) and actin and tropomyosin (A-Tm) 
were also analysed by this method.  
2.5.5 Loading Protocol for Flow Cells  
The flow cell was set at an angle of 30° with the frosted end of the microscope slide at the 
zenith. The protocol for loading the flow cell is illustrated in Figure 2.10. Each step is 
The construction of a flow motility cell, consisting of two flow motility chambers. 
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Table 2-4: 10 x thin filament preparation for the IVMA 
 
 
 
  
 
 
 
 
 
 
 
 
2.5.6 Loading of the flow motility cell 
 
The flow cell was placed at an angle of 30° with the frosted side of the microscope 
slide facing upwards. Each of the components was added separately, in the order 
indicated, to the flow cell with a 30 second gap (see Figure 2-8).  In each chamber, 
the same components were added apart from the parameter examined. Firstly, 100 µl 
of the affinity precipitated HMM was added followed by 100 µl of motility buffer B. 
100 µl of the reconstituted thin filaments were added (See section 2.5.5) and lastly 50 
µl of buffers C and D were loaded.  
Buffers C and D contained the free radical scavenging system to prevent 
photobleaching and also methylcellulose to keep the filaments attached to the flow 
cell. BSA also was contained in buffers C and D to remove and minimise any non-
specific binding of the proteins. If complete thin filaments were being examined then 
buffers C and D also contained Ca2+-EGTA buffer (see Section 2.5.7) and troponin (± 
drugs). The troponin and drug concentrations added in buffers C and D were the same 
as the concentration of 10 fold thin filament incubation (60 nM troponin for all the 
experimental setups, see Table 2-5). The incubation was diluted 10 fold by adding 5 
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µl of the incubation to 40 µl of buffers C or D. 5 µl of the EGTA- Ca2+ buffers were 
also added (see Table 2-6).  
 
Figure 2-8: Flow motility assay protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-5: 10 x troponin preparation for Buffers C and D 
 
 
  
 
 
100#µl#HMM###
100#µl#buﬀer#B###
100#µl#of#φ#ac3n±#
associated#thin#
ﬁlaments#±#drugs####
Pre?incubate#10#x#
Ac3n?Tm#or#Ac3n?
Tm?Tn#±#drugs#for#
15#min#
50#µl#buﬀer#C#or#40#
µl#buﬀer#C+#5#µl#
troponin#±#drugs#+#
5#µl#Ca2+?EGCTA#
buﬀer#
50#µl#buﬀer#C#or#40#
µl#buﬀer#C+#5#µl#
troponin#±#drugs#+#
5#µl#Ca2+?EGCTA#
buﬀer#
Visualisa3on#
This figure shows all the steps of the IVMA protocol including a small description of each 
step. 
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2.5.7 Preparation of Ca2+- EGTA buffers 
 
Different Ca2+ concentrations were incorporated into the IVMA by the addition of 
Ca2+-EGTA buffers into IVMA buffers C & D as previously stated. Ca2+-EGTA 
buffers were prepared as described in the method of McGuigan et al (McGuigan et al., 
1991). Buffers of different Ca2+ concentrations were made by mixing an EGTA buffer 
(50 mM KCl, 25 mM Imidazole pH 7.4, 50 mM EGTA, 1 mM EDTA, 4 mM MgCl2, 
95 mM KOH, 1.43 mM HCl, 8mM NaCl, pH adjusted using concentrated HCl) and a 
Ca2+-EGTA buffer (50 mM KCl, 25 mM Imidazole pH 7.4, 50 mM EGTA, 50 mM 
CaCl2, 1 mM EDTA, 4 mM MgCl2, 8 mM NaCl, pH adjusted using 1M KOH) at 
appropriate ratios to obtain Ca2+-EGTA buffers ranging from 1 nM to 3.9 µM. The 
free Ca2+ concentration values were determined using the Maxchelator computer 
programme.  
Table 2-6: The Ca2+- EGTA Buffers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
119 
 
2.5.6 Preparation of Ca2+ -EGTA Buffers  
Ca2+ concentrations were varied by the incorporation of Ca2+-EGTA buffers into IVMA 
buffers C & D as previously stated. Ca2+-EGTA buffers were prepared by adapting the 
method of McGuigan et al. (1991). Buffers of different [Ca2+] were made by mixing an 
EGTA buffer (50 mM KCl, 25 mM Imidazole pH 7.4, 50 mM EGTA, 1 mM EDTA, 4 mM 
MgCl2, 95 mM KOH, 1.43 mM HCl, 8mM NaCl, pH adjusted using concentrated HCl) and a 
Ca-EGTA buffer (50 mM KCl, 25 mM Imidazole pH 7.4, 50 mM EGTA, 50 mM CaCl2, 1 
mM EDTA, 4 mM MgCl2, 8 mM NaCl, pH adjusted using 1M KOH) at appropriate ratios to 
obtain Ca-EGTA buffers  ranging  from  1  nM  to  3.9  μM.    The  free  [Ca2+] values were 
determined using the Maxchelator computer programme (see Table 2.5).  
 
Table 2.5: Preparation of the Ca2+-EGTA buffers 
 
 
 
Solution 
Name 
Volume of 
50mM 
EGTA 
buffer 
added (ml) 
Volume of 
50mM 
Ca/EGTA 
buffer added 
(ml) 
Ratio pCa Free [Ca2+] 
A 47 0.5 94/1 9.00 1.00 x 10-9 
C 40 4 10/1 8.14 7.24 x 10-9 
D 40 10 4/1 7.74 1.82 x 10-8 
E 30 15 2/1 7.43 3.72 x 10-8 
F 25 17.5 1/0.7 7.24 5.75 x 10-8 
G 25 25 1/1 7.13 7.41 x 10-8 
H 20 30 1/1.5 6.95 1.12 x 10-7 
I 15 30 1/2 6.84 1.45 x 10-7 
J 10 30 1/3 6.64 2.29 x 10-7 
K 10 40 1/4 6.52 3.02 x 10-7 
L 8 40 1/5 6.42 3.80 x 10-7 
M 7 42 1/6 6.34 4.57 x 10-7 
N 6 42 1/7 6.28 5.25 x 10-7 
P 5 40 1/8 6.23 5.89 x 10-7 
Q 5 45 1/9 6.18 6.61 x 10-7 
R 2 40 1/20 5.88 1.32 x 10-6 
S 1.5 45 1/30 5.75 1.79 x 10-6 
T 0 50 -/1 5.43 3.9  x 10-6 
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2.5.8 Experimental strategy  
 
The IVMA was used to investigate the effects of different compounds on the Ca2+ 
regulation of donor and mutant reconstituted thin filaments. As mentioned previously, 
thin filaments were engineered using proteins of different origin.  
The first step of the IVMA was to make sure that the assay was functioning properly. 
For this reason, plain actin was first loaded into the flow cell to confirm the presence 
of thin filaments and also their motility. The experiments were automatically tracked 
(see Section 2.5.10.1) and the motility parameters were analysed. The normal sliding 
speed of the filaments was 2.8–3 µm/sec and the fraction motile was 70-90%. If these 
criteria were met, then we could proceed to the next step. On the occasion that this 
was not the case, this could have been because either the HMM, the flow cells, the φ 
actin or the buffers were faulty. To identify the faulty reagent, every component was 
replaced in turn. The next control experiment was to test actin with tropomyosin (A-
Tm), using 60 nM as tropomyosin concentration. Usually, one motility chamber 
consisted of plain actin and the other one with actin-tropomyosin. A slight increase in 
both sliding speed and percentage motility was observed with the addition of 
tropomyosin compared with plain actin, possibly due to better co-operativity of the 
system. In the case of skeletal mutant tropomyosin experiments, the second flow cell 
consisted of actin with wild type tropomyosin (A-TmWT) on one motility chamber 
and actin with mutant tropomyosin (A-TmMut) on the other motility chamber. Actin 
and tropomyosin are not Ca2+ regulated proteins, thus 50 µl of buffer C and D 
(without troponin/Ca2+-EGTA buffers) was added as the last component on the flow 
cell.  
After all the controls were performed ensuring that the IVMA was functioning 
adequately, reconstituted thin filaments with actin, tropomyosin and troponin 
mixtures were used for the completion of the experiment. The troponin concentration 
used for the study was 60 nM. Two experimental designs were carried out in this 
study: constructions of Ca2+ activation curves, where filaments were compared over a 
range of Ca2+ concentrations, and dose response curves, where different 
concentrations of the drug were compared using a single Ca2+ concentration. In the 
case of Ca2+ activation curves, 4-8 points were selected between 1 nM- 3.9 µM Ca2+ 
and a Ca2+ concentration curve could then be plotted by fitting the Hill equation on 
the data obtained (see Section 2.5.10.2). For the dose response curves, a single Ca2+ 
 97 
concentration was chosen according to the concentration that gave the biggest 
difference in the motile parameters on the Ca2+ curve. That was usually 0.0037 µM 
Ca2+ (Ca2+- EGTA buffer E) or 0.0074 µM Ca2+ (Ca2+- EGTA buffer G). More details 
about the dose response curves can be found in the appropriate chapters. The Hill 
equation was fitted to the data obtained. From the Hill equations, two important 
parameters can be obtained: The EC50 value, which is the value at which 50 % of the 
filaments were activated, and the Hill coefficient, which relates to the steepness of the 
fitted curve.  
2.5.9 Recording Apparatus  
 
The movement of thin filament over the immobilized bed of HMM was visualised by 
translocation of the fluorescently labelled actin. The microscope and recording 
apparatus was setup as illustrated in Figure 2-9. 
Figure 2-9: Recording apparatus 
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Figure 2.11: Schematic diagram of the visualisation and recording apparatus 
 
Recording apparatus of the IVMA showing the microscope, the thin filaments on the TV 
monitor from the live image and the computer monitor showing the analysis of the 
motility of the filaments.  
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The flow cell was placed in the metal temperature control chamber on the stage of the 
Zeiss Axiolab microscope, with a Zeiss 63x / 1.40 NA Plan Apochromat objective 
lens (44 07 60- 03) fitted with an epifluorescence illuminator (Zeiss, 39 26 42-9901) 
containing a 50 W mercury high pressure arc lamp (Osram, HBO 50W/3) and a 
rhodamine compatible filter set (Chrome technology, emission: HQ 595-50, 
excitation: D539-25, dichroic: 565-DRLP special). The microscope was connected 
through a C-mount (45 61 05), to a highly sensitive video camera (Hamamatsu 
C2400), which in turn was linked through a Time Base Corrector (DEC100) to both a 
television monitor and a Macintosh G4. A drop of immersion oil, type A (Cargille 
laboratories, 16482) was placed on the coverslip of the flow cell and the image of the 
fluorescently labelled actin filaments were brought into focus on the television screen. 
2.5.9.1 Temperature Control of the IVMA  
 
The temperature was controlled using a Bionomic Controller BC-100 (20/20 
Technology Inc.) This controller sets and maintains the temperature of a metal heating 
platform onto which a flow cell is placed. All IVMA experiments were completed at 
28°C. To obtain this temperature in the motility chamber, the temperature was set to 
30°C.  
2.5.9.2 Analysis of Filament Movement  
 
To complete quantitative analysis of filament movement, bespoke computer software 
had been designed and provided by ME Electronics (Reading, UK) for use on a 
Macintosh computer with Operating System 9 (Marston et al., 1996). The name of the 
software package was ‘Filament Tracker 2.0.3’. This was run using LabVIEW-3.1.1 
run-Time image analysis application (National Instruments Corp.). The software 
completes two tasks: the first was to digitise a series of filament images; the second 
was the image analysis function. This determines the movement of each filament by 
comparing sequential images. 
2.5.9.3 Acquisition of a Sequence of Images  
 
To record images using Filament Tracker 2.0.3 the following command sequence was 
followed (see Figure 2-10). The first step was to select the ‘Acquire Sequence’ in the 
tracking panel (Figure 2-10 A). Next the ‘Capture Setup’ was selected (Figure 2-10 
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B). This would open the ‘Capture Setup’ screen where the live image from the 
microscope could be viewed in the image window. Also displayed were four 
parameters that could be adjusted for optimal image acquisition, including ‘contrast’ 
and ‘brightness’, which along could be adjusted to improve the quality of the image. 
The number of images acquired and the time interval between image acquisitions 
could also be adjusted. The setting for the number of images acquired depended on 
the density of the filaments in the microscope field. The aim was to record 250-500 
filament vectors, which usually meant 10-16 images were acquired (Marston et al., 
1996) 
Figure 2-10: Image acquisition 
 
 
 
 
 
 
 
 
 
 
The time interval was dependent on filament sliding speed, and was set to allow 
filaments to move 1.6-1.8 µm between image acquisitions The distance had 
previously been determined to facilitate the most accurate results from the tracker 
software (Marston et al., 1996). A calibration curve for filament velocity and frame 
interval is shown below (Figure 2-11). Once set, time intervals were kept constant 
during a set of measurements. 
2.5.10 Analysis of Filament Movement 
2.5.10.1 Automatic Filament Tracking  
 
Image files of filament movement were analysed using the automatic-tracking 
segment of the tracker program. Auto tracking was selected from the main ‘Filament 
tracker’ panel, from there the desired set of images were loaded. In the ‘Pre-process’ 
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2.5.9.3 Acquisition of a Sequence of Images 
To record images using the Filament Tracker 2.0.3 the following command sequence was 
followed (see Figure 2.12).  The  first  step  was  to  select  the  ‘Acquire  Sequence’  in  the  tracking  
panel (Figure 2.12 A).  Next  the  ‘Capture  Set-up’  was  selected  (Figure 2.12 B). This would 
open  the  ‘Capture  Setup’  screen  where  the  live  image  from  the  microscope  could  be  viewed  
in the image window. Also displayed were four parameters that could be adjusted for optimal 
image  acquisition.  Two  of  these  parameters  were  the  ‘contrast’  and  ‘brightness’,  which  along  
with setting on the microscope and camera could be adjusted to improve the quality of the 
im ge. The number of images acquired and the tim  interval between image acquisition could 
also be adjusted. The setting for the number of images acquired depended on the density of 
the filaments in the microscope field. The aim was to record 250-500 filament vectors which 
usually meant 10-16 i age  were acquired (Marston et al., 1996). 
 
Figure 2.12: Sequential flow diagram of the process of image acquisition 
 
 
The time interval was dependant on filament sliding speed, and was set to allow filaments to 
move 1.6-1.8 Pm between image acquisitions The distance had previously been determined 
to facilitate the most accurate results from the tracker software (Marston et al., 1996). A 
A B C 
The process of how to acquire the IVMA data is shown, with the image of the filaments 
as a final step. 
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panel filaments that fulfilled the set criteria were displayed and highlighted as green 
objects on the original black and white image. Selection of the ‘Change Settings’ 
command allowed the adjustment of the movement analysis parameters. The 
maximum velocity cut-off was set at 8 µm/s, which is 2.5x mean velocity based on 
prior experiments in this configuration (Bayliss, 2012). Finally, the selection 
sensitivity was set to discriminate objects from noise. When these settings had been 
optimised, the ‘Extract Velocities’ command was selected (Figure 2-11 A) 
As the tracking progresses two images are superimposed over each other on a screen 
similar to the live image screen. In the first image the filaments are coloured green 
and in the second the filaments are coloured red (Figure 2-11 B). Therefore any 
filaments present in the same position in both images will appear yellow. The 
program searches for the centroid in the second image nearest the centroid in the first 
image for each object. We select short filaments and use low filament density to avoid 
tracking mistakes. White lines connecting two filaments represent the vectors of 
filament movement. 
After sequential tracking of all of the images is complete, a histogram will appear 
(Figure 2-11 C). On the left hand side three parameters to further optimise tracking 
can be set: the number of bins (e.g. size of velocity channels), maximum velocity and 
the velocity, which defines the threshold between non-motile and motile filaments. 
This velocity is a visually selected value deemed to separate motile and non-motile 
fractions, since quantitative analysis has shown that curve-fitting produces the same 
result as direct observation (Marston et al., 1996). Even at low Ca2+ or ATP 
concentrations, not all the filaments will remain static. One weakness of the tracker 
program is that it cannot distinguish between linear movement and oscillatory 
movement around a fixed point. Some filaments may move with a Brownian motion 
and other filaments may ‘wobble’ if only in the ‘weak’ binding state with myosin. By 
reviewing the results from a set of thin filaments in a high Ca2+ concentration in the 
presence of ATP, a value for this threshold is selected. For consistency, this value 
must remain constant for the entire data set. This was normally set at 1 µm/s. 
The calculated parameters: (filament density, motile fraction, motile velocity, 
standard deviation of velocities and velocities measures) are displayed on the right 
hand side. These values are manually recorded and linked to the experiment they 
represent. It was assumed the sliding speeds were distributed as a single Gaussian 
distribution, based on the initial setup of this system (Marston et al., 1996), Thus 
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mean values and standard deviation were calculated by the software. If the standard 
deviation was > 0.4 X mean sliding speed this data was discarded. 
Figure 2-11: Automatic filament tracking 
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Figure 2.15: Sequential flow diagram of automatic filament tracking 
 
 
In the foreground of panel A) Filaments are coloured green, B) two sets are overlayed showing filaments from 
the first (sequential) acquisition (green), filaments from the second acquisition (red), those that have not moved 
are therefore coloured yellow. Panel C shows an example of the final histogram. 
A
B
A 
B 
C 
This figure shows the automatic tracking of th  actin filaments. In A) filaments are 
shown in green. In B) filaments from the first image acquisition (green) are overlaid 
with filaments from the second image acquisition image acquisition (red); therefore, 
filaments that have not moved are yellow. In C) the histogram resulted from all the 
images is shown.   
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2.5.10.2 Construction of Ca2+ curves 
 
To produce a Ca2+ titration curve, measurements were completed on the same 
incubation of thin filaments (actin-Tm-Tn) over a range of concentrations from 1 nM 
to 3.9 µM. For the dose response, a single Ca2+ concentration was used with different 
incubations of thin filaments (actin-Tm-Tn± drugs).  
In the case of Ca2+ titration curve, histograms from measurements at the different Ca2+ 
concentration were taken. As an example, in Figure 2-12 histograms taken in 8 
different Ca2+ concentrations is shown. This demonstrates how the fraction of 
filaments moving and the sliding speed increases with the increase in Ca2+ 
concentration and how this is measured by the tracker software. In the case of the 
dose response curve, histograms were taken from measurements where the same Ca2+ 
concentration was used, but different incubations (concentration of the drug was the 
variable).  
It should be noted that for the experiments in this thesis four measurements were 
completed at each point (at each Ca2+ or drug concentration); therefore there are four 
histograms per point from areas of the flow cell chosen at random. In order to 
eliminate the effect of time in the motility of the filaments, two images were recorded 
first from one chamber of the motility flow motility cell, then all four images were 
recorded from the second motility chamber and lastly the remaining two images were 
recorded from the first chamber, so that four images per chamber are recorded. Data 
from obviously defective areas (low or zero motility, usually occurred when bubbles 
were incorporated into the flow motility cell) were discarded. The mean fraction 
motile values from these measurements were then plotted and fitted with the 4-
parameter Hill equation using KaleidaGraph  (Synergy Software, version 4.5). In 
some cases m1 and/or m2 were fixed at reasonable values to obtain a 3 or 2-parameter 
fit. A sample of a Ca2+ activation curve and its fitted equation are shown in Figure 
2-13. Two parameters were obtained by fitting the Hill equation to the data: the EC50 
that was used as a measure of thin filament Ca2+-sensitivity and the Hill co-efficient 
(nH), which is an indicator of co-operativity.  
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Hill equation: 
! = !!!!(!!!!! !!!)!!!!!!!!!   
 
Figure 2-12: Histograms from the tracking software to construct the Ca2+ activation 
curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
2.5.10.4 Production and Statistical Analysis of a Ca2+-concentration Titration 
 
Figure 2.16: Multiple histograms are used to build a Ca2+-concentration titration curve 
 
37.2 nM 
145 nM 
380 nM 
3.72 PM 525 nM 
229 nM 
74.1 nM 
1 nM 
Histogram produced at different Ca2+ concentrations (1 nM, 74.1 nM, 229 nM 
and 525 nM) from the tracker program is shown. Using these data, a Ca2+ 
titration curve can be produced (see Figure 2-13).  
m1#= min value m2#= max - min value m3#= nH m4#= EC50 
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Figure 2-13: Ca2+ activation curves of thin filaments reconstituted from proteins 
extracted from donor samples 
 
 
2.5.11 Statistical analysis  
 
Mean data values are shown alongside standard deviation of the mean unless 
otherwise stated. Extensive measurements by Dr Messer have established that this is 
true for the IVMA system used here (Messer et al., 2007). Considering 39 paired 
measurements of EC50 in donor and failing hearts using the same methods as in this 
thesis, it was shown that the distribution of the data produced was normal, see Figure 
2-14. 
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the same motility chamber. The Hill equation for percentage motility and motile velocity 
was fitted to the data and is shown under the Ca2+ activation curves. m1 represents the min 
value, m2 represents the max-min vale, m3 represents the Hill coefficient (nH) and m4 the 
EC50.  
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Figure 2-14: Distribution of the EC50 ratios Donor/Failing troponin 
 
 
 
 
 
 
 
 
 
 
 
 
For this reason, data was compared for statistical significance using the Student t-test 
where p < 0.05 was classed as significant. The Student t-test is the best method for 
significance tests on small populations, such as in this thesis (< 10 replicates) 
provided the distribution of the EC50 parameter is normal (Messer, 2007). 
Furthermore, 2- way ANOVA (Turkey correction) was also performed to see the 
combined phosphorylation status and response to treatment. 2-way ANOVA required 
equal numbers of samples for each treatment and this has meant some data is 
excluded from the analysis where the n value of some datasets was not equal.  
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both of these would have been acceptable (Walker et al., 2010). Mean data values are shown 
alongside standard deviation of the mean unless otherwise stated. Data was compared for 
statistical significance using the Student t-test where p < 0.05 was classed as significant. The 
Student t-test is the best method for significance tests on small populations, such as in this 
thesis (< 10 replicates) provided the distribution of the EC50 parameter is normal.  
 
Figure 2.17: Normal distribution of the EC50 ratio of donor / failing heart troponin 
 
 
 
The extensive measurements by Dr. Messer have established that this is true for the IVMA 
system used here (Messer et al., 2007). He considered 39 paired measurements of EC50 in 
donor and failing hearts using the same methods as in this thesis. It showed that the 
Distribution of EC50 donor/failing ratio shows that data are normally distributed.  
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3 Mutations in tropomyosin that cause gain of function in 
skeletal muscle myopathy patients 
 
3.1 Introduction 
 
As an introduction to the in vitro motility assay (IVMA) and to the proteins of the 
human myocyte, firstly I looked at tropomyosin mutations that lead to skeletal muscle 
myopathies. This helped me understand about the molecular mechanism of 
myopathies and structure-function relationships of protein mutations that lead to 
diseases, building on previous studies in the Marston lab. Tropomyosin mutations are 
commonly found in patients with congenital myopathies (Memo and Marston, 2013). 
There are many types of skeletal muscle myopathies, such as Nemaline myopathy, 
Cap disease and fibre type disproportion. Nemaline myopathy is the most widely 
studied of the skeletal myopathies and is characterized by nemaline (rod) bodies in the 
myocytes. Congenital myopathies can also be found in the form of cap-like structures 
at the periphery of the muscle (Cap disease) and congenital fibre-type disproportion 
(CFTD) with a pronounced hypertrophy of Type 1 skeletal muscle fibres. Histology 
of the different congenital myopathies can be found more detailed in APPENDIX. 
The diseases have different clinical and histological characteristics but they all result 
in muscle weakness and are caused by mutations in skeletal muscle proteins. For 
example, mutations in these diseases are found in TPM2, TPM3 and ACTC.  
Mutations in different positions in ACTA1 have been extensively studied in order to 
establish a mechanism in the single myofilament level that would be responsible for 
the diseases, however it was not possible to find such mechanism (Feng and Marston, 
2009).  
On the other hand, looking at mutations in specific positions helped us elucidate a 
common mechanism for mutations found in these positions. More specifically, 
mutations at the interface where tropomyosin interacts with actin are of particular 
importance. Starting with actin, the mutation K326N in ACTA1 found in a patient 
with stiff muscle showed an increase Ca2+ sensitivity which was associated with a 
hypercontractile phenotype in the patient (Jain et al., 2012). K326N mutation in actin 
is found close to one site of interaction with tropomyosin (Li et al., 2011).  
Studying tropomyosin mutations is easier due to tropomyosin’s simple structure. 
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Thus, mutations in tropomyosin could potentially help us identify a mechanism at the 
molecular level that is responsible for the onset of skeletal myopathies.   
So far, 27 mutations have been found in TPM2 gene and 22 mutations have been 
found in TPM3 gene (Marston et al., 2013, Marttila et al., 2014).  
The first tropomyosin mutation studied at the molecular level was TPM2 R91G and 
showed a hypercontractile function (Robinson et al., 2007). Another mutation that 
results in hypercontractile phenotype is a deletion on K7 residue in Tpm2.2 (ΔΚ7), 
which is a common mutation in patients with skeletal muscle myopathies (Davidson 
et al., 2013). This mutation has been found in nine families and clinical investigations 
found the presence of nemaline bodies as a common feature of patients with this 
mutation. Studies from skinned muscle isolated from patient biopsies and also in vitro 
motility studies showed that the mutation leads to an increased Ca2+ sensitivity, cross-
bridge kinetics and force, which is linked with the presence of a hypercontractile 
phenotype of the patients (Mokbel et al., 2013).  
Interestingly, this mutation is found near another site where tropomyosin interacts 
with actin. A high resolution structure of Tpm1.1 interacting with actin has been 
published, showing the interactions between tropomyosin and actin (Li et al., 2011). 
Li et al defined the interfaces between actin and tropomyosin using a combination of 
cryo-electron microscopy (cryo-EM) and computational simulations. The actin 
residues that appear to make contacts with tropomyosin include the basic amino acids 
Lys326, Lys328 and Arg147, the acidic amino acids Asp25 and Arg28 and the 
hydrophobic Pro333 (Figure 3-1A). Tropomyosin itself has a repeating amino acid 
motif in the 7 positions where it interacts with the actin molecules. These conserved 
seven amino acids are K6, K48, R90, K128, R167, K205 and R244 and interact with 
Asp25 on actin. Four of these share the same motif, with two basic amino acids next 
to each other: K6- K7, K48-K49, R90-R91 and R167-R168. 
 Figure 3-1 shows the structural motif of tropomyosin and its interaction with actin. 
This new structure could provide a molecular explanation of how mutations in 
tropomyosin would lead to diseases. Mutations in the second amino acid of all the 
four motifs have been reported in skeletal myopathies (Marston et al., 2013) and ∆K7 
and R91G are already known to be hypercontractile. In this chapter I will look at the 
mutations found in the actin-tropomyosin interface and propose a mechanism of how 
these mutations lead to diseases. The starting point of this study is that the loss of K7 
residue that, as explained, leads to a gain of function and is positioned adjacent to the 
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K6 residue, which interacts with Asp25 on actin. We therefore hypothesize that the 
mutations might destabilize the inhibitory action of tropomyosin to actin (the “off” 
state) leading to hypercontractility. Taking advantage of tropomyosin’s conserved 
structural motif at the sites of interaction with actin it would be interesting to see if 
other mutations found at these sites give a similar phenotype. I therefore predict that 
the mutations that are found in one of these conserved amino acids in Tpm2.2 and 
Tpm3.12 that interact with Asp25 would cause a gain of function like ΔΚ7. Mutations 
in acidic residues of tropomyosin where it interacts with Lys326 of actin have also 
been found (∆E139, E181K, ∆E218, ∆E224), so we predict mutations found in these 
amino acids would also lead to gain of function. It was discovered that some of the 
mutations that lead to skeletal myopathies are associated with a hypercontractile 
phenotype, thus being “gain of function” mutations. The hypercontractile phenotype 
indicates that mutations cause abnormalities in the contractile apparatus of the 
myocyte that influence the force production of the muscle.  
Figure 3-1: Tropomyosin- actin interactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Actin subunit showing the residues whereby it interacts with tropomyosin. Basic amino 
acids are coloured blue, acidic amino acids are coloured red and proline is pink (Li et al., 
2011). B) Surface model of tropomyosin  (blue) interacting with actin (grey). Actin Asp25 
is red and Lys326 is orange. C) Sequence Tpm2.2 divided in 7 periods. The purple circles 
represent the residues interacting with Asp25. The orange and red circles represent residues 
interacting with actin R147, K326 and K328.  The blue boxes represent β tropomyosin 
mutations and green boxes represent Tpm3.12 mutations. The mutations predicted to be 
gain of function are written in red and those predicted to be loss of function in black 
(Marston et al., 2013) 
 109 
3.2 Tropomyosin mutations in TPM2 and TPM3 that cause gain of 
function  
 
In this chapter, four mutations Tpm2.2 or Tpm3.12 predicted to cause gain of function 
based on their position relative to actin were studied. The mutations are the following: 
∆K49, ∆E139, R91G in Tpm2.2 and K168E in Tpm3.12. These mutations are found 
in the second amino acid of the motif where tropomyosin binds to actin and as ∆K7 
was found to be gain of function mutation, they are predicted to be gain of function 
too.   
∆K49 is associated with cap disease and has been found in one patient who had 
muscle weakness at the age of 8 with healthy relatives. Biopsies taken from the 
patient showed cap-like structures (Ohlsson et al., 2008). ∆E139 is also associated 
with cap disease and it was actually the first mutation in TPM3 known to be causative 
for the disease. The mutation was found on a patient diagnosed at age 11 with muscle 
weakness, hypotonia and who presented cap-like structures in Type 1 and Type 2 
fibres (Lehtokari et al., 2007). R91G is known to cause distal arthrogryposis and in 
vitro investigation showed that this mutation increased ATPase activity and caused 
incomplete relaxation (Robinson et al., 2007).  
TPM3 mutation K168E is linked to CFTD and was found in one family whose 
members were affected by this disease by Clarke et al (Clarke et al., 2008). The 
patient carrying the mutation was diagnosed at 4 years of age. All of these mutations 
are, like ∆K7, closely positioned to the place where tropomyosin interacts with actin 
and the location of these mutations can be found in Figure 3-2. 
Mutations in basic or acidic pairs in Tpm2.2 and Tpm3.12 lead to a charge reversal or 
loss placed one amino acid downstream of the site of interaction with Asp25 or K326 
on actin. In this chapter, the molecular mechanism of these mutations using the IVMA 
will be investigated, to elucidate whether all the mutations lead to a gain of function, 
as the structural model predict.  
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Figure 3-2: Location of TPM2 and TPM3 mutations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.1 In vitro motility analysis of TPM2 and TPM3 mutations  
 
Thin filaments were reconstituted using 60 nM skeletal troponin, 60 nM wild type 
(WT) or mutant tropomyosin that was produced by the providers using 
baculovirus/sf9 cells with native post translational modifications including N terminal 
acetylation and 10 nM rabbit skeletal actin. Each mutation was tested for both 100% 
and 50% reconstitution. Because the mutations are not expressed 100 % in vivo, thin 
The locations of the predicted gain of function mutations in relationship to Asp25 
(red) or Lys326 (blue) on actin. Actin is shown in shown in grey and tropomyosin is 
shown in blue or light blue. The residues in tropomyosin that interact with Asp25 on 
actin are indicated in purple and yellow and the residues interacting with Lys326 are 
indicated in orange. A) Tm K6-K7 B) Tm K48-K49 C) Tm R90-R91 D) Tm R167-
K168) E) Tm E139 with K326 on actin. 
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filaments reconstituted with 50% of the mutation might represent the physiological 
situation better. Three Ca2+ activation curves were performed for the 50% of each of 
the mutations and one for the 100% for the mutations. Figure 3-3, Figure 3-4, Figure 
3-5 and Figure 3-6 show representative Ca2+ activation curves for ∆K49 TPM2, R91G 
TPM2, ∆E139 TPM2 and K168E TPM3 mutations respectively. Data were combined 
with previous measurements from Dr Massimiliano Memo and Dr Andrew Messer 
and are summarised in Table 3-1. Interestingly, all the mutations showed an increase 
in Ca2+ sensitivity, as shown by the decrease in EC50, which is in line with the “gain 
of function” prediction. The motile velocities were not different between wild type 
(WT) and mutant thin filaments and there was no difference in the results between 
50% and 100% mutant thin filaments. Thus even the partial replacement of 
tropomyosin as occurs in vivo is likely to provoke the maximal abnormality in 
function.  
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Figure 3-3: Ca2+ activation curves for percentage motility and motile velocity of thin 
filaments reconstituted with ∆K49 mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative Ca2+ titration curves for motile velocity and percentage motility for thin 
filaments reconstituted with A) 100 % ∆K49 tropomyosin vs WT tropomyosin and B) 50% 
∆K49 tropomyosin vs WT tropomyosin. WT tropomyosin in blue and mutant tropomyosin in 
red.  
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Figure 3-4: Ca2+ activation curves for percentage motility and motile velocity of thin 
filaments reconstituted with R91G mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative Ca2+ titration curves for motile velocity and percentage motility for thin 
filaments reconstituted with A) 100 % R91G tropomyosin v WT tropomyosin and B) 50% 
R91G tropomyosin vs WT tropomyosin. WT tropomyosin in blue and mutant tropomyosin 
in red.  
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Figure 3-5: Ca2+ activation curves for motile velocity and percentage motility of thin 
filaments reconstituted with K168E mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative Ca2+ titration curves for motile velocity and percentage motility for thin 
filaments reconstituted with A) 100 % K168E tropomyosin v WT tropomyosin and B) 50% 
K168E tropomyosin vs WT tropomyosin. WT tropomyosin in blue and mutant tropomyosin 
in red.  
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Figure 3-6: Ca2+ activation curves for motile velocity and percentage motility of thin 
filaments reconstituted with ∆E139 mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative Ca2+ titration curves for motile velocity and percentage motility for thin 
filaments reconstituted with A) 100 % ∆E139 tropomyosin vs WT tropomyosin and B) 50% 
∆E139 tropomyosin vs WT tropomyosin. WT tropomyosin in blue and mutant tropomyosin 
in red.  
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Table 3-1: Summary of tropomyosin mutations in TPM2 and TPM3 which give gain 
of function 
 
 
 
 
 
 
 
 
 
 
 
3.3 Tropomyosin mutations in TPM3 that cause a loss of function 
 
Two tropomyosin mutations that are in the exact amino acid where tropomyosin 
interacts with actin rather than one amino acid downstream were examined. R167H 
and R244G in Tpm3.12 are found in the amino acid directly interacting with Asp25. 
R167H has been identified in a large study by Clarke et al, where they screened 23 
unrelated individuals affected with CFTD (Clarke et al, 2008). Position R167 in 
TPM3 is a hotspot for mutations, as multiple mutations in this position linked with 
skeletal muscle myopathies have been found, such as R167C linked to CFTD and Cap 
disease (Ohlsson et al., 2009) and R167H. R244G in TPM3 was another mutation 
identified in the study of Clarke et al and has been one of the mutations that cause 
CFTD. R244G is found in Tpm3.12 at the position where tropomyosin directly 
interacts with actin. It is noted that Tpm3.12 numbering is based on the native protein 
and is one less than the numbering based on the DNA sequence.  
 
 
Data were combined from experiments performed by Dr Massimiliano Memo, Dr 
Andrew Messer and myself. EC50 values were combined for percentage motility and 
motile velocity Ca2+ activation curves. **p<0.01, ***p<0.001 for single value t test 
compared to one. In brackets the n number.  
Muta%on( EC50(Mut,(µM( EC50(WT,(µM( Ra%o(EC50(WT/Mut( Max(sliding(speed(
rela%ve(to(WT,(%(
∆K49(100%( 0.04$±$0.002$(6)$ 0.08$±$0.01$(6)$ 2.42$±$0.25$(6)**$ 98.1$±$2.7$(3)$
((((((((50%( 0.03$±$0.002$(6)$ 0.09$±$0.003(6)$ 2.71$±$0.06$(6)***$ 101$±$0.6$$(3)$
R91G(100%( 0.05$±$0.01$(6)$ 0.09$±$0.01$(6)$ 1.83$±$0.18$(6)**$ 102.2$±$1$$(3)$
(((((((((((50%( 0.06$±$0.0$(6)$ 0.09$±$0.004(6)$ 1.55$±$0.05$(6)$**$ 100.2$±$0.6$(3)$
∆E139(100%( 0.03$±$0.004$(6)$ 0.12$±$0.03$(6)$ 2.95$±$0.43$(6)$**$ 101.1$±$2.4$$(3)$
((((((((((50%( 0.03$±$0.004$(6)$ 0.11$±$0.01$(6)$ 2.58$±$0.49$(6)$**$ 104.2$±$1.1$$(3)$
K168E(100%( 0.05$±0.01$(6)$ 0.08$±$0.01$(8)$ 2.17$±$0.32$(8)$**$ 107.2$±$1.6$$(4)$
(((((((((((((50%( 0.05$±$0.003$(12)$ 0.09$±$0.001$(12)$ 1.84$±$0.07$(12)$***$ 105.4$±$2.7$$(6)$
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3.3.1 In vitro motility assay analysis of R167H and R244G 
 
Thin filaments were reconstituted using 60 nM skeletal troponin, 60 nM wild type or 
mutant tropomyosin that was produced by the providers using baculovirus/sf9 cells 
and 10 nM rabbit skeletal actin.  Ca2+ activation curves were constructed for the 
percentage motility and motile velocity of thin filaments reconstituted with WT or 
mutant tropomyosin. Again, 100 % and 50% of the mutation was used for the 
production of the thin filaments. Three Ca2+ activation curves were produced for 
100% R167H and one for 50% R167H mutation versus WT, examples of which are 
shown in Figure 3-7. Three Ca2+ activation curves were produced for 100% R244G 
mutation and one for 50% R244G mutation versus WT, examples of which are shown 
in Figure 3-8. The data are summarized in Table 3-2. As we observe from the Ca2+ 
activation curves and also from the summary tables, both of these mutations showed a 
decreased in Ca2+ sensitivity or loss of function (EC50 WT/ R167H 100% = 0.59 ± 
0.08, n = 6, p = 0.04 and EC50 WT/ R244G 100%= 0.46 ± 0.08, n = 6, p = 0.001). 
Interestingly, 100% and 50% of the mutation gave similar changes to Ca2+ sensitivity 
for all the mutations.  
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Figure 3-7: Ca2+ activation curves for percentage motility and motile velocity of thin 
filaments reconstituted with mutant R167H tropomyosin vs WT 
 
 
 
 
Representative Ca2+ titration curves for motile velocity and percentage motility for thin 
filaments reconstituted with A) 100 % R167H tropomyosin vs WT tropomyosin and B) 
50% R167H tropomyosin vs WT tropomyosin. WT tropomyosin in blue and mutant 
tropomyosin in red.  
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Figure 3-8: Ca2+ activation curves for percentage motility and motile velocity of thin 
filaments reconstituted with R244G mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative Ca2+ titration curves for motile velocity and percentage motility for thin 
filaments reconstituted with A) 100 % R244G tropomyosin vs WT tropomyosin and B) 
50% R244G tropomyosin vs WT tropomyosin. WT tropomyosin in blue and mutant 
tropomyosin in red.  
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Table 3-2: Summary of the mutations in TPM3 that cause loss of function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EC50 values were combined for percentage motility and motile velocity Ca2+ activation 
curves. **p<0.01 for single value t test compared to one. In brackets the number of 
experiments.  
Muta%on( EC50(Mut,(µM( EC50(WT,(µM( Ra%o(EC50(WT/Mut( Max(sliding(speed(
rela%ve(to(WT,(%(
R167H(100%( 0.16%±%0.02%(6)% 0.07%±%0.01%(6)% 0.59%±%0.08%(6)%*% 98.1%±%2.7%(3)%
(((((((((((((50%( 0.13%±%0.002%(2)% 0.08%±%0.01%(2)% 0.59%±%0.01%(2)% 95%%(1)%
R245G(100%( 0.12%±%0.02%(6)% 0.05%±%0.02%(6)% 0.46%±%0.08%(6)*% 97.1%±%4.7%%(3)%
(((((((((((((50%( 0.11%±%0.003%(2)% 0.08%±%0.01(2)% 0.67%±%0.07%(2)%% 93.6%(1)%
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3.4 Two novel TPM3 deletions also cause a hypercontractile 
phenotype with gain of function.  
 
Two novel mutations in TPM3 in positions very close to each other have been 
recently identified in two unrelated stiff patients. These mutations were a deletion in 
Glutamine 224 (∆E224) and the other one in Glutamine 218 (∆E218) (Donkervoort et 
al., 2015). Gain of function associated with a stiff patient phenotype is rare. ACTA1 
K236N has been the only mutation so far that has been previously identified in a 
muscle protein.  
The proband carrying the ∆E224 mutation was 5 years old and was diagnosed with 
generalized muscle stiffness. The patient had a history of overheating and 
inappropriate sweating. He had problems of moving and breathing and he uses a 
Cough Assist device to help him with ventilation. The relatives of the individual were 
unaffected.  
The patient carrying the ∆E218 had a more severe phenotype. She was three years old 
when she was diagnosed with the disease but she presented severe muscle stiffness 
even from birth. The respiratory muscles were affected by the myopathy and the 
patient underwent three episodes of apnoea. She still remains fully respirator 
dependent at three years of age.  
The two mutations are found in the second acidic amino acid in the motif of where 
Tpm3.12 interacts with a basic cluster consisting of K326, K328 and R147 on actin 
(see Figure 3-9). It is predicted that these two mutations would also be gain of 
function mutations similar to the mutations in mutations described in the previous 
section.  
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Figure 3-9: Location of the novel mutations in TPM3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.1 In vitro motility analysis of ∆E224 and ∆E218 TPM3 mutations 
 
Thin filaments were reconstituted using 60 nM WT or ∆E224 and ∆E218 recombinant 
mutant Tpm3.12 provided by Dr Elyshia McNamara, 60 nM skeletal troponin and 10 
nM rabbit skeletal actin. Four Ca2+ activation curves were performed for each of the 
mutation comparing mutant or wild type thin filaments. Representative Ca2+ 
activation curves for percentage motility and motile velocity of the thin filaments are 
shown in Figure 3-10 and Figure 3-11 and data for percentage motility and motile 
velocity of thin filaments for each of the mutations are summarized in Table 3-3, 
Table 3-4, Table 3-5 and Table 3-6. ∆E218 increased the Ca2+ sensitivity by 2.5 fold 
for the percentage motility and by 2 fold for the motile velocity of the thin filaments. 
∆E224 also led to an increase in Ca2+ sensitivity in both mobile parameters, by 2.2 
Location of the novel mutations in Tpm3.12 ∆E224 and ∆E218 and their interaction with 
actin. A) the interface of tropomyosin (green) period 6 with actin (grey). K326, K328 and 
R147 in actin are shown in different shades of blue, E218 and 224 are shown in red and 
E219 and E223 are shown in pink. B) A closer view of the site of interaction of actin 
K326 with the two tropomyosin mutations.  
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fold and 3 fold respectively (EC50 ∆E224/WT = 0.46 ± 0.09, p = 0.01, n = 4 for 
percentage motility and EC50 ΔΕ224/WT = 0.33 ± 0.08, p = 0.004, n = 4 for sliding 
speed). These results indicate that both of these mutations also cause a gain of 
function. There was no significant difference in maximum sliding speed of the 
filaments, or the Hill coefficient between either of the mutations and wild type thin 
filament
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Figure 3-10: Ca2+ activation curve for percentage motility and motile velocity of thin 
filaments reconstituted with ∆E218 mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Representative Ca2+ titration curves for motile velocity (top) and percentage motility (bottom) 
for thin filaments reconstituted with 100 % ∆E218 tropomyosin (red) vs WT tropomyosin 
(blue). 
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Figure 3-11: Ca2+ activation curves for percentage motility and motile velocity of thin 
filaments reconstituted with ∆E224 mutant tropomyosin vs WT 
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Representative Ca2+ titration curves for motile velocity (top) and percentage motility 
(bottom) for thin filaments reconstituted with 100 % ∆E224 tropomyosin (red) vs WT 
tropomyosin (blue).  
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Table 3-3: Summary of motility data for motile velocity of thin filaments 
reconstituted with ∆E218 mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
Table 3-4: Summary of motility data for percentage motility of thin filaments 
reconstituted with ∆E218 mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXP$
N$
EC50$$
%$Mo,lity,$µM$
WT$
EC50$$
%$Mo,lity,$
µM$∆E218$
EC50$Ra,o$
Mut/WT$
nH$$
%$Mo,lity$
WT$
nH$$
%$Mo,lity$
∆E218$
Max$%$
Mo,le$
WT$
Max$%$Mo,le$
∆E218$
1$ 0.10$±$0.004$ 0.05$±$0.01$ 0.55$ 4.12$±$0.84$ 2.06$±$$0.53$ 89.5$±$$3.9$ 95$±$$0.82$
2$ 0.099$±$$0.0002$ 0.05$±$0.004$ 0.5$ 4.87$±$$0.072$ 1.87$±$$0.3$ 86.5$±$$3.11$ 94.25$±$$1.71$
3$ 0.36$±$$0.078$$ 0.12$±$0.003$ 0.33$ 0.97$±$0.19$ 0.99$±$0.02$ 74.5$±$6.36$ 84.5$±$3.05$
4$ 0.25$±$0.049$ 0.06$±$0.096$ 0.24$ 1$±0.16$ 0.88$±$0.16$ 78$±$16.25$ 84.67$±$4.73$
Mean$
±$SE$
0.20$±$0.06$ 0.07$±$0.02$ 0.4$±$0.07*$ 2.74$±$1.02$ 1.45$±$0.3$ 82.13$±$3.52$ 89.6$±$2.90$
EXP$
N$
EC50$$
Mo+le$velocity,$
µM$WT$
EC50$$
Mo+le$velocity,$
µM$∆E218$
EC50$Ra+o$
Mut/WT$
nH$$
Mo+le$velocity$
WT$
nH$$
Mo+le$velocity$
∆E218$
Max$Sliding$
speed$
WT$
Max$Sliding$
speed$
∆E218$
1$ 0.11$±$0.0073$ 0.07$±$0.01$ 0.69$ 3.66$±$1.17$ 2.11$±$$0.77$ 2.15$±$$0.14$ 2.37$±$$0.28$
2$ 0.12±$$0.003$ 0.072$±$0.0094$ 0.62$ 3.69±$$0.46$ 2.25±$$0.48$ 2.48$±$$0.54$ 2.91$±$$0.20$
3$ 0.46$±$$0.031$$ 0.06$ 0.13$ 0.99$±$0.06$ 1.94$ 2.74$±$0.06$ 2.6$
4$ 0.22$±$0.063$ 0.11$±$0.058$ 0.69$ 0.98$±0.16$ 0.88$±$0.22$ 2.92$±$0.22$ 3.11$±$0.33$
Mean$
±$SE$
0.22$±$0.08$ 0.08$±$0.01$ 0.48$±$0.12*$ 2.33$±$0.77$ 1.72$±$0.38$ 2.57$±$0.16$ 2.75$±$0.16$
* p<0.05 for single value t test compared to one.  
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Table 3-5: Summary of motility data for motile velocity of thin filaments 
reconstituted with ∆E224 mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
Table 3-6: Summary of motility data for percentage motility of thin filaments 
reconstituted with ∆E224 mutant tropomyosin vs WT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXP$
N$
EC50$$
Mo+le$velocity,$
µM$WT$
EC50$$
Mo+le$velocity,$
µM$∆E224$
EC50$Ra+o$
Mut/WT$
nH$$
Mo+le$velocity$
WT$
nH$$
Mo+le$velocity$
∆E224$
Max$Sliding$
speed$
WT$
Max$Sliding$
speed$
∆E224$
1$ 0.14%±%0.044% 0.08%% 0.57% 1.89%±%0.81% 2.53%±%%0.29% 2.86%±%%0.46% 2.88%±%%0.1%
2$ 0.27%±%%0.18% 0.078%±%0.0063% 0.29% 0.99±%%0.5% 2.65%±%%0.57% 2.82%±%%0.71% 2.58%±%%0.16%
3$ 0.52%±%%0.0024%% 0.015%±%0.08% 0.30% 1.18%±%0.01% 0.65%±%%0.15% 2.73%% 2.97%±%0.08%
4$ 0.29%±%0.4% 0.05%±%0.034% 0.17% 0.7%±%0.56% 0.61%±%0.44% 3.16%±%0.46% 2.66%±%0.96%
Mean$
±$SE$
0.3$±$0.08$ 0.09$±$0.02$ 0.33$±$0.08*$ 1.19$±$0.25$ 1.61$±$0.56$ 2.89$±$0.09$ 2.77$±$0.09$
* p<0.05 for single value t test compared to one.  
EXP$
N$
EC50$$
%$Mo,lity,$µM$
WT$
EC50$$
%$Mo,lity,$
µM$∆E224$
EC50$Ra,o$
Mut/WT$
nH$$
%$Mo,lity$
WT$
nH$$
%$Mo,lity$
∆E224$
Max$%$
Mo,le$
WT$
Max$%$Mo,le$
∆E224$
1$ 0.09$±$0.01$ 0.06$±$0.03$ 0.68$ 3.18$±$1.01$ 1.91$±$$0.19$ 84.5$±$$2.38$ 92.33$±$$4,4$
2$ 0.11$±$$0.12$ 0.06$ 0.54$ 2.98$±$$1.06$ 2$±$$0.26$ 94.75±$$6.18$ 96.25$±$$4.35$
3$ 0.31$±$$0.003$ 0.08$±$0.013$ 0.25$ 1.96$±$0.05$ 1.03$±$0.15$ 61$±$2.24$ 61.5$±$3.11$
4$ 0.22$±$0.011$ 0.09$±$0.001$ 0.39$ 1.65$$±0.02$ 1.33$±$0.03$ 82.5$±$16.25$ 84.67$±$4.73$
Mean$
±$SE$
0.19$±$0.05$ 0.07$±$0.01$ 0.46$±$0.09*$ 2.44$±$0.37$ 1.57$±$0.23$ 79.81$±$7.06$ 83.15±$7.77$
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3.5 Discussion 
 
3.5.1 IVMA Advantages and Limitations 
 
The main technique used for the experiments in this thesis was the in vitro motility 
assay (IVMA). This assay relies on the ability of thin filaments to move over a bed of 
immobilised myosin. A silane-coated glass was the substrate for attaching the HMM, 
and this replaced the more widely adopted nitrocellulose surface (Marston, 2003). In 
the case of a nitrocellulose surface, thin filaments are completely stalled at low Ca2+ 
concentrations, so with increasing Ca2+ concentrations the filaments start moving at 
increasing speed, until the point where the Ca2 saturation is reached. On the other 
hand, on the silane-coated surface there are two populations of filaments, one of 
which will be moving and the other one not. The moving population will have a 
motile velocity even at low Ca2+concentration, which most of the times exceeds 2 
µm/sec. At high Ca2+ concentration, the population of moving filaments will be 
larger, so in this context the percentage motile represents the fragment of thin 
filaments that are in the “moving” or activated population. The Hill equation can be 
fitted for both percentage motility and motile velocity data and the EC50 can be 
calculated, which represents the Ca2+ sensitivity of the filaments, and also the nH, 
which represents the co-operativity of the system. It is noted that when tropomyosin 
and troponin are added to the system, the percentage motility and the motile velocity 
increase slightly compared to plain actin, suggesting that the co-operativity of the 
system has increased. The Ca2+ activation curves for both parameters, percentage 
motility and motile velocity gave very similar results, showing that the IVMA is a 
reliable assay for the experimental questions. Motile velocity also is dependent of the 
cross-bridge cycle rate turnover and thus can also give information about the cross-
bridge cycle kinetics.  
The IVMA relies in a large extent to the purity of the reconstituted proteins, and also 
in their half-life. For example, both cardiac troponin and actin are unstable (viable for 
3 days and four weeks respectively), which can be a limitation to the IVMA 
experiments. An advantage of the IVMA is that the filaments can be reconstituted 
using sarcomeric proteins from different species (mouse, human, rabbit or 
recombinant proteins), which makes IVMA a good model to study the response of 
different proteins to different Ca2+ concentration. Therefore, the IVMA is an 
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appropriate technique for this thesis, looking at both skeletal muscle diseases and 
cardiomyopathies. Reconstituting the thin filaments with either skeletal or cardiac 
troponin means that both of these types of diseases can be efficiently studied.  
As the rest of the proteins used in IVMA are the same, the effect of the change in one 
of the proteins or the addition of a drug can be observed. Before each experiment the 
different components are tested individually, making sure that the assay works 
correctly prior to performing the experiment and incubating all the proteins together. 
The different repeats gave consistent results, even though the proteins were not 
necessarily of the same isolation. This assay has been used in our lab and others for 
many years and is thus a well-established technique. The assay uses very small 
amounts of sample and small differences between samples can be detected.  
However, the fact that that proteins from different species are used for the assay, for 
example rabbit myosin and actin are used make the IVMA not really representative of 
the human condition. It would be more appropriate to model human disease if human 
cardiac myosin and actin could be used. Furthermore, the IVMA only represents 
individual reconstituted filaments and not a higher-order system. In reality, the 
filaments all come together to form myofilaments and in their turn they form 
myocytes that interact with each other so there are more components in the 
physiological condition. IVMA can be a useful tool to study the molecular mechanism 
of myopathies but should be combined with other studies to provide a more complete 
result. 
3.5.2 Structure of the tropomyosin-actin interface predicts mutations that 
cause gain of function in skeletal muscle diseases 
 
Here I show for the first time that it is possible to predict the function of mutations in 
tropomyosin based on their location. In total six of the motifs where tropomyosin 
interacts with actin and has a structural motif of two basic or acidic amino acids next 
to each other were investigated. It was found that all of the mutations lead to a “gain 
of function” as demonstrated by an increase in Ca2+ sensitivity.  
The mutations were ∆K49, R91G in TPM2 and K168E, ∆E224 and ∆E218 in TPM 3 
that interact with Asp25 on actin. ∆E139 mutation in TPM2 interacts with actin on 
K326 and was also found to be a gain of function mutation. This investigation was 
inspired by the observation that a mutation in K326 of actin to Asparagine was found 
in a child with stiff muscles (Jain et al., 2012). The next observation was that the 
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TPM2 ∆K7 mutation that interacts with Asp25 on actin also leads to a gain of 
function. Thus, with these two studies, the key initial results were already known 
when we started. Li et al have calculated the electrostatic interactions of tropomyosin 
and F-actin, identifying protein complexes that make contacts in both molecules (Li et 
al., 2011). This enable us to predict similar motifs on tropomyosin interacting with 
Asp25 and Lys326 in which mutations would also cause gain of function.  
Initially four motifs were identified; ∆K49, ∆E139, R91G and K168E. ∆K218 and 
∆K224 are novel and were recently identified in two unrelated patients. All of the 
mutations involve a change in a motif of two basic or acidic amino acids next to each 
other. There are nine such motifs in all tropomyosin isoforms. Together with other 
groups, we have identified gain of function mutations in eight of these motifs, and 
∆E224 and ∆E218 were the last mutations in such domains to be identified.  
The structure-function relationship described here is further supported by the fact that 
the two mutations TPM3 R167H and R245G in skeletal muscle myopathy patients 
that are found adjacent to the predicted gain of function sites produced the exact 
opposite effect and lead to a loss of function, demonstrated by a decrease in Ca2+ 
sensitivity. Figure 3-12 summarises the predicted gain of function mutations versus 
loss of function mutations found by us and others predicted by the molecular model 
by Li et al. 
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Figure 3-12: Synopsis of the effect of skeletal muscle myopathy mutations on Ca2+ 
sensitivity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.3 Linkage between the Ca2+ sensitivity caused by skeletal muscle myopathy 
and patient phenotype 
 
Historically, skeletal muscle myopathy patients are characterized by the 
histopathology of the muscle. In our case, there is no correlation between the disease 
classification and the gain of function phenotype. Among all the mutations studied by 
us and others, patients were diagnosed with a range of skeletal muscle myopathies, 
such as Cap disease, Nemaline Myopathy, CFTD, rod-core disease, distal 
arthrogryposis and trismus-pseudocamptodactyly. Actually, different diseases can 
sometimes be found within patients carrying the same mutations. For example, the 
single mutation ∆K7 studied in 10 families included diagnosis of rod-core disease, 
CTFD and trismus-pseudocamptodactyly (Davidson et al., 2013, Mokbell et al., 
2013). Similarly, as mentioned before, mutations in R167 also give diverse 
Ca2+ sensitivity effect on mutations that are predicted to cause gain (black bars) or 
loss of function (white bars) based on the structure by Li et al, found by us and 
others. a) From Mokbell et al (Mokbell et al, 2007) b) From Ochala et al (Ochala et 
al., 2012) c) From Martilla et al (Marttila et al., 2012) d) From Ochala et al (Ochala 
et al., 2008)  
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phenotypes, where patients with Nemaline myopathy, cap disease and mixed 
pathologies carry mutation in this amino acid.  
It was very interesting that in 8 out of 9 sites of tropomyosin/actin interactions with 
the same motif mutations causing congenital skeletal muscle diseases have been 
found and all of them are associated with a gain of function at the molecular level. 
The gain of function observed in the Tpm2.2 and Tpm3.12 mutations described in this 
study, are sometimes associated with hypercontractile phenotype in patients but not 
always (Table 3-7). For example, distal arthrogryposis that was found in patients with 
E181K, R91G and ∆K7 is linked to hypercontractility. It is noted that this study led to 
the re-assessment of the diagnosis. However, hypercontractility was not found in 
patients with all the mutations. Patients with three gain of function mutations, ∆K49, 
∆E139 and K168E were not diagnosed with a hypercontractile phenotype, but in these 
cases muscle weakness is not congenital. The reason of these discrepancies might be 
the progress of the disease and the secondary effects to the muscle. It is noted that 
these patients were not examined from birth, and a hypocontractile phenotype from 
birth would clearly exclude a gain of function type of mutation. For example, the 
patient carrying the ∆E139 mutation was only diagnosed at age 11.  
 
Table 3-7: Summary of tropomyosin mutations causing gain of function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ac#n/&Tm&interface& Tm&Muta#on&& My&contribu#on&
Asp$25$ K6/K7$$ ∆K7$#$
K48/K49$ ∆K49$$ ✔$
R90/R91$ R91G$#$ ✔$
K167/K168$ K168E$ ✔$
K326$ E138/E139$ ∆E139$$ ✔$
K328$ E180/E181$ E181K$#$
K147$ E218/D219$ ∆E218$#$ ✔$
E223/E224$ ∆E224$#$ ✔$
E257/E258$ N/A$
Mutations in 8 out of 9 sites of tropomyosin/ actin interaction with the 
same motif have been found and are all gain of function at the molecular 
level. # indicates mutations associated with a gain of function 
(hypercontractile) phenotype in patients. N/A, not applicable.  
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In that respect, the situation can be compared to Hypertrophic Cardiomyopathy 
(HCM), which is also associated with increased Ca2+ sensitivity. In HCM, symptoms 
develop later on in life. In HCM a hypercontractile phenotype which is demonstrated 
by an increase of Ca2+ sensitivity and hypertrophy may later on cause 
hypocontractility as shown in biopsies of interventricular septum of these patients 
(Elliott and McKenna, 2004). It is possible that this is the case also in patients with 
gain of function mutations, where the hypercontractile phenotype is masked by the 
secondary effects of the skeletal muscle disease later on.   
A special case has been made for ∆E224 and ∆E218 patients. These two patients 
showed a severe phenotype of skeletal muscle diseases from a young age. Both 
patients showed a marked hypercontractile phenotype with muscle stiffness and no 
indication of muscle weakness. The hypercontractility had major implications in 
patients respiratory system, especially for the more severe patient. In the case of these 
two mutations, the IVMA results completely support the clinical characteristics of the 
patients. Furthermore, an increase in the Ca2+ sensitivity was reported in skinned 
fibres from the ∆E224 patient.  
Cross-bridge cycle kinetics was shown to be reduced in ∆E224 skinned fibres. 
However, the IVMA results suggest that the mutations do not alter the cross-bridge 
cycle kinetics, as the maximum sliding speed was not affected by the mutations. 
Unfortunately cross-bridge cycle kinetics could not be studied from the ∆E218 
patients but in both patients there was a reduced force generation in skinned fibres 
(Donkervoort et al., 2015). Histopathologically the two patients could not be assigned 
to conventional myopathies, as characteristics from different types of myopathies 
were found in biopsies of both patients, such as nemaline rods, CFTD or cap-like 
structures.  
Based on these results, the interesting question why these patients have a stiff 
phenotype from birth arises. This might be because the mutations are in TPM3, the 
slow skeletal isoform. TPM2 is expressed in both fast and slow twitch fibres. Patients 
with distal arthrogryposis, which is associated with increased Ca2+ sensitivity and 
muscle hypercontractility, have mutations in genes which are encoded specifically to 
fast switch fibres (Robinson et al, 2007). Fast switch fibres typically develop 
prenatally and do not change over development. It is possible that Tpm3.12 in which 
the mutations ∆E224 and ∆E218 mutations are found is predominantly expressed in 
slow fibres, such as diaphragm and may thus have particular effects on respiration.  
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3.5.4 Structural analysis of tropomyosin-actin regulation. 
 
The regulation of muscle occurs through interactions between proteins of the thick 
and thin filaments, myosin, actin, troponin and tropomyosin. A review by Lehrer and 
Geeves relates the actin/tropomyosin/troponin complex to the haemoglobin/ aspartate 
transcarbamylase complex, where troponin and Ca2+ coordinate transitions between 
“on” and “off” states of the system. Ca2+ sensitivity is therefore a way to identify the 
position of the equilibrium between the system states (Lehrer and Geeves, 1998). 
Figure 3-13 illustrates the “on” and “off” states of actin/tropomyosin complex. Li et al 
have resolved a structure of skeletal muscle tropomyosin on actin and have shown 
that when actin is free from inhibition by the troponin molecule, tropomyosin 
localizes to a favourable position on F-actin (Li et al, 2011). The position of 
tropomyosin to actin is calculated to be at the “closed” or “off” state (Lehman et al., 
2009). Energy landscape calculations have shown that tropomyosin is located in a 
shallow energy well on actin (Lehman et al., 2013). Structural studies have shown 
that the “open” or “on” state is energetically unfavourable and it becomes favourable 
in the presence of myosin binding to actin (Behrmann et al., 2012).  
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Figure 3-13: Tropomyosin and actin complex open and closed states 
 
 
 
 
 
 
 
 
 
The mutations in all the cases are found in a location critical to the interaction 
between actin and tropomyosin in the “off” state according to these structures. We 
hypothesize that all the gain of function mutations destabilize the “off” state of the 
system, driving the equilibrium towards the “on” or “open” state of the system. In that 
way, the protein complex has more probability to be “active” and so a gain of 
function is observed. The increase of the Ca2+ sensitivity as measured by the IVMA 
can be an indicator of the change between states. In four of the gain of function 
mutations reported in this study, ∆K7, ∆K49, R91G and ∆E139 it was found to be 
decreased affinity of tropomyosin and actin (Marttila et al., 2012) (Mokbel et al., 
This picture shows the two states of the tropomyosin/actin complex, open and closed 
state. K1 is the initial actin/binding constant which is independent of myosin, Ca2+ and 
troponin. K2 is the isomerization constant, which allows myosin to bind weakly to actin 
and requires the actin/tropomyosin complex to be in “open” state. Ca2+ and troponin 
additionally affect the L0 equilibrium constant from “closed” to “open” state.  
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2013) (Ochala et al., 2008) supporting our hypothesis. Furthermore, energy landscape 
calculations have shown that in the gain of function mutation in actin K326N, which 
was the first gain of function mutation reported, the most energetically favourable 
position of tropomyosin is in the “open” state (Orzechowski et al., 2013).  
It is very peculiar that two mutations found just next to the amino acid mutation that 
causes the gain of function phenotype, are loss of function mutations. Although this 
result provided the negative control to our study, it is difficult to explain these results. 
This might have to do with the nature of the interactions between tropomyosin and 
actin. It would be interesting to look at mutations that occur at the site where 
tropomyosin interacts with the hydrophobic Pro333. Another unexplained 
phenomenon is the fact that most of the gain of function mutations are found in 
tropomyosin and not in actin. This might be related to the fact that only four amino 
acids in actin interact with tropomyosin, opposed to 18 amino acids in tropomyosin 
interacting with actin thus there are more probabilities of having a mutation in 
tropomyosin. Furthermore, most actin mutations do not affect actin-tropomyosin 
interactions at all (Feng and Marston, 2009).  
In summary, these results suggest that it is possible to predict the effect of mutations 
in tropomyosin in terms of muscle function based on the structure. This is partly 
because tropomyosin has a repeating like structure with conserved motifs. This study 
has also important implications for therapy, as it would be possible to treat gain of 
function mutations with agents that desensitise the thin filaments to Ca2+, such as 
EGCG, Silybin and their analogues. These drugs and their action on the cardiac 
muscle proteins will be described in detail in Chapter 5 and 6.   
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 Investigation of the effect of Ca2+ sensitisers on 4
reconstituted human heart thin filaments 
 
4.1 General Introduction  
In the previous chapter I looked at the molecular mechanism of mutations in 
tropomyosin that cause skeletal muscle myopathies. In the next chapters of the thesis I 
will investigate the molecular mechanisms of mutations in the cardiac thin filament 
proteins that cause cardiomyopathies, giving particular importance to the “uncoupling 
phenomenon”. Dilated Cardiomyopathy (DCM) and Hypertrophic Cardiomyopathy 
(HCM) are inherited diseases that can arise in the case of mutations on the genes that 
encode proteins of the contractile apparatus of the myocardium (Kamisago et al., 
2000) (Elliott and McKenna, 2004). Some of these mutations that cause HCM or 
DCM are found in the proteins of the thin filament (troponin, tropomyosin or actin) 
and investigations of these mutations have shown abnormalities in the Ca2+ regulatory 
system of the thin filament that have been proposed to be the cause of the diseases 
(Marston, 2011).  
HCM mutations lead to an increased Ca2+ sensitivity of the myofilament. However, 
the situation in DCM seems to be more complex because DCM mutations have been 
found to increase or decrease the Ca2+ sensitivity of the myofilament. Recent data 
have indicated that the common molecular mechanism of DCM is the absence of the 
response in the Ca2+ sensitivity upon troponin I (TnI) phosphorylation (uncoupling). 
TnI is phosphorylated upon the adrenergic response and this leads to a decrease of the 
Ca2+ sensitivity of the cardiac muscle, so that the muscle is able to relax. In DCM, the 
change of the Ca2+ sensitivity is uncoupled to the TnI phosphorylation (Memo et al., 
2013) blunting the response of the diseased heart to adrenaline. The uncoupling 
phenomenon seems to be also present in some HCM-causing mutations in the thin 
filament (Messer and Marston, 2014).  
The uncoupling phenomenon may thus be a common feature of thin filament 
cardiomyopathies (see Section 1.5). We hypothesise that there is a specific interaction 
between the TnI and troponin C (TnC) upon phosphorylation, which transduces the 
signal from the TnI to the TnC and thus changing the Ca2+ dissociation rate, causing 
the Ca2+ sensitivity to decrease. Therefore, we predict that in case of a mutation in the 
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thin filament, this interaction is abolished and the Ca2+ sensitivity cannot change upon 
phosphorylation, giving rise to the uncoupling phenomenon. The objective of this 
thesis is to test this hypothesis, and to discover the molecular mechanism that is 
responsible for the uncoupling. This can be done with the aid of different agents that 
can bind to troponin and therefore could affect the TnC-TnI interaction in a similar 
fashion to mutations.  
Ca2+ sensitisers alter the Ca2+ sensitivity of the myofilament by binding to TnC but 
their effect on coupling of the Ca2+ sensitivity with TnI phosphorylation has never 
been considered. The purpose of this study is to investigate the effects of these 
molecules that increase the Ca2+ sensitivity of the thin filament in relationship with 
the phosphorylation of TnI, which is a downstream effector of the adrenergic 
response. The two Ca2+ sensitisers used in this study are EMD 57033 and Bepridil.  
The method by which this question will be investigated is the well-established 
technique of in vitro motility assay (IVMA). As it was demonstrated in the previous 
chapter, in this method, actin thin filaments slide over a bed of immobilised myosin in 
response to Ca2+. The two parameters measured is the percentage motility of the 
sliding actin thin filaments and also the sliding speed, which are indicators of thin 
filament switching, co-operativity and cross-bridge cycling. The IVMA allows for 
direct comparison between samples, because they have equal experimental factors 
during the assay, apart from one factor, so that any differences due to this particular 
factor (for example presence of mutant protein, phosphorylation status or effect of a 
drug) can be detected. This method has been extensively used by the Marston’s lab to 
study the uncoupling phenomenon because direct phosphorylation of troponin can be 
manipulated in donor and mutant thin filaments (Memo et al., 2013, Bayliss et al., 
2012b). Phosphorylation studies in the heart samples have been done in the lab by Dr 
Andrew Messer and thus the phosphorylation status of all the samples is known 
(Messer, 2007). Moreover, the effect of mutations can be investigated because mutant 
proteins can be incorporated in the assay instead of native.  
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4.2 Investigation of the effects of EMD 57033 on human heart thin 
filaments 
4.2.1 Introduction 
 
The first sensitiser studied was EMD 57033 which is a small molecule found to 
increase the Ca2+ sensitivity of the cardiac muscle (Baudenbacher et al., 2008). EMD 
57033 is one of the enantiomers of thiadiazinone EMD 53998, a sensitiser drug 
originally developed by E.Merck (Darmstadt). The other enantiomer of EMD 53998 
is EMD 57439 which is a phosphodiesterase inhibitor, making EMD 53998 both a 
Ca2+ sensitiser through the action of EMD 57033 and a phosphodiesterase inhibitor 
through the action of EMD 57439 (Solaro et al., 1993). The clinical development of 
EMD 57033 was stopped because of lack of bioavailability of the drug (Kass and 
Solaro, 2006). However, EMD 57033 is a useful tool to study thin filament properties 
since it increases the Ca2+ sensitivity of the myofilament through interaction with the 
sarcomeric proteins. The structure of EMD 57033 is shown in Figure 4-1.  
 
Figure 4-1: Chemical structure of EMD 57033  
 
 
 
 
 
 
EMD 57033 increases the myofilament sensitivity to Ca2+ by binding to the 
hydrophobic cleft of the cardiac TnC (Wang et al., 2001). This region is close to the N 
terminal peptide of the TnI where the phosphorylation of Serine 22 and 23 take place, 
making this region important for the transduction of the Ca2+ binding signal to the N-
lobe. The fact that EMD 57033 binds close to this TnC-TnI interaction led to the 
hypothesis that EMD 57033 would have an effect on the coupling between TnI 
phosphorylation and Ca2+ sensitivity. In this section I will describe the effects of 
tural studies have identified the docking sites of a group of
cardiotonic drugs (Fig. 2) in the cTnC–cTnI interface. In
this review, we focus on the available structural data
describing drug binding to the troponin complex with the
goal of delineating the mode of action of diﬀerent cardio-
tonic drugs. This analysis will provide a comprehensive
molecular insight into the concepts underlining the Ca2+-
sensitizing eﬀects of these compounds and the potential
of cTnC–cTnI interface as a target for future rational drug
design for the treatment of heart disease. We first present
the five compounds (bepridil, TFP, levosimendan, anapoe,
and W7) that bind to the N-domain followed by EMD
57033 that interacts with the C-domain of cTnC.
Bepridil
Bepridil (Fig. 2) is a Ca2+ channel blocker and a cal-
modulin (CaM) antagonist. Early evidence indicated that
it is able to enter cardiomyocytes and bind to the thin fila-
ment [52,53]. Studies have demonstrated direct binding of
bepridil to cTnCÆ3Ca2+ with a KD of !10 lM and found
that it enhances Ca2+ binding to the regulatory site of
cTnC both free in solution and in skinned fiber bundles
[53]. Using stopped flow fluorescence techniques, Mac-
Lachlan et al. showed that bepridil slows the Ca2+ release
from the N-domain of cTnC [54]. An NMR study, using
Met residues as markers, identified three bepridil binding
sites in cTnC [55]. By monitoring amide chemical shift
changes, another NMR study detected only one bepridil
binding site (KD = !140 lM) in the N-domain of cTnC
when in complex with cTnI [56]. Thus, it is likely that the
interaction of cTnI with cTnC blocks two of the three
bepridil sites that may not be functionally relevant. All of
these studies agree that binding of bepridil requires site II
in cTnC to be occupied by Ca2+. The X-ray structure of
cTnCÆ3Ca2+Æ3bepridil provided detailed structural data
on the interaction of cTnC and bepridil [57]. In this struc-
ture, two bepridil molecules pull the N- and C-domains
together to result in a compact structure for cTnC while
a third bepridil appears to stabilize an ‘open’ cNTnC con-
formation by binding to the center of the hydrophobic
pocket, much like the switch region cTnI147–163. Interpreta-
tion of the structural data in relation to the biochemical
and functional data led to the conclusion that the two
bepridils located in the hydrophobic cavity between the
two cTnC domains would be replaced by cTnI in the tropo-
nin complex. The binding of bepridil impedes closure of the
N-domain hydrophobic pocket, thereby slowing Ca2+
release from site II and enhancing the Ca2+-sensitivity of
the myofilament.
The fact that both the switch region of cTnI, cTnI147–163,
and bepridil can induce a structural ‘opening’ in
cNTnCÆCa2+ by interacting with the hydrophobic patch
prompted us to explore whether cTnI147–163 and bepridil
compete for cNTnCÆCa2+ [58]. Using 2D {1H, 15N} HSQC
NMR spectroscopy, we examined the binding of bepridil to
cNTnCÆCa2+ in the absence and presence of cTnI147–163
and of cTnI147–163 to cNTnCÆCa
2+ in the absence and pres-
ence of bepridil. The results show that bepridil and
cTnI147–163 bind to cNTnCÆCa
2+ simultaneously but the
aﬃnity of cTnI147–163 for cNTnCÆCa
2+ is reduced !3.5-fold
by bepridil an vice versa. This is consistent with a NMR
study showing a weaker binding of bepridil to cTnC in
the cTnC–cTnI complex than to isolated cTnC [56]. The
observed negative cooperativity between bepridil and cTnI
for cTnC suggests that the eﬀect of bepridil on muscle
fibers may result from a combination of many integrated
eﬀects within the myofibrillar lattice. The NMR structure
of the cNTnCÆCa2+ÆcTnI147–163Æbepridil ternary complex
reveals a binding site for cTnI147–163 primarily located on
the A/B interhelical interface and a binding site for bepridil
in the hydrophobic core of cNTnCÆCa2+ (Figs. 3 and 7A).
In the structure, the N-terminus of the peptide clashes with
part of the bepridil molecule due t both the steric hin-
Fig. 2. The chemical structures of bepridil, TFP, levosimendan, W7, anapoe, and EMD 57033.
M.X. Li et al. / Biochemical and Biophysical Research Communications 369 (2008) 88–99 91
Structure of EMD 57033.  
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EMD 57033 on phosphorylated, dephosphorylated donor and mutant reconstituted 
human heart thin filaments.  
The mutation studied in this chapter is TPM1 Glu54Lys (E54K), a mutation that 
causes DCM in human. This mutation was first identified by Olson et al, in a study 
screening a big cohort of DCM patients for mutations in the TPM1 gene. One patient 
was identified with the E54K mutation and although the patient had a normal 
echocardiogram at the age of 17, he was diagnosed with DCM at the age of 26 after 
presenting shortness of breath, oedema, and non-sustained ventricular tachycardia. 
The patient died at the age of 27, and his father and uncle also died from heart failure 
at ages of 27 and 49 respectively (Olson et al., 2001). The mutation results in a charge 
reversal from acidic to basic in a conserved region of the tropomyosin molecule and it 
is proposed that this disrupts the structural integrity of the sarcomere that would lead 
to defected cardiomyocyte contraction and myocyte death under stress. A transgenic 
mouse model carrying the mutation E54K was developed by Rajan et al that 
developed DCM, further linking the mutation to the disease (Rajan et al., 2007). This 
mutation was studied in depth in the Marston lab by Dr Mahmooda Mirza and Dr 
Massimiliano Memo, and it was found that mutant reconstituted thin filaments were 
insensitive to Ca2+ sensitivity change upon TnI phosphorylation (uncoupling) (Memo 
et al., 2013, Mirza et al., 2005).  
4.2.2 In vitro motility analysis on EMD 57033 on donor thin filaments  
4.2.2.1 Ca2+ titration curves using different concentrations of EMD 57033 on donor 
reconstituted thin filaments.  
 
Thin filaments were reconstituted using troponin from donor heart, wild type Tpm1.1 
produced from baculovirus/sf9 cells and φ actin from rabbit skeletal muscle. Full Ca2+ 
activation curves were constructed using donor thin filaments or donor thin filaments 
in the presence of different concentrations of EMD 57033. The phosphorylation 
studies performed previously by Dr Andrew Messer have shown that the donor hearts 
were highly phosphorylated, the level of TnI phosphorylation being 1.62 ± 0.02 mols 
Pi/mols TnI (Messer et al., 2009). 
To construct the filaments 10 nM actin was used together with 60 nM tropomyosin 
and 60 nM troponin. A titration of troponin from 30 nM- 60 nM has been performed 
previously by Dr Andrew Messer and Dr Massimiliano Memo and it was found that 
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60 nM of troponin gives the best switch (Memo, 2012). Rabbit skeletal actin alone 
gave a motility of 66.9 ± 3.7 % at a speed of 2.33 ± 0.56 µm/sec. With the addition of 
60 nM tropomyosin the motility of the filaments increased to 78 ± 6 % at a speed of 
2.38 ± 0.47 µm/sec. Upon the addition of cardiac troponin at high Ca2+ (3.9 µM Ca2+) 
thin filaments were motile at a percentage of 73 ± 5 % and velocity of 2.65 ± 0.18 
µm/sec. In low Ca2+ concentration (1 nM) the thin filaments were switched off with 
the percentage motile falling to 1.38 ± 1.19 % and the velocity falling to 1.31 ± 0.006 
µm/sec. These data are graphically presented in Figure 4-2.  
 
Figure 4-2: In vitro motility measurements comparing the addition of troponin and 
tropomyosin to actin filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr Weihua Song has performed experiments examining the action of EMD 57033 on 
isolated papillary muscle of wild type and E99K transgenic mice and found a working 
optimal concentration of 30 µM (Song, personal communication). For this reason, 
Ca2+ sensitivity curves were produced using 15-60 µM EMD 57033 to find the 
optimal EMD 57033 concentration for the IVMA. EMD 57033 was pre-incubated in 
different concentrations (15, 30 and 60 µM) along with actin (10 nM), tropomyosin 
(60 nM) and troponin (60 nM). In the same flow cell, donor troponin or donor 
Means and SE were made from the first two experiments comparing Actin, Actin-
Tropomyosin (Tm) and Actin –Tropomyosin- Troponin (Tn). Percentage motility and 
motile velocity is of donor thin filaments is shown and error bars represent SEM. In the 
presence of troponin, filaments were Ca2+ regulated.  
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troponin + EMD 57033 were added in the two different motility chambers so direct 
comparison for the presence or absence of dug could be performed for each Ca2+ 
point. Two complete Ca2+ titrations were performed comparing thin filaments 
reconstituted with donor troponin and different concentrations of EMD 57033 (shown 
in Figure 4-3). Summary of the experiments can be found in APPENDIX. 
From the Ca2+ curve we can observe that EMD 57033 increases the Ca2+ sensitivity of 
the thin filaments. The maximal calcium sensitivity was seen with 30 µM EMD 
57033 (EC50 = 0.12 ± 0.02, n = 2 compared to donor troponin with EC50 = 0.22 ± 0.04, 
n = 2) whereas when the EMD 57033 concentration was increased to 60 µM the 
movement of the filaments was inhibited (EC50 = 0.19 ± 0.03, n = 2).  EMD 57033 
had a positive effect also on the maximum sliding speed of the filaments. 30 µM of 
EMD 57033 increased the maximum sliding speed from 2.65 ± 0.13 µm/sec, n = 2 to 
2.97 ± 0.02 µm/sec, n = 2.  
However, performing full Ca2+ activation curves is very time-consuming. To save 
time, the drug dose response was detected by selecting the Ca2+ concentration that 
gave the biggest motility difference between the donor thin filaments and thin 
filaments treated with EMD 57033. The corresponding Ca2+ concentration was 0.037 
µM Ca2+ for donor thin filaments treated with EMD 57033. Different concentrations 
of EMD 57033 were tested in thin filaments at 0.037 µM Ca2+ to create a dose 
response curve. 
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Figure 4-3: The effect of EMD 57033 on thin filaments containing donor troponin 
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native donor troponin was measured over a range of Ca2+ concentrations in the 
same experiment of IVMA. Blue solid lines represent donor thin filaments and different 
shades of orange represent thin filaments treated with 15 µM EMD 57033 (light orange) 
30 µM EMD 57033 (orange), or 60 µM EMD 57033 (dark orange). 
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4.2.2.2 Dose response curve of EMD 57033 on donor thin filaments 
One Ca2+ concentration was used for the dose response curve, 0.037 µM Ca2+. For 
this Ca2+ point, different EMD 57033 concentrations were tried out. This specific Ca2+ 
point was also included in the Ca2+ titration curves.  
Figure 4-4 shows the dose response curve for EMD 57033 for motile velocity and 
percentage motility of the filaments treated with EMD 57033. We can see from the 
dose response curves that the maximal EMD 57033 concentration was 30 µM, which 
increased the percentage motility of the filaments from 4.25 ± 0.56 % (n = 6) to 22.6 
±3.49 % (n = 5, p < 0.05) and the sliding speed of the filaments from 1.66 ± 0.05 (n = 
7) to 2.08 ± 0.05 (n = 6, p < 0.05). When the EMD 57033 concentration was increased 
to 60 µM, the percentage motility dropped to 6.42 ± 0.87 % (n = 3) and the motile 
velocity to 1.93 ± 0.13 (n = 5) µm/sec. For the rest of the experiments 30 µM EMD 
57033 was used, which was the optimal concentration.  
 
Figure 4-4: Dose response curve for EMD 57033 on donor thin filaments 
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Motile velocity (left) and percentage motility (right) and of thin filaments reconstituted 
with native donor troponin treated with 0-60 µM EMD 57033 was measured at 0.037 
µM Ca2+ to create a dose response curve. A single EMD 57033 concentration was tested 
in one motility flow chamber.  
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4.2.3 The effect of EMD 57033 on the coupling between TnI phosphorylation 
and Ca2+ sensitivity on donor thin filaments.  
 
The effect of EMD 57033 on the relationship between Ca2+ sensitivity and TnI 
phosphorylation was then studied. In order to do so, extracted troponin was 
dephosphorylated using Shrimp Alkaline Phosphatase (SAP), see Section 2.2.5.2. 
Then Ca2+ sensitivity of the dephosphorylated troponin was tested against donor 
samples using IVMA. 
To make sure that all the proteins used for the experiments had the correct 
phosphorylation status, a Phos-tag gel was run and a western blot was performed in 
all the troponin samples. The donor troponin had a high phosphorylation status (1.9 
mol Pi/mol TnI) and the dephosphorylated troponin had very low phosphorylation 
levels (0.08 mol Pi/mol TnI). (Figure 4-5) 
 
Figure 4-5: TnI Western blot of Phos-tag gels 
 
 
 
 
 
  
Troponin samples and dephosphorylated troponin samples used for the IVMA for four 
experiments performed (Exp 1-4) were run on Phos-tag gel, transferred to a membrane 
and incubated with anti-TnI antibody. This blot shows the different phosphorylation 
levels of cardiac TnI. TnI can be separated in three phosphorylation states: P0; which 
indicates dephosphorylated TnI; P1 which indicates the first phosphorylated state of 
the protein and P2; which indicates fully phosphorylated protein. TnI from Donor 
troponin was found mostly in the P2 state, whereas TnI from dephosphorylated 
troponin was found mostly in the P0 state.  
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Four Ca2+ titration curves were performed with phosphorylated or dephosphorylated 
donor troponin treated with 30 µM EMD 57033. An example of such a Ca2+ titration 
curve can be found in Figure 4-6. All the titration curves gave similar EC50 and nH 
values and the data for both percentage motility and motile velocity of the thin 
filaments are summarized in Table 4-1 and Table 4-2. The raw data for all the 
experiments are shown in APPENDIX. The EC50 and nH values were also similar 
between Ca2+ curves of percentage motility and motile velocity. The Ca2+ sensitivity 
of dephosphorylated thin filaments was significantly decreased compared to 
phosphorylated thin filaments (mean ratio EC50P/EC50dP = 1.77 ± 0.13, p<0.01, n = 4 
for percentage motility and 1.87 ± 0.12, p<0.01, n = 4 for motile velocity) in 
accordance with previous measurements (Messer et al., 2007).  
As expected, 30 µM EMD 57033 increased the Ca2+ sensitivity of phosphorylated thin 
filaments as shown previously, from 0.16 ± 0.03 to 0.057  ± 0.01 µM (p<0.05, n = 4) 
for percentage motility and from 0.14 ± 0.049 to 0.038  ± 0.006 µM (p<0.01, n = 4) 
for motile velocity.  
Interestingly, we observe that 30 µM of EMD 57033 increased the Ca2+ sensitivity of 
phosphorylated thin filaments more than this of dephosphorylated troponin (mean 
ratio EC50 P/EC50 P + EMD 57033 = 3.07 ± 0.71, p<0.001, n = 4 in phosphorylated 
compared with a mean ratio of EC50 dP/EC50 dP + EMD 57033 = 1.83 ± 0.36, p = 
0.07, n = 4 in dephosphorylated thin filaments for percentage motility). Consequently, 
in the presence of 30 µM EMD 57033 the Ca2+ sensitivity of the filaments became 
uncoupled from the TnI phosphorylation (mean ratio EC50 P + EMD 57033/EC50 dP + 
EMD 57033 = 1.08 ± 0.03, p = 0.06, n = 4 for percentage motility and EC50 P + EMD 
57033/EC50 dP + EMD 57033 = 1.07 ± 0.038, p = 0.06, n = 4 for motile velocity). 
Treatment with 30 µM EMD 57033 also decreased the nH of phosphorylated thin 
filaments. EMD 57033 increased sliding speed slightly at saturating 
Ca2+concentration in phosphorylated thin filaments and in dephosphorylated thin 
filaments by 18.4 ± 4.1% (p = 0.02, n = 4).  
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Figure 4-6: Ca2+ activation curves comparing donor thin filaments containing 
phosphorylated or dephosphorylated troponin treated with 30 µM EMD 57033  
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
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measured over a range of Ca2+ concentrations in the same experiment of IVMA. Blue 
lines represent donor thin filaments and orange lines represent thin filaments treated 
with 30 µM EMD 57033.  
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Table 4-1: Ca2+ sensitivity data for motile velocity of phosphorylated vs 
dephosphorylated thin filaments treated with 30 µM EMD 57033 
 
 
 
 
 
 
 
 
 
Table 4-2: Ca2+ sensitivity data for percentage motility of phosphorylated vs 
dephosphorylated thin filaments treated with 30 µM EMD 57033 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** p<0.01; for presence and absent of reagent. † p<0.05, †† p<0.01; for the effect of 
phosphorylation. p values were calculated using one-way ANOVA. p values for the ratios 
were calculated using value t test compared to 1. EC50 was rounded to two significant 
figures. In brackets the number of experiments.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
Donor((((((((((((P( 0.14%±%0.049%(4)% 1.87%±%%
0.12%(4)%††%
3.42%±%0.91%(4)% 2.93%±%0.06%(4)%
Donor(((((((((((dP( 0.08%±%0.04%(4)% 1.42%±%0.32%(4)% 2.82%±%0.05%(4)%
EMD(57033((((P( 0.038%±%%0.006%(4)% 1.07%±%
0.038%(5)%
0.87%±%0.027%(4)**% 3.068%±%0.082%(4)%
EMD(57033((dP( 0.035%±%0.0051%(4)% 0.94%±%%0.028%(4)% 3.06%±%0.065%(4)%
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
Donor(((((((((((((P( 0.16%±%0.03%(4)% 1.77%±%%%
0.13%(4)%††%
2.08%±%0.14%(4)% 79.69%±%1.06%(4)%
Donor((((((((((((dP( 0.091%±%0.019%(4)% 1.51%±%0.25%(4)% 79.38%±%2.05%(4)%
EMD(57033((((P( 0.057%±%%0.01%(4)% 1.08%±%
0.026%(5)%
1.26%±%0.07%(4)*% 82.56%±%2.07%(4)%
EMD(57033(((dP( 0.053%±%0.01%(4)%†% 1.34%±%%0.14%(4)% 81.81%±%2.14%(4)%
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4.2.4 Investigation of the effects of EMD 57033 on DCM E54K mutant human 
thin filaments.  
 
Next, the effect of EMD 57033 on TPM1 E54K mutant phosphorylated and 
dephosphorylated thin filaments was studied. Previously, Dr Massimiliano Memo has 
found that in E54K mutant filaments the Ca2+ sensitivity is uncoupled from TnI 
phosphorylation (Memo et al., 2013). Thin filaments were reconstituted with rabbit 
skeletal muscle actin (10 nM), human cardiac troponin (60 nM) and 60 nM E54K 
tropomyosin purified from baculovirus/sf9 pellets. Three experiments were performed 
comparing phosphorylated or dephosphorylated E54K reconstituted thin filaments 
treated with 30 µM EMD 57033. An example of such an experiment is show in Figure 
4-7. Summary of the data for the percentage motility of the thin filaments and the 
motile velocity can be found in Table 4-3 and Table 4-4.  
30 µM EMD 57033 increased the Ca2+ sensitivity of phosphorylated E54K thin 
filaments by 3.07 ± 0.35 fold for percentage motility (p<0.01, n = 3) and by 3.41 ± 0.6 
fold for motile velocity (n = 3). The Ca2+ sensitivity was independent of TnI 
phosphorylation in the E54K thin filaments and remained independent after the 
treatment with 30 µM EMD 57033 (mean ratio EC50P + EMD 57033/EC50dP + EMD 
57033 = 1.00 ± 0.013, p = 0.38, n = 3 for percentage motility, mean ratio EC50P + 
EMD 57033/EC50dP + EMD 57033 = 1.06 ± 0.05, p = 0.94, n = 3 for motile velocity) 
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Figure 4-7: Ca2+ activation curves comparing thin filaments containing 
phosphorylated or dephosphorylated troponin and E54K mutant tropomyosin treated 
with EMD 57033 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
0.001 0.01 0.1 1 10
TmE54K P
TmE54K dP
TmE54K P + EMD 
TmE54K dP + EMD 
M
ot
ile
 V
elo
cit
y, 
µm
/se
c
[Ca2+], µM
ErrorValueP
0.41.35nH
0.0450.16EC50
ErrorValuedP
0.321.65nH
0.0180.14EC50
ErrorValueP
0.281.43nH
0.00960.068EC50
ErrorValuedP
0.101.59nH
0.00260.061EC50
0
20
40
60
80
100
0.001 0.01 0.1 1 10
TmE54K P
TmE54K dP
TmE54K P + EMD
TmE54K dP + EMD 
Pe
rc
en
ta
ge
 M
ot
ilit
y
[Ca2+], µM
ErrorValueP
0.42.63nH
0.00350.11EC50
ErrorValuedP
0.793.21nH
0.00290.11EC50
ErrorValueP
0.401.71nH
0.00550.043EC50
ErrorValuedP
0.301.54nH
0.00510.045EC50
Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) donor troponin and mutant 
E54K tropomyosin was measured over a range of Ca2+ concentrations in the same 
experiment of IVMA. Red lines represent E54K thin filaments and orange lines 
represent thin filaments treated with 30 µM EMD 57033. 
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Table 4-3: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated E54K mutant thin filaments treated with EMD 57033 
 
 
 
!
 
 
 
 
 
Table 4-4: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated E54K mutant thin filaments treated with 30 µM EMD 57033 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** p<0.01 for presence and absent of reagent. †† p<0.01 for the effect of phosphorylation. p values 
were calculated using one- way ANOVA. p values for the ratios were calculated using value t test 
compared to 1. EC50 was rounded to two significant figures. In brackets the number of experiments.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
E54K((((((((((((((P( 0.12%±%0.024%(3)% 1.03%±%%
0.075%(3)%
2.39%±%0.63%(3)% 3.20%±%0.23%(3)%
E54((((((((((((((((dP( 0.11%±%0.015%(3)% 2.24%±%0.66%(3)% 3.21%±%0.21%(3)%
EMD(57033((((P( 0.053%±%%0.008%(3)% 1.06%±%
0.05%(3)%
2.07%±%0.035%(3)% 3.24%±%0.17%(3)%
EMD(57033((dP( 0.051%±%0.0056%(4)% 2.21%±%%0.39%(3)% 3.2%±%0.11%(3)%
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
E54K(((((((((((((((P( 0.13%±%0.014%(3)% 1.08%±%%%
0.06%(3)%††%
2.33%±%0.14%(3)% 85.58%±%3.89%(3)%
E54K((((((((((((((dP( 0.11%±%0.008%(3)% 2.85%±%0.56%(3)% 84.83%±%3.19%(3)%
EMD(57033((((P( 0.041%±%%0.0018%(3)%**% 1%±%0.013%
(3)%
2.38%±%0.46%(3)% 85.33%±%3.8%(3)%
EMD(57033(((dP( 0.04%±%0.002%(3)%**% 2.07%±%%0.31%(3)% 86%±%3.68%(3)%
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4.3 The effect of Bepridil on human heart thin filaments 
4.3.1 Introduction 
 
The other Ca2+ sensitiser used in this study is Bepridil (trade name Vascor) that acts 
as a Ca2+ channel blocker and calmodulin antagonist and was used for the treatment 
of hypertension and chronic stable angina. It is no longer for sale in the US, as it 
caused ventricular arrhythmias as a side effect (Drugbank). Bepridil has the ability to 
penetrate the cardiomyocytes and bind to the thin filament of the sarcomere. The 
chemical structure of Bepridil is shown in Figure 4-8. Early studies have found that it 
binds to the N-terminal region of the TnC with a KD of around 10 µM and as a 
consequence promotes the Ca2+ release from the N terminal domain of the cTnC 
(Maclachlan et al., 1990). Later studies have found that Bepridil has actually three 
binding sites on TnC (Kleerekoper et al., 1998, Abusamhadneh et al., 2001) but it is 
possible that TnI binding can inhibit two of the sites, because an NMR study by 
Abusamhadneh et al found only one Bepridil binding site in the cTnC N terminal 
region (Abusamhadneh, Abbott et al. 2001). The region where Bepridil binds is 
important because it is at the site where TnI147-163 switch region acts, that is 
responsible for promoting the tropomyosin-actin interaction and consequently the 
muscle contraction in the presence of Ca2+. Similarly to EMD 57033, the effect of 
Bepridil on the coupling between the phosphorylation of TnI peptide and Ca2+ release 
has never been studied before. In this section I will describe the effect of Bepridil in 
terms of Ca2+ sensitivity and TnI phosphorylation in donor and E54K mutant thin 
filaments.  
 
Figure 4-8: Chemical structure of Bepridil 
 
 
 
     
 
 
tural studies have identified the docking sites of a group of
cardiotonic drugs (Fig. 2) in the cTnC–cTnI interface. In
this review, we focus on the available structural data
describing drug binding to the troponin complex with the
goal of delineating the mode of action of diﬀerent cardio-
tonic drugs. This analysis will provide a comprehensive
molecular insight into the concepts underlining the Ca2+-
sensitizing eﬀects of these compounds and the potential
of cTnC–cTnI interface as a target for future rational drug
design for the treatment of heart disease. We first present
the five compounds (bepridil, TFP, levosimendan, anapoe,
and W7) that bind to the N-domain followed by EMD
57033 that interacts with the C-domain of cTnC.
Bepridil
Bepridil (Fig. 2) is a Ca2+ channel blocker and a cal-
modulin (Ca ) antagonist. Early evidence indicated that
it is able to enter cardiomyocytes and bind to the thin fila-
ment [52,53]. Studies have demonstrated direct binding of
bepridil to cTnCÆ3Ca2+ with a KD of !10 lM and found
that it enhances Ca2+ binding to the regulatory site of
cTnC both free in solution and in skinned fiber bundles
[53]. Using stopped flow fluorescence t chniques, Mac-
Lachlan et al. showed that bepridil slows the Ca2+ release
from the N-domain of cTnC [54]. An NMR study, using
Met residues as markers, identified three bepridil binding
sites in cTnC [55]. By monitoring amide chemical shift
changes, another NMR study detected only one bepridil
binding site (KD = !140 lM) in the N-domain of cTnC
when in complex with cTnI [56]. Thus, it is likely that the
interaction of cTnI with cTnC blocks two of the three
bepridil sites that may not be functionally relevant. All of
these studies gr e that binding of bepridil requires site II
in cTnC to be occupied by Ca2+. The X-ray structure of
cTnCÆ3Ca2+Æ3bepridil provided detailed structural data
on the interaction of cTnC and bepridil [57]. In this struc-
ture, two bepridil molecules pull the N- and C-domains
together to result in a compact structure for cTnC while
a third bepridil appears to stabilize an ‘open’ cNTnC con-
formation by binding to the center of the hydrophobic
pocket, much like the switch region cTnI147–163. Interpreta-
tion of the structural data in relation to the biochemical
an functional da a led to the conclusion that the two
bepridils located in the hydrophobic cavity between the
two cTnC domains would be replaced by cTnI in the tropo-
nin complex. The binding of bepridil impedes closure of the
N-domain hydrophobic pocket, thereby slowing Ca2+
release from site II and enhancing the Ca2+-sensitivity of
the myofilament.
The fact that both the switch region of cTnI, cTnI147–163,
and bepridil can induce a structural ‘opening’ in
cNTnCÆCa2+ by interacting with the hydrophobic patch
prompted us to explore whether cTnI147–163 and bepridil
compete for cNTnCÆCa2+ [58]. Using 2D {1H, 15N} HSQC
NMR spectroscopy, we examined the binding of bepridil to
cNTnCÆCa2+ in the absence and presence of cTnI147–163
and of cTnI147–163 to cNTnCÆCa
2+ in the absence and pres-
ence of bepridil. The results show that bepridil and
cTnI147–163 bind to cNTnCÆCa
2+ simultaneously but the
aﬃnity of cTnI147–163 for cNTnCÆCa
2+ is reduced !3.5-fold
by bepridil and vice versa. This is consistent with a NMR
study showing a weaker binding of bepridil to cTnC in
the cTnC–cTnI complex than to isolated cTnC [56]. The
observed negative cooperativity between bepridil and cTnI
for cTnC suggests that the eﬀect of bepridil on muscle
fibers may result from a combination of many integrated
eﬀects within the myofibrillar lattice. The NMR structure
of the cNTnCÆCa2+ÆcTnI147–163Æbepridil ternary complex
reveals a binding site for cTnI147–163 primarily located on
the A/B interhelical interface and a binding site for bepridil
in the hydrophobic core of cNTnCÆCa2+ (Figs. 3 and 7A).
In the structure, the N-terminus of the peptide clashes with
part of the bepridil molecule due to both the steric hin-
Fig. 2. The chemical structures of bepridil, TFP, levosimendan, W7, anapoe, and EMD 57033.
M.X. Li et al. / Biochemical and Biophysical Research Communications 369 (2008) 88–99 91
Structure and chemical groups of Bepridil.  
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4.3.2 Dose response curve of Bepridil on donor human heart thin filaments 
 
In the previous section I described an assay in the in vitro motility system for 
performing dose responses for the drugs, using a single Ca2+ concentration. The effect 
of Bepridil was tested by this method in reconstituted thin filaments with 60 nM 
donor troponin, 60 nM human cardiac tropomyosin and 10 nM rabbit skeletal actin.  
0, 25, 50, 100, 200 and 300 µM of Bepridil were screened, at the same Ca2+ 
concentration as used for the dose response of EMD 57033, 0.037 µM Ca2+ and the 
data are shown in Figure 4-9. The resulting dose response curve was co-operative and 
thus the Hill equation was fitted to the data to determine the EC50 and the Hill 
coefficient. The optimal Bepridil concentration is 100 µM and the EC50 of the dose 
response curve is 48.8 ± 2.86 µM for the percentage motility and 54.35 ± 5.08 µM for 
the motile velocity of the filaments.  
 
Figure 4-9: Bepridil dose response curve on reconstituted donor thin filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity (left) and percentage motility (right) and of thin filaments reconstituted 
with native donor troponin treated with 0-300 µM Bepridil was measured at 0.037 µM 
Ca2+ to create a dose response curve. A single Bepridil concentration was tested in one 
motility flow chamber. The Hill equation was fitted to the data to calculate the EC50 and 
nH of the dose response curve.  
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4.3.3 The effect of Bepridil on the coupling between phosphorylated and 
dephosphorylated donor thin filaments      
 
Ca2+ activation curves were then performed using phosphorylated or 
dephosphorylated donor thin filaments to observe the effect of Bepridil on the 
relationship between phosphorylation and Ca2+ sensitivity. Since the optimal Bepridil 
concentration was 100 µM, this concentration was used for the rest of the 
experiments. Thin filaments were reconstituted with 60 µM phosphorylated or 
dephosphorylated troponin extracted from donor heart, 60 µM human cardiac 
tropomyosin and 10 µM rabbit skeletal actin. Six Ca2+ activation curves were 
performed with phosphorylated and dephosphorylated thin filaments treated or not 
with Bepridil. An example of such is shown in Figure 4-10. A summary of all the 
experiments can be found in Table 4-5 and Table 4-6. The raw data for all the 
experiments are shown in APPENDIX.  
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Figure 4-10: The effect of Bepridil on phosphorylated and dephosphorylated donor 
thin filaments 
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) donor troponin was 
measured over a range of Ca2+ concentrations in the same experiment of IVMA. Blue 
lines represent donor thin filaments and brown lines represent thin filaments treated with 
100 µM Bepridil. 
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Table 4-5: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated donor thin filaments treated with 100 µM Bepridil 
 
 
 
 
 
 
 
 
 
Table 4-6: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated donor thin filaments treated with 100 µM Bepridil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  p<0.05, ** p<0.01; for presence and absent of reagent. † p<0.05, †† p<0.01; for the effect of 
phosphorylation. p values were calculated using one-way ANOVA. p values for the ratios were 
calculated using value t test compared to 1. EC50 was rounded to two significant figures. In 
brackets the number of experiments.  
 
 
 
 
 
 
 
 
 
Table 0-1: Ca2+ sensitivity data for the motile velocity of phosphorylated and 
dephosphorylated donor thin filaments treated with 100 µM Bepridil. 
 
 
Treatment( EC50,(µM( Ratio(EC50(
P/dP(
nH( Max(motile(
velocity,(μm/sec(
Donor((((((((((((((P( 0.13%±%0.011%(6)% 1.67%±%0.12%
†%
2.1%±%0.24% 2.05%±%0.18%(6)%
Donor((((((((((((dP( 0.077%±%0.0056%(6)%†% 1.33%±%0.15% 2.13%±%0.20%(6)%
Bepridil(((((((((P( 0.046%±%0.007%(6)%**% 0.98%±%0.11%% 1.36%±%0.14% 2.35%±%0.20%(6)*%
Bepridil((((((((dP( 0.047%±%0.0037%(6)%**% 1.43%±%0.16% 2.24%±%0.16%(6)%
Motile velocity (top) and percent ge motility (bo tom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) donor troponin was 
measured over a range of Ca2+ concentrations in the same experiment of IVMA. Blue 
lines represent donor thin filaments and orange lines represent thin filaments treated 
with 100 µM Bepridil (brown)  
 
Table 0-2: Ca2+ sensitivity data for the motile velocity of phosphorylated and 
dephosphorylated donor thin filaments treated with 100 µM Bepridil 
 
 
 
 
 
 
 
 
 
From the Ca2+ sensitivity curves it can be observed that there is a decrease in Ca2+ 
sensitivity upon phosphorylation of TnI in the donor heart, as expected from the 
response of the donor heart to adrenaline. The Ca2+ sensitivity change was from 
EC50= 0.13 ± 0.005 of phosphorylated to EC50= 0.072 ± 0.002 of dephosphorylated 
donor thin filaments for percentage motility (n=6, p<0.01) and from EC50= 0.13 ± 
0.011 of phosphorylated to EC50= 0.072 ± 0.002 of dephosphorylated donor thin 
filaments for motile velocity (n=6, p<0.05). It is noted that the EC50 and nH values 
were very similar for the percentage motility Ca2+ activation curves and the motile 
velocity curves. 100 µM of Bepridil increased the Ca2+ sensitivity of phosphorylated 
thin filaments by 2.8  ± 0.14 fold (p<0.0001, n=6) and of dephosphorylated donor thin 
filaments by 3.09  ± 0.59 (p<0.01, n=6) for percentage motility.  
 
Similar Ca2+ sensitivity curves were found in phosphorylated and dephosphorylated 
donor thin filaments treated with Bepridil. Thus, the Ca2+ sensitivity is uncoupled 
Treatment( EC50,(µM( Ratio(EC50(
P/dP(
nH( Max(%(motile(
Donor((((((((((((((P( 0.13%±%0.005%(6)% 1.73%±%0.03%%
††%
2.51%±%0.28%(6)% 93%±%1.93%(6)%
Donor((((((((((((dP( 0.072%±%0.002%(6)††% 1.96%±%0.08%(6)% 95.13%±%1%(6)%
Bepridil((((((((((P( 0.046%±%0.001%(6)**% 1.03%±%0.01%% 1.97%±%0.10%(6)% 95.6%±%0.83%(6)%
Bepridil((((((((dP( 0.045%±%0.001%(6)**% 2.03%±%0.13%(6)% 96.46%±%0.83%(6)%
*  p<0.05, ** p<0.01; for presence and absent of reagent. † 0<0.05, †† p<0.01 for the effect of 
phosphorylation. p values were calculated using one- way ANOVA. p values for the ratios were 
calculated using value t test compared to 1. EC50 was rounded to two significant figures. In brackets the 
number of experiments.  
 157 
From the Ca2+ sensitivity curves it can be observed that there is a decrease in Ca2+ 
sensitivity upon phosphorylation of TnI in the donor troponin, as expected. The Ca2+ 
sensitivity change was from EC50 = 0.13 ± 0.005 for phosphorylated to EC50 = 0.072 ± 
0.002 for dephosphorylated donor thin filaments for percentage motility (n = 6, 
p<0.01) and from EC50 = 0.13 ± 0.011 for phosphorylated to EC50 = 0.072 ± 0.002 for 
dephosphorylated donor thin filaments for motile velocity (n = 6, p<0.05). It is noted 
that the EC50 and nH values were very similar for the percentage motility Ca2+ 
activation curves and the motile velocity curves. 100 µM of Bepridil increased the 
Ca2+ sensitivity of phosphorylated thin filaments by 2.8  ± 0.14 fold (p<0.0001, n = 6) 
and of dephosphorylated donor thin filaments by 1.6  ± 0.06 fold (p<0.01, n = 6) for 
percentage motility.  
Ca2+ sensitivity curves that are different in phosphorylated and dephosphorylated 
donor troponin were found to be the same in phosphorylated and dephosphorylated 
donor thin filaments treated with Bepridil. Thus, the Ca2+ sensitivity is uncoupled 
from the TnI phosphorylation in thin filaments treated with 100 µM Bepridil (mean 
ratio EC50 P + Bepridil/EC50 unP + Bepridil = 1.08 ± 0.03, p = 0.04, n = 6 for 
percentage motility and EC50 P + Bepridil/EC50 unP + Bepridil = 0.98 ± 0.11, p = 
0.84, n = 6 for motile velocity). Bepridil had no effect on the nH for either 
phosphorylated or dephosphorylated donor thin filaments. Finally, Bepridil increased 
the motile velocity of the phosphorylated donor thin filaments at saturating Ca2+ 
concentrations significantly (by 14.8 ± 3.2%, p = 0.006, n = 6) but not in 
dephosphorylated thin filaments (velocity only increased by 7.2  ± 4.6 %, p = 0.18, n 
= 6). Therefore, similar to EMD 57033, Bepridil increased the Ca2+ sensitivity of 
donor thin filaments and also caused uncoupling of the Ca2+ sensitivity from TnI 
phosphorylation.  
4.3.4 The effect of Bepridil on DCM E54K mutant thin filaments 
 
In this section the effect of Bepridil on DCM mutant thin filaments will be 
investigated. Thin filaments were reconstituted with 60 nM troponin extracted from 
donor heart, 60 nM Tpm1.1 E54K from baculovirus/sf9 and 10 µM actin. 2 Ca2+ 
activation curves were performed using 100 µM Bepridil on phosphorylated and 
dephosphorylated DCM E54K mutant thin filaments. An example of such curve in 
shown in Figure 4-11. Table 4-7 and Table 4-8 show the summary of the two 
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experiments performed. As we can see from these results, Bepridil increased the Ca2+ 
sensitivity of phosphorylated and dephosphorylated thin filaments equally (from EC50 
= 0.14 ± 0.008 to EC50 = 0.063 ± 0.001, n = 2 for phosphorylated and from EC50 = 
0.14 ± 0.014 to EC50 = 0.061 ± 0.008, n = 2 for dephosphorylated thin filaments, for 
percentage motility parameter). The Ca2+ sensitivity was uncoupled from TnI 
phosphorylation in E54K mutant thin filaments and remained uncoupled for the E54K 
mutant thin filaments treated with Bepridil (mean ratio EC50 P/dP = 1.05 ± 0.02, n = 
2, EC50 P + Bepridil/ dP + Bepridil = 1.01  ± 0.12, n = 2 for percentage motility and 
mean ratio EC50 P/dP = 1.062  ± 0.038, n = 2, EC50 P + Bepridil/EC50 dP + Bepridil = 
1.057  ± 0.11 for motile velocity). In conclusion, Bepridil showed the same effects as 
EMD 57033 in both donor and E54K mutant thin filaments.  
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Figure 4-11: Ca2+ activation curve of phosphorylated and dephosphorylated E54K 
mutant thin filaments treated with 100 µM Bepridil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) donor troponin and mutant 
E54K tropomyosin was measured over a range of Ca2+ concentrations in the same 
experiment of IVMA. Red lines represent E54K thin filaments and brown lines 
represent E54K thin filaments treated with Bepridil. 
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Table 4-7: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated E54K mutant thin filaments treated with 100 µM Bepridil 
 
 
 
 
 
 
 
 
 
Table 4-8: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated E54K mutant thin filaments treated with 100 µM Bepridil 
 
 
 
 
 
 
 
 
 
Table 3-10: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated E54K reconstituted thin filaments treated with 100 µM Bepridil !!!!
!!!!!!
Table 3-11: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated E54K reconstituted thin fil ments reated with 100 µM B pridil !!!
!!!!!!!
3.4 Discussion !
Treatment( EC50,(µM( Ratio(EC50(
P/dP(
nH( Max(%(motile(
E54K((((((((((((((P( 0.14%±%0.008%(2)% 1.05%±%0.02%%
(2)%
1.93%±%0.16%(2)% 93.13%±%1.85%(2)%
E54K((((((((((((dP( 0.14%±%0.014%(2)% 2.24%±%0.49%(2)% 92.38%±%0.13%(2)%
Bepridil((((((((((P( 0.063±%0.001%(2)% 1.01%±%0.12%
(2)%
1.45%±%0.56%(2)% 95.5%±%2%(2)%
Bepridil((((((((dP( 0.061%±%0.008%(2)% 1.3%±%0.23%(2)% 95.38%±%0.88%(2)%
Treatment( EC50,(µM( Ratio(EC50(
P/dP(
nH( Max(motile(
velocity,(μm/sec(
Donor((((((((((((((P( 0.14%±%0.06%(2)% 1.062%±%
0.038%†%
1.72%±%0.26%(2)% 3.54%±%0.1%(2)%
Donor((((((((((((dP( 0.13%±%0.0013%(2)%% 1.95%±%0.45%(2)% 3.45%±%0.045%(2)%
Bepridil(((((((((P( 0.071%±%0.015%(2)%% 1.057%±%
0.11%%
0.85%±%0.2%(2)% 3.71%±%0.095%(2)%
Bepridil((((((((dP( 0.067%±%0.0071%(2)%% 1.01%±%0.09%(2)% 3.67%±%0.01%(2)%
Values for Ca2+ sensitivity data for motile velocity and percentage motility in 
reconstituted E54K thin filaments. EC50 was rounded to two significant figures. In 
brackets the n number. Note that statistical analysis could not be performed due to 
lack of experimental repeats.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity(
E54K((((((((((P( 0.14%±%0.06%(2)% 1.062%±%%
%0.038%(2)%
1.72±%0.26%(2)% 3.54%±%01%(2)%
E54K((((((((dP( 0.13±%0.0013%(2)% 1.95%±%0.45%(2)% 3.45%±%0.045%(2)%
Bepridil((((P( 0.071%±%%0.015%(2)%% 1.057%±%
0.11%(2)%
0.85%±%0.2%(2)% 3.71%±%0.095%(2)%
Bepridil(((dP( 0.067%±%0.0071%(2)% 1.01%±%%0.09%(2)% 3.67%±%0.01%(2)%
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4.4 Discussion 
4.4.1 Studying the mechanism of the uncoupling phenomenon using 
pharmacological agents  
 
The objective of this chapter was to investigate the effects of two known Ca2+ 
sensitisers that bind to TnC on human muscle heart thin filaments in relationship to 
TnI phosphorylation. This contributes to the overall objective of my PhD thesis to 
investigate the molecular mechanism of the uncoupling phenomenon. Is the TnC-TnI 
N terminal extension interaction responsible for the uncoupling phenomenon seen in 
HCM and DCM mutations? Can agents that bind to TnC and affect the TnC-TnI 
interaction have an effect on the coupling between TnI phosphorylation and Ca2+ 
sensitivity? As we observed from the previous chapter, the IVMA is a very reliable 
assay for this investigation because the Ca2+ sensitivity of reconstituted thin filaments 
can be accurately measured and thus the molecular mechanism can be established. 
Functional cardiac troponin can be successfully extracted from samples of human 
heart and the phosphorylation status can also be manipulated using phosphatases or 
kinases (see Section 2.2.5). The uncoupling phenomenon was itself discovered using 
this assay (Memo et al, 2013, Bayliss et al, 2012) and the effect on the Ca2+ regulation 
of a single parameter (for example a mutation, effect of the phosphorylation status or 
addition of a drug) could be directly observed.  
4.4.2 Ca2+ sensitisers mimic the effects of HCM mutations 
 
The first agents that bind to TnC that I looked at were two Ca2+ sensitisers, EMD 
57033 and Bepridil. The effect of EMD 57033 and Bepridil was first tested in thin 
filaments reconstituted with donor troponin. EMD 57033 increased the Ca2+ 
sensitivity of the thin filaments, in agreement with previous measurements showing 
the action of EMD 57033 as a Ca2+ sensitiser on myofilaments in mice (Baudenbacher 
et al., 2008). Bepridil also increased the Ca2+ sensitivity of the native donor thin 
filaments by 3 fold. In addition, here for the first time I showed that the Ca2+ 
sensitisers EMD 57033 and Bepridil are able to uncouple the Ca2+ sensitivity response 
to the TnI phosphorylation by increasing the Ca2+ sensitivity of phosphorylated thin 
filaments more than the Ca2+ sensitivity of the dephosphorylated thin filaments. The 
uncoupling phenomenon has been proposed to be causative of DCM and has also 
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been found in some HCM mutations at the single filament level (reviewed by Messer 
and Marston, 2014). Thus the effect of the Ca2+ sensitisers on thin filaments is parallel 
to the effect of these HCM mutations, since it increases the Ca2+ sensitivity of the thin 
filaments and also uncouples the Ca2+ sensitivity from TnI phosphorylation.  
4.4.3 Mechanism of action of the Ca2+ sensitisers  
 
As we can observe from the IVMA experiments, EMD 57033 and Bepridil affected 
the EC50 of the Ca2+ activation curves rather than the maximum velocity, which 
suggest that it is likely that the Ca2+ sensitisers act directly on troponin to modulate 
the Ca2+ sensitivity rather than the cross-bridge cycle of the system. In fact, it has 
been shown that EMD 57033 binds to the C terminal domain of cTnC, using direct 
binding studies (Pan and Johnson, 1996) but also NMR studies (Maclachlan et al., 
1990). The binding of Bepridil to the hydrophobic pocket of TnC has been shown by 
the crystal structure of cTNC-3Ca2+-3 Bepridil (Li et al., 2000b).  
NMR studies on the binding of the small molecules to the troponin complex can give 
insights about the mechanism by which the molecules alter the Ca2+ sensitivity of the 
filaments. The sensitising action of EMD 57033 is considered to be indirect, by 
modifying the interaction of TnC with the TnI inhibitory peptide, thus promoting the 
“open” structure of troponin. EMD 57033 is shown to compete with TnI34-71 peptide 
for cTnC, but not with TnI128-147 (the inhibitory peptide). It is thought that EMD 
57033 disrupts the interaction of TnC-TnI34-71 and thus promoting the binding of the 
switch region of TnI to TnC (the troponin “open state”) (Wang et al., 2001). On the 
other hand, Bepridil is thought to also promote the troponin “open” state directly. 
Bepridil binds to the centre of the hydrophobic pocket of the TnC, at the same 
position where the switch peptide TnI147-163 binds. Bepridil is able to bind to the TnC- 
TnI147-163 complex, but with negative co-operativity. NMR studies of the TnC/TnI147-
163/Bepridil complex have shown that Bepridil can decrease the binding affinity of 
TnI147-163 for the hydrophobic pocket of TnC by 3.5 fold and vice versa (Wang et al., 
2002). Binding of Bepridil promotes the opening of the complex, inhibiting the 
release of Ca2+ and thereby enhancing the Ca2+ sensitivity of the myofilament (Li et 
al., 2008). Figure 4-12 shows the binding of EMD 57033 and Bepridil to TnC.   
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Figure 4-12: Binding of the Ca2+ sensitisers to TnC 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Ca2+ sensitivity of the myofilament is modulated by the phosphorylation of 
Serine 22 and 23 on the N terminal peptide of TnI, TnI1-30. This peptide interacts with 
the N terminal domain of the cTnC, close to the Ca2+ binding site and when the two 
Serines get phosphorylated, this interaction is changed. I propose that the Ca2+ 
sensitisers can induce uncoupling because they disrupt this interaction of the N 
terminal region of TnI with TnC allosterically. As mentioned earlier, EMD 57033 is 
able to displace TnI31-70. Bepridil binding is more complicated because not many 
recent studies have looked at this interaction directly. A study by Abusamhadneh et 
al, has shown through NMR that Bepridil and the N terminal extension of TnI binding 
give similar chemical shifts to the regulatory domain of cTnC (Abusamhadneh et al., 
2001).  It is possible that both Ca2+ sensitisers interfere with the modulation of Ca2+ 
A) NMR structure of Bepridil /cTnC/TnI147-163/Ca2+ complex in green. On the left, TnI 
is represented as helix and on the right, TnC is represented as surface and TnI147-163 is 
represented as a helix. B) NMR structure of EMD 57033/ cTnC/2Ca2+ complex in red, 
as helical representation on the left and as a surface on the right. The black sphere 
represents the Ca2+. Adapted from Li et al (Li et al., 2008)  
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sensitivity upon phosphorylation by displacing the TnI1-30 helix. TnI1-30 is intrinsically 
disordered therefore its structural location cannot be defined by structural strategies 
such as NMR or X-ray crystallography. One possible way to determine the exact 
mechanism by which EMD 57033 and Bepridil induce uncoupling is via molecular 
dynamics (MD) simulation of the whole troponin molecule. The effect of Ca2+ 
sensitisers that are found to uncouple the Ca2+ sensitivity from the TnI 
phosphorylation highlights the important role of the TnI N terminal peptide and its 
interaction with TnC. As mentioned earlier, DCM or HCM mutations found in any 
component of the thin filament also have the capability of uncoupling, and they might 
also do so by destabilising this interaction allosterically although its actual structure 
remains unknown.  
Interestingly, in experiments measuring isometric force in cardiac muscle myofibrils, 
EMD 57033 increased Ca2+ sensitivity but only caused uncoupling at short 
sarcomere lengths (Vikhorev et al., 2014).  Thus uncoupling may not be an all-or-
none phenomenon.  One possibility is that uncoupling may be related to 
Ca2+sensitivity if the Ca2+ sensitiser shifts the conformational equilibrium so far 
towards the N terminal bound conformation that it cannot be significantly influenced 
by phosphorylation of the N terminal peptide of TnI.  
EMD 57033 had a maximal effect at 30 µM in IVMA, which is in accordance with 
the in vivo experiments that also showed the same optimum concentration for 
enhancing contractility (Song, unpublished data). Furthermore, EMD 57033 had a bi-
phasic dose response curve, compared with Bepridil that reached a plateau at 100 µM. 
EMD 57033 concentrations higher than 30 µM inhibited the motility of thin filaments. 
It has been proposed that EMD 57033 also acts upon myosin apart from troponin and 
prevents it from denaturation (Radke et al., 2014). It might be possible that EMD 
57033 at high concentration acts upon myosin and this leads to the inactivation of the 
filaments. However, there has not been much evidence in the recent years about the 
action of EMD 57033 on myosin, thus a conclusion on that cannot be reached. 
Another possibility is that high concentrations of EMD 57033 inhibit troponin 
activation resulting in the promotion of the “off” state.  
In conclusion, the major finding was that the two small molecules that act as Ca2+ 
sensitisers, EMD 57033 and Bepridil, increased the Ca2+ sensitivity of actin thin 
filaments in vitro by 2.8 and 3.5 fold respectively. Furthermore, both small molecules 
uncoupled the Ca2+ sensitivity from TnI phosphorylation, mimicking the effect of 
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HCM mutations on the thin filaments. I propose that small molecules can induce 
uncoupling by altering the interaction of the phosphorylatable peptide in TnI with 
TnC.  
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5 Investigation of the effect of EGCG on reconstituted 
human thin filaments  
 
5.1 Introduction  
 
In the previous chapter I examined the effect of two Ca2+ sensitisers in terms of the 
relationship between the Ca2+ sensitivity and troponin I (TnI) phosphorylation in 
mutant and donor thin filaments. In this chapter I will examine the effect of a Ca2+ 
desensitiser for the same property.  
The Ca2+ desensitiser used in this chapter is Epigallocatechin-3-gallate (EGCG) 
(Tadano et al., 2010). EGCG is the most abundant polyphenol of green tea. The 
structure of EGCG can be found in Figure 5-1. Its benefits have been linked to many 
diseases, such as cancer (Chen et al., 2011), Alzheimer’s disease (Walker et al., 2015) 
and diabetes (Ahmad et al., 2015). EGCG also has antioxidant properties and it can 
affect many pathways such as growth factor-mediated pathways, the mitogen-
activated protein kinase-dependent pathway and the ubiquitin/proteasome degradation 
pathway (Mereles and Hunstein, 2011) Recently it has also been found to be 
cardioprotective, mainly ascribed to its antioxidant and anti-inflammatory properties. 
For example, EGCG protected the cardiovascular system of rats that were on a high 
fat diet (Zhong et al., 2015)  
 
Figure 5-1: Chemical structure of EGCG 
 
 
 
 
 
 
 
 
 
Int. J. Mol. Sci. 2011, 12             
 
5593
offered therapy options. Inveterate foes were the colleg  physicians, e pecially all those that worked 
on scientific projects concerning this rare disease with poor prognosis and limited therapeutic 
alternatives. Patients took the decision to go on and try this over-the-counter choice, sometimes even 
hidden from the negative posture of their attending physicians. This made it possible to extend our 
analysis from a case report to a report of cases in a cohort of these patients [2]. Furthermore, based on 
these findings, as well as on precedent basic research [3–5] and in spite of the difficulties concerning 
ethical matters related to the discussion as to whether EGCG is a drug or just a dietary supplement, a 
world leading research group is planning to start the first clinical trial with EGCG in patients wit   
AL amyloidosis [6,7]. 
A quick look at EGCG and/or green tea on PubMed.gov [8] today results in a listing of more than 
4000 publications since 1940. The first publications on EGCG alone as main polyphenol in green tea is 
dated 1985; an actualized review on health promoting effects of EGCG from green tea is currently 
available [9] (Figure 1). From these publications, the impression arises that EGCG could prevent, or 
even cure almost every disease: a panacea-related discredit cannot be denied. However, basic research 
provides clear support for hypotheses on the use of EGCG, and in spite of this fact, an apparent 
discrepancy between those results and the occurrence of awaited effects in clinical trials seems to 
linger on. 
Figure 1. Chemical structure of EGCG. Some currently documented structure-function 
relationships are depicted in this figure. The pyrogallol-type structure on the B-ring 
induces apoptosis and possesses strong antioxidative activity undergoing autooxidation to 
form reactive oxygen species [10,11]. The galloyl moiety (D-ring, gallate group) is the 
critical structure in the inhibition of fatty-acid synthase leading to cytotoxicity in human 
cancer cells [12]. Both components B and D contribute to the exertion of biological 
activities related to the cell-surface 67 kDa laminin receptor [13,14]. EGCG molecular 
docking fractions for amyloid remodeling activity are still not known.
 
Structure of Epigallocatechin-3-gallate (EGCG).  
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EGCG has been found also to interact with the myofilament, and more specifically 
with cardiac troponin C (cTnC) (Tadano et al., 2010, Robertson et al., 2009, Fuchs 
and Grabarek, 2013). EGCG has been found to decrease the Ca2+ sensitivity of 
skinned cardiac muscle fibres (Tadano et al., 2010). It also decreased slightly the 
sensitivity of skeletal fibres, but the effect was much weaker. Using NMR approaches 
it was then proposed that EGCG decreases the affinity of Ca2+ to the cTnC by binding 
to cTnC. EGCG binds to the C terminus of the cTnC, in the presence of cTnI, as 
opposed to other cardiotonic molecules such as EMD 57033 (Botten et al., 2013). 
EGCG is another molecule that could affect the TnC-TnI interaction that we 
hypothesise being crucial for the uncoupling phenomenon found in cardiomyopathies 
of the thin filament. The aim of this chapter is to observe the effect of EGCG on the 
coupling between the TnI phosphorylation and the Ca2+ sensitivity in wild type (WT) 
and Dilated Cardiomyopathy (DCM) or Hypertrophic Cardiomyopathy (HCM) 
mutant thin filaments using the in vitro motility assay (IVMA).  
 
5.2 Investigation of the effect of EGCG on donor thin filaments  
 
5.2.1 In vitro motility assay results of donor phosphorylated and 
dephosphorylated thin filaments treated with EGCG.  
 
Based on the results of Tadano et al (Tadano et al., 2010) 100 µM EGCG was tested 
on donor thin filaments. Two Ca2+ curves were determined using phosphorylated and 
dephosphorylated thin filaments. Thin filaments were reconstituted using 60 nM 
human cardiac tropomyosin, 60 nM troponin extracted from donor heart and 10 nM 
rabbit skeletal actin. Six experiments were performed with phosphorylated and 
dephosphorylated thin filaments treated with EGCG. An example of a Ca2+ curve is 
shown in Figure 5-2 and a summary of the experiments can be found in Figure 5-2. 
Full tables for all the data can be found in APPENDIX.  
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Figure 5-2: Ca2+ activation curve of phosphorylated or dephosphorylated donor thin 
filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted with 
native (solid lines) or dephosphorylated (dotted lines) donor troponin was measured over a 
range of Ca2+ concentrations in the same experiment of IVMA. Blue lines represent donor 
thin filaments and green lines represent donor thin filaments treated with 100 µM EGCG. 
The black dashed line represents 0.074 µM Ca2+ concentration. 
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Table 5-1: Ca2+ sensitivity data for motile velocity of donor thin filaments treated 
with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
Table 5-2: Ca2+ sensitivity data for percentage motility of donor thin filaments treated 
with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  p<0.05, ** p<0.01; for presence and absent of reagent. †† p<0.01; for the effect of 
phosphorylation. p values were calculated using one- way ANOVA. p values for the ratios were 
calculated using single value t test compared to 1. EC50 was rounded to two significant figures. In 
brackets the n number.  
Treatment( EC50,(µM( Ra1o(EC50(P/
unP(
nH( Max(mo1le(
velocity,(µm/sec(
Donor(((((((((((((P( 0.11$±$0.082$(6)$ 2.11$±$
0.25$(6)$††$
1.73$±$$0.34$(6)$ 3.31$±$0.15$(6)$
Donor(((((((((((dP( 0.053$±$0.014$(6)$ 1.63$±$0.2$(6)$ 3.38$±$0.11$(6)$
EGCG(((((((((((((P( 0.3$±$$0.059$(6)$$ 2.91$±$$
0.44$(6)$††$
1.42$±$0.23$(6)$ 2.79$±$0.099$(6)*$$
EGCG((((((((((((dP( 0.1$±$0.01$(6)$ 1.54$±$0.18$(6)$ 2.94$±$0.12$(6)$*$
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
Donor(((((((P( 0.14%±%0.03%(6)% 2.24%±%%
%0.1%(6)%††%
1.67±%0.22%(6)% 88.17%±%4.45%(6)%
Donor((((((dP( 0.059%±%0.01%(6)% 1.5%±%0.21%(6)% 88.42%±%4.81%(6)%
EGCG(((((((((P( 0.25%±%%0.029%(6)%% 1.73%±%
0.16%(6)%††%
2.04%±%0.27%(6)% 79.83%±%4.81%(6)%
EGCG(((((((dP( 0.15%±%0.02%(6)%**% 1.78%±%%0.3%(6)% 83%±%4.99%(6)%
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We can see from the Ca2+ sensitivity curves that 100 µM EGCG decreased the Ca2+ 
sensitivity of both phosphorylated and dephosphorylated thin filaments. The Ca2+ 
sensitivity decreased for the phosphorylated thin filaments by 2.15 ± 0.45 fold and by 
2.80 ± 0.48 fold for the dephosphorylated thin filaments, as measured by the mean 
ratio of EC50 P + EGCG/EC50 P for percentage motility of the filaments. The motile 
velocity gave similar results, with a mean ratio of EC50 P + EGCG/ EC50 P = 2.74 ± 
0.48 for phosphorylated and a mean ratio of EC50 dP + EGCG/ EC50 dP = 2.07 ± 0.31 
for dephosphorylated thin filaments. From these results, we can observe that EGCG 
does not have the same effect as EMD 57033 and Bepridil, as it retains the coupling 
between Ca2+ sensitivity and TnI phosphorylation on donor thin filaments. 
Furthermore, EGCG had an effect on the maximum motile velocity of the filaments. 
EGCG decreased the maximum velocity of the filaments (from 3.38 ± 0.17 to 2.79 ± 
0.099 µm/sec for phosphorylated thin filaments, p = 0.03, n = 6 and from 3.38 ± 0.17 
to 2.94 ± 0.12 µm/sec for dephosphorylated thin filaments, p = 0.01, n = 6). EGCG 
had no effect on nH.  
5.2.2 Dose response curve of EGCG on donor thin filaments  
 
The next step was to determine a dose response curve for EGCG on donor thin 
filaments using the established technique of the IVMA and testing different 
concentrations of EGCG at a single Ca2+ concentration. Thin filaments were 
reconstituted using 60 nM phosphorylated or dephosphorylated troponin extracted 
from donor hearts, 60 nM human cardiac tropomyosin and 10 nM rabbit skeletal 
actin. Because EGCG decreased the Ca2+ sensitivity of the filaments, a slightly higher 
Ca2+ concentration was chosen compared to this one used for EMD 57033 and 
Bepridil. The chosen Ca2+ concentration was 0.074 µM Ca2+. A dose response curve 
for phosphorylated and dephosphorylated donor thin filaments was created. One 
experiment was performed with 0, 25, 50, 100 and 200 µM EGCG in filaments 
containing phosphorylated and dephosphorylated troponin extracted from donor heart, 
shown in Figure 5-3. From the dose response curve for the percentage motility and 
motile velocity we can observe that EGCG inhibited the movement of the filaments. 
EGCG decreased the percentage motility of phosphorylated thin filaments from 24.25 
± 2.87 to 4.5 ± 0.58% (with 200 µM) and the motile velocity from 2.14 ± 0.07 to 1.45  
± 0.01 (with 200 µM). The percentage motility of dephosphorylated thin filaments 
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was decreased from 50.75 ± 5.12 to 9.5 ± 1.73 (200 µM) and the motile velocity from 
2.58 ± 0.064 to 1.58 ± 0.03 (200 µM). EGCG does not saturate and the dose response 
curve is not co-operative. The change of fraction motile was plotted for 
phosphorylated and dephosphorylated filaments treated with different concentrations 
of EGCG and the Hill equation was fitted to the data. The dose response in both cases 
reached a plateau at concentration of 100 µM, with an EC50 of 70 ± 7 µM and nH of 
1.3 ± 0.2 for the phosphorylated and EC50 of 60 ± 1 µM and nH 1.3 ± 0.1 for the 
dephosphorylated thin filaments.  
 
Figure 5-3: EGCG dose response curve for phosphorylated and dephosphorylated thin 
filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity (left) and percentage motility (right) and of thin filaments reconstituted with 
phosphorylated (sold lines) or dephosphorylated (dotted lines) donor troponin treated with 
0-200 µM EGCG was measured at 0.074 µM Ca2+ to create a dose response curve. A single 
EGCG concentration was tested in one motility flow chamber. The inset plots the change in 
fraction motility at 0.074 Ca2+ of phosphorylated (solid lines) and dephosphorylated (dotted 
lines) thin filaments treated with increased EGCG concentrations. The Hill curve was fitted 
to the data to calculate the EC50 and nH.  
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5.2.3 Reversibility of the action of EGCG 
 
The reversibility of EGCG effect was tested in reconstituted thin filaments from 
donor proteins. Thin filaments were reconstituted by incubating these components: 60 
nM phosphorylated or dephosphorylated troponin extracted from donor heart, 60 nM 
human cardiac tropomyosin, 10 nM rabbit skeletal actin with or without 100 µM 
EGCG, in a similar fashion to all the experiments carried out in this chapter. Thin 
filaments were then added to the flow cell chambers. Subsequently, Buffers C and D 
containing 0.074 µM Ca2+ and 100 µM EGCG were added to the flow cell in the same 
manner as for the dose response curves, and images were recorded. To wash out the 
drug, buffers C and D containing 0.074 µM Ca2+ without EGCG were added in the 
same flow cell and images were recorded. Results of the reversibility experiment is 
shown in Figure 5-4. It is clear from the graph that after the EGCG was washed out, 
the percentage motility and the motile velocity at 0.074 µM Ca2+ were returned to the 
initial values without EGCG, making EGCG fully reversible.  
 
Figure 5-4: Reversibility of EGCG 
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Motile velocity (left) and percentage motility (right) of thin filaments treated with 100 µM 
EGCG at 0.074 µM Ca2+ before and after drug washout. 4 measurements of motility of 
phosphorylated or dephosphorylated donor thin filaments were taken. Phosphorylated thin 
filaments were added in one motility chamber and dephosphorylated thin filaments in the 
other motility chamber of the same motility cell. For the reversibility experiment, 4 
measurements were taken of thin filaments treated with 100 µM (C and D buffers 
containing 100 µM EGCG) and then the same motility chamber was washed out with 50 µl 
of buffers C and D without EGCG and 4 measurements were taken. Bar charts represent the 
average of the 4 motility measurements for both percentage motility parameter and motile 
velocity with SEM.  
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5.3 The effect of EGCG on TPM1 mutations that cause DCM or 
HCM  
5.3.1 The effect of EGCG on TPM1 E54K DCM mutation mutant thin 
filaments 
 
After the effect of EGCG on donor thin filaments was tested, the effect of EGCG on 
mutant thin filaments was tested. The first mutation that was examined was the DCM 
mutations TPM1 E54K. The tropomyosin was purified from baculovirus/sf9 cells so 
they are easy to study by the IVMA since proteins do not need to be extracted from 
tissue.  
Every experiment described in this section was performed using thin filaments 
reconstituted using 60 nM phosphorylated or dephosphorylated troponin extracted 
from cardiac tissue, 60 nM recombinant Tpm1.1 E54K and 10 nM rabbit skeletal 
actin.  
E54K thin filaments were reconstituted with phosphorylated or dephosphorylated 
troponin and were treated with 100 µM EGCG similar to the donor thin filaments. 
Five experiments were performed comparing phosphorylated and dephosphorylated 
mutant thin filaments treated with 100 µM EGCG and representative Ca2+ curves for 
percentage motility and motile velocity are shown in Figure 5-5. A summary of the 
experiments can be found in Table 5-3 and Table 5-4.  We can see from the Ca2+ 
curves, the Ca2+ sensitivity of phosphorylated and dephosphorylated E54K mutant 
thin filaments is very similar. This is also shown from the calculated EC50 of the Ca2+ 
activation curves (mean ratio of EC50P/dP = 0.97 ± 0.041 for motile velocity and 
mean ratio EC50P/dP = 0.95 ± 0.0035 for percentage motility). This confirms the 
experiments with E54K thin filaments described in Section 4.2.4 and Section 4.3.4 
and also the results found by Dr Massimiliano Memo.  100 µM EGCG decreased the 
Ca2+ sensitivity of phosphorylated thin filaments by 2.33 ± 0.53, n = 5 for percentage 
motility and 1.45 ± 0.43, n = 5 as measured by the mean ratio EC50P + EGCG/EC50 P. 
However, 100 µM increased the Ca2+ sensitivity slightly for dephosphorylated thin 
filaments (mean ratio dP EC50 + EGCG/ EC50 dP = 0.68 ± 0.1 for percentage motility 
and 0.47 ± 0.072 for motile velocity). This had as a result to re-couple the Ca2+ 
sensitivity to TnI phosphorylation (mean ratio EC50P/unP = 3.17 ± 0.37, p = 0.008, n 
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= 5 for percentage motility and mean ratio EC50P/dP = 2.75 ± 0.44, p = 0.016, n = 5 
for motile velocity). 
 
Figure 5-5: Ca2+ activation curve comparing phosphorylated or dephosphorylated 
E54K mutant thin filaments treated with 100 µM EGCG 
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) donor troponin and mutant 
E54K tropomyosin was measured over a range of Ca2+ concentrations in the same 
experiment of IVMA. Red lines represent E54K thin filaments and green lines represent 
thin filaments treated with 100 µM EGCG.   
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Table 5-3: Ca2+ sensitivity data for motile velocity of phosphorylated or 
dephosphorylated E54K DCM mutant reconstituted thin filaments treated with 100 
µM EGCG 
 
 
 
 
 
 
 
 
Table 5-4: Ca2+ sensitivity data for percentage motility of phosphorylated or 
dephosphorylated E54K DCM mutant reconstituted thin filaments treated with 100 
µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† p<0.05, †† p<0.01; for the effect of phosphorylation. p values were calculated using 
one-way ANOVA. p values for the ratios were calculated using single value t test 
compared to 1. EC50 was rounded to two significant figures. In brackets the n number.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
E54K(((((((((((((P( 0.11$±$0.013$(5)$ 0.95$±$$
0.0033$(5)$
3.4$±$0.39$(5)$ 89.98$±$0.48$(5)$
E54K(((((((((((dP( 0.11±$0.019$(5)$ 3.84$±$0.48$(5)$ 90.45$±$3.53$(5)$
EGCG(((((((((((P( 0.27$±$$0.034$(5)$ 3.17$±$
0.37$(5)$††$
$
3.68$±$0.78$(5)$ 84.3$±$3.37$(5)$
EGCG(((((((((dP( 0.071$±$0.0046$(5)$†$ 3.25$±$$0.34$(5)$ 88.55$±$3.31$(5)$
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
E54K(((((((((((((P( 0.15%±%0.043%(5)% 0.97%±%%
0.0413%(5)%
2.73%±%0.55%(5)% 3.27%±%0.29%(5)%
E54K(((((((((((dP( 0.16%±%0.043%(5)% 2.8%±%0.63%(5)% 3.26%±%0.24%(5)%
EGCG(((((((((((P( 0.17%±%%0.021%(5)% 2.75%±%
0.44%(5)%†%
%
2.18%±%0.59%(5)% 2.64%±%0.024%(5)%
EGCG(((((((((dP( 0.062%±%0.0058%(5)%†% 3.33%±%%1.15%(5)% 2.9%±%0.11%(5)%
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5.3.2 The effect of EGCG on TPM1 E40K DCM mutant thin filaments 
 
TPM1 E40K was identified in the same study as E54K by Olson et al as a DCM 
causing mutation (Olson et al., 2001). This mutation has been also extensively studied 
by the Marston group. E40K mutation causes a decrease in the Ca2+ sensitivity as 
shown by IVMA experiments with reconstituted thin filaments but also using ATPase 
assay (Mirza et al., 2005, Mirza et al., 2007)). Memo et al confirmed these findings 
and furthermore showed that this mutation causes uncoupling in reconstituted thin 
filaments (Memo et al, 2013).  
E40K thin filaments reconstituted with phosphorylated or dephosphorylated troponin 
and recombinant E40K Tpm1.1 were treated with 100 µM EGCG similar to the donor 
thin filaments. Three Ca2+ curves were constructed comparing phosphorylated or 
dephosphorylated E40K mutant thin filaments treated or untreated with 100 µM 
EGCG, and a representative Ca2+ curve for percentage motility and motile velocity is 
shown in Figure 5-6. Data for phosphorylated and dephosphorylated E54K thin 
filaments were combined with data from Dr Massimiliano Memo’s thesis. Two Ca2+ 
activation curves were performed; only comparing treated phosphorylated and 
dephosphorylated thin filaments, to increase the n numbers for the treatment group. It 
is noted that paired one-way ANOVA could not be performed using all the data 
because it requires data to be available for all the four groups.  For this reason, the 
data for E40K were analysed using paired t test. Summary of all the data can be found 
in Table 5-5 and Table 5-6. Thin filaments reconstituted with both E40K and E54K 
showed a similar trend. Phosphorylated and dephosphorylated E40K thin filaments 
had analogous Ca2+ sensitivities, as shown from the Ca2+ curves and the EC50P/dP 
ratios (EC50P/dP ratio for motile velocity = 1.02 ± 0.055, n = 6 and EC50P/dP ratio for 
percentage motility = 1.02 ± 0.0069, n = 8). 100 µM EGCG decreased the Ca2+ 
sensitivity of phosphorylated thin filaments by 1.7 ± 0.43 fold, n = 3 for percentage 
motility and 1.56 ± 0.13 fold, n = 3 for motile velocity. On the other hand, EGCG 
increased the Ca2+ sensitivity of dephosphorylated thin filaments from EC50 = 0.11 ± 
0.022 (n = 6) to EC50 = 0.062 ± 0.0085 (n = 5) for motile velocity and EC50 = 0.17 ± 
0.03 (n = 8) to EC50 = 0.052 ± 0.013 (n = 5, p<0.05) for percentage motility. This 
resulted in Ca2+ sensitivity restoration upon TnI phosphorylation, shown by the EC50 
ratios (EC50P/dP + EGCG= 3.05 ± 0.56, n = 5, p = 0.02 for motile velocity and 
EC50P/dP + EGCG = 4.63 ± 0.95, n = 5, p = 0.02 for percentage motility). 
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Figure 5-6: Ca2+ activation curve comparing phosphorylated or dephosphorylated 
E40K mutant thin filaments treated with 100 µM EGCG 
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) donor troponin and mutant 
E40K tropomyosin was measured over a range of Ca2+ concentrations in the same 
experiment of IVMA. Red lines represent E40K thin filaments and green lines represent 
thin filaments treated with 100 µM EGCG.   
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Table 5-5: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated E40K thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
Table 5-6: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated E40K mutant thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
E40K(((((((((((((P( 0.18%±%0.029%(8)% 1.02%±%%
0.0069%(8)%
2.04%±%0.33%(8)% 90.74%±%1.37%(8)%
E40K(((((((((((dP( 0.17±%0.03%(8)% 2.03%±%0.27%(8)% 91.85%±%1.48%(8)%
EGCG(((((((((((P( 0.22%±%%0.038%(5)% 4.63%±%
0.95%(5)%†%
%
2.82%±%0.48%(5)% 89.3%±%2.76%(5)%
EGCG(((((((((dP( 0.052%±%0.013%(5)%*†% 1.46%±%%0.36%(5)% 91.85%±%1.78%(5)%
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
E40K(((((((((((((P( 0.11$±$0.019$(6)$ 1.02$±$$
0.055$(6)$
2.56$±$$0.55$(6)$ 3.02$±$0.17$(6)$
E40K(((((((((((dP( 0.11±$0.022$(6)$ 2.74$±$0.85$(6)$ 3.13$±$0.2$(6)$
EGCG(((((((((((P( 0.18$±$$0.033$(5)$*$ 3.05$±$
0.56$(5)$†$
$
2$±$0.39$(5)$ 2.86$±$0.047$(5)$
EGCG(((((((((dP( 0.062$±$0.0085$(5)$†$ 1.84$±$0.4$(5)$ 3.15$±$0.11$(5)$
*  p<0.05; for presence and absent of reagent. † p<0.05; for the effect of phosphorylation. p 
values were calculated using multiple t tests. p values for the ratios were calculated using 
single value t test compared to 1. EC50 was rounded to two significant figures. In brackets 
the n number.  
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5.3.3 The effect of EGCG on TPM1 E180G HCM mutant thin filaments 
TPM1 E180G mutation was first identified in a study by Thierfelder et al, where a 
family affected by fHCM was screened for mutations in the α tropomyosin gene 
(Thierfelder et al., 1994). The affected individuals were heterozygous for the mutation 
at nucleotide position 595 at exon 5 of the TPM1 gene, which encodes for an 
exchange of a glutamic acid residue to a glycine residue in position 180.  A previous 
study by the Marston lab has shown that reconstituted thin filaments with 
recombinant AS α tropomyosin E180G had an increased Ca2+ sensitivity (Bing et al., 
1997), consistent with the hypothesis that the molecular mechanism of HCM is 
increased Ca2+ sensitivity. A transgenic (TG) mouse model expressing Tpm1.1 
E180G has been developed that showed signs of hypertrophy: increased body weight 
ratios, fibrosis and increased sensitivity to Ca2+ of the myofilaments (Prabhakar et al., 
2001). Since the two DCM mutations in Tpm1.1 uncouple the Ca2+ sensitivity to TnI 
phosphorylation and EGCG can reverse this, we asked whether the same applied to 
HCM. There are no data on the coupling between TnI phosphorylation and Ca2+ 
sensitivity in the E180G mutation on the thin filaments.  
Experiments with E180G mutant thin filaments were performed using the same 
protocols as previously described. A representative Ca2+ titration curve is shown in 
Figure 5-7 and the results are summarized in Table 5-7 and Table 5-8. Three Ca2+ 
activation curves were performed with phosphorylated or dephosphorylated E180G 
mutant tropomyosin treated or untreated with 100 µM EGCG. Two additional Ca2+ 
activation curves were performed, only comparing phosphorylated and 
dephosphorylated E180G mutant thin filaments treated with 100 µM EGCG. In order 
to be able to include all the data in the analysis, a t test was performed.  For the first 
time it was demonstrated that E180G mutant thin filaments were uncoupled, with 
EC50 = 0.086 ± 0.013 µM for the percentage motility of phosphorylated thin filaments 
and EC50 = 0.087 ± 0.011 µM for dephosphorylated thin filaments, giving a ratio of 
0.98 ± 0.022 (n = 3). However, in the presence of 100 µM EGCG, the EC50 was 0.11 
± 0.011 µM for phosphorylated and 0.048 ± 0.0033 µM for dephosphorylated thin 
filaments, giving a ratio of 2.41 ± 0.32 (p = 0.01, n = 5). The motile velocities data 
gave very similar results. EGCG also had an effect on the maximum velocities of the 
filaments, where there was a decrease of V max from 3.1 ± 0.17 µm/sec to 2.7 ± 
0.094 µm/sec (n = 5, p = 0.03). These results also show that EGCG restored the Ca2+ 
sensitivity response to TnI phosphorylation.  
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Figure 5-7: Ca2+ activation curve comparing phosphorylated and dephosphorylated 
E180G mutant thin filaments treated with 100 µM EGCG 
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) donor troponin and mutant 
E180G tropomyosin was measured over a range of Ca2+ concentrations in the same 
experiment of IVMA. Purple lines represent E180G thin filaments and green lines 
represent thin filaments treated with 100 µM EGCG.   
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Table 5-7: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated E180G mutant thin filaments treated with EGCG 
 
 
 
 
 
 
 
 
 
 
 
Table 5-8: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated E180G mutant thin filaments treated with EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  p<0.05; for presence and absent of reagent. † p<0.05; for the effect of 
phosphorylation. p values were calculated using multiple t tests. p values for the 
ratios were calculated using single value t test compared to 1. EC50 was rounded to 
two significant figures. In brackets the n number.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
E180G((((((((((P( 0.086%±%0.013%(3)% 0.98%±%%
0.022%(3)%
5.38%±%1.8%(3)% 93.91%±%1.23%(3)%
E180G((((((((dP( 0.087%±%0.011%(3)% 4.38%±%0.98%(3)% 92.92%±%1.06%(3)%
EGCG(((((((((((P( 0.11%±%%0.011%(5)% 2.41%±%
0.32%(5)%†%
%
3.3%±%0.69%(5)% 82.77%±%2.2%(5)%
EGCG(((((((((dP( 0.048%±%0.0033%(5)%*†% 2.68%±%%0.84%(5)% 90.4%±%2.43%(5)%
Treatment( EC50,(µM( Ra1o(
EC50(P/
unP(
nH( Max(mo1le(
velocity,(µm/sec(
E180G((((((((((((P( 0.089%±%0.0019%(3)% 0.86%±%%
0.13%(3)%
2.66%±%%0.13%(3)% 3.1%±%0.17%(3)%
E180G((((((((((dP( 0.11%±%0.019%(3)% 3.74%±%0.61%(3)% 3.04%±%0.13%(3)%
EGCG(((((((((((P( 0.11%±%%0.0076%(5)%% 2.71%±%
0.78%(5)%†%
%
2.87%±%0.88%(5)% 2.7%±%0.094%(5)%
EGCG(((((((((dP( 0.058%±%0.0045%(5)%*†% 2.7%±%0.094%(5)% 2.87%±%0.057%†(5)%
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5.3.4 Dose response curve of re-coupling by EGCG 
 
Similarly to the dose response of EGCG in phosphorylated and dephosphorylated 
donor thin filaments (see Section 5.2.2), a dose response curve was constructed using 
Tpm1.1 E180G thin filaments. 25-200 µM EGCG were tested in a single Ca2+ 
concentration, 0.037 µM Ca2+. The dose response curve for percentage motility and 
motile velocity of the filaments is shown in Figure 5-8. Initially motility is the same 
but with increasing concentrations of EGCG, motility of phosphorylated thin 
filaments was reduced and motility of dephosphorylated thin filaments was increased 
at 0.037 µM Ca2+, indicating that EGCG re-coupled the Ca2+ change due to the 
phosphorylation. The Ca2+ curves reached a plateau at 100 µM. The difference in 
percentage motility between phosphorylated and dephosphorylated mutant filaments 
was plotted and Hill equation was fitted to the data. The calculated EC50 was 58.7 ± 
11.9 µM and the nH was 3.16 ± 1.8.  
 
Figure 5-8: Dose response curve for EGCG on E180G mutant thin filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A) Motile velocity (top) and percentage motility (bottom) of phosphorylated (sold lines) or 
dephosphorylated (dotted lines) E180G mutant thin filaments treated with 0-200 µM EGCG 
was measured at 0.037 µM Ca2+. B) Percentage motility difference between phosphorylated 
and dephosphorylated E180G mutant filaments treated with increased EGCG concentrations 
at 0.037 µM Ca2+. The Hill curve was fitted to the data to calculate theEC50 and nH.  
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5.4 The effect of EGCG on three further DCM mutations  
5.4.1 The effect of EGCG on TNNC2 G159D DCM mutant thin filaments 
 
In the initial studies tropomyosin mutation were investigated because native mutant 
tropomyosin can be produced by baculovirus/sf9 cells and tested against human 
cardiac troponin. DCM and some HCM mutations in troponin and actin are also able 
to uncouple the Ca2+ sensitivity from the TnI phosphorylation. In order to determine 
whether re-coupling by EGCG is a general feature of DCM and HCM more mutants 
were examined. First of all, the effect of EGCG was tested in the TnC mutation 
G159D. The missense mutation in TnC (TNNC2) Gly159Asp (G159D) was first 
discovered by Mogensen et al, in a study screening 235 patients with idiopathic DCM 
(Mogensen et al., 2004b). Steve Marston’s lab obtained a cardiac muscle sample from 
an affected member of the original family from this study who has had a heart 
transplant.  
Structural studies have shown that the position of the mutation is close to the N 
terminal regulatory peptide of TnI, which is important for the phosphorylation 
dependent modulation of Ca2+ sensitivity. Dr Massimiliano Memo has performed 
IVMA experiments with this DCM mutation and has found that there is uncoupling of 
the Ca2+ sensitivity from the TnI phosphorylation (Memo et al., 2013) For this reason, 
this mutation was selected to observe the action of EGCG on the coupling between 
Ca2+ sensitivity and TnI phosphorylation.  
Thin filaments were reconstituted using 60 nM human cardiac tropomyosin, 60 nM 
troponin extracted from human heart sample containing the G159D mutation and 10 
nM rabbit skeletal actin. To investigate the effect of EGCG on the Ca2+ sensitivity in 
relationship with TnI phosphorylation, the G159D extracted troponin was divided into 
two samples. One sample was kept in the native form and the other one was 
thoroughly dephosphorylated (see section 2.2.6.2). The original phosphorylation level 
of G159D sample was 1.47 molsPi/mol TnI and after dephosphorylation was 0.2 
molsPi/mol TnI (see APPENDIX). Five Ca2+ activation curves were constructed 
comparing phosphorylated and dephosphorylated G159D mutant thin filaments with 
and without 100 µM EGCG. A representative Ca2+ curve for percentage motility and 
motile velocity is shown in Figure 5-9. The data are summarised in Table 5-9 and 
Table 5-10. We can see from the Ca2+ sensitivity curves, that in G159D mutant thin 
 184 
filaments the Ca2+ sensitivity is uncoupled to the TnI phosphorylation (EC50 P/dP = 
0.97 ± 0.035 for percentage motility and 0.92 ± 0.0031 for motile velocity, n = 5), 
supporting the results of Dr Massimiliano Memo and Dr Emma Dyer. In the presence 
of 100 µM EGCG, the Ca2+ sensitivity was re-coupled to TnI phosphorylation 
(EC50P/dP + EGCG = 2.25 ± 0.41, p = 0.04, n = 5 for percentage motility and 
EC50P/dP + EGCG = 2.29 ± 0.46, p = 0.048, n = 5 for motile velocity). EGCG also 
had an effect on the motile velocity of the G159D reconstituted thin filaments, 
decreasing the motile velocity of phosphorylated thin filaments from 3.65 ± 0.15 µM 
to 2.47 ± 0.13 µM, p<0.05, n = 5.  
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Figure 5-9: Ca2+ activation curves for phosphorylated and dephosphorylated G159D 
mutant thin filaments treated with EGCG 
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with native (solid lines) or dephosphorylated (dotted lines) troponin from G159D 
sample was measured over a range of Ca2+ concentrations in the same experiment of 
IVMA. Red lines represent G159D thin filaments and green lines represent thin 
filaments treated with 100 µM EGCG.   
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Table 5-9: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated G159D DCM mutant thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
Table 5-10: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated G159D mutant thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  p<0.05; for presence and absent of reagent. † p<0.05; for the effect of phosphorylation. p 
values were calculated using one-way ANOVA. p values for the ratios were calculated using 
single value t test compared to 1. EC50 was rounded to two significant figures. In brackets the n 
number.  
Treatment( EC50,(µM( Ra1o(
EC50(P/
unP(
nH( Max(mo1le(
velocity,(µm/sec(
G159D((((((((((((P( 0.091%±%0.0062%(5)% 0.92%±%%
0.031%(5)%
2.33%±%%0.77%(5)% 3.65%±%0.15%(3)%
G159D(((((((((dP( 0.1%±%0.009%(5)% 2.65%±%1.12%(3)% 3.56%±%0.15%(3)%
EGCG(((((((((((P( 0.17%±%%0.037%(5)%% 2.29%±%
0.46%(5)%†%
%
1.73%±%0.4%(5)% 2.47%±%0.13%(5)%*%
EGCG(((((((((dP( 0.074%±%0.011%(5)%*% 2.53%±%1.51%(5)% 2.83%±%0.19%†(5)%
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
G159G(((((((((P( 0.092%±%0.0041%(5)% 0.97%±%%
0.035%(5)%
2.79%±%0.93%(5)% 94.5%±%0.54%(5)%
G159D(((((((dP( 0.095%±%0.0054%(5)% 2.52%±%0.79%(5)% 95.65%±%0.48%(5)%
EGCG(((((((((((P( 0.19%±%%0.029%(5)% 2.25%±%
0.41%(5)%†%
%
2.26%±%0.48%(5)% 89.1%±%2.89%(5)%
EGCG(((((((((dP( 0.088%±%0.0046%(5)% 2.69%±%%0.87%(5)% 92.05%±%1.53%(5)%
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5.4.2 The effect of EGCG on TNNI3 K36Q DCM mutant thin filaments 
 
The mutation in TnI Lys36Gln (K36Q) was identified by Carballo et al, 2009. K36Q 
in TNNI3 was one autosomal dominant missense mutations linked to the disease. A 
cardiac muscle sample of the transplanted heart from the original patient has been 
provided to the Marston’s lab. K36Q is a DCM mutation that has been proven to 
uncouple the Ca2+ sensitivity from TnI phosphorylation in the study by Memo et al, 
therefore it was chosen to study the effects of EGCG on a TnI mutation.  
Thin filaments were reconstituted using 60 nM human donor cardiac tropomyosin, 60 
nM phosphorylated or dephosphorylated troponin containing the K36Q mutation and 
10 nM actin. Due to the limitation of the sample, K36Q troponin was produced by 
exchange of the native TnI subunit of a donor troponin with mutant recombinant 
K36Q TnI subunit (See Section 2.2.5.3). Recombinant proteins are naturally non-
phosphorylated, thus to perform the experiments the exchanged troponin was divided 
into two samples, one was phosphorylated and the other dephosphorylated (See 
Section 2.2.6.1 and 2.2.6.2, APPENDIX). Three Ca2+ curves were performed 
comparing phosphorylated and dephosphorylated K36Q mutant thin filaments treated 
or not with EGCG, an example of which is shown in Figure 5-10. Additionally two 
Ca2+ curves were produced comparing phosphorylated and dephosphorylated thin 
filaments reconstituted with exchanged troponin treated with 100 µM EGCG. The 
data are summarised in Table 5-11 and Table 5-12) Student t test was used to perform 
the statistical analysis between the groups because not all the data could be used for 
paired one-way ANOVA. In all the experiments performed, the Ca2+ sensitivity was 
uncoupled from TnI phosphorylation. 100 µM EGCG restored the phosphorylation 
dependency of Ca2+ sensitivity in K36Q mutant thin filaments (EC50P/dP + EGCG = 
1.97 ± 0.12, p<0.01, n = 5 for percentage motility and EC50P/dP + EGCG = 1.97 ± 
0.22, p = 0.01 n = 5 for motile velocity). EGCG also had an effect on the motile 
velocity of the K36Q reconstituted thin filaments, decreasing the motile velocity of 
dephosphorylated thin filaments from 3.69 ± 0.15 µm/sec to 2.99 ± 0.17 µm/sec, 
p<0.01, n = 5.  
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Figure 5-10: Ca2+ activation curves for phosphorylated and dephosphorylated K36Q 
mutant thin filaments treated with 100 µM EGCG.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with phosphorylated (solid lines) or dephosphorylated (dotted lines) exchanged 
recombinant K36Q troponin was measured over a range of Ca2+ concentrations in the 
same experiment of IVMA. Red lines represent K36Q thin filaments and green lines 
represent thin filaments treated with 100 µM EGCG.   
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Table 5-11: Ca2+ sensitivity data for motile velocity of thin filaments reconstituted 
with phosphorylated or dephosphorylated exchanged K36Q troponin treated with 100 
µM EGCG 
 
 
 
 
 
 
 
 
 
Table 5-12: Ca2+ sensitivity data for percentage motility of thin filaments 
reconstituted with phosphorylated and dephosphorylated exchanged K36Q troponin 
treated with EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
* p<0.05, ** p<0.01; for presence and absent of reagent. † p<0.05, †† p<0.01; for the effect 
of phosphorylation. p values were calculated using multiple t tests. p values for the ratios 
were calculated using single value t test compared to 1. EC50 was rounded to two significant 
figures. In brackets the n number. All experiments were performed by myself using 
exchanged recombinant K36Q troponin.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
K36Q((((((((P( 0.077$±$0.0057$(3)$ 1.15$±$$
0.13$(3)$
3.32±$1.46$(3)$ 92$±$3.52$(3)$
K36Q(((((((dP( 0.069$±$0.011$(3)$ 3$±$1.46$(3)$ 93.75$±$0.75$(3)$
EGCG(((((((((P( 0.19$±$$0.018$(5)$ 1.97$±$
0.12$(5)$††$
2.69$±$0.84$(5)$ 87.11$±$1.65$(5)$
EGCG(((((((dP( 0.096±$0.0086$(5)$*††$ 2.21$±$$0.72$(5)$ 90.77$±$1.89$(5)$
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
K36Q(((((((((((((P( 0.094%±%0.0076%(3)% 1.16%±%%0.13%
(3)%
1.52%±%%0.46%(3)% 3.74%±%0.23%(3)%
K36Q((((((((((((dP( 0.082%±%0.0025%(3)% 2.08%±%1.045%(3)% 3.67%±%0.15%(3)%
EGCG(((((((((((((P( 0.14%±%%0.015%(5)%% 1.97%±%0.22%
(5)%†%
2.01%±%0.69%(5)% 2.71%±%0.14%(5)%%
EGCG((((((((((((dP( 0.073%±%0.007%(5)% 1.49%±%0.44%(5)% 2.99%±%0.17%(5)**%
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5.4.3 The effect of EGCG on ACTC E361G DCM mutant thin filaments  
The missense mutation in ACTC Glutamine 361 to Glycine (E361G) was first 
described by Olson et al in a study where two families affected by idiopathic DCM 
were screened. The E361G mutation is located in subdomain 1 of the actin monomer 
and it is proposed that it is an altered actin function rather than an loss of function that 
leads to the disease (Olson et al., 1998).  
TG mice carrying the ACTC E361G mutation were generated in Prof Steve Marston’s 
lab in collaboration with Dr Dominick Wells. TG mice expressed the E361G mutant 
actin at 50% of the total cardiac actin.  
IVMA experiments performed by Dr Massimiliano Memo showed that thin filaments 
reconstituted with E361G mutant actin had equal Ca2+ sensitivity as thin filaments 
reconstituted with actin extracted from wild type mice (Song et al., 2010). When 
phosphorylated and dephosphorylated E361G mutant thin filaments were compared, it 
was found that Ca2+ sensitivity was independent from TnI phosphorylation and it was 
the first demonstration of uncoupling due to mutations. These findings make this 
mutation of particular importance for the investigation of the effect of EGCG on the 
uncoupling phenomenon.  
Thin filaments were reconstituted with 60 nM human cardiac tropomyosin, 60 nM 
phosphorylated or dephosphorylated troponin from donor heart and 60 nM actin 
isolated from E361G transgenic mice. Five Ca2+ curves were performed comparing 
phosphorylated and dephosphorylated E361G DCM mutant thin filaments treated 
with 100 µM EGCG. A representative curve can be shown in Figure 5-11 and data are 
summarized in Table 5-13 and Table 5-14. As we can see from the Table, the Ca2+ 
sensitivity is uncoupled from TnI phosphorylation in E361G mutant thin filaments 
(Ratio EC50 P/dP = 1.08 ± 0.024, n = 5 for percentage motility, ratio EC50 P/dP = 1.04 
± 0.04, n = 5 for motile velocity). EGCG was able to restore the Ca2+ sensitivity upon 
TnI phosphorylation, as it decreased the Ca2+ sensitivity of phosphorylated thin 
filaments by 2.26 ± 0.27 for percentage motility and by 1.22 ± 0.042 for motile 
velocity (EC50 P = 0.087 ± 0.0023, EC50 P + EGCG = 0.2 ± 0.0022, p = 0.03, n = 5, 
all data for percentage motility). EGCG did not have an effect on dephosphorylated 
E361G thin filaments (EC50 dP = 0.08 ± 0.0017, EC50 dP + EGCG = 0.081 ± 0.0016, 
n = 5). The ratio EC50 P/dP + EGCG was 2.41 ± 0.28, n = 5, p<0.001 for percentage 
motility and 1.51 ± 0.0062, n = 5, p<0.001 for motile velocity. EGCG also had an 
effect on the maximum velocity of the filaments, reducing the velocity of 
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phosphorylated thin filaments from 3.66 ± 0.11 µm/sec to 2.71 ± 0.089 µm/sec, n = 5, 
p<0.01 and this of dephosphorylated thin filaments from 3.56 ± 0.15 µm/sec to 2.2 ± 
0.17 µm/sec, n = 5, p<0.001.  
 
Figure 5-11: Ca2+ activation curves comparing phosphorylated and dephosphorylated 
E361G mutant thin filaments treated with 100 µM EGCG 
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Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with phosphorylated (solid lines) or dephosphorylated (dotted lines) donor troponin and 
E361G mutant actin was measured over a range of Ca2+ concentrations in the same 
experiment of IVMA. Red lines represent E361G thin filaments and green lines 
represent thin filaments treated with 100 µM EGCG.   
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Table 5-13: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated E361G mutant thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
Table 5-14: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated E361G thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
E361G(((((((((((P( 0.094%±%0.0067%(5)% 1.04%±%%0.04%
(5)%
1.72%±%%0.41%
(5)%
3.66%±%0.11%(5)%
E361G((((((((((dP( 0.092%±%0.0095%(5)% 1.78%±%0.47%(5)% 3.56%±%0.15%(5)%
EGCG(((((((((((((P( 0.11%±%%0.0073%(5)%*% 1.51%±%
0.0062%(5)††%
2.91%±%0.74%(5)% 2.71%±%0.089%(5)**%%
EGCG((((((((((((dP( 0.077%±%0.0062%(5)%††% 2.3%±%0.74%(5)% 2.2%±%0.17%(5)%**†%
*  p<0.05, for presence and absent of reagent. † p<0.05, †† p<0.01; for the effect of 
phosphorylation. p values were calculated using one-way ANOVA. p values for the ratios were 
calculated using single value t test compared to 1. EC50 was rounded to two significant figures. In 
brackets the n number.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
E361G(((((((P( 0.087%±%0.0023%(5)% 1.08%±%%
0.024%(5)%
2.91±%0.81%(5)% 92.8%±%2.262%(5)%
E361G(((((dP( 0.08%±%0.0017%(5)% 2.3%±%0.74%(5)% 91.45%±%2.07%(5)%
EGCG(((((((((P( 0.2%±%%0.022%(5)%*% 2.41%±%
0.28%(5)%††%
2.87%±%1.11%(5)% 84.3%±%4.37%(5)%
EGCG(((((((dP( 0.081%±%0.0016%(5)%†% 2.44%±%%0.28%(5)% 88.07%±%3.07%(5)%
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5.5 The effect of EGCG on two HCM mutations 
5.5.1 The effect of EGCG on TNNT2 K280N HCM mutant thin filaments 
 
In the previous section the re-coupling properties of EGCG on DCM was 
investigated. EGCG has also been able to restore the Ca2+ sensitivity difference upon 
phosphorylation in E180G HCM mutant thin filaments as well. The aim of this 
section is to investigate the re-coupling properties of EGCG on two further HCM 
mutations that have been found to be uncoupled. These mutations are K280N in TnT 
and E99K in actin. The missense mutation of Lysine to Asparagine at position 280 in 
TNNT2 (K280N) is novel and has been identified in a biopsy sample from the left 
ventricle of a 26-year old male who had a heart transplant by Dr Jolanda Van der 
Velden. The patient was homozygous for the mutation and had previously undergone 
a myectomy operation. Prof Cris Dos Remedios has made the sample available to our 
lab, in a collaboration with Dr Jolanda Van der Velden and Prof Corrado Poggesi. 
The rate constant of active tension after maximal Ca2+ activation (KACT) as well as the 
rate constant of isometric relaxation (KREL) of myofibrils extracted from the K280N 
tissue sample was faster than the control, suggesting that the K280N mutation acts by 
altering cross-bridge kinetics of the sarcomere (Ferrara et al., 2015). Dr Christopher 
Bayliss and Dr Andrew Messer in the Marston lab have been working on this sample 
for many years. It has been found that the phosphorylation status of the sample was 
the same as the donor patients. IVMA experiments comparing phosphorylated and 
dephosphorylated K280N troponin extracted from the sample have been performed 
and it was found that the Ca2+ sensitivity was independent of TnI phosphorylation. 
Furthermore, experiments were performed comparing phosphorylated and 
dephosphorylated troponin from donor sample, where the TnT was fully exchanged 
with recombinant mutant K280N TnT. In that case, the Ca2+ sensitivity was also 
independent of TnI phosphorylation. Since the patient was homozygous for the 
mutation, exchanging the TnT subunit entirely with K280N mutant TnT represents 
the physiological situation. In this section I will investigate the effect of EGCG on the 
coupling between TnI phosphorylation and Ca2+ sensitivity.  
 
Thin filaments were reconstituted using troponin extracted from donor heart where 
the TnT subunit was exchanged with mutant K280N TnT (See Section 2.2.6.3). 
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Troponin was then divided into two samples, whereby one was phosphorylated (See 
Section 2.2.6.2) and the other one remained dephosphorylated (see APPENDIX). In 
that way, phosphorylated and dephosphorylated thin filaments could be compared. 
Three Ca2+ activation curves were performed comparing phosphorylated and 
dephosphorylated K280N mutant thin filaments treated or untreated with 100 µM 
EGCG, a representative experiment shown in Table 5-10. Two further experiments 
were performed comparing phosphorylated and dephosphorylated K280N thin 
filaments treated with 100 µM EGCG. Two experiments were also included in the 
analysis performed by Dr Andrew Messer only comparing phosphorylated and 
dephosphorylated thin filaments. Data for K280N thin filaments are summarized in 
Table 5-15 and Table 5-16. We can see from the Ca2+ activation curves, that in 
K280N mutant thin filaments the Ca2+ sensitivity is uncoupled from the TnI 
phosphorylation (EC50 P/dP = 1.08 ± 0.042 for percentage motility and 0.06 ± 0.0067 
for motile velocity, n = 5), supporting previous results. In the presence of 100 µM 
EGCG, the Ca2+ was re-coupled to TnI phosphorylation (EC50P/dP  + EGCG = 1.67 ± 
0.24, p = 0.02, n = 5 for percentage motility and EC50P/dP + EGCG = 3.27  ± 1.41, p 
= 0.1, n = 5). EGCG also had an effect on the motile velocity of the K280N 
reconstituted thin filaments, decreasing the motile velocity of phosphorylated thin 
filaments from 3.22 ± 0.27 µm/sec to 2.49 ± 0.021 µm/sec, p = 0.03, n = 5.  
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Figure 5-12: Ca2+ activation curves for phosphorylated and dephosphorylated thin 
filaments reconstituted with exchanged K280N HCM mutant troponin treated with 
100 µM  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with phosphorylated (solid lines) or dephosphorylated (dotted lines) exchanged 
recombinant K280N troponin was measured over a range of Ca2+ concentrations in the 
same experiment of IVMA. Purple lines represent K280N thin filaments and green lines 
represent thin filaments treated with 100 µM EGCG.   
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Table 5-15: Ca2+ sensitivity data summary for motile velocity of phosphorylated and 
dephosphorylated thin filaments reconstituted with K280N HCM mutant troponin 
treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
Table 5-16: Ca2+ sensitivity data summary for percentage motility of phosphorylated 
and dephosphorylated thin filaments reconstituted with K280N HCM mutant troponin 
treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  p<0.05, for presence and absent of reagent. † p<0.05; for the effect of phosphorylation. p 
values were calculated using multiple t tests. p values for the ratios were calculated using single 
value t test compared to 1. EC50 was rounded to two significant figures. In brackets the n number.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
K280N((((((((((((P( 0.096%±%0.0046%(5)% 1.06%±%%
0.067%(5)%
3.25%±%%1.32%(5)% 3.22%±%0.27%(5)%
K280N((((((((((dP( 0.093%±%0.0095%(5)% 2.14%±%0.49%(5)% 3.11%±%0.22(5)%
EGCG(((((((((((((P( 0.26%±%%0.1%(5)%% 3.27%±%1.41%
(5)%†%
1.62%±%0.44%(5)% 2.49%±%0.021%(5)*%%
EGCG((((((((((((dP( 0.081%±%0.0037%%(5)% 3.51%±%0.5%(5)% 2.78%±%0.15%(5)%
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
K280N((((((((P( 0.11$±$0.0073$(5)$ 1.08$±$$
0.042$(5)$
2.76$±$0.53$(5)$ 94.25$±$0.92$(5)$
K280N((((((dP( 0.1$±$0.004$(5)$ 3.45$±$0.8$(5)$ 94.25$±$0.45$(5)$
EGCG(((((((((P( 0.2$±$$0.031$(5)$ 1.67$±$
0.24$(5)$†$
2.59$±$0.86$(5)$ 84.85$±$2.95$(5)$
EGCG(((((((dP( 0.1±$0.004$(5)$*†$ 4.56$±$$0.091$(5)$ 88.85$±$0.71$(5)$
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5.5.2 The effect of EGCG on ACTC E99K HCM mutant thin filaments  
 
The last HCM mutation explored in this study is ACTC Glu99Lys (E99K). This 
mutation was first identified as a cause of HCM by Olson et al (Olson et al., 2000).  
Monserat et al have characterized the mutation in 76 individuals from 10 families in 
Spain and these patients present symptoms of HCM such as apical hypertrophy, left 
ventricular non- compaction and septal defects (Monserrat et al., 2007).  
A TG mouse line has been developed in Prof Steve Marston’s lab carrying the E99K 
mutation. TG mice express 50% of E99K mutant actin of the total actin (Song et al., 
2011) 
The E99K mouse model recapitulated many of the same characteristics of HCM in 
human. At the molecular level, the E99K mutation was associated with increased Ca2+ 
sensitivity, as shown by the IVMA and also by testing skinned papillary muscle 
directly. Increased Ca2+ sensitivity is a characteristic common to all HCM mutations 
tested so far (Marston, 2011). 21-week-old mice showed enlarged atria, myocyte 
disarray and increased interstitial fibrosis, also common characteristics of HCM (See 
Figure 5-13). Hypertrophy was also observed mainly in the apex of the heart, as 
shown by MRI and end-systolic volume and pressure were found to be increased 
(Song et al., 2011). Contractile force of isolated papillary muscles and also of 
myofibrils from E99K transgenic mouse was 4 times greater and the rate of muscle 
relaxation was slower. In E99K myofibrils the Ca2+ sensitivity of force was increased, 
suggesting that the increased Ca2+ sensitivity observed in E99K mutant mice causes 
the hypercontractility of the cardiac muscle (Song et al., 2013). 
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Figure 5-13: Heart morphology of 21-week-old E99K mouse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr Christopher Bayliss and Dr Andrew Messer have performed IVMA experiments 
comparing phosphorylated and dephosphorylated thin filaments containing E99K 
mutant actin. It was found that Ca2+ sensitivity was uncoupled from TnI 
phosphorylation. This finding was supported by echocardiography experiments on the 
E99K transgenic mice, whereby 21 and 38 week old mice showed a blunted response 
to β adrenergic stimulation. Since uncoupling has been clearly demonstrated in both 
actin mutations, in this chapter I will demonstrate the effect of EGCG on the 
uncoupling phenomenon of thin filaments reconstituted E99K mutant actin.  
Thin filaments were reconstituted using 60 nM human cardiac tropomyosin, 60 nM 
phosphorylated or dephosphorylated troponin extracted from donor heart and 10 nM 
mutant actin extracted from E99K mouse. Five Ca2+ activation curves were created 
with phosphorylated or dephosphorylated thin filaments treated with 100 µM EGCG 
and a representative curve is shown in Figure 5-14. Data are summarized in Table 
5-17 and Table 5-18 and full data for all the experiments can be found in APPENDIX. 
Consistent with previous measurements, E99K mutant thin filaments were uncoupled 
(Ratio EC50 P/dP = 0.99 ± 0.021, n = 5, p = 0.8 for percentage motile and Ratio EC50 
P/dP = 0.99 ± 0.028, n = 5, p = 0.8 for motile velocity). 100 µM EGCG reduced the 
EC50 of phosphorylated E99K thin filaments by 2.9 ± 0.28 fold, but not this of 
E99K transgenic mouse hearts have enlarged atria but normal ventricles. 
Adapted from Song et al (Song et al., 2011). 
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dephosphorylated thin filaments. As a result, the Ca2+ sensitivity upon TnI 
phosphorylation was restored (EC50 P/dP + EGCG = 2.02 ± 0.21, n = 5, p<0.01 for 
percentage motility and EC50 P/dP + EGCG = 2.25 ± 0.55, n = 5, p = 0.08). Likewise 
E361G, EGCG had an effect on motile velocity on E99K thin filaments as well: the 
maximum motile velocity was reduced in phosphorylated thin filaments from 3.52 ± 
0.44 µm/sec to 2.9 ± 0.13 µm/sec, n = 5, p = 0.02. 
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Figure 5-14: Ca2+ activation curve comparing phosphorylated and dephosphorylated 
E99K mutant thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity (top) and percentage motility (bottom) of thin filaments reconstituted 
with phosphorylated (solid lines) or dephosphorylated (dotted lines) donor troponin and 
E99K mutant actin was measured over a range of Ca2+ concentrations in the same 
experiment of IVMA. Purple lines represent E99K thin filaments and green lines 
represent thin filaments treated with 100 µM EGCG.   
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Table 5-17: Ca2+ sensitivity data for percentage motility of phosphorylated and 
dephosphorylated E99K mutant thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
Table 5-18: Ca2+ sensitivity data for motile velocity of phosphorylated and 
dephosphorylated E99K mutant thin filaments treated with 100 µM EGCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(mo1le(
velocity,(µm/sec(
E99K(((((((((((((((P( 0.073%±%0.0088%(5)% 0.99%±%
%%0.028%(5)%
1.21%±%%0.18(5)% 3.52%±%0.44%(5)%
E99K(((((((((((((dP( 0.073%±%0.0074%(5)% 1.36%±%0.22%(5)% 3.62%±%0.11%(5)%
EGCG(((((((((((((P( 0.25%±%%0.067%(5)%% 2.25%±%0.55%
(5)%
1.46%±%0.26%(5)% 2.9%±%0.13%(5)*%%
EGCG((((((((((((dP( 0.11±%0.019%(5)% 1.55%±%0.15%(5)% 3.34%±%0.14%(5)%†%
*  p<0.05, for presence and absent of reagent. † p<0.05, †† p<0.05; for the effect of 
phosphorylation. p values were calculated using one-way ANOVA. p values for the ratios were 
calculated using single value t test compared to 1. EC50 was rounded to two significant figures. In 
brackets the n number.  
Treatment( EC50,(µM( Ra1o(EC50(
P/unP(
nH( Max(%(mo1le(
E99K((((((((((P( 0.074%±%0.0052%(5)% 0.99%±%%
0.021%(5)%
1.9±%0.26%(5)% 94.9%±%0.26%(5)%
E99K((((((((dP( 0.074%±%0.0054%(5)% 1.93%±%0.24%(5)% 94.45%±%0.77%(5)%
EGCG(((((((((P( 0.21%±%%0.026%(5)%*% 2.02%±%
0.21%(5)%††%
1.74%±%0.16%(5)% 85.35%±%3.14%(5)%
EGCG(((((((dP( 0.1±%0.0069%(5)%†% 2.3%±%%0.76%(5)% 90.55%±%1.91%(5)%
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5.6 DISCUSSION 
 
5.6.1  The uncoupling phenomenon and its relationship to EC50 
 
In this chapter, I have tested the effect of the Ca2+ desensitiser EGCG on the coupling 
between TnI phosphorylation and Ca2+ sensitivity on DCM and HCM mutant thin 
filaments. The coupling between Ca2+ sensitivity and TnI phosphorylation has been 
previously studied in most of the mutations that I investigated, and this was the reason 
behind the selection of the particular mutations. In this study, only mutations in the 
thin filament proteins have been considered. Uncoupling of Ca2+ sensitivity to TnI 
phosphorylation by PKA has been previously found by other members of Steve 
Marston’s group in all of the mutations described in this chapter: G159D in TnC, 
K280N in TnT, K36Q in TnI, E50K and E54K in Tm and E361G and E99K in actin.  
My experiments further confirmed these results, as it was found that Ca2+ sensitivity 
was the same in phosphorylated and dephosphorylated DCM or HCM mutant thin 
filaments. Uncoupling in the Tpm1.1 E180G mutation was a novel finding. The table 
from Messer and Marston shows that this phenomenon has been noticed in other labs 
(see Section 1.4 for more details and review by Messer and Marston, 2014).  
The absolute Ca2+ sensitivity was not necessarily similar across all experiments. For 
example, with K36Q mutation in TnI, different Ca2+ sensitivities were observed when 
using troponin extracted from the K36Q tissue sample (experiments performed by Dr 
Massimiliano Memo and Dr Andrew Messer, (Memo, 2012)) than when K36Q 
mutant troponin was produced by exchanging the TnI subunit of donor troponin with 
a mutant recombinant TnI subunit containing the K36Q mutation. Thus, the diverse 
source of the sample can account for the differences in the absolute Ca2+ sensitivity 
that were observed. However, uncoupling was observed independently of the absolute 
value of the Ca2+ sensitivity.  
Myofibrillar experiments have been performed for the two actin mutations whereby 
the Ca2+ sensitivity of myofibrillar force was measured from myofibrils extracted 
from mouse hearts. The Ca2+ sensitivity of single myofibres in E361G transgenic 
mice is calculated to be 0.38 ± 0.05 µM for phosphorylated and 0.43 ± 0.06 µM for 
dephosphorylated myofibres. These values do not correspond to the values I found 
using IVMA (0.087 ± 0.0023 µM for phosphorylated and 0.08 ± 0.0017 µM for 
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dephosphorylated thin filaments) but in both cases phosphorylated and 
dephosphorylated thin filaments have equal Ca2+ sensitivities compared to control 
(Vikhorev et al., 2014), so the Ca2+ sensitivity was uncoupled to TnI phosphorylation 
in both IVMA and in the myofibrilar assay. The EC50 found in the IVMA system is 
much smaller than the EC50 produced in the myofibrilar assay. This is due to the fact 
that the myofibrilar assay is force dependent whereas the IVMA measures unloaded 
filaments.  In order to investigate this matter more, the relationship between the 
coupling constant (defined as the EC50 ratio of phosphorylated to dephosphorylated 
filaments) and the EC50, which represents the Ca2+ sensitivity, was plotted (Figure 
5-15 A). We can observe that the coupling constant is related to the Ca2+ sensitivity in 
the case of treatment of donor thin filaments with EMD 57033, meaning that it is a 
possibility that EMD 57033 pushes the equilibrium on the Tn complex so far towards 
the N terminal bound conformation that the phosphorylation of troponin cannot have 
an effect. (See Section 4.4.3). On the other hand, the coupling constant is not related 
to Ca2+ sensitivity in the case of mutations, where absolute Ca2+ sensitivity seems to 
be independent from uncoupling.  
When ratios were plotted for the EC50 WT/mutant to investigate the effect of a 
mutation on the absolute Ca2+ sensitivity. We can see from Figure 5-15 B that 
mutations can either increase or decrease the absolute Ca2+ sensitivity but there is 
always a limit at around 2.0 and 0.5 fold. This is consistent with the fact that the Ca2+ 
sensitivity decreases by 2-3 fold upon phosphorylation. It is very interesting to point 
out that EGCG restored the ratio of EC50P/dP to these values.  
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Figure 5-15: The relationship between EC50 and uncoupling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6.2 The Ca2+ desensitiser EGCG restores coupling to thin filaments with 
HCM and DCM mutations.  
 
The observation that EGCG reduces Ca2+ sensitivity in human donor thin filaments 
with small effects on sliding speed or Hill coefficient is also in accord with previous 
measurements in skinned cardiac muscle fibres (Liou et al., 2008, Tadano et al., 
2010). The phosphorylation-dependent change in Ca2+ sensitivity was unaffected by 
EGCG in reconstituted thin filaments, in contrast to Ca2+ sensitisers. For the first 
time, I show that EGCG was able to restore the Ca2+ sensitivity change upon TnI 
phosphorylation, which is otherwise uncoupled in thin filament cardiomyopathies. 
This was because EGCG was able to decrease the Ca2+ sensitivity of phosphorylated 
thin filaments containing DCM or HCM causing mutations, but it had different effects 
A) Coupling constant (EC50 P/dP) is plotted against the EC50 P value. Blue symbols 
represent untreated donor thin filaments or single myofibrils from wild type mice 
treated with EMD 57033 and green symbols represent HCM or DCM mutations 
treated with EGCG.  Red represents donor thin filaments treated with Ca2+ 
sensitisers B) The EC50 WT/mutant ratio is plotted for P/dP (blue), HCM (purple), 
DCM mutations that decrease the Ca2+ sensitivity (red), DCM mutations that 
increase the Ca2+ sensitivity (red), loss of function mutations in skeletal muscle 
(black) and gain of function mutations in skeletal muscle (green). Values are shown 
± SEM and p values were calculated using a single value t test against 1.  
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on phosphorylated and dephosphorylated thin filaments. EGCG either had no effect or 
increased (in the case of the three tropomyosin mutations) the Ca2+ sensitivity of 
dephosphorylated mutant thin filaments. This resulted in the reversal of uncoupling of 
the TnI phosphorylation to Ca2+ sensitivity in all the DCM and HCM thin filament 
mutations studied (Table 5-19 and Figure 5-16). The effect of EGCG was also tested 
in myofibrils of E361G mice. EGCG decreased the Ca2+ sensitivity of myofibrils from 
wild type mice and also from heterozygous E361G mice (experiments performed by 
Dr Petr Vikhorev). EGCG was also able to restore the Ca2+ sensitivity difference upon 
TnI phosphorylation in myofibrils extracted from the E361G transgenic mice, 
confirming the results from the IVMA (Papadaki et al., 2015)(see Figure 5-17) 
 
Figure 5-16: The effect of EGCG on the coupling between TnI phosphorylation and 
Ca2+ sensitivity on DCM and HCM mutations 
 
 
 
 
 
 
 
 
 
 
Figure 5 Papadaki et al.
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The Ratio of EC50 P/dP thin filaments is plotted with (red, green or purple) and 
without EGCG (blue). In red the DCM mutations are shown, in purple the 
HCM mutations and the donor are indicated with the color green. We can see 
that in all the mutant thin filaments treated with EGCG the EC50 P/dP ratio is 
restored to normal value.  
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Table 5-19: Ca2+ sensitivity data for DCM and HCM thin filaments treated with EGCG ! 3!
 
Table 2: Effect of EGCG and TnI phosphorylation on the Ca2+-sensitivity of thin filaments containing HCM and DCM mutations.  
* p<0.05, ** p<0.01; for presence and absence of EGCG, † p<0.05, †† p<0.01; unphosphorylated compared with phosphorylated using paired t test.  
Ratios: single value t test compared with 1.  ANOVA analysis of this dataset is shown in the Supplement. EC50 values rounded to 2 significant figures.  
In brackets is the number of experiments. 
 
Mutation EC50 of thin 
filaments 
containing 
phosphorylated 
troponin  
µM ± SEM 
EC50 of thin 
filaments 
containing 
unphosphorylated 
troponin  
µM ± SEM 
Ratio EC50  
P / unP  
± SEM 
EC50 of thin 
filaments treated 
with EGCG 
containing 
phosphorylated 
troponin  
µM ± SEM 
EC50 of thin 
filaments treated 
with EGCG 
containing 
unphosphorylated 
troponin  
µM ± SEM 
Ratio EC50  
P + EGCG / 
unP + EGCG 
 ± SEM 
Ratio EC50         
P + EGCG / 
P  
± SEM 
Ratio EC50  
unP + EGCG 
/ unP  
± SEM 
WT 0.14 ± 0.03(7) 0.059 ± 0.011(6)†† 2.24 ± 0.10(6)†† 0.26 ± 0.02(7)** 0.15 ± 0.02(6)**†† 1.73 ± 0.16(6)†† 2.15 ± 0.45(7) 2.80 ± 0.48(6) 
DCM       
TPM1 E54K 0.11 ± 0.013(5) 0.11 ± 0.02(5) 0.95 ± 0.03(5) 0.23 ± 0.03(5)*  0.071 ± 0.005(5)†† 3.17 ± 0.37(5)†† 2.33 ± 0.53(5) 0.68 ± 0.10(5) 
TPM1 E40K 0.18 ± 0.03(8) 0.17 ± 0.03(8) 1.02 ± 0.007(8) 0.22 ± 0.04(5) 0.052± 0.01(5)*† 4.63 ± 0.96(5)† 1.70 ± 0.43(3) 0.34 ± 0.05(3) 
TNNC1 G159D 0.092 ± 0.004(5) 0.095 ± 0.005(5) 0.97 ± 0.03(5) 0.19 ± 0.03(5)* 0.088 ± 0.005(5)*† 2.25 ± 0.41(5)† 2.13 ± 0.36(5) 0.93 ± 0.02(5) 
TNNI3 K36Q 0.18 ± 0.03(10) 0.18 ± 0.04(10) 1.02 ± 0.05(10) 0.19 ± 0.02(5) 0.10 ± 0.009(5)*† 1.97 ± 0.12(5)† 2.32 ± 0.29(3) 1.28 ± 0.04(3) 
ACTC E361G 0.087 ± 0.002(5) 0.080 ± 0.002(5) 1.08 ± 0.02(5) 0.20 ± 0.02(5)** 0.081 ± 0.002(5)†† 2.41 ± 0.28(5)†† 2.27 ± 0.28(5) 1.01 ± 0.02(5) 
HCM       
TPM1 E180G 0.086 ± 0.013(3) 0.087 ± 0.011(3) 0.98 ± 0.02(3) 0.11 ± 0.01(5)* 0.048 ± 0.003(5)*† 2.41 ± 0.32(5)†  1.36 ± 0.10(3) 0.51 ± 0.06(3) 
TNNT2 K280N 0.11 ± 0.007(5) 0.10 ± 0.004(5) 1.08 ± 0.04(5) 0.20 ± 0.03(5)* 0.10 ± 0.004(5)† 1.96 ± 0.24(5)†  2.15 ± 0.18(3) 1.09 ± 0.006(3) 
ACTC E99K 0.074 ± 0.005(5) 0.074 ± 0.005(5) 0.99 ± 0.02(5) 0.21 ± 0.03(5)** 0.10 ± 0.007(5)*†† 2.03 ± 0.21(5)†† 2.85 ± 0.28(5) 1.43 ± 0.13(5) 
Mary Papadaki  17/5/2015 19:05
Comment [2]: It!looks!dodgy!if!we!write!all!data!included!!As!if!we!didn’t!include!all!the!data!!
Mary Papadaki  17/5/2015 19:05
Deleted:  (al
* p<0.05, ** p<0.01; for presence and absence of EGCG, † p<0.05, †† p<0.01; unphosphorylated compared with 
phosphorylated using paired t test.  Ratios: single value t test compared with 1.  ANOVA analysis of this dataset is 
shown in the APPENDIX. EC50 values rounded to 2 significant figures.  In brackets is the number of experiments. 
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Figure 5-17: The effect of EGCG on myofibrils from E361G transgenic mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6.3 Mechanistic insights on the action of EGCG  
 
The uncoupling phenomenon was first discovered as a common molecular mechanism 
for DCM caused by thin filament mutations, in a study by Memo et al. This study 
considered the mutations TPM1 E54K, E40K and D230N, TNNI3 K36Q, TNNT2 
R141W and ΔK210, TNNC2 G159D and ACTC E361G; some of them are also 
included in this study. Thin filaments carrying any of these mutations showed 
independence of Ca2+ sensitivity to the TnI phosphorylation. The fact that EGCG was 
able to restore the phosphorylation dependent relationship of Ca2+ sensitivity in the 
case of a mutation in any protein of the thin filament equally, is compatible with a 
common mechanism for uncoupling and re-coupling by EGCG.  
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A) Ca2+ activation curve for myofibrils extracted from the E361G transgenic mouse in the 
absence (red) and presence (green) of 10 µM EGCG. Solid lines represent phosphorylated 
myofibrils and dotted lines represent dephosphorylated myofibrils. B) Effects of EGCG 
mutation, phosphorylation and EGCG treatment on the EC50 of myofibrillar contraction. *** 
indicates p<0.001 and ** indicates p<0.01between phosphorylated and dephosphorylated 
myofibrils calculated by unpaired student t test. Data produced by Dr Petr Vikhorev (Papadaki 
et al., 2015). 
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Several studies have shown that EGCG binds to C terminal domain of cTnC that is 
responsible for the desensitizing action of EGCG to the myofilament (Liou et al., 
2008). Solution NMR structures of TnC-EGCG have shown that EGCG binds to the 
hydrophobic cleft of cTnC C terminal domain, in a position similar to this of EMD 
57033. However, unlike EMD 57033 that binds deep into the hydrophobic core of 
cTnC, EGCG can bind closer to the surface of the pocket in the same way as cTnI34-
71. EGCG binds in complex with TnI34-71 with a KD of 1.64 ± 0.24 µM. (Robertson et 
al., 2009). Molecular Dynamics simulations also show that EGCG is able to bind in 
complex with TnC and TnI34-71 in different interchangeable orientations (Botten et al., 
2013).  
I suggest that it is possible that EGCG can re-stabilise the TnC- TnI interaction that is 
hypothesized to be unstable in uncoupled DCM and HCM mutants, restoring the Ca2+ 
response to phosphorylation in thin filament cardiomyopathies. Molecular Dynamics 
simulations have shown that the DCM mutation G159D that has also been found to 
uncouple strengthens the binding of TnI34-71 peptide to the hydrophobic cleft of TnC, 
whilst EGCG weakens this interaction (Botten et al., 2013), compatible with their 
opposite effects on coupling.   
Dr Petr Vikhorev showed that in myofibrils from wild type mice, EGCG slightly 
decreased (p = 0.059) the kACT (rate of force development measured at high Ca2+) in 
unphosphorylated TnI. EGCG also had an effect on kACT in phosphorylated and 
dephosphorylated myofibrils from E361G mice (Papadaki et al, 2015). In IVMA 
EGCG also had an effect on the maximum velocity for some of the mutations, 
suggesting that unlike EMD 57033, EGCG might have an effect on the cross-bridge 
activation kinetics of the sarcomere. It is possible that EGCG reduces Ca2+ sensitivity 
by slowing Ca2+ activation kinetics.  EGCG did not affect the EC50 P/dP or TLIN in 
wild type myofibrils but changed this of E361G myofibrils suggest that EGCG can 
restore coupling independently of its Ca2+ desensitizing action (see Table 5-20) 
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Table 5-20: Effect of E180G mutation, phosphorylation and EGCG on myofibrillar contractility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* p<0.05, ** p<0.01, *** p<0.001; EGCG treated compared with no EGCG,  
† p<0.05, †† p<0.01, ††† p<0.001; unphosphorylated compared with phosphorylated, 
§ p<0.05, §§ p<0.01, §§§ p<0.001; ACTC E361G compared with wild-type,  
‡ p<0.05, ‡‡ p<0.01, ‡‡‡ p<0.001; ACTC E361G EGCG treated compared with no EGCG wild-type, ¶ Vikhorev et al. 2014. 
In brackets is the number of experiments.  Statistical analysis carried out by un-paired t test (equal variance). 
 
! 4!
  Fmax, kN/m2 EC50, µM nH kACT, s-1 tLIN, ms kREL, s-1 
WT¶ P 100.9±6.3(14) 0.93±0.06(11) 10.43±1.84(10) 4.16±0.43(11) 50.8±3.5(12) 35.0±4.0(10) 
unP 87.1±6.0(16) 0.51±0.06(14)††† 4.74±0.66(13)†† 4.50±0.24(15) 67.0±4.2(16)† 23.2±2.8(11)††† 
WT+EGCG P 92.5±5.0(15) 1.85±0.17(9)*** 4.30±0.85(8)** 4.44±0.24(15) 46.7±3.9(12) 41.0±4.0(12) 
unP 92.6±8.9(8) 1.13±0.13(5)††*** 5.08±1.24(5) 3.47±0.55(6) 88.9±9.9(7)†††* 22.3±1.2(7)†† 
E361G¶ P 93.5±8.9(11) 0.38±0.05(12)§§§ 5.39±1.26(9)§ 4.51±0.32(13) 75.4±6.5(10)§§ 21.6±2.8(10)§§§ 
unP 89.3±8.6(10) 0.43±0.06 (10) 4.48±0.70(8) 4.12±0.32(11) 70.8±9.7(11) 21.6±2.1(10) 
E361G+EGCG P 89.1±4.5(12) 2.07±0.20(5)*** ‡‡‡ 7.18±1.54(5) 3.43±0.20(13)*§ ‡‡ 49.7±3.3(12)** 31.0±2.6(12)*§ 
unP 96.3±11.1(11) 1.28±0.10(8)††*** ‡‡‡ 4.14±0.42(7)† 3.25±0.26(11)*** ‡‡ 63.0±4.7(12)†§ 31.0±2.0(12)**§§ ‡‡ 
 
Table 3: Effect of phosphorylation, ACTC E361G mutation and EGCG on Ca2+-regulation of myofibril contraction. 
In brackets is the number of experiments.  Statistical analysis carried out by un-paired t test (equal variance). 
* p<0.05, ** p<0.01, *** p<0.001; EGCG treated compared with no EGCG. 
† p<0.05, †† p<0.01, ††† p<0.001; unphosphorylated compared with phosphorylated. 
§ p<0.05, §§ p<0.01, §§§ p<0.001; ACTC E361G compared with wild-type. 
‡ p<0.05, ‡‡ p<0.01, ‡‡‡ p<0.001; ACTC E361G EGCG treated compared with no EGCG wild-type. 
¶ Vikhorev et al. 2014 11. 
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5.6.4 Clinical relevance of re-coupling by EGCG 
 
EGCG is an extract from green tea, the consumption of which has been found to be 
beneficial for cardiovascular diseases in epidemiological studies (Hertog et al., 1993). 
Common treatment for heart failure can include agents that work through the β 
receptor such as dobutamine but in long term they can lead to arrhythmias. Dugs that 
act on the myofilament directly and alter the Ca2+ sensitivity thus target the effect of 
the mutations directly can provide a good alternative.  
Such an example is EGCG, which acts directly on thin filament. EGCG can be 
beneficial especially for the treatment of HCM, as it is always associated with 
increased Ca2+ sensitivity and data from this study also show that additionally the 
Ca2+ sensitivity is uncoupled to TnI phosphorylation. Ca2+ antagonists have been 
suggested as a potential treatment for HCM (Semsarian et al., 2002). EGCG is able to 
both decrease the Ca2+ sensitivity and re-couple the Ca2+ sensitivity to 
phosphorylation. The ability to re-couple DCM mutant could also be favourable, since 
uncoupling seems to be the primary cause of DCM and also the Ca2+ sensitivity of 
phosphorylated and dephosphorylated thin filaments was restored to normal values.  
EGCG is a polyphenol that has been described as a promiscuous molecule and has 
many pharmacological properties thus it is not specific for troponin (Ingólfsson et al., 
2014). In fact, EGCG in nM concentrations has a positive inotropic action because it 
can bind to ryanodine receptor type 2, Na+/K+ ATPase and Na/Ca2+ exchanger (Feng 
et al., 2012), which may override the desensitising action on the contractile apparatus.  
Although EGCG is too non- specific to be a viable drug for treatment of HCM this 
study has demonstrated an important proof of principle: that it is possible to directly 
reverse the primary effects found in thin filament cardiomyopathies 
pharmacologically. 
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6 The effect of EGCG analogues on human heart thin 
filaments  
 
6.1 Introduction  
 
In the previous chapter I showed the action of the desensitiser Epigallocatechin-3-
gallate (EGCG) and its potential role as a therapeutic candidate for thin filament 
cardiomyopathies. However, EGCG is a promiscuous molecule, limiting its potential 
as a therapeutic agent. As part of collaboration with Dr Brian Blagg from the 
University of Kansas we received 30 compounds that have a similar structure to 
EGCG. These compounds have been originally developed as Hsp90 inhibitors, as 
EGCG has been found to inhibit Hsp90 by directly binding to it (Khandelwal et al., 
2013b).  
Silibinin or Silybin is constituent of silimarine, which is an extract of the plant 
silybum (milk thistle), shown in Figure 6-1 and is another Hsp90 inhibitor (Zhao et al, 
2011). Two of the given compounds were structural analogues of Silybin. 
 
Figure 6-1: Chemical structure of Silybin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Chemical structure of Silybin. B. Silybum marinaum (milk thistle) from 
where silybin is extracted 
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The aim of this chapter is to test EGCG analogues identified as Hsp90 inhibitors as 
potential re-couplers of Ca2+ sensitivity to troponin I (TnI) phosphorylation. In order 
to address this specific aim, a quick screening method needed to be developed to 
identify the drugs that recouple TnI phosphorylation to changes in Ca2+ sensitivity. 
Then, the most potent re-couplers were selected for further analysis. Miss Alice 
Sheehan contributed to the majority of the experiments described in this chapter, as 
part of her MRes project in Biomedical Research under my direction.   
6.2 Rapid screening assay to identify re-couplers 
6.2.2 Developing a screening methodology  
 
To assess the recoupling properties of the analogues, the in vitro motility assay 
(IVMA) was used. However, a different methodology was used for the screening, 
which resulted in a quick way to detect small molecules with promising re-coupling 
abilities. The analogues were tested directly on mutant thin filaments to screen for 
their desensitising action and their recoupling properties. As the potential 
desensitising and re-coupling properties would be beneficial for Hypertrophic 
Cardiomyopathy (HCM), an HCM-causing mutation was chosen for the screening 
assay. The HCM-causing mutation of choice is the TPM1 E180G mutation, because 
recombinant E180G tropomyosin from baculovirus/sf9 was available in large stocks 
and could be combined with troponin from human donor heart, saving time in the 
preparation for the IVMA.  
The assay is based on the observation that at an intermediate Ca2+ concentration of the 
Ca2+ activation curve, percentage motility and motile velocity of phosphorylated and 
dephosphorylated HCM thin filaments is equal because of uncoupling, but in case of 
recoupling due to the addition of drug they would be separate. Figure 6-2 shows the 
concept behind the screening assay and the possible outcomes of the analogues 
regarding a change in Ca2+ sensitivity and re-coupling of the mutant thin filaments. 
This screen would highlight small molecules that have recoupling properties as 
candidates for further investigation. The Ca2+ concentration chosen for the screening 
assay is 0.037 µM. Initially, a single compound concentration of 100 µM was tested 
as this concentration was optimal for the activity of EGCG in the IVMA (see Section 
5.3.4).  
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Figure 6-2: Drug screening assay concept and possible outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) The effect of EGCG on Ca2+ activation curves of thin filaments reconstituted with 
E54K mutant tropomyosin. B) EGCG dose response curve of percentage motility for 
E54K thin filaments at 0.037 µM Ca2+ concentration corresponding to the Ca2+ EC50. 
Purple and pink broken lines illustrate the relationship between the percentage motility of 
phosphorylated and dephosphorylated thin filaments at a constant Ca2+ concentration. C) 
shows possible outcomes of the assay for percentage motility and motile velocity at a 
specific Ca2+ concentration (0.037 µM). Red lines represent mutant thin filaments and 
green lines represent thin filaments treated with EGCG or compounds. Solid lines 
represent phosphorylated thin filaments and broken lines represent dephosphorylated thin 
filaments.  
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6.2.3 Results of the rapid screening assay 
 
Thin filaments were reconstituted using 60 nM phosphorylated or dephosphorylated 
troponin, 60 nM E180G mutant tropomyosin and 10 nM rabbit skeletal actin. After 
ensuring that the motility assay was working using only mutant tropomyosin and actin 
as control, troponin was also tested with low and high Ca2+ buffers to make sure that 
filaments are regulated correctly with Ca2+. Thin filaments reconstituted with 
phosphorylated or dephosphorylated troponin, tropomyosin and actin were incubated 
with 100 µM of the different compounds. For the screening experiments a single Ca2+ 
concentration was used, 0.037 µM Ca2+, and in every flow motility cell a different 
compound was tested. One flow motility chamber contained phosphorylated thin 
filaments and the other flow motility chamber contained dephosphorylated thin 
filaments. In that way, a direct comparison between phosphorylated and 
dephosphorylated thin filaments can be made. A control cell containing only 
phosphorylated and dephosphorylated E180G thin filaments was performed every 4-5 
drugs screened. An example of drug screening is shown in Figure 6-3. Dr Brian Blagg 
had suggested several compounds most likely to re-couple based on their structural 
similarity to EGCG and these compounds were tested first. Drugs number 4 and 9 
(shown in the Figure) were re-couplers at 100 µM.  
Figure 6-4 shows the data for the preliminary drug screen for all the compounds. 
Because the compounds were dissolved in DMSO according to the instructions given 
by their manufacturers, the effect of DMSO alone was also tested in thin filaments. 
DMSO had no effect on the motility of the filaments. The coupling constant as 
indicated by the ratio P/dP (screen ratio) and the motility difference between 
phosphorylated and dephosphorylated thin filaments (screen difference) were plotted. 
The screen ratio and the screen difference had a similar trend across the compounds, 
although difference in motility gave a more pronounced difference compared to 
ratios. For this reason, data are represented as the motility difference between 
phosphorylated and dephosphorylated thin filaments (P-dP) for the following study.  
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Figure 6-3: A screening example of two different compounds using the E180G HCM 
model 
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Motile velocity (top) and percentage motility (bottom) of phosphorylated and 
dephosphorylated E180G mutant thin filaments treated with 100 µM of drugs 
number 4 and number 9 were measured at 0.037 µM Ca2+. Motility 
parameters of phosphorylated and dephosphorylated E180G mutant filaments 
without treatment were also tested. Each motility flow cell contained a 
different combination of the parameters (phosphorylation and compound).  
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Figure 6-4: Screening summary of all the compounds tested with IVMA 
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6.3 Evaluation of best candidates on TPM1 E180G HCM mutant 
thin filaments 
 
From the screening assay described, the 10 analogues that were the most potent re-
couplers (i.e. gave the biggest coupling ratio and motility difference) were selected 
for further analysis. The selected drugs were:  Silybin and drug numbers 2, 4, 7, 9, 12, 
14, 19, 26 and S2. Drugs number 2, 4, 9, 12, 19 and 26 (EGCG analogues) were 
chosen because they gave the largest screen difference. Number 7 was chosen because 
it gave an interesting  “negative” screen ration and S2 was the Silybin analogue that 
gave the best difference in the screening assay. Number 12 had a screening ratio of 1 
so it was randomly chosen as a control analogue. Dose-response curves were created 
for these drugs using reconstituted E180G thin filaments. Thin filaments were 
reconstituted using 60 nM phosphorylated or dephosphorylated troponin, 60 nM 
E180G recombinant mutant tropomyosin from baculovirus/sf9 and 10 nM rabbit 
skeletal actin. Thin filaments were incubated with the analogues mentioned in 
concentrations between 25-200 µM. The dose response curves for percentage motility 
and motile velocity can be found in Figure 6-5 and Figure 6-6. The difference in 
percentage motility between phosphorylated and dephosphorylated thin filaments 
treated with the analogues was also plotted and is shown in Figure 6-7. The Hill 
equation was fitted on the data for the percentage motility difference between 
phosphorylated and dephosphorylated thin filaments and the values of the EC50, the 
nH and the magnitude difference (motility difference P-dP, ∆ %) were calculated for 
each of the drugs (See Figure 6-8 and Table 6-1). In some cases where data for a 
certain dose was not available (for example number 9) the m2 (max-min value) of the 
Hill equation was fixed according to the raw data of maximum and minimum values 
from IVMA to obtain the EC50. We can observe that the most potent drug was number 
26, with an EC50 value of 24.6 ± 1.19 µM and magnitude of 37.8 ± 1.4 %. EGCG, 
Silybin and drug numbers 2, 4, 9, 14, 19 and S2 showed similar levels of potency, the 
EC50 ranging between 30.5 ± 0.4 and 47.2 ± 2.66 µM. Drug number 12 was the 
control drug, as it had no effect on either phosphorylated or dephosphorylated thin 
filaments at the tested concentrations. Drug number 12 had no effect also in the 
preliminary screen, giving more confidence on the screening results. Drug number 7 
had a unique property, that increased the motility parameters of phosphorylated thin 
 218 
filaments and decreased the motility parameters of the dephosphorylated thin 
filaments, resulting in “reverse recoupling”. 
 
 
Figure 6-5: Small molecule dose response data for percentage motility in TPM1 
E180G mutant thin filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Percentage motility of phosphorylated or dephosphorylated E180G thin filaments was 
measured at a constant Ca2+ concentration of 0.037 µM with increasing drug doses. A) 
EGCG B) Silybin C) No 2 D) No 4 E) No 7 F) No 12 G) No 14 H) No 9 I) No 19 J) No 26 
K) S-2. The drug compounds are in order of the screening experiments performed.  
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Figure 6-6: Small molecule dose response data for motile velocity of TPM1 E180G 
mutant thin filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity of phosphorylated or dephosphorylated E180G mutant thin 
filaments was measured at a constant Ca2+ concentration of 0.037 µM with 
increasing drug doses. A) EGCG B) Silybin C) No 2 D) No 4 E) No 7 F) No 12 G) 
No 14 H) No 9 I) No 19 J) No 26 K) S-2 
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Figure 6-7: Dose response data for percentage motility difference between 
phosphorylated and dephosphorylated TPM1 E180G mutant thin filaments treated 
with different compounds 
 
 
 
 
 
 
 
 
 
 
Percentage motility difference between phosphorylated or dephosphorylated 
E180G mutant thin filaments. Motility was measured at a constant Ca2+ 
concentration of 0.037 µM with increasing drug doses. A) EGCG B) Silybin C) 
No 2 D) No 4 E) No 7 F) No 12 G) No 14 H) No 9 I) No 19 J) No 26 K) S-2 
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Figure 6-8: Dose response data summary for percentage motility difference between 
phosphorylated and dephosphorylated TPM1 E180G mutant thin filaments treated 
with different compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage motility difference of phosphorylated and dephosphorylated thin 
filaments treated with different compounds. Percentage motility was measured at 
0.037 µM Ca2+ and the Hill equation was fitted to the data to create the curves 
(dotted lines). Different colored lines represent different compounds.  
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Table 6-1: Data summary for the difference between phosphorylated and 
dephosphorylated TPM1 E180G HCM mutant thin filaments treated with different 
compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E180G&+&Drug& EC50,&µM& nH& Magnitute&
(%&diﬀerence)&
EGCG& 58.83%±%13.31% 2.15%±%0.89% 30.23%±%4.81%
Silibinin& 47.21%±%2.66% 1.3%±%0.078% 43.74%±%1.29%
2& 30.5%±%0.41% 2.02%±%0.067% 31.31%±%2.24%
4& 33.98%±%2.13% 2.69%±%0.43% 28.52%±%1.05%
7& 67.05%±%20.31% 1.71%±%0.57% 28.16%±%5.3%
9& 34.83%±%2.91% 2.22%±%0.37% 29.32%±%1.9%
12& No%Eﬀect%% No%Eﬀect% No%Eﬀect%%
14& 36.23%±%0.82% 1.81%±%0.08% 21.44%±%0.29%
19& 30.79%±%2.9% 1.54%±%0.3% 29.68%±%1.63%
26& 24.59%±%1.49% 1.37%±%0.2% 37.8%±%1.4%
SE2& 32.24%±%0.4% 2.28%±%0.071% 28.57%±%0.21%
Percentage motility difference between phosphorylated and dephosphorylated E64K 
mutant thin filaments treated with Silybin or drug numbers 2, 4, 7, 9, 12, 14, 19, 26 
and S2. The effect of reverse recoupling by drug number 7 is also shown. EC50 was 
calculated from the Hill equation fitted to the percentage motility difference between 
phosphorylated and dephosphorylated filaments and was rounded in two significant 
figures.  
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6.4 Evaluation of the best drug candidates in TPM1 E54K DCM 
mutant thin filaments  
 
Next, the effect of the best candidate drugs was examined in Dilated Cardiomyopathy 
(DCM) thin filaments. The selected DCM mutation was TPM1 E54K because of the 
availability of recombinant E54K tropomyosin. From the careful examination of the 
dose response data with the E180G mutation, the most potent drugs were selected: 
Silybin, and drug numbers 26, 14 and S2. The interesting drug number 7 (“reverse 
recoupling”) was also selected and drug number 12 was the control (no effect). Thin 
filaments were reconstituted using 60 nM E54K recombinant tropomyosin, 60 nM 
phosphorylated or dephosphorylated troponin extracted from donor heart and 10 nM 
rabbit skeletal actin. Different concentrations of the drugs from 25 to 200 µM were 
tested in phosphorylated and dephosphorylated thin filaments at a fixed Ca2+ 
concentration of 0.074 µM. The dose response results for the percentage motility and 
the motile velocity can be found in Figure 6-9 and the percentage motility difference 
between phosphorylated and dephosphorylated thin filaments in Figure 6-10. A 
summary of the differences between phosphorylated and dephosphorylated E54K 
DCM mutant thin filaments for each drug concentration is illustrated in Figure 6-11. 
For each of the drug, the Hill equation was fitted to the data and the nH, EC50 and the 
magnitude difference (∆ %) was calculated (Table 6-2). Comparable to the E180G 
mutation, the uncoupling of Ca2+ sensitivity to TnI phosphorylation was restored with 
similar magnitude for Silybin and drug numbers 14, 26 and S-2. Drug number 26 had 
the largest effect of coupling, with a magnitude of 37.8 ± 1.4 while S-2 was the most 
potent with an EC50 of 36.6 ± 5.46 µM, nH of 1.9 ± 0.54 and magnitude 28.75. Silybin 
and drug numbers 14 and 26 showed similar levels of potency when comparing the 
values of EC50, where the EC50 range was from 55.18 ± 7.47 µM to 77.1 ± 7.93 µM. 
As expected, drug number 12 did not have any effect on the percentage motility and 
motile velocity of the thin filaments, consistent with the E180G dose response curve 
and also the initial screening. Drug number 7 had also the same effect with E180G, 
where it reverse coupled the phosphorylated and dephosphorylated mutant thin 
filaments. Drug number 7 increased the motility parameters of the dephosphorylated 
E54K thin filaments, while decreased the parameters of phosphorylated E54K thin 
filaments. 
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Figure 6-9: Small molecule dose response data for motile velocity and percentage 
motility of phosphorylated and dephosphorylated TPM1 E54K DCM mutant thin 
filaments 
 
 
 
 
 
 
Motile velocity and percentage motility difference between phosphorylated or 
dephosphorylated E54K mutant thin filaments. Motility was measured at a 
constant Ca2+ concentration of 0.074 µM with increasing drug doses. A) 
Silybin B) No 7 C) No 12 D) No 14 E) 26 F) S-2 
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Figure 6-10: Percentage motility difference between phosphorylated and 
dephosphorylated TPM1 E54K DCM mutant thin filaments dose response curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage motility difference between phosphorylated or dephosphorylated 
E54K mutant thin filaments. Motility was measured at a constant Ca2+ 
concentration of 0.074 µM with increasing drug doses. A) Silybin B) No 7 C) 
No 12 D) No 14 E) 26 F) S-2  
G"
 226 
Figure 6-11: Summary of percentage motility difference between phosphorylated and 
dephosphorylated TPM1 E54K DCM mutant thin filaments treated with different 
compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-2: Data summary for the percentage motility difference between 
phosphorylated and dephosphorylated TPM1 E54K DCM mutant thin filaments 
treated with different compounds 
 
 
 
 
 
 
 
 
 
 
Percentage motility difference of phosphorylated and dephosphorylated thin 
filaments treated with different compounds. Percentage motility was measured at 
0.074 µM Ca2+ and the Hill equation was fitted to the data to create the curves. 
Different colored lines represent different compounds.  
 
Percentage motility difference between phosphorylated and dephosphorylated E64K 
mutant thin filaments treated with Silybin or drug numbers 14, 26 and S2. The effect 
of reverse recoupling by drug number 7 is also shown. EC50 was calculated from the 
Hill equation fitted to the percentage motility difference between phosphorylated 
and dephosphorylated filaments and was rounded in two significant figures. N/A= 
Not Applicable, N/D= Not Determined.  
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Silybin% 77.13%±%7.93% 2.69%±%0.52% 30.03%±%2.47%
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SD2% 36.62%±%5.46% 1.9%±%0.54% 28.75%
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6.5 Evaluation of the best drug candidates on ACTC E99K HCM 
mutant thin filaments  
 
 
The analogues were then tested in HCM ACTC E99K mutant thin filaments. This 
mutation was selected because we have the E99K transgenic mouse line in the 
laboratory. The E99K mice have blunted response to adrenaline so the experiments 
described in this chapter would provide preliminary data for potentially treating the 
animals with the compounds (Song et al, 2011). Thin filaments were reconstituted 
with 60 nM human cardiac tropomyosin, 60 nM phosphorylated or dephosphorylated 
troponin extracted from donor human heart and 10 nM actin extracted from transgenic 
E99K mice. Percentage motility and motile velocity of the thin filaments was 
calculated at 0.037 µM Ca2+. Silybin and drugs number 7, 14, 26 and S-2 were tested 
in E99K thin filaments at different concentrations. Percentage motility and motile 
velocity of phosphorylated and dephosphorylated E99K thin filaments treated with 
the different drugs can be shown in Figure 6-12. The percentage motility difference 
between phosphorylated and dephosphorylated thin filaments treated with increasing 
concentrations of the different compounds is shown in Figure 6-13. A summary of the 
percentage motility difference results is shown in Figure 6-14 where all the different 
compounds were plotted on the same graph. Like previously, the Hill equation was 
fitted to the data so that the EC50, the nH and the Δ % (magnitude of percentage 
motility difference) was determined. Table 6-3 summarises the results. Similar effects 
to E180G and E54K mutations of the different drugs were observed in the E99K 
mutant thin filaments as well. Silybin, drug numbers 14, 26 and S-2 were able to re-
couple the uncoupled E99K mutant thin filaments in concentrations more than 50 µM. 
The most potent drug was found to be Silybin with an EC50 of 62.58 ± 3.14 µM. 
Unfortunately, the EC50 and nH could not be determined accurately for drug numbers 
14 and 26 due to lack of experimental data on high drug concentrations. 26 showed a 
large difference in the motility parameters between phosphorylated and 
dephosphorylated thin filaments with a magnitude of 30. Drug S-2 showed the highest 
magnitude, 38.26 ± 0.0082. Drug number 7 reversed coupled the thin filaments, 
decreasing the motility of dephosphorylated E99K thin filaments and increasing 
slightly the motility of E99K phosphorylated thin filaments. 
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Figure 6-12: Small molecule dose response summary for percentage motility and 
motile velocity of ACTC E99K HCM mutant thin filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile velocity and percentage motility difference between phosphorylated or 
dephosphorylated E99K mutant thin filaments. Motility was measured at a 
constant Ca2+ concentration of 0.037 µM with increasing drug doses. A) 
Silybin B) No 7 C) No 14 D) No 26 E) S-2. 
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Figure 6-13: Small molecule data for percentage motility difference between 
phosphorylated and dephosphorylated ACTC E99K HCM mutant thin filaments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage motility difference between phosphorylated or dephosphorylated 
E99K mutant thin filaments. Motility was measured at a constant Ca2+ 
concentration of 0.037 µM with increasing drug doses. A) Silybin B) No 7 C) 
No14 D) No 26 E) S-2  
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Figure 6-14: Summary of the percentage motility difference between phosphorylated 
and dephosphorylated ACTC E99K HCM mutant thin filaments treated with different 
compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-3: Data summary of the percentage motility difference between 
phosphorylated and dephosphorylated ACTC E99K HCM mutant thin filaments 
treated with different compounds 
 
 
 
 
 
 
 
 
 
 
Percentage motility difference of phosphorylated and dephosphorylated thin 
filaments treated with different compounds. Percentage motility was measured at 
0.037 µM Ca2+ and the Hill equation was fitted to the data to create the curves. 
Different coloured lines represent different compounds.  
Percentage motility difference between phosphorylated and dephosphorylated 
E64K mutant thin filaments treated with Silybin or drug numbers 14, 26 and S2. 
The effect of reverse recoupling by drug number 7 is also shown. EC50 was 
calculated from the Hill equation fitted to the percentage motility difference 
between phosphorylated and dephosphorylated filaments and was rounded in two 
significant figures. N/A= Not Applicable, N/D= Not Determined.  
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6.6 The effect of the compounds on donor thin filaments.  
 
The initial property of EGCG is its desensitising action on donor thin filaments 
(decrease in Ca2+ sensitivity). In this section, the best candidate drugs as well as the 
anomalous drug number 7 were tested for their effect as desensitisers. Thin filaments 
were reconstituted using 60 nM human cardiac tropomyosin, 60 nM phosphorylated 
or dephosphorylated troponin extracted from donor heart and 10 nM rabbit skeletal 
actin. From the previous experiments it was shown that 100 µM was sufficient to 
produce the effect of the drug. For this reason, 100 µM of Silybin and drug numbers: 
2, 14, 7, 26 and S-2 were tested. Full Ca2+ activation curves were performed for the 
percentage motility and the motile velocity of phosphorylated and dephosphorylated 
donor thin filaments treated with the different drugs. The Ca2+ activation curves are 
shown in Figure 6-15. The EC50 of phosphorylated and dephosphorylated donor thin 
filaments, which is an indicator of the Ca2+ sensitivity, was measured for the 
percentage motility of different drugs as well as the EC50 P/dP ratios (Table 6-4)  
Interestingly, from the EC50P data we can observe that drug numbers: 2, 7, 14, 26 and 
S-2 did not decrease the Ca2+ sensitivity of donor thin filaments.  The EC50 of the 
donor phosphorylated thin filaments was 0.11 ± 0.0018 µM and the EC50 for the 
phosphorylated donor thin filaments treated with the different drugs ranged from 
0.079 ± 0.0059 to 0.11 ± 0.00067 µM. The Ca2+ sensitivity remained coupled to the 
TnI phosphorylation in all cases as the EC50P/dP ratio was greater than one. This is an 
unexpected result because EGCG was originally identified as a re-coupler due to its 
known action as a Ca2+ desensitiser. Silybin has the same properties as EGCG, where 
it decreased the Ca2+ sensitivity of phosphorylated thin filaments (EC50 P = 0.21 ± 
0.013) and the Ca2+ sensitivity remained coupled to the TnI phosphorylation (EC50 
P/dP ratio = 0.75).
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Figure 6-15: Ca2+ activation curves for phosphorylated and dephosphorylated donor 
thin filaments treated with different compounds 
 
 
Motile velocity and percentage motility was measured over a range of Ca2+ 
concentrations to create Ca2+ activation curves for both phosphorylated (solid 
lines) and dephosphorylated (dotted lines). A) Silybin (green) and donor 
untreated (blue) B) No 2 C) No 7 D) No 14 E) No 26 F) S-2 
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Table 6-4: Summary of Ca2+ sensitivity for percentage motility of phosphorylated and 
dephosphorylated donor thin filaments treated with different compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.7 The re-coupling effect of known Hsp90 inhibitors 
 
The compounds given to us by Dr Brian Blagg have the common characteristic that 
they are all inhibitors of Hsp90 by directly binding to it. Preliminary experiments 
were performed in order to investigate whether other known inhibitors of Hsp90 can 
also re-couple uncoupled HCM mutant thin filaments. Known inhibitors of Hsp90 
include geldanamycin (Stebbins et al., 1997), novobiocin (Matts et al., 2011), 
resveratrol (Sahin et al., 2012) and pterostilbene (Kostin et al., 2012). E180G HCM 
mutant thin filaments were reconstituted using 60 nM phosphorylated or 
dephosphorylated troponin extracted from donor heart, 60 nM E180G recombinant 
Tpm1 from baculovirus/sf9 cells and 10 nM rabbit skeletal actin. Thin filaments were 
treated with 100 µM of the four Hsp90 inhibitors and their percentage motility and 
motile velocity was measured at 0.037 µM Ca2+. The percentage motility of E180G 
Drug% EC50%P% EC50%dP% EC50%P/dP%
Ra/o%
Donor%untreated% 0.11%±%0.0018% 0.051%±%0.0006% 2.16%
+%EGCG*% 0.26%±%0.%03% 0.15%±%0.02% 1.7%
+%Silybin% 0.21%±%0.013% 0.12%±%0.011% 1.75%
+%No%2% 0.079%±%0.0059% 0.048%±%0.034% 1.65%
+%No%7% 0.12%±%0.01% 0.07%±%0.01% 1.7%
+%No%14% 0.13%±%0.0027% 0.058%±%0.0033% 2.24%
+%No%26% 0.08%±%0.005% 0.05%±%0.01% 1.6%
+%No%S;2% 0.11%±%0.00067% 0.032%±%0.0038% 3.44%
Summary showing the Ca2+ sensitivity for percentage motility and motile 
velocity of donor thin filaments treated with EGCG, SIlybin or drug numbers 
2, 7, 14, 26 and S2. EC50 values were calculated from the Ca2+ activation 
curves for the percentage motility of thin filaments treated with different 
drugs. * EGCG data was taken from measurements described in the previous 
chapter 
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thin filaments treated with Hsp90 inhibitors is shown in Figure 6-16. We can observe 
from the preliminary experiments that all four of these compounds restore the 
coupling between TnI phosphorylation and Ca2+ sensitivity, like EGCG, Silybin and 
other structural analogues.  
 
Figure 6-16: Percentage motility of Tpm1 E180G phosphorylated and 
dephosphorylated thin filaments treated with different known Hsp90 inhibitors 
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mutant tropomyopsin and rabbit skeletal actin treated with Hsp90 inhibitors (100 
µM): Resveratrol (R), Geldanamycin (G), Novobiocin (N) and Pterostilbene (P).  
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6.8 Discussion 
 
6.8.1 Rapid screening methodology 
 
As part of our collaboration with Dr Brian Blagg, we received 30 compounds 
structurally similar to EGCG or Silybin to be tested for their recoupling properties. 
For the purpose of the screening experiments, a screening assay needed to be 
developed using the IVMA. The methodology was based on the fact that re-coupling 
can be observed in a single Ca2+ concentration and a full Ca2+ activation curve was not 
necessary, permitting for a rapid experimental procedure. HCM-causing mutation 
TPM1 E180G was the choice of the first screening, because the mutant tropomyosin 
is already made from baculovirus/sf9 and thin filaments can be reconstituted easily. 
From the first screening, several potent re-couplers could be identified for thorough 
examination. For the initial screening, only 100 µM of the compounds were used in 
the assay. It is possible that some of the drugs that found to have no effect from the 
rapid screening might still be re-couplers at a higher dose. Drug number 12 gave a 
negative result in the rapid screening and was selected as a negative control for the 
dose response curves for E180G and E54K mutant thin filaments. 25-200 µM of drug 
number 12 had no effect on neither or these mutations, confirming the results of the 
rapid screen. Four known Hsp90 inhibitors were also tested for their recoupling 
properties in E180G thin filaments and it was found that all of them re-coupled the 
uncoupled thin filaments, suggesting a potential structural similarity between Hsp90 
and troponin.  
 
6.8.2 Further analysis of potent re-couplers allows for insights about the 
uncoupling phenomenon  
 
Testing the most potent compounds selected from the rapid screening assay in 
different backgrounds and doses, gave some very interesting insights about the 
mechanism of the uncoupling phenomenon. A summary of the results for all the 
compounds can be found in Table 6-5.  
The more detailed dose response assay gave important information about the potency 
of the compounds to re-couple Ca2+ sensitivity from TnI phosphorylation. Silybin, 
which is also a natural occurring compound, re-coupled E180G mutant thin filaments 
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with a similar potency to EGCG (EC50 of Silybin 47.2 ± 2.66 µM compared to that of 
EGCG 58.8 ± 13.3 µM). Drug numbers 2, 4, 9, 14, 19, 26 and S-2 also re-coupled 
E180G mutant thin filaments with similar or slightly higher potency. The fact that 
some of the compounds had an effect and others did not, implies that there are key 
functional groups that account for the re-coupling and/or the desensitising properties. 
These have been removed or replaced from the drugs that had no effect on the Ca2+ 
sensitivity on mutant thin filaments, such as drug number 12. The structures of the 
compounds are unknown (Brian Blagg lab proprietary information) and the important 
functional groups could not be identified.  
We can observe that drugs have very similar effects across the three mutations 
studied. For example, all the compounds that re-coupled E180G HCM thin filaments, 
also re-coupled E54K DCM and E99K HCM thin filaments. Drug number 12 had no 
effect on the Ca2+ sensitivity of E180G and E54K mutant thin filaments. In the E54K 
thin filaments Silybin and drug numbers 14 and 26 showed re-coupling properties 
with an EC50 roughly 50% weaker than this of the same drugs in the E180G mutation. 
Drug S-2 had very similar EC50 across all the three mutations, with an EC50 of 36.6 ± 
5.46 µM for the E54K mutation, 32.2 ± 0.398 µM for the E180G mutation and 32.06 
± 0.005 µM for the E99K mutation. Silybin was a potent re-coupler also for the E99K 
mutant thin filaments, but with a greater EC50 value of 62.58 ± 3.14 µM comparable 
to an EC50 of 77.13 ± 7.93 µM for the E54K mutation. Silybin had an EC50 of 47.21 ± 
2.66 µM for the E180G mutation. From these results we can conclude that the overall 
effect of the drugs was preserved across the three mutations studied, however the 
potency of the drugs slightly changed within the three mutations. This prevented us 
from finding a single compound that was the most potent for all three cardiomyopathy 
mutations.  
From this study it was discovered a novel reverse recoupling molecule number 7 that 
decreased the Ca2+ sensitivity of dephosphorylated thin filaments and slightly 
increased the Ca2+ sensitivity of phosphorylated thin filaments in all three mutations. 
This is an unexpected result because the reverse recoupling has never been observed 
physiologically. Reverse recoupling elucidates the chemical differences between drug 
number 7 and other EGCG related compounds. All the small molecules provided by 
Dr Brian Blagg had similar structure to EGCG but some of the chemical groups were 
slightly changed. The chemical differences between number 7 and EGCG can provide 
new insights about the structure-function relationship of the uncoupling mechanism as 
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well as leading to the design of tailored drugs that could modulate the coupling of TnI 
phosphorylation and Ca2+ sensitivity in thin filament cardiomyopathy.  
The last but equally important finding from the detailed examination of the potent re-
couplers is the effect of the re-couplers on the regulation of Ca2+ sensitivity of the 
donor thin filaments. Silybin and drugs number 2, 4, 7, 26 and S-2 were tested for 
their effect on the Ca2+ sensitivity of phosphorylated and dephosphorylated donor thin 
filaments. Ca2+ sensitivity was coupled to TnI phosphorylation, which is also a 
property of the donor thin filaments. Although Silybin and EGCG decreased the Ca2+ 
sensitivity of donor thin filaments, the rest of the small molecules did not alter the 
Ca2+ sensitivity of the donor thin filaments. This was an unpredictable result because 
the lead compound EGCG was chosen on the basis that it was a Ca2+ desensitiser. 
These results suggest that the coupling between TnI and Ca2+ sensitivity might be 
independent of the thin filament Ca2+ sensitivity and that it is possible to act on the 
coupling without altering the absolute Ca2+ sensitivity of the thin filaments. In that 
aspect, it was lucky that EGCG, which was a known Ca2+ desensitiser also re-coupled 
the Ca2+ sensitivity to the TnI phosphorylation in thin filament cardiomyopathies.  
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Table 6-5: Small molecule screening summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug% E180G%
P/dP%
difference%
(initial%screen)%
E180G%
EC50,%µM%
E54K%%
EC50,%µM%
E99K%%
EC50,%µM%
No%drug% !1# 58.7#±#11.9#*# # #
EGCG% 23# 58.83#±#13.31# # #
Silybin% 12# 47.21#±#2.66# 77.13#±#7.93# 62.99#±#5.59#
1% 1# # # #
2% 27# 30.5#±#0.41# # #
3% 8# # # #
4% 27# 33.98#±#2.21# # #
5% 2# # # #
6% 1# # # #
7% !11# 67.05#±#20.31# ~#100# ~100#
8% No#Effect# # # #
9% 20# 34.83#±#2.9# # #
10% No#Effect# # # #
11% 7# # # #
12% !1# No#Effect# No#Effect# #
13% No#Effect# # # #
14% 17# 36.23#±#0.82# 61.99#±#1.5# #
15% 13# # # #
16% 6# # # #
17% 3.5# # # #
19% 24# 30.79#±#0.82# 62#±#1.5# #
20% 2# # # #
22% 25# # # #
22% 7# # # #
23% 9# # # #
24% 8# # # #
26% 26# 24.59#±#1.49# 55.18#±#7.47# #
27% 4# # # #
28% 4# # # #
SJ1% 22# # # #
SJ2% 20# 32.23#±#0.4# 36.62#±#5.46# 32.06#±#0.005#!
Summary of the compound screening experiments. Motility difference between 
phosphorylated and dephosphorylated E180G mutant thin filaments as calculated 
from the initial screen is shown and EC50 for mutations E180G (HCM), E54K 
(DCM) and E99K (HCM), which was calculated from the Hill equation fitted to the 
percentage motility difference between phosphorylated and dephosphorylated 
filaments dose response curves. * calculated from the previous chapter 
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6.8.3 Limitations 
 
Although this study gave positive outcomes in terms of potent re-couplers and 
provided some very interesting insights about the uncoupling phenomenon in a short 
period of time, there are several limitations that need to be taken into account. Firstly, 
although it was possible to shorten the experimental time with the developments of 
the screening assay, IVMA is not a high- throughput assay for testing many different 
compounds simultaneously. In order to develop such an assay, a different 
experimental method needs to be developed, such as using DCM or HCM mutant cell 
lines where such assay is possible.  
Due to the nature of the IVMA screening assay and the limitation of time, only n=1 
was performed, because I wanted to quickly identify re-couplers. Therefore, statistical 
analysis could not be performed. However, it is noted that in general the IVMA is 
quite reproducible and there is not much experimental error in the previous findings 
using the IVMA. More experimental repeats are needed in order to draw conclusions.  
Finally, the structures of the small molecules are not known to us, so no conclusions 
can be made about the structure-function mechanism of the small molecules. All the 
compounds were identified by Dr Brian Blagg originally as Hsp90 inhibitors. The 
reason why these compounds work as both Hsp90 inhibitors and as re-couplers of TnI 
phosphorylation to Ca2+ sensitivity in the cardiac thin filaments remains unknown. It 
is important to find out the structure of these compounds to identify the functional 
groups that account for the re-coupling properties. Also it would be important to 
identify the place where these compounds bind to troponin in relationship with EGCG 
and Silybin. 
 
6.8.4 Clinical perspectives 
 
In this chapter I investigated the effect of different compounds structurally similar to 
EGCG for their potential to re-couple uncoupled DCM and HCM thin filaments. 
Using a rapid screening methodology in the IVMA some of the compounds showed 
potent re-coupling properties. Furthermore, it was made clear that uncoupling and 
Ca2+ sensitivity act by two separate mechanisms as some of the re-couplers did not 
alter the Ca2+ sensitivity of donor thin filaments. This has implications for new 
therapeutic agents capable of targeting the coupling of the sensitivity to 
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phosphorylation with or without altering the absolute native Ca2+ sensitivity if 
required. The finding of potent re-couplers indicates that it is possible to have a 
targeted therapy for thin filament cardiomyopathies because the promiscuous groups 
have been removed from all the compounds (Brian Blagg personal communication).  
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7 FINAL DISCUSSION 
 
7.1 Aims of the thesis 
 
The aim of this thesis was to investigate the molecular mechanisms of the uncoupling 
phenomenon. The initial hypothesis was based on previous work by Memo et al, 
showing that uncoupling Ca2+ sensitivity from troponin I (TnI) phosphorylation is the 
molecular mechanism behind Dilated Cardiomyopathy (DCM) (Memo et al., 2013). 
Uncoupling has also been demonstrated in some cases of Hypertrophic 
Cardiomyopathy (HCM) (reviewed by Messer and Marston). Uncoupling has also 
been reported in human myectomy samples where there is no thin filament protein 
mutation (Bayliss et al., 2012).  
Cardiac TnI has a unique N terminal extension that is phosphorylated by PKA. The 
consequence of this is that the myofibrillar Ca2+ sensitivity and rate of Ca2+ release is 
modulated 2-3 fold in response to β adrenergic stimulation via PKA dependent 
phosphorylation of TnI Serine 22 and 23. In that way, Ca2+ sensitivity of the 
myofilament can decrease and the muscle can relax upon the action of adrenaline.  
Based on the structural models it has been suggested that there are specific 
interactions between the N terminal lobe of troponin C (TnC) and TnI1-30 that are 
phosphorylation dependent and this modulates the Ca2+ sensitivity change upon TnI 
phosphorylation (Ward et al., 2004, Howarth et al., 2007, Cheng et al., 2014, Solaro et 
al., 2008). Memo et al hypothesised that these interactions are unstable and can be 
disrupted or changed by many perturbations of which HCM/DCM-causing mutations 
are the best-known examples. As a result, troponin is in the same state as when 
phosphorylated, independently of the phosphorylation level (uncoupled). The 
molecular mechanism of uncoupling has been examined in this thesis, by testing 
several pharmacological agents that bind to TnC and alter the Ca2+ sensitivity of the 
thin filament, like mutations do, and therefore might affect the coupling between Ca2+ 
sensitivity and TnI phosphorylation. At the same time, the nature of TnI and TnC 
interactions upon phosphorylation has been unravelled using molecular dynamics by 
the molecular dynamics group (Dr Ian Gould, Mr Juan Eiros Zamora, Miss Alice 
Sheehan and Mr David Wilson).  
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7.2 Uncoupling by mutations as a disease-causing process.  
 
Uncoupling occurs as a consequence of a mutation in any protein of the thin filament, 
which would be the genetic cause of DCM or HCM. It is now known that uncoupling 
is the widespread mechanism for DCM, having important implications for the disease 
progression (Memo et al., 2013, Messer and Marston, 2014). The decrease of the Ca2+ 
sensitivity upon TnI phosphorylation is a downstream effect of the β adrenergic 
response. Uncoupling of Ca2+ sensitivity to TnI phosphorylation would lead to 
blunting the lusitropic response and as a consequence this would affect also the 
inotropic response. The physiological consequences of the uncoupling phenomenon 
have been demonstrated with the ACTC E361G transgenic (TG) mice as a model for 
DCM. Extracted myofibrils from the TG animals have shown increased Ca2+ 
sensitivity of force compared to wild type. Dephosphorylated transgenic mice did not 
show any alteration in the Ca2+ sensitivity of isometric force or the relaxation 
parameter, TLIN and kREL upon phosphorylation, showing that the DCM mutation 
blunts the β adrenergic response through phosphorylation without affecting other 
parameters such as length-dependent activation (Vikhorev et al., 2014). In vivo and ex 
vivo experiments with these animals further support these findings; papillary muscle 
relaxation of E361G animals was unaffected by β1 adrenergic stimulation treatment 
with dobutamine showing blunting of the lusitropic response. The ionotropic effect 
was also blunted, as shown by the reduced effect of dobutamine in end-systolic 
pressure and end-systolic volume (Wilkinson et al., 2015).  
The blunting of lusitropic response which is a downstream physiological effect of 
uncoupling would lead to a loss of cardiac reserve that could eventually lead to heart 
failure (Figure 7-1). Wilkinson et al showed this, by chronic angiotensin II treatment 
whereby E361G TG mice develop hypertrophy initially and then dilation with 
reduced cardiac output compared to the WT mice (Wlkinson et al., 2015). Other 
DCM transgenic animals have shown blunted response to β agonists (reviewed by 
Messer and Marston, 2014). Uncoupling has also been observed in studies using 
cardiomyocytes from induced Pluripotent Stem Cells (iPSCs) from patients with 
DCM. The experiment of Sun et al with iPSC- cardiomyocytes containing the TNNT2 
R173W DCM mutation has shown a reduced initial response to nor epinephrine 
followed by a loss of contractility over 6 hours (Sun et al., 2012).  
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Figure 7-1: The physiological consequences of uncoupling in DCM 
 
 
 
 
 
 
 
The situation of uncoupling in HCM is more complicated. Cases of uncoupling in 
HCM have been found in vitro (Deng et al., 2001, Dong et al., 2008, Gomes et al., 
2005, Schmidtmann et al., 2005) including the TPM1 mutation E180G shown for the 
first time in this thesis. However, in whole muscle system using explanted heart tissue 
several cases have been observed where normal coupling occurs (Sequeira et al., 
2013). Furthermore, a study with the TPM1 E180G transgenic mouse have shown 
normal coupling comparing phosphorylated and pseudophosphorylated mouse 
skinned fibres (Alves et al., 2014) contradicting  my own results in in vitro motility 
assay (IVMA). These discrepancies can occur because there might be a compensatory 
mechanism in the whole organism that is masking the uncoupling phenomenon. 
Preliminary experiments with ACTC E99K myofibrils done by Dr Petr Vikhorev and 
Mr Yousef Sebzali have also shown discrepancies in uncoupling in HCM, E99K 
myofibrils being “partially” coupled, even though they showed a clear uncoupling in 
IVMA (Figure 7-2). The EC50 ratio of ACTC E99K myofibrils (coupling constant) is 
1.22 compared to 0.99 in thin filaments in IVMA and 2.24 in WT mouse myofibrils. 
This means that for HCM mutations uncoupling of force production may not be an 
all-or-nothing response, as it is in unloaded assays. This may be very interesting 
especially for HCM and it needs to be explored further. Also the extent of uncoupling 
is important to be examined beyond thin filament mutations, for example in case of 
mutations in titin, myosin or Myosin Binding Protein C (MyBP-C) at both singe 
filament and myofibrillar level.  
 
 
Flow chart showing the physiological effects of uncoupling and how it leads to 
DCM/heart failure. Diagram kindly provided by Mr Ross Wilkinson.  
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Figure 7-2: Uncoupling in E99K myofibrils 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3 Small molecules can modulate coupling 
 
My main investigation was to test agents that bind to TnC for their ability to induce 
uncoupling mimicking the mutations. The Ca2+ sensitiser EMD 57033 was the first 
small molecule to be examined and it indeed induced uncoupling in thin filaments 
reconstituted with donor contractile proteins. This showed that EMD 57033 mimics 
HCM-causing mutations at the molecular level, by increasing the Ca2+ sensitivity and 
also uncoupling the Ca2+ sensitivity from the TnI phosphorylation. The other Ca2+ 
sensitiser tested, Bepridil, showed the same result. This indicates that the coupling of 
Ca2+ sensitivity and TnI phosphorylation is a labile property of troponin and can be 
A) EC50 of phosphorylated and dephosphorylated E99K myofibrils B) nH of 
phosphorylated and dephosphorylated E99K myofibrils C) A typical Ca2+ curve of 
phosphorylated (red) and dephosphorylated (green) E99K myofibrils. Force is 
normalized from 0 to 1 with 0 indicating minimal contraction and 1 indicating 
maximal contraction. Data were kindly provided by Mr Yousef Sebzali and Dr Petr 
Vikhorev. 
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manipulated either by mutations or by small molecules. It is possible that the 
mechanism of uncoupling is through disruption or change of the TnC-TnI specific 
interactions, as also confirmed by structural studies showing that EMD 57033 
compete with TnI34-71 (Wang et al., 2011, Botten et al., 2013, Li et al., 2004) Bepridil 
affects the affinity of TnI147-163 with TnC and binds to a different position than EMD 
57033, but the effect of Bepridil on the N terminal peptide of TnI has not been looked 
at so no conclusions can be drawn. In any case, it is interesting that although the two 
molecules bind to two different positions, the effect on the coupling is the same. 
These results confirm the original hypothesis; that it is possible to manipulate 
uncoupling pharmacologically.  
 
7.4 Ca2+ desensitisers like EGCG can reverse the uncoupling 
phenomenon.  
 
The major discovery of my PhD thesis was the fact that green tea extract 
Epigallocatechin-3-Gallate (EGCG) which is also a Ca2+ desensitiser was able to 
reverse the uncoupling of Ca2+ sensitivity to TnI phosphorylation in all the DCM and 
HCM mutations studied that had previously been found to be uncoupled. This 
function of EGCG was not expected, as EGCG was initially tested due to its 
desensitising properties as demonstrated by Tadano et al, (Tadano et al., 2010). 
EGCG binds to TnC and its effects on coupling were examined because it was 
predicted that EGCG would also alter the TnC-TnI interactions. It was very surprising 
when it was discovered that EGCG does not induce uncoupling in donor thin 
filaments, but rather reverses the uncoupling observed in DCM and HCM mutant thin 
filaments. IVMA was the most appropriate method for this investigation, because the 
effect of the small molecules on the proteins can be measured and the phosphorylation 
level of TnI can be easily controlled. These results were very robust, as the 
uncoupling was reversed in many mutations, and furthermore it was confirmed in 
myofibrils of E361G TG mice (experiments performed by Dr Petr Vikhorev). Several 
structural models have been proposed for the binding of EGCG to TnC, including 
NMR and molecular dynamics (MD) models. Unlike EMD 57033 it has been 
suggested that EGCG binds in complex with TnI34-71 peptide so that would suggest 
that it is possible that EGCG enhances the signal from TnI to TnC through 
interactions which is lost in cardiomyopathies. Figure 7-3 shows the binding of 
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EGCG to TnC as determined by Botten et al. Botten et al in his study showed by MD 
simulations that EGCG had the opposite effects of the DCM mutation G159D on the 
TnC-TnI interaction, confirming the results described in this thesis. All these findings 
demonstrate that the uncoupling phenomenon is a general rather than a specific 
mechanism, as all the different mutations cause uncoupling, and EGCG restores the 
uncoupling in all the mutations respectively.  
 
Figure 7-3: EGCG binding to TnC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taking TPM1 E180G as a paradigm of uncoupling in HCM mutations, it has been 
found that other small molecules that are structurally similar to EGCG can also 
recouple uncoupled thin filaments; their effect also confirmed in the DCM mutation 
TPM1 E54K and HCM mutation ACTC E99K. Another natural derivative that is a 
desensitiser and re-coupler is Silybin from the plant Silibum. For this part of the 
project, I developed a quick screening method to test the analogues for their 
recoupling potential using the IVMA.  
EGCG binding to TnC/ Ca2+/ TnI34-71. TnC as calculated with MD simulations is shown 
in green, the TnI34-71 peptide is shown in red, purple spheres are the Ca2+, residue G159 
in TnC which is mutated in DCM is shown in blue and TnC residues that make contact 
with EGCG in orange. Adapted from Botten et al, 2013 
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The only known feature that these compounds have in common is that they are all 
inhibitors of Hsp90 via its C terminus (Khandelwal et al., 2013, Zhao et al., 2011). 
This suggests that there might be some structural common features between TnC and 
Hsp90; perhaps there is sequence homology. It is noted that even though EGCG is a 
promiscuous molecule acting on many different targets (Ingolfsson et al, 2014), a 
structural group that gives promiscuity has been removed from some of the analogues 
without loss of function (Dr Brian Blagg, personal communication). Preliminary 
experiments have been performed investigating the re-coupling effect of four other 
Hsp90 inhibitors: geldanamycin, novobiocin, resveratrol and pterostilbene. 
All four of these compounds restore the coupling between TnI phosphorylation and 
Ca2+ sensitivity, like EGCG, Silybin and other structural analogues. The C terminal 
small molecule binding site where novobiocin binds has been elucidated (Matts et al., 
2011) and it was found that it binds at the interface between the two subunits of 
Hsp90. This is analogous to EGCG that also acts on the interface between TnC and 
TnI subunits. Resveratrol and pterostilbin also bind to the C terminal binding site 
while Geldanamycin binds at the N terminal small molecule binding site of the 
Hsp90. (Stebbins et al., 1997). Geldanamycin was the least effective of all the 
molecules studied therefore maybe there is a structural similarity between the C 
terminal binding site of Hsp90 and troponin. However, all these are just speculations 
which brings difficulties on drawing conclusions about the structural similarities 
between troponin and Hsp90.  
Another very important finding from the analogues study is the separation of the 
effect on Ca2+ sensitivity from the uncoupling phenomenon. Some agents were able to 
re-couple uncoupled E180G mutant thin filaments without changing the Ca2+ 
sensitivity of wild type thin filaments. This indicates that the increased or decreased 
Ca2+ sensitivity observed in DCM and HCM is a separate property from uncoupling. 
In that respect, it has been very fortuitous that EGCG was found to be a desensitiser 
and also a re-coupler. The fact that uncoupling seems to be independent from Ca2+ 
sensitivity may be important regarding the potential therapy for inherited 
cardiomyopathies, that it is possible to target uncoupling irrespectively of the effect of 
mutations on the Ca2+ sensitivity.  
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7.5 Insights for troponin regulatory mechanism 
 
As previously mentioned, the results have given rise to some interesting insights 
about the molecular mechanism of the uncoupling phenomenon and as a result, about 
the mechanism of regulation of Ca2+ sensitivity by the adrenergic response and how it 
is disrupted in disease. The results from the Ca2+ sensitisers and desensitisers indicate 
that there are structural and functional changes in the interaction between TnI1-30 
peptide and the N terminal of the TnC, having important effects on the binding of 
Ca2+ to TnC so that the Ca2+ sensitivity can change. As discussed in Section 5.6.1, 
phosphorylation, HCM and DCM mutations in cardiac muscle and gain of function 
and loss of function mutations in the skeletal muscle only change the Ca2+ sensitivity 
by a certain extent. This implies that the TnI1-30 peptide seems to be involved in a 
fixed transition with a 2-3 fold Ca2+ sensitivity change readout. DCM and HCM-
causing mutations and Ca2+ sensitisers that cause uncoupling block this transition, but 
the way by which this happens is uncertain.  
Opposed to the Ca2+ switch, the exact mechanism by which TnI phosphorylation 
modulates Ca2+ sensitivity has been an unsolved problem for many years. The 
problem arises from the fact that the TnI1-30 peptide is unstable and it is not present in 
the crystal structure by Takeda et al. The first to give some light on this matter was a 
study by Ward al, in which the structure of phosphorylated and dephosphorylated 
troponin including the TnI1-30 peptide was elucidated using NMR. According to this 
model, there is a weak ionic interaction between the TnI N terminal peptide and TnC, 
which is absent upon phosphorylation (Ward et al., 2004). Following this study, 
Howarth et al determined the structure of TnI1-30 peptide in phosphorylated and 
unphosphorylated states and used these to build a model of the whole troponin 
(Howarth et al., 2007). However, this model has been updated with more recent 
concepts. The N terminal extension of dephosphorylated troponin has been recently 
described as an intrinsically disorder region interacting with TnC and orienting it 
relative to the rest of the troponin complex, resulting in an increased Ca2+ affinity. 
This delicate interaction is abolished upon phosphorylation (Hwang et al., 2014). 
These results are also in line with my data, since the re-couplers seem to affect the 
phosphorylated state more, which is predicted to be more unstable.  
The intrinsic disorder nature of the N terminal extension of TnI is a concept that has 
not been addressed by structural biologists, which needs to be taken into account in 
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order to determine the mechanism of Ca2+ sensitivity changes upon phosphorylation. 
In fact, being disordered is important for the phosphorylation itself and it has been 
found that the majority of the proteins that get phosphorylated in nature have domains 
close to the phosphorylation site similar to proteins that have been characterized as 
intrinsically disordered (Iakoucheva et al., 2004). Unfortunately, this makes the 
molecular mechanism of the cardiac muscle regulation upon phosphorylation difficult 
to study, since structural studies by NMR and crystallography will not give any 
further information.  
The way forward would be to use molecular dynamics (MD) simulations to elucidate 
the structural changes upon troponin phosphorylation. This technique views the 
proteins as moving objects rather than as stable peptides like in the case of NMR and 
crystallography. As part of my PhD thesis I have started a collaboration with Dr Ian 
Gould from the Department of Chemistry which has provided some insightful data 
about the matter.  
Phosphorylated and unphosphorylated troponin structural model have been 
developed, containing the complete human sequence of troponin, including the N 
terminal extension of TnI1-30 and 137-148 and the entire TnT including the C terminal 
not present in the crystal structure. Figure 7-4 shows the phosphorylated and 
unphosphorylated structure of troponin as defined using MD. The multiple 
simulations run for a long time (7.25 µs for the unphosphorylated and 2.65 µs for the 
phosphorylated structure) in order for the obtained results to be as reliable as possible.  
Analysis of the changes upon phosphorylation has been performed measuring the 
interactions between the different peptides in order to understand the structural 
changes that occur upon TnI phosphorylation. Interactions between TnI, TnC and TnT 
have been analysed by measuring the Root Mean Square Fluctuation (RMSF). Figure 
7-5 shows the changes between the amino acid interactions in TnC, TnT and TnI.  In 
general it can be observed that no massive changes occur upon phosphorylation in 
either of the subunits. This is in line with other MD studies that showed that 
phosphorylation of Serine 22 and 23 did not have significant effects on TnC and Ca2+ 
binding but rather increased the overall fluctuations of the troponin complex and 
induced interactions between the N terminal extension and the inhibitory peptide of 
TnI, regulating the switch (Cheng et al, 2014). Furthermore these results are rational 
considering that the Ca2+ sensitivity change upon phosphorylation is just 2-fold 
indicating that only subtle changes would occur.  
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From the MD results it can be observed that the most differences are actually found 
on the TnI N terminus and the C terminus of TnT. This is very interesting because 
TnT does not influence Ca2+ binding, phosphorylation or thin filament switching 
directly but rather co-ordinates the whole process, which complicates the model 
further. This finding is also thought provoking because it can be combined with 
experimental results in IVMA. When exchange experiments in troponin were 
performed to observe which of the troponin subunits is responsible for uncoupling it 
was found that the TnT was necessary for uncoupling in thin filaments reconstituted 
with troponin from Hypertrophic Obstructive Cardiomyopathy (HOCM). However, 
the exact abnormality within the TnT could not be defined using standard structural 
methods (Bayliss et al, 2012). It is also noted that the phosphorylated structure is 
slightly less mobile than the unphosphorylated structure, which is against the simple 
trend but is compatible with a shift between disordered states.  
 
Figure 7-4: Structure of phosphorylated and unphosphorylated troponin determined 
by MD simulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribbon diagram of troponin representing the whole human sequences of TnC (blue), TnI 
(red), TnT (green). Ca2+ is represented by a gray sphere. The N terminal extension of TnI is 
shown in orange and the phosphorylation is indicated. A) unphosphorylated B) 
phosphorylated. The figure was created using chimera and the PDBs of the simulations were 
kindly provided by Mr Juan Eiros Zamora. 
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Figure 7-5: Amino acid changes in troponin subunits upon phosphorylation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From all these studies it can be concluded that troponin has a rather dynamic 
structure, owing to the intrinsically disorder domains such as the N terminal extension 
of TnI. This makes it difficult to elucidate its exact structure and thus the mechanisms 
of its regulation, at least by using the standard structural techniques. Determining the 
structure of troponin mobile regions will not only lead to understanding the changes 
that occur upon its regulation, but also to predicting the effect of a mutation or a 
pharmacological agent.  
Root Mean Square Fluctuations (RMSF) of phosphorylated and unphosphorylated 
troponin calculated using AMBER. RMSF of the amino acids in all the troponin 
subunits is shown (TnC at the top, TnT in the middle and TnI at the bottom). Red 
represents unphosphorylated (Wild Type) and blue represents phosphorylated. The 
figure was produced by Mr Juan Eiros Zamora.  
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For example, just by knowing the structure of tropomyosin and its exact interactions 
with actin it has been possible to predict the effect of mutations. The experiments I 
did with the tropomyosin gain of function mutations shows what is possible if there is 
a well-defined structure known. In Chapter 3 I showed that all the tropomyosin 
mutations that are found in the site of interaction of tropomyosin- actin lead to a gain 
of function, as demonstrated by an increase in the Ca2+ sensitivity. This correlated 
with a hypercontractile phenotype in patients, showing that it possible to make 
structure-function predictions when the structure has been unravelled based on the 
stabilisation of tropomyosin interactions with actin Asp25, 326, 328 and 147. With 
troponin it is not possible to make such predictions at the moment, as the exact 
structure is still unresolved. However, MD simulations can be a good way to go 
forward with troponin, as the molecule is perceived as a moving object and not as a 
rigid structure.  
7.6 Clinical implications of the uncoupling phenomenon 
 
Uncoupling the Ca2+ sensitivity from TnI phosphorylation has important implications 
both for the diagnosis and the treatment of cardiomyopathies.  
Idiopathic DCM patients can be divided into two categories; the ones that are 
responsive to dobutamine treatment, which is a drug used to treat acute heart failure 
by stimulating the β adrenergic response, and the ones that are not responsive to the 
therapy (Borow et al., 1988, Dubois-Randé et al., 1992, Naqvi et al., 1999). It might 
be possible that the ones that are non responsive are the ones with inherited DCM 
showing uncoupling, thus even if TnI gets phosphorylated the Ca2+ sensitivity would 
not change, giving the patient resistance to dobutamine and poor prognosis. If this is 
the case it would allow distinguishing the cases of DCM to inherited and idiopathic 
DCM and will be possible for the clinics to assign the DCM patients the right 
treatment. 
The effects of the EGCG are also translationally important. EGCG was able to restore 
the uncoupling in all of the DCM and HCM cases with mutations in the thin filament. 
This has significant implications for the correct therapy of DCM and HCM, as EGCG 
has the ideal profile in vitro. This is especially true for HCM as EGCG can both 
decrease the Ca2+ sensitivity and re-couple, although the DCM cases did not have 
significantly different Ca2+ sensitivity levels to normal after treatment with EGCG. 
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However, EGCG is quite a promiscuous molecule with increased inotropic effects 
(Ingolffson et al., 2014, Feng et al., 2012), which makes EGCG itself not a good 
candidate for therapy. 
With EGCG analogues like the ones provided by Dr Brian Blagg the problem of 
promiscuity can be overcome, as it might be possible to make the drugs specific for 
troponin by manipulating the chemical groups of EGCG. It is also possible to separate 
the Ca2+ sensitising property from the re-coupling property, thus it would be likely to 
“cure” any cardiomyopathy cases that have TnI phosphorylation uncoupled to Ca2+ 
sensitivity irrespective of their effect on absolute Ca2+ sensitivity. Knowing the 
structure of the analogues would be important to understand the functional group 
which is responsible for re-coupling and thus making drugs that can be used in the 
clinic. The functional homology with the C terminal of Hsp90 inhibitors is also a 
worthwhile direction of study since these have been very extensively investigated 
already (Hall et al., 2014) 
7.7 Future work 
 
Although many interesting discoveries have been made in this thesis, many questions 
have also arisen. First of all, the structural changes of troponin upon phosphorylation 
need to be found, in order to understand the exact mechanism of regulation of 
troponin by phosphorylation, which accounts for the β adrenergic response. As 
explained in the previous sections, a good approach to solve this problem is through 
MD simulations. DCM and HCM-causing mutations can be incorporated into the 
simulations in the phosphorylated and unphosphorylated state, and thus the structural 
mechanisms that account for the uncoupling phenomenon can be revealed. Similarly, 
it would be possible to model the actions of the different drugs studied in this thesis, 
such as EGCG, Silybin, EMD 57033 and Bepridil. In that way the molecular 
mechanism between the uncoupling and how it is reversed by molecules such as 
EGCG can be discovered. My work has made finding a common mechanism possible, 
because there are now many different perturbations with derived functional effects 
that can be tested against structural models.  
Another important aspect that needs to be examined is the physiological implication 
of uncoupling, especially in HCM. As mentioned previously, the uncoupling 
phenomenon in HCM is not clear, as there are discrepancies between in vitro and in 
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vivo studies. Uncoupling in HCM mutations should be investigated using IVMA to 
see whether all mutations cause uncoupling in vitro.  
My in vitro experiments suggest re-couplers would be good agents to treat HCM and 
DCM. It is now important to investigate the effect of EGCG and EGCG-like 
compounds in vivo. This can be done using the transgenic mouse lines E361G (DCM) 
and E99K (HCM). The physiological consequences of the uncoupling phenomenon 
has been studied in these models in vivo by Pressure Volume loops and 
Echocardiography and ex vivo by force measurements of the papillary muscle (Song 
et al, 2011, Song et al, 2013, Wilkinson et al, 2015). It would be important to inject 
EGCG and/or its structural analogues into the E99K or the E361G mouse model in 
the presence of dobutamine and observe whether the disease symptoms are reduced. 
To view the effect on the muscle alone, the effect of the drugs can be observed on 
isolated papillary muscle using the AURORA apparatus. Phosphorylation levels in the 
mouse can also be manipulated by propranolol injections before sacrifice (Vikhorev et 
al., 2014). Thus, the effect of EGCG and its analogues can be observed in a 
physiological system. This would give interesting insights for the use of these 
compounds as treatment for DCM and HCM in mouse, and by extension potentially 
in humans.  
In this thesis a medium-throughput method for screening of candidate compounds for 
the treatment of DCM and HCM has been developed. In the future, it is important for 
a high-throughput screening to be developed to find the most potent compound. A 
way to do this would be to use adult cardiomyocytes with a known DCM or HCM 
mutation in 96-well plates. Apart from the screening of the drugs, this would also give 
insights about the uncoupling phenomenon in a cellular system, something that has 
never been looked at before. The adrenergic response of the cardiomyocyte 
contractility in response to dobutamine can be assessed as well as the effect of the 
drugs. If uncoupling occurs then DCM and HCM cells would not respond to 
dobutamine, as preliminary experiments of Sun et al show (Sun et al., 2012). Cellular 
contractility can be measured in presence or absence of dobutamine and then in the 
presence of re-coupling drugs to test if the effect will be reversed. Toxicity of the 
drugs can be tested by measuring apoptosis of the cells and hypertrophy of the cells 
can also be measured by cell size and sarcomere alignment therefore reversibility of 
disease characteristics by re-couplers can be tested.  
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To assess the compound effect on human heart the more potent drug candidates can 
also be tested in Engineered Heart Tissue (EHT). Mr Thomas Owen in our lab has 
already optimized the EHT development and is now in the process of producing EHT 
from iPSC-derived cardiomyocytes with the ACTC E99K mutation. It will be 
interesting to see the effect of the compounds at the force of the mutant muscle. 
All these together will shed light into all aspects of the uncoupling phenomenon, from 
the molecular mechanism, the physiological consequences and most importantly the 
potential to reverse it using EGCG-like compounds.  
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APPENDIX 
 
From Section 3.1:  
 
Nemaline Myopathy histological characteristics: 
 
 
 
 
 
 
 
 
 
 
Cap disease histological characteristics: 
 
 
 
 
 
 
 
 
 
 
 
73 
NM); Amish NM, intermediate congenital form (20%); typical congenital form (46%); 
childhood-onset form (13%); and adult-onset (late-onset) form (4%) (North, 2010). 
 
Figure 1.23: Nemaline myopathy histology 
 
A) Gomori trichrome-stained transverse section of skeletal muscle biopsy of a nemaline myopathy patient. Rods 
appear in every fibre as darkly staining bodies all across the cytoplasm (small arrows), or underneath the 
sarcolemma (large arrows), (Sanoudou and Beggs, 2001). B) Electron micrograph showing typical nemaline 
rods developing from the Z-line and disrupting the normal sarcomeric architecture (Wattanasirichaigoon et al., 
2002). 
 
 
Muscle weakness is usually most severe in the face, the neck flexors, and the proximal limb 
muscles, but it can also involve the distal ones. When it has congenital onset the face is 
usually elongated and expressionless, the palate arched, and the tongue small. Many patients 
cannot lift their head from supine position, have hyperlordotic spine and respiratory capacity 
restricted, with risk of nocturnal hypoxia or sudden respiratory failure. Cardiac contractility 
and intelligence are usually normal (North et al., 1997). 
The distribution of nemaline rods can be considered quite random, but they tend to cluster 
under the sarcolemma and around the nuclei, with a variable presence in different fibres, 
although in some patients they are present only in type I fibres. The rods themselves measure 
1-7 µm in length and 0.3-2 µm in width, with a surrounding layer of desmin. They are 
considered as deriving from the lateral expansion of Z-disks because on EM they are in 
A) Gomori trichrome triple stain of a histological section of skeletal muscle biopsy 
of a patient with skeletal muscle myopathy. Rods are found across the cytoplasm 
(dark circles indicated with small arrows) or underneath the sarcolemma (dark 
circles indicated with large arrows) (Sanoudou and Beggs, 2001) B) Electron 
microgram showi g typical rods found in Nemal ne myopathy patients developing 
in the Z line and disrupting the skeletal muscle structure (Wattanasirichaigoon et 
al., 2002).   
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Figure 1.24: Cap disease histology 
 
A) Light microscopy of a skeletal muscle biopsy of a cap disease patient stained with NADH-TR. The black 
arrows indicate the peripheral sub-sarcolemmal cap structures. B) Electron microscopy of the same biopsy 
showing a cap structure (black arrow). C) Magnification of the cap structure shown in B. It consists of 
unorganised myofibrils with lack of thick filaments and enlarged Z-lines. Adapted from Cuisset et al. (2006). 
 
 
The cap-like structure seems to be made of disoriented and disorganised myofibrils with a 
lack of thick filaments and Z-disk abnormalities (Figure 1.24 C), like rod formations. Z-lines 
look thickened even in regularly assembled sarcomeres. In the caps have been reported to be 
localised mainly desmin, troponin T, nebulin, actin, α-actinin, tropomyosin, myotilin and 
SERCA2, with rare occasions of myosin and vimentin. Cap disease patients show also a quite 
consistent fibre type disproportion, with many more hypotrophic type I fibres and few 
hypertonic type II fibres (Lehtokari et al., 2007). 
Later four other β-tropomyosin mutations have been identified and linked to cap disease, 
∆K49, G53dup, N202K, E41K (Ohlsson et al., 2008, Tajsharghi et al., 2007). Another report 
on E41K gave the first insight on the functional properties of cap disease related mutations 
suggesting a negative effect on contractile properties, with a decrease in Ca2+-sensitivity and 
contracting speed in skinned muscle fibres (Ochala et al., 2008). 
 Also two mutations in the TPM3 gene, R167C and R167H, have been associated with cap 
disease in two different reports, and a mutation in the ACTA1 gene, M47V, proving the 
genetic heterogeneity of the disease (Ohlsson et al., 2009, De Paula et al., 2009, Hung et al., 
A) Light microscopy of a skeletal muscle biopsy of a patient with Cap disease. 
B) Electron microscopy of the same sample where the cap structure is indicated 
with an arrow. C) Magnification of the cap structure in B. It consists of 
myofibrils lacking thick filaments and enlarged Z lines. (Cuisset et al., 2006) 
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CFTD histology 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A, B and C show varying degrees of fibre size disproportion. Muscle 
biopsies from CFTD patients and stained with ATPase. Type 1 fibres are 
dark, type 2A are light and type 2B are intermediate (Clarke and North, 
2003) 
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2009). It is notable that only thin filament proteins have been linked to the disease and a 
characteristic irregular and coarse-meshed intermyofibrillary network with jagged Z-lines has 
been described as a common feature (Ohlsson et al., 2008).  Some  of  these  γ- and  β-
tropomyosin mutants have also been linked with other diseases (see 1.5.4). 
One important observation made on different cap disease patients is that the onset can be 
neonatal or infant, with the neonatal form being more severe, showing caps in 70 - 75% of 
the fibres and leading to premature death, whereas the infant form is milder, with caps in only 
10 - 30% of the muscle fibres and a better prognosis (Fidzianska, 2002, De Paula et al., 2009, 
Hung et al., 2009). This could be related to the expression of the mutant protein in different 
developmental stages. 
1.5.3 Congenital Fibre Type Disproportion (CFTD) 
Congenital fibre type disproportion (CFTD) is a term coined by Brooke in 1973, after 
describing 12 patients with the same abnormalities on muscle biopsy that was seen in several 
other patients earlier in the 1960s and early 1970s (Brooke, 1973). 
 
Figure 1.25: CFTD histology 
 
Muscle biopsies stained with ATPase of patients with varying degrees of fibre size disproportion associated 
with CFTD. Type 1 fibres are dark,  type 2A are pale and 2B are intermediate. (Clarke and North, 2003) 
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From Section 4.2.2.1 
 
Ca2+ sensitivity data for donor troponin treated with different concentrations of EMD 
57033 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Motile'Velocity'
Donor' SD Donor'+'15'µM'EMD SD Donor'+'30'µM'EMD SD Donor'+'60'µM'EMD SD
Exp1% 0.066 0.013 0.06 0.0045 0.053 0.0042 0.11 0.018
Exp2% 0.11 0.013 0.054 0.011 0.047 0.013 0.11 0.011
Mean 0.088 0.057 0.050 0.110
SE 0.022 0.003 0.003 0.00
Percentage'Motility
Donor' SD Donor'+'15'µM'EMD SD Donor'+'30'µM'EMD SD Donor'+'60'µM'EMD SD
Exp1% 0.18 0.05 0.2 0.069 0.1 0.0075 0.16 0.0061
Exp2% 0.26 0.027 0.19 0.069 0.14 0.036 0.22 0.05
Mean 0.22 0.20 0.12 0.19
SE 0.04 0.01 0.02 0.03
EC50,'µM
EC50,'µM
Motile'Velocity'
Donor' SD Donor'+'15'µM'EMD SD Donor'+'30'µM'EMD SD Donor'+'60'µM'EMD SD
Exp1% 2.12 0.61 1.11 0.094 2.21 0.29 2.22 0.76
Exp2% 2.12 0.5 1.36 0.37 1.3 0.48 3.08 1.19
Mean 2.12 1.235 1.76 2.65
SE 0.00 0.125 0.46 0.43
Percentage'Motility
Donor' SD Donor'+'15'µM'EMD SD Donor'+'30'µM'EMD SD Donor'+'60'µM'EMD SD
Exp1% 2.5 1.46 1.78 0.95 1.87 0.22 3.03 0.27
Exp2% 4.12 1.87 1.21 0.48 1.07 0.28 2.34 0.98
Mean 3.31 1.50 1.47 2.69
SE 0.81 0.29 0.40 0.35
Hill'Coefficient
Hill'Coefficient
Motile'Velocity'
Donor' SD Donor'+'15'µM'EMD SD Donor'+'30'µM'EMD SD Donor'+'60'µM'EMD SD
Exp1% 2.52 0.025 2.78 0.06 2.95 0.034 2.85 0.12
Exp2% 2.78 0.059 2.83 0.022 2.99 0.13 2.81 0.047
Mean 2.65 2.81 2.97 2.83
SE 0.13 0.025 0.02 0.02
Percentage'Motility
Donor' SD Donor'+'15'µM'EMD SD Donor'+'30'µM'EMD SD Donor'+'60'µM'EMD SD
Exp1% 69.25 4.65 84.25 4.35 89 2 83.5 5.2
Exp2% 76.75 2.99 83.5 3 89.8 2.08 78.25 2.22
Mean 73.00 83.88 89.40 80.88
SE 3.75 0.38 0.40 2.63
Max'%'Motile'
Max'Motile'Velocity,'µm/sec
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From Section 4.2.3  
 
 
Analysis of measurements of the Ca2+-dependence of fraction motile and motile velocity measured by in vitro motility assay. The effects 
of TnI phosphorylation on donor thin filaments in the presence and absence of EMD 57033. EC50, nH, maximum fraction motile and maximum 
sliding speed are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Effect&of&EMD&on&wild&type&troponin&
Percentage motility
P SD unP SD P SD unP SD P SD unP SD P + EMD SD unP + EMD SD P + EMD SD unP + EMD SD P + EMD SD unP +EMD SD
Exp1 0.12 0.01 0.06 0.01 2.00 2.34 0.75 1.97 0.33 81.75 3.59 83.00 3.74 0.03 0.003 0.03 0.002 1.07 1.16 0.14 1.19 0.13 87.00 1.41 85.75 1.71 3.44 1.84
Exp2 0.15 0.04 0.11 0.02 1.44 1.72 0.52 1.19 0.21 81.25 1.71 80.75 2.22 0.08 0.017 0.07 0.011 1.01 1.16 0.29 1.09 0.18 81.75 3.86 80.75 1.71 2.05 1.44
Exp3 0.13 0.01 0.08 0.01 1.71 2.28 0.29 1.88 0.21 77.50 3.70 80.25 1.89 0.07 0.002 0.06 0.004 1.12 1.23 0.05 1.37 0.11 84.25 3.10 84.50 1.29 1.87 1.23
Exp4 0.23 0.01 0.12 0.02 1.93 1.98 0.08 0.98 0.15 78.25 3.20 73.50 2.12 0.05 0.002 0.04 0.003 1.11 1.47 0.14 1.72 0.69 77.25 5.56 76.25 4.79 4.91 2.83
Mean 0.16 0.09 1.77 2.08 1.51 79.69 79.38 0.06 0.05 1.08 1.26 1.34 82.56 81.81 3.07 1.83
Std Error 0.03 0.01 0.13 0.14 0.25 1.06 2.05 0.01 0.01 0.03 0.07 0.14 2.07 2.14 0.71 0.36
Motile velocity
P SD unP SD P SD unP SD P SD unP SD P + EMD SD unP + EMD SD P + EMD SD unP + EMD SD P + EMD SD unP +EMD SD
Exp1 0.08 0.01 0.04 0.005 2.08 5.11 2.21 1.94 0.57 1.23 0.02 1.30 0.05 0.03 0.01 0.03 0.01 1.06 0.93 0.32 1.00 0.39 1.70 0.12 1.69 0.12 1.38 1.30
Exp2 0.09 0.01 0.04 0.003 2.06 3.02 1.28 1.60 0.22 1.38 0.07 1.33 0.03 0.03 0.01 0.03 0.01 1.14 0.82 0.20 0.96 0.28 1.58 0.09 1.51 0.08 1.14 1.14
Exp3 0.09 0.02 0.05 0.005 1.74 4.50 2.13 1.65 0.30 1.26 0.08 1.38 0.04 0.03 0.01 0.03 0.01 0.96 0.89 0.24 0.90 0.21 1.59 0.09 1.63 0.09 1.26 1.18
Exp4 0.29 0.07 0.18 0.074 1.58 1.03 0.22 0.50 0.10 1.73 0.35 1.19 0.13 0.05 0.03 0.05 0.03 1.11 0.82 0.35 0.88 0.43 1.32 0.15 1.33 0.16 0.76 1.12
Mean 0.14 0.08 1.87 3.42 1.42 1.40 1.30 0.04 0.04 1.07 0.87 0.94 1.55 1.54 1.14 1.18
Std Error 0.01 0.01 0.13 0.46 0.15 0.14 0.20 0.01 0.004 0.11 0.17 0.16 0.15 0.16 0.13 0.04
EC50, µM Ratio    
P/unP
Hill coefficient Max % Motile EC50, µM Ratio 
P+E/unP+E
Hill coefficient Max % Motile Ratio 
P/P+EMD
Ratio 
unP/unP+EMD
Ratio 
P+E/unP+E
∆Vmax, µm/secHill coefficient Ratio 
P/P+EMD
Ratio    
unP/unP + EMD
EC50, µM Ratio    
P/unP
Hill coefficient ∆Vmax, µm/sec  EC50, µM
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From Section 4.3.3  
 
 
Analysis of measurements of the Ca2+-dependence of fraction motile and motile velocity measured by in vitro motility assay. The effects 
of TnI phosphorylation on donor thin filaments in the presence and absence of Bepridil. EC50, nH, maximum fraction motile and maximum 
sliding speed are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect&on&Bepridil&on&wild&type&troponin&
Fraction motile
P SD unP SD P SD unP SD P SD unP SD P+Bepridil SD unP+Bepridil SD P+Bepridil SD unP+Bepridil SD P+Bepridil SD unP+Bepridil SD
Exp1 0.11 0.002 0.06 0.00720 1.74 3.44 0.59 1.74 0.330 94.50 5.97 97.75 2.63 0.04 0.0011 0.04 0.001 1.06 1.87 0.11 1.69 0.31 98.75 2.50 99.50 1.00 2.56 1.57
Exp2 0.14 0.029 0.08 0.00340 1.83 1.81 0.58 2.08 0.160 97.25 2.50 97.50 2.08 0.05 0.0015 0.04 0.001 1.04 1.77 0.12 2.37 0.13 97.33 3.06 95.25 2.22 3.06 1.73
Exp3 0.14 0.016 0.08 0.00056 1.74 1.94 0.43 1.86 0.021 93.75 2.75 92.50 1.91 0.04 0.0041 0.04 0.001 1.00 1.92 0.37 1.86 0.12 97.25 0.96 95.75 2.22 3.19 1.84
Exp4 0.13 0.006 0.07 0.01300 1.77 2.36 0.31 1.81 0.490 91.50 0.71 92.25 2.22 0.04 0.0003 0.04 0.001 1.05 1.71 0.02 1.73 0.09 93.25 2.06 94.00 0.82 2.92 1.72
Exp5 0.12 0.002 0.07 0.00003 1.68 3.28 0.38 2.25 0.002 94.00 0.82 94.25 0.96 0.05 0.0005 0.05 0.003 1.01 2.23 0.04 2.32 0.24 96.00 1.83 96.00 1.63 2.35 1.41
Exp6 0.11 0.017 0.07 0.00094 1.62 2.23 1.04 2.03 0.043 97.75 1.50 96.50 1.29 0.05 0.0007 0.05 0.003 1.01 2.31 0.08 2.22 0.28 96.25 1.50 98.25 0.96 2.44 1.52
Mean 0.13 0.07 1.73 2.51 1.96 94.79 95.13 0.05 0.04 1.03 1.97 2.03 96.47 96.46 2.75 1.63
Std Error 0.01 0.002 0.03 0.48 0.08 1.93 1.01 0.001 0.001 0.01 0.08 0.13 1.27 0.83 0.35 0.16
Motile velocity
P SD unP SD P SD unP SD P SD unP SD P+Bepridil SD unP+Bepridil SD P+Bepridil SD unP+Bepridil SD P +Bepridil SD unP +Bepridil SD
Exp1 0.12 0.001 0.09 0.022 1.34 2.91 0.18 1.17 0.34 2.29 0.01 2.41 0.18 0.06 0.013 0.05 0.0095 1.28 1.13 0.36 1.85 1.56 2.70 0.18 2.57 0.08 1.99 1.74
Exp2 0.18 0.012 0.09 0.013 1.91 1.12 0.69 0.89 0.12 2.44 0.64 2.58 0.14 0.07 0.049 0.06 0.0150 1.13 1.32 0.52 1.17 0.35 2.95 0.87 2.59 0.25 2.48 1.46
Exp3 0.10 0.007 0.06 0.003 1.71 1.95 0.27 1.40 0.08 1.73 0.06 1.78 0.03 0.03 0.002 0.04 0.0026 0.93 1.46 0.13 1.41 0.18 2.06 0.04 1.86 0.06 3.24 1.76
Exp4 0.14 0.019 0.07 0.005 2.10 2.06 0.53 1.43 0.17 1.45 0.07 1.38 0.04 0.02 0.011 0.05 0.0110 0.49 0.91 0.39 0.93 0.26 1.76 0.15 1.79 0.11 5.91 1.38
Exp5 0.12 0.005 0.09 0.031 1.33 2.40 0.34 1.14 0.44 1.84 0.05 1.98 0.27 0.05 0.001 0.05 0.0015 1.02 1.39 0.05 1.32 0.07 1.93 0.02 2.04 0.03 2.53 1.94
Exp6 0.11 0.002 0.07 0.006 1.64 2.21 0.11 1.98 0.25 2.55 0.03 2.64 0.11 0.05 0.002 0.05 0.0001 1.01 1.96 0.13 1.90 0.01 2.67 0.05 2.61 0.00 2.40 1.48
Mean 0.13 0.08 1.67 2.11 1.34 2.05 2.13 0.05 0.05 0.98 1.36 1.43 2.35 2.24 3.09 1.63
Std Error 0.01 0.01 0.13 0.46 0.15 0.08 0.04 0.01 0.004 0.11 0.17 0.16 0.05 0.08 1.44 0.22
Ratio 
P+B/unP+B
EC50, µM Ratio    
P/unP
Hill coefficient Max % Motile EC50, µM Ratio 
P+B/unP+B
EC50, µM Ratio    
P/unP
Hill coefficient ∆Vmax, µm/sec  EC50, µM Hill coefficient ∆Vmax, µm/sec Ratio 
P+B/P
Ratio 
unP+B/unP
Hill coefficient Max % Motile Ratio 
P+B/P
Ratio 
unP+Bp/unP
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From Section 5.2.1  
 
 
Analysis of measurements of the Ca2+-dependence of fraction motile and motile velocity measured by in vitro motility assay. The effects 
of TnI phosphorylation on donor thin filaments in the presence and absence of Bepridil. EC50, nH, maximum fraction motile and maximum 
sliding speed are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect&of&EGCG&on&wild&type&troponin
Percentage motility
P SD unP SD P SD unP SD P SD unP SD P + EGCG SD unP + EGCG SD P + EGCG SD unP + EGCG SD P + EGCG SD unP + EGCG SD
Exp1 0.18 0.055 1.30 0.44 77.00 3.16 0.27 0.0660 1.51 0.530 60.25 2.22 1.51
Exp2 0.15 0.020 0.06 0.009 2.42 2.59 0.88 1.72 0.42 77.75 0.96 85.25 3.77 0.18 0.0120 0.14 0.02 1.33 3.24 0.380 3.27 1.36 86.00 4.24 82.75 3.30 1.24 2.25
Exp3 0.27 0.026 0.11 0.063 2.53 1.39 0.16 0.75 0.36 71.25 3.77 65.75 1.71 0.34 0.0540 0.21 0.04 1.61 1.65 0.470 1.53 0.31 65.75 2.36 64.25 1.26 1.24 1.95
Exp4 0.08 0.013 0.04 0.045 1.91 0.98 0.24 2.06 1.08 92.25 2.63 93.00 2.16 0.35 0.0350 0.20 0.03 1.70 2.39 0.540 1.39 0.17 65.25 1.26 72.67 2.08 4.58 5.15
Exp5 0.13 0.017 0.06 0.003 2.15 1.49 0.26 1.87 0.13 95.00 1.41 95.50 2.38 0.22 0.0120 0.14 0.02 1.54 1.60 0.099 1.31 0.17 85.50 4.04 92.00 2.71 1.69 2.36
Exp6 0.07 0.010 0.03 0.007 2.04 1.82 0.40 1.01 0.28 95.75 1.50 95.50 1.91 0.20 0.0350 0.08 0.01 2.50 1.49 0.290 1.53 0.19 84.75 3.10 92.00 1.83 2.77 2.26
Exp7 0.12 0.001 0.05 0.001 2.39 1.68 0.03 1.61 0.03 97.00 1.41 95.50 1.29 0.24 0.0003 0.14 0.02 1.72 1.87 0.003 1.68 0.35 91.75 3.50 94.25 1.89 2.05 2.84
Mean 0.14 0.06 2.24 1.61 1.50 86.57 88.42 0.26 0.15 1.73 1.96 1.79 77.04 82.99 2.15 2.80
Std Error 0.03 0.01 0.10 0.19 0.21 4.08 4.81 0.02 0.02 0.16 0.24 0.30 4.82 4.99 0.45 0.48
Motile velocity
P SD unP SD P SD unP SD P SD unP SD P + EGCG SD unP + EGCG SD P + EGCG SD unP + EGCG SD P + EGCG SD unP + EGCG SD
Exp1 0.14 0.0370 1.31 0.38 1.51 0.19 0.27 0.0520 1.42 0.380 0.84 0.090 1.96
Exp2 0.12 0.0130 0.05 0.020 2.21 2.72 0.59 1.76 0.56 1.43 0.12 1.45 0.27 0.15 0.0064 0.11 0.003 1.35 1.94 0.140 1.87 0.09 1.35 0.030 1.34 0.02 1.28 2.09
Exp3 0.13 0.0280 0.04 0.006 3.00 1.52 0.40 1.91 0.51 1.45 0.15 1.25 0.08 0.24 0.0570 0.12 0.009 2.09 2.13 0.690 1.92 0.26 1.27 0.150 1.23 0.05 1.90 2.74
Exp4 0.11 0.0430 0.04 0.014 2.53 0.86 0.31 1.26 0.79 2.09 0.22 1.85 0.10 0.57 0.1600 0.14 0.056 3.98 0.84 0.190 0.75 0.23 1.22 0.160 1.19 0.14 5.06 3.21
Exp5 0.11 0.0028 0.06 0.014 1.70 1.17 0.03 1.07 0.01 2.01 0.02 2.04 0.18 0.32 0.0170 0.08 0.006 4.09 0.89 0.210 1.38 0.14 1.50 0.160 1.64 0.05 2.96 1.23
Exp6 0.07 0.0004 0.05 0.004 1.29 2.80 0.03 2.38 0.29 2.67 0.01 2.74 0.11 0.24 0.0003 0.09 0.019 2.84 1.63 0.002 1.69 0.57 1.84 0.001 1.95 0.21 3.52 1.59
Exp7 0.11 0.0110 0.06 0.001 1.94 1.30 0.16 1.41 0.05 2.18 0.10 2.18 0.02 0.27 0.0500 0.09 0.009 3.12 1.11 0.190 1.63 0.26 1.63 0.120 1.74 0.09 2.52 1.57
Mean 0.11 0.05 2.11 1.67 1.63 1.91 1.92 0.30 0.10 2.91 1.42 1.54 1.38 1.52 2.74 2.07
Std Error 0.01 0.003 0.25 0.29 0.20 0.18 0.22 0.05 0.01 0.44 0.19 0.18 0.12 0.13 0.48 0.31
Hill coefficient ∆Vmax, µm/sec Ratio 
P+EGCG/P
Ratio 
unP+EGCG/ unP
Hill coefficient Max % Motile Ratio 
P+EGCG/P
Ratio 
unP+EGCG/unP
Ratio 
P+E/unP+E
EC50, µM Ratio    
P/unP
Hill coefficient Max % Motile  EC50,  µM Ratio 
P+E/unP+E
EC50, µM Ratio    
P/unP
Hill coefficient ∆Vmax, µm/sec   EC50, µM
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tropomyosin cause gain of function in skeletal
muscle myopathy patients
Steven Marston1,∗, Massimiliano Memo1, Andrew Messer1, Maria Papadaki1, Kristen Nowak2,
ElyshiaMcNamara2,RoystonOng2,MohammedEl-Mezgueldi3,XiaochuanLi4 andWilliamLehman4
1NHLI, Imperial College London, London,W12 0NN, UK, 2Centre for Medical Research, University ofWestern Australia,
WA Institute forMedical Research, Nedlands, Australia, 3Department of Biochemistry, University of Leicester, Leicester,
UK and 4Department of Physiology and Biophysics, Boston University School of Medicine, Boston, MA, USA
Received June 14, 2013; Revised and Accepted July 17, 2013
The congenital myopathies include a wide spectrum of clinically, histologically and genetically variable neuro-
muscular disordersmany of which are caused bymutations in genes for sarcomeric proteins. Some congenital
myopathy patients have a hypercontractile phenotype. Recent functional studies demonstrated that ACTA1
K326N and TPM2 DK7 mutations were associated with hypercontractility that could be explained by increased
myofibrillar Ca21 sensitivity. A recent structure of the complex of actin and tropomyosin in the relaxed state
showed that both thesemutations are located in the actin–tropomyosin interface. Tropomyosin is an elongated
molecule with a 7-fold repeatedmotif of around 40 amino acids corresponding to the 7 actin monomers it inter-
acts with. Actin binds to tropomyosin electrostatically at two points, through Asp25 and through a cluster of
amino acids that includes Lys326, mutated in the gain-of-function mutation. Asp25 interacts with tropomyosin
K6, next to K7 that was mutated in the other gain-of-function mutation. We identified four tropomyosin motifs
interacting with Asp25 (K6-K7, K48-K49, R90-R91 and R167-K168) and three E-E/D-K/R motifs interacting with
Lys326 (E139, E181 and E218), and we predicted that the known skeletal myopathy mutations DK7, DK49, R91G,
DE139, K168E and E181K would cause a gain of function. Tests by an in vitro motility assay confirmed that
these mutations increased Ca21 sensitivity, while mutations not in these motifs (R167H, R244G) decreased
Ca21sensitivity.Thework reportedhereexplains themolecularmechanismfor6outof49knowndisease-causing
mutations in the TPM2 and TPM3 genes, derived from structural data of the actin–tropomyosin interface.
INTRODUCTION
The congenital myopathies include a wide spectrum of clinical-
ly, histologically and genetically variable neuromuscular disor-
ders, many of them caused bymutations in genes for sarcomeric
proteins (1). Thesemyopathies are generally defined on the basis
ofmuscleweakness and histological abnormalities in themuscle
fibres. Nemaline myopathy, characterized by nemaline (rod)
bodies onmuscle biopsy, is themostwidely studied but congeni-
tal myopathy can also be associated with cap-like structures
located under the sarcolemma (Cap disease) or with congenital
fibre-type disproportion (CFTD). Mutations in the skeletal
muscle a-actin gene (ACTA1) account for "20% of congenital
myopathies and over 200 different mutations have been identi-
fied. Recently, disease-causing mutations have also been found
in b- and g- tropomyosins encoded by TPM2 and TPM3 genes,
respectively; 27 mutations have been reported in the TPM2
gene and 22 mutations have been reported in the TPM3 gene
(1–14) (see Supplementary Material, figures.)
A small proportion of congenital myopathies are associated
with a hypercontractile phenotype; this is a very heterogeneous
disease category that includes distal arthrogryposis, trismus-
pseudocamptodactyly syndrome and Escobar syndrome, and
some of these cases are reported to be due to mutations in
ACTA1, TPM2 or TPM3 (12–16). These apparent ‘gain-of-
function’ mutations are particularly interesting because of their
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parallelswithhypertrophic cardiomyopathy that also presents as a
hypercontractile phenotype and is associated with mutations in
sarcomeric proteins, including actin and tropomyosin (ACTC
and TPM1 genes (17)). Enhanced contractility indicates that the
abnormalitycausedby themutation is likely tobewithin the force-
producing contractilemachinery,whereas a loss of function could
be due to defects in force production, force transmission, force
sensing or sarcomere assembly.
Tropomyosin, together with actin and troponin, constitutes
the basic thin filament structural andCa2+-regulatorymachinery
that interacts with myosin whenmuscle contracts. Tropomyosin
forms a 40 nm long parallel coiled-coil dimer and is able to poly-
merize head-to-tail with other tropomyosin molecules into long
strands spanning the whole thin filament length. Each tropomy-
osinmolecule binds to seven different actinmonomers along the
helical actin chain involving seven quasi repeats of about 40
aminoacids each.Thekey functionof tropomyosin is in coopera-
tively switching the location of the actin–tropomyosin interface
between active and relaxed states under the control of troponin,
Ca2+ and myosin heads.
Previously, we studied the effect of actin and tropomyosin
mutations on Ca2+ regulation of muscle contractility at the
single filament level in order to establish a genotype–phenotype
relationship. In most biopsies from patients with ACTA1 muta-
tions, it was not possible to establish any mechanism (18–20)
but two mutations are of particular note, since they showed dis-
tinctive abnormalities in their regulatory interaction with tropo-
myosin. The ACTA1 D292V mutation resulted in an actin with
normal activity that was irreversibly switched off by tropomy-
osin (19), whilst the ACTA1 K326N mutation from a patient
with stiff muscles was indistinguishable from wild-type actin
on its own but, when incorporated into thin filaments, showed
an increase in Ca2+ sensitivity and a crossbridge turnover rate
consistent with the hypercontractile phenotype (21).
Since tropomyosin has a relatively simple structure and inter-
acts only with itself, actin, tropomodulin and troponin, we
expected that it would be easier tomake amolecular explanation
of the disease phenotype than for actin mutations. Most of the
tropomyosin mutations reported to date are linked to different
skeletal muscle myopathies characterized by generalized
muscle weakness and, at the molecular level, a reduced cross-
bridge cycling rate and Ca2+ sensitivity. Examples of these
mutations on b-tropomyosin are E41K and E117K linked to
nemaline myopathy or cap disease (11,22).
Sometropomyosinmutationshavebeenassociatedwitharthro-
gryposis and a gain of function (15). TPM2 R91G was the first
investigated at the molecular level and this showed a hypercon-
tractile phenotype (23). Recently, we have investigated in detail
a commonb-tropomyosinmutation,DK7, that hasbeendescribed
in a total of nine families (13,24). A histological inspection of bi-
opsies taken frompatients of all families showed nemaline bodies
as a common feature. Most of the patients were therefore diag-
nosed with nemaline myopathy, although some were independ-
ently diagnosed with core-rod myopathy or distal arthrogryposis
VII. Lysine 7 is placed in a region of crucial importance for tropo-
myosin, as it participates in the head-to-tail polymerisation of
tropomyosin (25), is close to a residue binding to actin (26) and
may also be involved in the binding of troponin T (27). Mokbel
et al. showed that the mutation strongly impairs the ability of
the protein to incorporate in the sarcomere and causes its
accumulation in the nemaline bodies in transfected C2C cells.
Nevertheless, the expressed mutant is incorporated into muscle
thin filaments and it acts as a poison peptide in vivo. Studies
withchemicallyskinnedmusclefrompatientbiopsiesandisolated
thinfilaments using an in vitromotility assay showed that thismu-
tation increases the Ca2+ sensitivity, the cross-bridge turnover
rate and maximum force, producing a gain of function. In retro-
spect, itwasnoted that all thepatientswith thismutationpresented
a hypercontractile phenotype in childhood. Distal arthrogryposis,
exhibited by some of the patients, is characterized by hypercon-
traction andmostof theDK7patients did notpresent evidentmyo-
pathic symptomsuntil their teens, proving that theirweakmuscles
were not congenital.
Recently, a high resolution structure of a-tropomyosin bound
to actin has been proposed, froma study involving electronmicros-
copy and computational chemistry (26), which highlights the elec-
trostatic interactions holding tropomyosin on F-actin. In this
structure (corresponding to the closed-state, roughly equivalent to
the OFF functional state (28)), tropomyosin blocks myosin’s
strong binding in accordance with the well-known observation
that skeletalmuscle tropomyosinon itsown inhibits actinactivation
of myosin ATPase. This structure provides the framework for
understanding how the mutation could cause the gain of function.
In this manuscript, we have examined the location of tropomy-
osin and actin mutations in the new structure of the actin–
tropomyosin interface. The K7 residue is positioned just on the
sideof theK6 residue,whichbinds toAsp25on the actinmolecule,
therefore we can propose that the mutation DK7 destabilizes this
inhibitory interaction.
Moreover, since tropomyosin is a modular protein, these
binding motifs are repeated in some of the other actin-binding
repeats, thus the structure gives us a unique opportunity to
predict where other mutations might cause a similar phenotype.
We found that four out of the seven quasi-repeats, present in all
tropomyosin isoforms, share the feature of a second basic
residue downstream of the basic residue binding to Asp25:
K6-K7, K48-K49, R90-R91, R167-K168. It is interesting to
note that mutations linked to skeletal muscle myopathies have
been reported in all the four downstream basic amino acids:
DK7, DK49 and R91G on b-tropomyosin and K168E on
g-tropomyosin and thus,we predict theywill cause a gain of func-
tion like DK7. A second actin–tropomyosin interface involves
Lys326 of actin, the amino acids mutated in the ‘stiff’ patient
and, interestingly, mutations have been reported in the acidic
aminoacids of tropomyosin (DE139,E181K,DE218) that interact
with actin K326 sowe predict thesewould lead to the same effect
as the K326N gain-of-function mutation. In this study, we have
tested the effect of tropomyosin mutations on the actomyosin
interaction by measuring Ca2+-regulation of skeletal muscle
thinfilaments containing skeletalmyopathy-causing tropomyosin
mutationsandhaveconfirmed themolecularphenotypepredicted.
RESULTS
Structural analysis of the actin–tropomyosin interface
predicts gain-of-function mutations in tropomyosin
Li et al. (26) determined the structure ofa-tropomyosin bound to
actin, nevertheless tropomyosin isoforms are highly conserved,
and in fact the sequences around the actin contacts studied here
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are identical in the a-, b-, and g-isoforms (see Supplementary
Material). The Li et al. structure shows that tropomyosin is not
closely bound to actin and makes electrostatic contact at just
two points on every actin; at D25 andwith a cluster of basic resi-
dues, K326, K328 and R147. This pattern is illustrated in
Figure 1. The amino acids in tropomyosin that interact with
actin are mapped in Figure 1B, in which the sequence
is divided into the seven actin-binding repeats proposed by
McLachlan and Stewart (29), based on the analysis of the
amino acid sequence. They predicted that the alpha band
sequences bound to actin when actin–tropomyosin was in the
relaxed state. Itwill be seen that the basic amino acids interacting
with D25 are found at or near the beginning of the alpha bands
and the acidic amino acids interacting with the K326, K328,
R147 cluster occur at two places near the end of the alpha
band. In the latter case, the first site, 12–17 amino acids into
the alpha band showed interactions in every period of tropomy-
osin, while the second site, 16–20 amino acids into the alpha
band showed interaction in only six of the seven periods.
Tropomyosin interaction with residue Aspartic acid 25 of actin
Wenoted that the gain-of-functionmutationDK7wasone amino
acid downstream from K6 that interacts with actin D25 as
described above. Figure 2A shows the interface at high reso-
lution. Our initial hypothesis was that disruption of one of a
cluster of basic amino acids (K5, K6, K7) would perturb the
actin–tropomyosin interface, destabilizing this structure but
not have such a large effect that the mutation would be lethal.
This structure corresponds to a functionally relaxed state of
muscle, since it is well established that skeletalmuscle tropomy-
osin inhibits actin-activated ATPase and this position of tropo-
myosin relative to actin is present with troponin in the absence
of myosin heads (30). Consequently destabilizing the structure
would shift the equilibrium towards the active state of actin–
tropomyosin, thus accounting for the gain of function observed
with the DK7 mutation.
The motif observed with K6 and K7 is repeated in four of the
periods of tropomyosin: K6-K7, K48-K49, R90-R91 and
R167-K168, and the structures of the interface for the four
motifs is very similar (Fig. 2A–D). The other three periods
have a single basic amino acid that interacts with D25 (see
Fig. 1). If our hypothesis on the mechanism of the gain of func-
tion due to theDK7mutation is correct, wewould expect charge-
change mutations at K49, R91 and K168 to also cause a gain of
function. In fact, the mutation R91G in Period 3 of TPM2 is
known to cause a hypercontractile phenotype, distal arthrogry-
posis and an in vitro investigation of the effect of this mutation
did indeed find that it causes enhanced actomyosin ATPase
and incomplete relaxation, although Ca2+ sensitivity was not
very different fromwild type (23) (Fig. 2C).A survey of the pub-
lished mutations in TPM2 and TPM3 reveals that mutations
DK49 (Period 2) and K168E (Period 5) have been identified in
Figure 1. Structure of the actin–tropomyosin interface. (A) Structure of one of the two tropomyosinmolecules (cyan) bound to the actin double helix (grey). Surface
rendering using PyMolwith coordinates fromLi et al. (26). ActinAsp25 is coloured red andLys 326 is coloured blue. (B) Theb-tropomyosin sequence divided in the
seven quasi-repeating periods and a- and b-bands as defined by Mclachlan and Stewart (29). The purple circles highlight residues interacting with actin Asp25; the
orange and red circles highlight the residues interacting with actin R147, K326 and K328 as defined by Li et al. (26). Theb-tropomyosin (TPM2) mutations are indi-
cated inblueboxes, and theg-tropomyosin (TPM3)mutations are indicated ingreenboxes.Themutations increasing theCa2+ sensitivity arewritten in red,while those
decreasing it are written in black.
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single patients (Fig. 2B and D) (7,31), but not associated with a
hypercontractile phenotype, whereas no mutations have been
reported in the equivalent positions of Periods 4, 6 and 7. Muta-
tions at the amino acid directly interacting with D25 were
reported in skeletal myopathy patients: K128E in TPM2 and
R90C, R167H and R244G in TPM3, and we would predict that
these would have a different, perhaps opposite, effect on
muscle function. In order to test our hypothesis, we have deter-
mined the effect of these mutations on Ca2+ regulation of
muscle thin filaments.
Tropomyosin interaction with actin residues 326, 328 and 147
This cluster of amino acids on the surface of actin forms a second
interface presenting basic amino acids to tropomyosin (Fig. 3)
with at least one of the three residues involved in interaction in
every period of tropomyosin (Fig. 1). The actin (ACTA1)
K326N mutation has been found in a baby suffering from a
hypercontractile phenotype characterized by generalized stiff-
ness (21). In that study, in vitro motility assay studies showed
that the mutation was sufficient to generate an increased Ca2+
sensitivity that explains thehypercontractile phenotype.Wepro-
posed that the loss of positive charge in the K326N mutant
actin destabilized the inhibitory interaction with tropomyosin
in the same way as the DK7 TPM2 mutation. Consequently,
we would expect that charge-change mutations in the cognate
amino acids of tropomyosin would have a similar effect. K326
binds to tropomyosin in five tropomyosin periods and one of
these involves the residue E181 (Fig. 1B). The mutation
E181K in TPM2was reported in two cases of distal arthrogrypo-
sis, and this mutation caused an increase in Ca2+ sensitivity of
force production in skinned fibres from the patient (12,32).
Figure 4 shows the interface between actin K326 and tropomy-
osin E181 as defined by the Li et al. structure. Thus, destabiliza-
tion of this interaction by loss of charge at either the actin or the
tropomyosin residue produces the same increase in Ca2+ sensi-
tivity. There is an EEK (or EDK or EER) motif in tropomyosin
homologous to the actin K326-Tm 181 interface in just three
of the seven periods (See Fig. 1).We examined publishedmyop-
athy mutations in these motifs in the other periods of the tropo-
myosin sequence and found DE139 and DE218 in TPM2
(Fig. 4) (8,10). It is remarkable that there are three such motifs
and three reported mutations, while none have been reported at
the equivalent position in other periods that do not have this
motif. To test the predictions, we investigated whether these
mutations also caused a gain of function in vitro.
Actin D292 mutation
The mutation ACTA1 D292V was found in a patient with weak
muscles and congenital fibre-type disproportion (19,33).
In vitro studies of actin purified from this patient’s skeletal
muscle showed a very strong molecular phenotype. The
Figure 2.Details of the interactions of tropomyosinwith actinAsp25.Magnified
views of the Li et al. structure from Figure 1A show the locations of proposed
gain-of-function mutations in tropomyosin relative to actin Asp 25 for the first
(K6, K7), second (K46, K47), third (R90, R91) and fifth (R167, K168) periods
of tropomyosin.
Figure 3. Location of actin residues Lys326, Lys328, Arg147 and Asp272.
Magnified views of the Li et al. structure from Figure 1A. Left, actin alone is
shown; right, tropomyosin is overlaidat 50%transparency.Aminoacids are iden-
tified in the figure. The lower cluster is viewed face on while the upper cluster is
rotated to the right.
Figure 4. Details of the interactions of tropomyosin with actin Lys326, Lys328
and Arg147. Magnified views of the Li et al. structure from Figure 1A show the
locations of proposedgain-of-functionmutations in tropomyosin relative to actin
Lys326, Lys328 and Arg147 in the fourth (E139), fifth (E181) and sixth (E218,
D219) periods.
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patient sample contained !45% mutant actin and with actin
alone the interaction with myosin in the in vitro motility assay
was the same as normal actin; however, when tropomyosin
was added, the filament motility appeared to be completely
switched off. Li et al.’s structure provides a possible reason for
this effect. The acidic amino acid D292 is located on the
surface of actin close to the K326, K328, R147 cluster (Fig. 4);
it does not participate in binding but is close to tropomyosin.
It is possible that the acidic residue in this position may act to
moderate the binding affinity of the K326, K328, R147 cluster
so that the binding is not so tight that the transition of tropomy-
osin fromOFF toONstate has a physiologically impossibly high
energy barrier. If so, one could hypothesize that the loss of nega-
tive charge in theD292Vmutationwould strengthenbinding and
stabilize the OFF state. We have investigated this mutation
further to test the hypothesis.
Effect of mutations studied by an in vitro motility assay
Tropomyosin mutations
We expressed wild-type b-tropomyosin and the mutations
DK49, R91G and DE139 and wild-type g-tropomyosin and the
mutations R167H, K168E and R244G in the baculovirus/sf9
system that preserves native N-terminal acetylation. Thin fila-
ments were reconstituted using the expressed tropomyosin
with rabbit skeletal muscle actin and troponin and the regulation
of their movement over immobilized heavy meromyosin
(HMM)was studied in the in vitromotility assay. Thin filaments
containing mutant tropomyosin species were fully functional in
this assay. When Ca2+ regulation of mutant thin filaments was
compared with thin filaments, containing the appropriate wild-
type tropomyosin isoform, it was observed that all the predicted
gain-of-function mutations produced a higher Ca2+ sensitivity
(curve shifted to the left for DK49, R91G, DE139 and K168E;
Fig. 5) and a slightly higher maximum sliding speed similar to
the previously investigated gain-of-function mutations, DK7
and E181 K (24,32). In contrast, the four skeletal muscle myop-
athy mutations that were expected to give a hypocontractile
phenotype showed lower Ca2+ sensitivity (Fig. 5) and lower
sliding speeds (b-tropomyosin E41K, E117K and g-tropomyosin
R167H andR245G; Table 1). This also corresponds to previous-
ly published data on E41K and R167H contraction in biopsy
samples from Ochala’s laboratory (22,32). It is interesting to
note that thin filaments containing 100 or 50% mutant
Figure 5.Comparison of Ca2+ regulation of thin filaments containingwild-type andmutant tropomyosin. Thin filamentmotilitywasmeasured by an in vitromotility
assay over a range of (Ca2+) in paired cells. The fraction of filamentsmotile is plotted as a function of (Ca2+) for a typical experiment. The points are themean+SEM
of four determinations of fraction motile measured in one motility cell. The curves are fits of the data to the Hill equation. Solid lines and points, wild-type thin fila-
ments, dashed lines and open points, thin filaments with mutant tropomyosin. The mean values of EC50 from replicate experiments are plotted in Figure 6 and sum-
marized in Table 1.
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tropomyosin gave similar alterations in thin filament function
(Table 1). (Fig. 6)
ACTA1 D292V mutation
In a previous study, the ACTA1D292Vmutation appeared to sta-
bilize the inactive state of actin–tropomyosin. (19). We investi-
gated the properties of the D292V mutation using actin
extracted from a patient biopsy containing themutation. Addition
of tropomyosin caused theD292Vactin filaments to stopmoving,
while it did not affect the fractionmotile and slightly increased the
sliding speed of wild-type actin (Fig. 7). In the presence of
activating concentrations of Ca2+, troponin did not re-activate
the thin filaments containing D292V actin and tropomyosin. We
then added N-ethylmaleimide-treated myosin subfragment 1
(NEM-S-1) to actin–tropomyosin; this modified S-1 forms rigor
bonds with actin even in the presence of ATP, therefore a small
quantity will cooperatively switch on thin filaments. However,
NEM-S-1was incapable of switching onD292Vactin-containing
filaments at double the concentration that switched on native thin
filaments in theabsenceofCa2+(34,35).Anactinmutation,E93K,
which causes thin filaments to be inhibited by tropomyosin has
been observed before, but this mutation was reactivated by
either troponin or NEM-S-1 (34). Thus, the D292V mutation
seems to have induced a very profound change in the ON–OFF
equilibrium towards the OFF state since neither of these treat-
ments restored motility (Fig. 7).
DISCUSSION
Structure of the actin–tropomyosin interface predicts
gain-of-function mutations in skeletal muscle
Our investigation of gain-of-function mutations was sparked by
the observation that lysine 326 of actin, mutated to asparagine in
the muscles of the ‘stiff’ child, was in a critical position in the
interface between actin and tropomyosin, according to the struc-
ture of Li et al. (21,26). The next observationwas that, unexpect-
edly, theTPM2DK7mutation also caused again of function, and
that it was located near another critical part of the actin–tropo-
myosin interface close to Asp25 (24). The detailed information
contained in Li et al.’s structure combinedwith the repeating se-
quence of tropomyosin enabled us to identify a total of four
similar motifs interacting with Asp25 and three motifs interact-
ing with Lys326, and we anticipated that charge-change muta-
tions at these sites would also cause a gain of function. Indeed,
mutations at two of these sites, R91G and E181K, have
already been reported to cause distal arthrogryposis, a hypercon-
tractile phenotype, and enhanced contractility, consistent with a
gain-of-function phenotype (23,32). In the current study, we
have investigated the effect of the remaining predicted gain-of-
function mutations, and confirmed that they did indeed increase
Ca2+ sensitivity. The structure–function connection that we
have observed is further supported by our observation that
Figure 6. The effect of skeletal myopathymutations in tropomyosin on thin fila-
ment Ca2+ sensitivity. Data from this paper and published work are combined.
Black, predicted gain-of-function mutations, white, predicted loss-of-function
mutations. Ratio of EC50 of mutant thin filaments relative to EC50 of wild-type
troponin–tropomyosin is plotted.Error bars showSEMofup to12 replicate com-
parative measurements (see Table 1). (A) from Mokbel et al. (24). (B) from
Ochala et al. (32). (C) from Marttila et al. (11). (D) from Ochala et al. (22)
Table 1. The effect of tropomyosin mutations on Ca2+ sensitivity and the maximum sliding speed in reconstituted skeletal muscle thin filaments measured by an in
vitromotility assay
Mutation EC50 Mut,
mM+SEM, n,P
EC50 WT, mM+SEM,
n,P
Ratio EC50 WT/EC50
Mut+SEM, n,P
Max sliding speed relative to WT,
mm/s+SEM, n,P
DK49 100% 0.04+0.002 0.08+0.01 2.42+ 0.25, n ¼ 6, P ¼ 20.002 98.1+2.7%, n ¼ 3, P ¼ 0.555
50% 0.03+0.002 0.09+0.003 2.71+ 0.06, n ¼ 6, P , 0.0001 101.0+0.6%
R91G 100% 0.05+0.01 0.09+0.01 1.83+ 0.18, n ¼ 6, P ¼ 0.006 102.2+1.0%, n ¼ 3, P ¼ 0.160
50% 0.06+0.01 0.09+0.004 1.55+ 0.05, n ¼ 6, P ¼ 0.0002 100.2+0.6%
DE139 100% 0.03+0.004 0.12+0.03 2.95+ 0.43, n ¼ 6, P ¼ 0.006 101.1+2.4%, n ¼ 3, P ¼ 0.687
50% 0.03+0.004 0.11+0.01 2.58+ 0.49, n ¼ 6, P ¼ 0.003 104.2+1.1%
R167H 100% 0.16+0.02 0.07+0.01 0.59+ 0.08, n ¼ 6, P ¼ 0.004 92.5+2.6%, n ¼ 3, P ¼ 0.101
50% 0.13+0.02 0.08+0.01 0.59+ 0.01, n ¼ 2 95.0%
K168E 100% 0.05+0.01 0.08+0.01 2.17+ 0.32, n ¼ 8, P ¼ 0.008 107.2+1.6%
50% 0.05+0.003 0.09+0.001 1.84+ 0.07, n ¼ 12, P, 0.0001 105.4+2.7%
R245G 100% 0.12+0.02 0.05+0.02 0.46+ 0.08, n ¼ 6, P ¼ 0.001 97.1+4.7%, n ¼ 3, P ¼ 0.598
50% 0.11+0.003 0.08+0.01 0.67+ 0.07, n ¼ 2 93.6%
Combined data from n replicate Ca2+-activation curvemeasurements similar to those shown in Figure 5. The significance,P, of deviation of theEC50 ratio from1was
determined by a single value t-test.
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charge-change mutations at positions adjacent to the predicted
gain-of-function sites (R167H and R244G) produced the oppos-
ite effect, namely a reduced Ca2+ sensitivity.
The finding that the Li et al. structure can accurately predict
seven gain-of-function mutations in tropomyosin strongly sup-
ports the validity of actin–tropomyosin interface structure on
which it is based.
Implications for diagnosis of skeletal muscle disease-
histopathology is an inappropriate criterion
Skeletalmusclemyopathies are historically defined by the histo-
pathology of the muscle; however, the determination of the
disease-causing mutations and the advent of functional studies
suggest a different approach to diagnosis is needed (36).
No relationship between the conventional disease classifica-
tion and the gain-of-function phenotype could be ascribed.
Among the seven mutations investigated, diagnoses include
cap myopathy, nemaline myopathy, CFTD, rod-core disease,
distal arthrogryposis and trismus-pseudocamptodactyly. In
fact, the single mutation DK7 studied in 10 families included
diagnoses of rod-core disease, CFTD and trismus pseudocamp-
todactyly (13,24).A similar range of diagnoseswas given for the
R167mutations found in 14 families where nemalinemyopathy,
CFTD, cap disease and mixed pathologies were reported (14).
Whilemuscle histology provides no clues about the basis of the
myopathy, consideration of muscle contractility is more predict-
ive, especially for the gain-of-function mutations. This aspect
was thoroughly investigated for the DK7 mutation, where some
patients were re-evaluated and re-diagnosed in the light of con-
tractility measurements (24). Besides the overt hypercontractility
seen in arthrogryposis (E181K,R91G,DK7) therewas a tendency
for the gain-of-function patients to have contractures in infancy
and abnormal gait whilst major symptoms of muscle disorders
were delayed; for instance the DE139 patient was first examined
at 11 years for a muscular-skeletal disorder (10). A clearly hypo-
contractilephenotype frombirthwould ruleoutagain-of-function
type of mutation. These features may not be considered in most
neuromuscular clinics: it will be noted that the patients with the
three gain-of-function mutations investigated here (DK49,
DE139 and K168E) were not diagnosed with a hypercontractile
phenotype (7,10,31).
This situation somewhat parallels hypertrophic cardiomyop-
athy (HCM), which is also associated with increased Ca2+-
sensitivity, where symptoms frequently do not develop until an
individuals’s second and third decades. In both cases, an initially
Figure 7. The effect of the actin Asp292Val mutation on actin–tropomyosin interaction measured by the in vitromotility assay. Actin movement over immobilized
HMM was recorded and analysed. Two parameters were calculated: fraction of filament motile and the sliding speed of motile filaments. Rhodamine–phalloidin
labelled actin concentration was 10 nM. Solid lines: wild-type actin, dotted lines D292V actin. (A) The effect of up to 30 nM tropomyosin on wild-type and mutant
actin motility. (B) The effect of adding 50 nM troponin to actin–tropomyosin at 3.6 × 10–5 M Ca2+. (C) The effect of adding 18 nMNEMS-1 to actin–tropomyosin.
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hypercontractile phenotype can trigger secondary muscle dys-
function leading to a hypocontractile phenotype mimicking the
more common loss-of-function mutations as discussed by
Mokbel et al. for the DK7 mutation (24). In HCM, enhanced
Ca2+ sensitivity is the primary defect that triggers hypertrophy
but biopsies of interventricular septumfromsuchpatients invari-
ably have a hypocontractile phenotype, indeed up to 30% of
untreated patients subsequently develop symptoms of heart
failure (17,37)
Implications for the structural analysis of tropomyosin
regulation
The control of striatedmuscle activity is mediated through Ca2+
regulation of the thin filament and this has been shown to be due
to a series of allosteric-cooperative transitions between activity
states involvingevery protein componentof the thinfilament and
myosin, largely defined by the position of tropomyosin on the
surface of actin (38). Measurement of Ca2+ sensitivity is there-
fore a very sensitive method to detect changes in equilibria
between states. The Li et al. structure of skeletal muscle tropo-
myosin on the surface of actin filaments indicates that, when
freed of constraints imposed by troponin, myosin or other actin-
binding proteins, tropomyosin localizes to a favoured position
on F-actin defined primarily by electrostatic interactions that
corresponds most closely to the blocked and closed states as
defined by Lehman et al. in 2009 (26,39). Recent energy land-
scape calculations confirm that tropomyosin is located in a
shallow energy well (28) and that the ‘open’ conformation is en-
ergetically unfavoured, except in the presence of strong myosin
binding to actin, as demonstrated in the recent determination of
the actin–tropomyosin-S-1 structure (40).
It is logical to propose that the mutations in tropomyosin and
actin that cause a gain of function by de-stabilizing the actin–
tropomyosin B/C-states and therefore shifting the equilibrium
slightly in favour of the open state. The shift in equilibrium is
detected as a higher Ca2+ sensitivity since the change in activity
state andCa2+ switchingof the thinfilament are linked equilibria
(38). There is, in fact, direct evidence for this: first, the affinity
of tropomyosin for actin is reported to be reduced in the gain-
of-function mutations DK7, DK49, R91G and DE139
(11,23,24), and second, energy landscape calculations of the
effect of the actin K326N gain-of-function mutation actually
show that the interaction energy (van derWaals + electrostatic)
is reduced from 3286 to 2306 kcal/mol, and the energetically
most favoured position of tropomyosin is shifted in the direction
of the open state (41).
A similar analysismay explainwhy the actinD292Vmutation
is so profoundly inhibitory; the location of negative charge rela-
tive to the three basic amino acids K326, K328 and R147may be
crucial in defining the shallow energy minimum of tropomyosin
in theCstate that is necessary to allow the regulatory transition to
the other states with a minimal energy expenditure. Preliminary
energy landscape calculations indicate that actin–tropomyosin
interaction energy is increased when D292 is mutated to valine
from 23286 to 23442 kcal/mol based on the charge change
alone. The mutation of the negatively charged amino acid to a
hydrophobic amino acid could also allow a conformational
change that makes the energy well deeper thus trapping tropo-
myosin in the C-state.
The information provided by these studies gives new insights
into the structure–function properties at the actin–tropomyosin
interface. One important implication of these results is the obli-
gate requirement of charged residues in key positions to achieve
normal regulation.
It is more difficult to explain why tropomyosin mutations
causing a gain of function are located not in the amino acid
that interacts directly with actin Asp25, but in the adjacent
amino acid. There is no other pattern: two are deletions, one is
a charge reversal andone is a charge loss.Onemight hypothesize
that a positive charge-reducing mutation at the interaction site
itself would have such a large effect as to be lethal and therefore
not be seen for that reason; however, this argument fails since
mutations ofArg167 toCys,His orGly are oneof the commonest
of skeletal myopathy-causing mutations, having been identified
in 14 families.
Likewise, there is no obvious explanation of why the gain-of-
function mutations involved with interaction with Lys326 in
actin are located at the amino acid in tropomyosin that interacts
with actin.
On a more general point, these studies indicate that when the
molecular structure and function of a protein–protein interface
is well understood, it is possible to make quite precise and test-
able predictions about the effect of disease-causing mutations,
especially in a repeating structure like tropomyosin. The work
reported here suggests a molecular mechanism for just 6 out of
49 known TPM2 and TPM3 mutations. It is interesting to note
that none of the 26mutations inTPM1 identified as causes of car-
diomyopathy are involved in the actin-binding motifs described
here (see Supplementary Material), indicating a different mech-
anism of modification of function for these phenotypes. The
effect of mutations in tropomyosin and actin on the interface in
the ON state as described by Behrman et al. (40) has not yet
been investigated, and the study of mutations in tropomyosin’s
interfaces with troponin and tropomodulin awaits further struc-
tural analysis. In the future, such studies could define which
other residues in the protein are key for optimal regulation and
potentially highlight therapeutic targets or treatments.
METHODS
Sources of contractile proteins
Skeletal muscle myosin, HMM, troponin and a-actin were
prepared as described by Bing et al. in 1997 (35). Tropomyosin
was expressed in a baculovirus/Sf9 system and purified with a
protocol based on that of Akkari et al. (42) as described by
Memo et al. (43). Age-matched normal and D292V human
skeletal muscle actin was obtained from muscle biopsies as
described by Clarke et al. (19).
Quantitative in vitro motility assay
Thin filaments were reconstituted with 10 nM rabbit skeletal
musclea-actin (labelledwith TRITC phalloidin) (44), tropomy-
osin (20–30 nM) and troponin (10–30 nM) to studyCa2+ regula-
tion of filament motility by the quantitative in vitro motility
assay (45,46). Thin filament movement over a bed of immobi-
lized rabbit fast skeletal muscle HMM (100 mg/ml) was com-
pared in paired motility cells in which troponin varied by a
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single factor (mutation or phosphorylation state). Filament
movement was recorded and analysed as previously described
(47), yielding two parameters, the fraction of filaments moving
and the speed of moving filaments. In our motility system,
both these parameters are regulated by Ca2+. The fraction
motile changes from ,0.1 to .0.8 in the range 1 nmol/l to
3.7 mmol/l free Ca2+. The Ca2+-dependent change of sliding
speedwas less andmorevariable (0–50%change), as previously
noted Song et al. (48).
The fraction motile and the sliding speed were measured over
a range of Ca2+ concentrations to generate Ca2+-activation
curves. Each experiment involved the preparation of test and
control troponins at the same time. To keep intra-experiment
variability as low as possible, test and control thin filaments
were reconstituted together and for each Ca2+-concentration
point they were pipetted into two channels of the dual chamber
motility cell. Motility was then measured in each chamber
within a couple of minutes of each other. The data were fitted
to the four-variable Hill equation to yield a value for EC50.
EC50 values from replicate experiments were analysed by a
paired t-test since the distribution of EC50 has been shown to
be normal (45,46). The absolute value of EC50 was slightly vari-
able between different troponin andmyosin preparations, but the
ratio of control to test was very consistent (Table 1).
Molecular structures
Structural analysis used a refined version of the structure of the
actin–tropomyosin interface published by Li et al. (26). PDB
files describing the coordinates of 15 actins and one tropomyosin
in this structure were rendered using MacPyMol. The pdb files
are included in Supplementary Material.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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Aims Heart muscle contraction is regulated via the b-adrenergic response that leads to phosphorylation of Troponin I (TnI)
at Ser22/23, which changes the Ca2+ sensitivity of the cardiac myofilament. Mutations in thin filament proteins that
cause dilated cardiomyopathy (DCM) and some mutations that cause hypertrophic cardiomyopathy (HCM) abolish
the relationship between TnI phosphorylation and Ca2+ sensitivity (uncoupling). Small molecule Ca2+ sensitizers
and Ca2+ desensitizers that act upon troponin alter the Ca2+ sensitivity of the thin filament, but their relationship
with TnI phosphorylation has never been studied before.
Methods and
results
Quantitative in vitro motility assay showed that 30 mM EMD57033 and 100 mM Bepridil increase Ca2+ sensitivity of
phosphorylated cardiac thin filaments by 3.1- and 2.8-fold, respectively. Additionally they uncoupled Ca2+ sensitivity
from TnI phosphorylation, mimicking the effect of HCMmutations. Epigallocatechin-3-gallate (EGCG) decreased Ca2+
sensitivity of phosphorylated and unphosphorylated wild-type thin filaments equally (by 2.15+ 0.45- and 2.80+0.48-
fold, respectively), retaining the coupling. Moreover, EGCG also reduced Ca2+ sensitivity of phosphorylated but not
unphosphorylated thin filaments containing DCM and HCM-causing mutations; thus, the dependence of Ca2+ sensitiv-
ity upon TnI phosphorylation of uncoupledmutant thin filaments was restored in every case. In single mouse heart myo-
fibrils, EGCG reduced Ca2+ sensitivity of force and kACT and also preserved coupling. Myofibrils from the ACTC E361G
(DCM) mouse were uncoupled; EGCG reduced Ca2+ sensitivity more for phosphorylated than for unphosphorylated
myofibrils, thus restoring coupling.
Conclusion We conclude that it is possible to both mimic and reverse the pathological defects in troponin caused by cardiomyop-
athy mutations pharmacologically. Re-coupling by EGCG may be of potential therapeutic significance for treating
cardiomyopathies.
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Cardiomyopathies
1. Introduction
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy
(DCM) are common inherited diseases. HCM is detected in 1 in 500
of the adult population, and the causative mutations are overwhelming-
ly in the proteins of the cardiac muscle contractile apparatus.1,2 At least
30% of cases of idiopathic DCM are of genetic origin, and DCMwith no
additional complications such as conduction disease is usually caused
by mutations in the contractile apparatus.3,4 In many cases, the
cardiomyopathies result from missense mutations in one of the
proteins of the muscle thin filament (actin, tropomyosin, troponin I,
C, or T). Investigations of the mechanisms that cause HCM and
DCM have generally found that mutations in the muscle thin filament
cause abnormalities in the Ca2+ regulatory system of the muscle.5–7
HCM is closely associated with enhanced myofilament Ca2+ sensi-
tivity, although the process by which chronically high Ca2+ sensitivity
leads to the symptoms of HCM, hypertrophy, fibrosis, and arrhythmias,
is uncertain. In DCM, the situation is more complex. It has been
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suggested that DCM-causing mutations are associated with a reduced
Ca2+ sensitivity,8 but comprehensive surveys now show that
DCM-causing mutations in thin filament proteins can increase or de-
crease Ca2+ sensitivity.5,9 However, the DCM phenotype is always
linked to the absence of modulation of Ca2+ sensitivity by troponin I
(TnI) phosphorylation (uncoupling), and this has been proposed to
be causative of the DCM phenotype.9,10 In addition, the coupling be-
tween TnI phosphorylation and change of Ca2+ sensitivity seems to
be lost due to HCM mutations in thin filament proteins when studied
by in vitro motility assay (IVMA) techniques and by myofibrilar
assays,11 – 15 but in permeabilized muscle, this phenomenon is not
observed.16 Thus, in HCM, the relationship between TnI phosphoryl-
ation and Ca2+ sensitivity is not clear.
Uncoupling appears to be closely associated with mutations in thin
filament proteins that cause cardiomyopathies. The decrease in Ca2+
sensitivity upon phosphorylation of TnI and the corresponding increase
in the rate of Ca2+ dissociation from troponin C (TnC) is a key
component of the lusitropic response to b1-adrenergic stimulation
in the heart. The uncoupling reported in DCM and HCM is likely to
impact on cardiac reserve pathologically, and indeed, most studies of
mouse models with cardiomyopathy mutations in thin filament
proteins report a blunted response to adrenergic stimulation in vivo
(reviewed in Ref. 17).
A number of small molecules have been found that alter myofilament
Ca2+ sensitivity by binding to troponin and act as either Ca2+ sensiti-
zers or Ca2+ desensitizers. The effect of these reagents on Ca2+ sen-
sitivity is well documented, but the effect of small molecules on the
coupling between Ca2+ sensitivity and TnI phosphorylation has not
previously been considered.
EMD57033 and Bepridil are well-established Ca2+ sensitizers acting
directly upon TnC.18–20 Epigallocatechin-3-gallate (EGCG), the princi-
pal polyphenol isolated from green tea, is reported to be a Ca2+ desen-
sitizer that also acts via a binding site on TnC.21–23 Structural studies
indicate that the regulatory Ca2+ binding site (Site II in the N-terminal
lobe of TnC) is closely coupled both to the binding of the TnI switch
peptide (147–163), critical for neutralizing the inhibitory action of
TnI, and the cardiac-specific N-terminal peptide of TnI (1–30) that
contains the phosphorylatable serines 22 and 23.24–28 We have pro-
posed that DCM-causing mutations in thin filament proteins uncouple
phosphorylation from the change in Ca2+ sensitivity by disrupting this
coupled allosteric system.9,17 It is likely that Ca2+ sensitizers and desen-
sitizers binding to TnC would also have an effect on the coupling be-
tween Ca2+ sensitivity and TnI phosphorylation by modulating the
coupled system.
We have therefore investigated how EMD57033, Bepridil, and
EGCG affect the Ca2+ regulation and its modulation by phosphoryl-
ation in native human heart thin filaments and how these reagents
interact with mutations in thin filament proteins associated with
HCM or DCM. Using IVMA and single myofibril contractility, we
have confirmed the Ca2+-sensitizing effects of EMD57033 and
Bepridil and demonstrated that they also uncouple Ca2+ sensitivity
from the TnI phosphorylation level, thus mimicking the effects of
HCM-causing mutations. In contrast, EGCG decreases Ca2+ sensitiv-
ity in native thin filaments while retaining the modulation of Ca2+ sen-
sitivity by TnI phosphorylation. Moreover, EGCG has the unique
ability to restore the coupling to uncoupled HCM and DCM mutant
thin filaments and myofibrils, thus antagonizing the disease-causing
defect. This property of EGCG may be of therapeutic significance
for treating some cardiomyopathies.
2. Methods
2.1 Sources of contractile proteins
Donor heart tissue, used as control, and end-stage failing heart tissue from
explanted hearts were obtained from the Sydney Tissue Bank Sydney, Aus-
tralia.1,2 Ethical approval for collection and use of tissue samples was ob-
tained from the St Vincent’s Hospital, Sydney and Brompton, Harefield
and NHLI Research Ethics Committees.
Troponin was isolated from 100 mg of human heart muscle using an
anti-cardiac TnI mAb affinity column as described by Messer.29 Troponin
containing the TNNC1 G159D mutation was purified from explanted heart
samples as previously described.9,30,31 Recombinant TNNT2 K280N and
TNNI3 K36Qwas introduced into donor heart troponin by exchange as de-
scribed.29,32 Wild-type a-tropomyosin (Tpm1.1) and the mutants E40K,
E54K, and E180G were expressed in a baculovirus/Sf9 system with a proto-
col based on that of Akkari et al.9,33,34 Native, E361G, and E99K mutant
mouse cardiac actins were extracted from transgenic mouse hearts as
described by Song et al.35
2.2 Manipulation and measurement of TnI
phosphorylation level
Troponin isolated from human heart samples has a high level of phosphor-
ylation, which was reduced by treatment with shrimp AP (Sigma P9088).
Recombinant TnI was phosphorylated by treatment with protein kinase
A (PKA) catalytic subunit (Sigma, P2645–400) as previously described.9,32
To dephosphorylate mouse heart troponin, mice were treated with pro-
pranolol as described.10 TnI phosphorylation levels in myofibrils and iso-
lated troponin were measured by Phosphate affinity SDS–PAGE as
described;9,36 results are shown in Supplementary material online, SC.
2.3 Quantitative IVMA
Thin filaments were reconstituted with 10 nM rabbit skeletal or mouse car-
diac muscle a-actin (labelled with TRITC phalloidin), tropomyosin (40–
60 nM), and troponin (60 nM) to study Ca2+ regulation of filament motility
by the quantitative IVMA.29,37 Thin filament movement over a bed of immo-
bilized rabbit fast skeletal muscle heavy meromyosin (100 mg/mL) was
compared in paired motility chambers in which troponin varied by a single
factor (mutation, phosphorylation state, or treatment with drug). Filament
movement was recorded and analysed as previously described,38 yielding
two parameters, the fraction of filaments moving, and the speed of moving
filaments.
2.4 Contraction of isolated myofibrils
Contraction and relaxation of isolated mouse myofibrils were initiated
using a fast-solution change system and sensitive force transducer sys-
tem recently described.10 Further details are in Supplementary material
online, SA.
3. Results
3.1 Relationship between phosphorylation
and Ca21 sensitivity
We measured the Ca2+ dependence of thin filaments containing
human heart troponin by the IVMA. The assay yields two parameters,
fraction of filaments motile and sliding speed of the motile thin fila-
ments. Both parameters are Ca2+ dependent, and Ca2+ activation
curves were plotted (Figure 1). 3.9 mM Ca2+ increased the fraction of
filaments motile from 0.03 to 0.83 and the sliding speed from 1.5 to
3.0 mm/s. The EC50 and Hill co-efficient (nH) determined by fitting
the Hill equation to the data were similar for both parameters under
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all conditions; therefore, in this manuscript we have only shown the
fraction motile parameter. Full data for both parameters are shown
in Supplementary material online, SB.
Human heart troponin has a high level of TnI phosphorylation in the
1.4–1.8 mol Pi/mol range.36 This is reduced to ,0.3 mol Pi/mol by
treatment with phosphatase, see Supplementary material online, SC.
The Ca2+ sensitivity of unphosphorylated thin filaments is 1.88+
0.10 (P, 0.0001, n ¼ 16) times greater than the native phosphorylated
thin filaments as reported previously.29 nH was significantly reduced
from 2.11+ 0.18 for phosphorylated to 1.72+0.11 for unphosphory-
lated thin filaments, P ¼ 0.017, n ¼ 16. The maximum sliding speed was
not significantly affected by phosphorylation level (Table 1, Figure 1A).
We have investigated thin filaments incorporating six DCM-causing
mutations that have been shown to abolish this relationship (uncouple)
in previous studies9 and three HCM mutations that uncouple in vitro
(Figure 1B15,39).
Figure 1 Relationship between EC50 and TnI phosphorylation in native human thin filaments and thin filaments containing HCM-causing mutation
TPM1 E180G. Sliding speed and fraction of filaments motile, measured in the same experiment by IVMA, are plotted against [Ca2+] for representative
experiments. Raw data from one experiment are shown here; the mean values of EC50 from replicate experiments are shown in Table 2. Solid lines
and points, phosphorylated troponin (P); dotted lines and open points, unphosphorylated troponin (unP). Error bars represent SEM of four measure-
ments of motility in the same motility chamber. Blue, native thin filaments; purple, HCM-causing mutation TPM1 E180G present. (A) Native thin fila-
ments: phosphorylation increased EC50 (decreased Ca
2+ sensitivity) but had no effect on the maximum sliding speed or fraction of filaments motile at
saturating Ca2+. (B) Thin filaments containing TPM1 E180G HCM-causing mutation. The relationship of Ca2+ sensitivity to TnI phosphorylation is
uncoupled.
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3.2 EMD57033 and Bepridil increase Ca21
sensitivity and uncouple TnI
phosphorylation from changes in Ca21
sensitivity
EMD57033 and Bepridil substantially increased the Ca2+ sensitivity
(Figure 2A and D) and slightly increased the maximum sliding speed of
native human thin filaments as expected.
The effect of EMD57033 on EC50 for Ca
2+ activation of motility was
biphasic with a maximum at 30 mM and an EC50 in the range of 15–
20 mM (Figure 2C). Interestingly, we observed that 30 mM EMD57033
increased the Ca2+ sensitivity of thin filaments containing phosphory-
lated troponin more than unphosphorylated TnI (mean ratio EC50
P/EC50 P + EMD57033 ¼ 3.07+ 0.71, P ¼ 0.0001, n ¼ 4 in phos-
phorylated compared with a mean ratio of EC50 unP/EC50 unP +
EMD57033 ¼ 1.83+ 0.36, P ¼ 0.07, n ¼ 4 in unphosphorylated,
Table 1, Figure 2A, see Supplementary material online, SB). Consequent-
ly, in the presence of EMD57033, Ca2+ sensitivity of thin filaments was
the same, independent of the level of phosphorylation (EC50 P +
EMD57033/EC50 unP + EMD57033 ¼ 1.08+ 0.03, P ¼ 0.06, n ¼ 4).
EMD57033 increased sliding speed slightly at saturating Ca2+ concen-
tration in phosphorylated thin filaments and in unphosphorylated thin
filaments by 18.4+4.1% (P ¼ 0.02, n ¼ 4). nH was slightly decreased in
phosphorylated but not in unphosphorylated thin filaments.
EMD57033 also increased the Ca2+ sensitivity of thin filaments con-
taining the DCM-causing mutations, TPM1 E40K and E54K. In both
these cases, Ca2+ sensitivity was independent of troponin phosphoryl-
ation (uncoupled) due to the mutation (Table 1, Figure 2B).
A similar pattern of results was observed with Bepridil. The dose–re-
sponse curve was cooperative with a calculated EC50 of 52 mM
(Figure 2F). At 100 mM,which is the saturated concentration, the increase
in Ca2+ sensitivity of phosphorylated donor thin filaments (measured by
the mean ratio EC50 P/EC50 P + Bepridil) was 2.8+0.14-fold for frac-
tion motile (P, 0.0001, n ¼ 6) and 3.09+0.59-fold for sliding speed
(P ¼ 0.016, n ¼ 6), see Supplementary material online, SB.
Bepridil increased the Ca2+ sensitivity of thin filaments and also un-
coupled Ca2+ sensitivity from TnI phosphorylation, as shown by the
EC50 ratios of phosphorylated to dephosphorylated troponin (EC50
P/EC50 unP ¼ 1.73+ 0.03, P, 0.0001; EC50 P + Bepridil/EC50
unP + Bepridil ¼ 1.03+0.01, P ¼ 0.04, n ¼ 6) (Figure 2D, see Supple-
mentary material online, SB). Bepridil increased sliding speed at satur-
ating Ca2+ concentrations significantly in phosphorylated thin filaments
(14.8+3.2%, P ¼ 0.006, n ¼ 6) but did not have a significant effect in
unphosphorylated thin filaments (7.2+ 4.6%, P ¼ 0.18, n ¼ 6); it had
no significant effect on nH. Bepridil also reversibly increased the
Ca2+ sensitivity of both phosphorylated and unphosphorylated thin
filaments containing the DCM-causing TPM1 E54K mutation, and these
mutant thin filaments remained uncoupled (Table 1, Figure 2E, see
Supplementary material online, SE).
3.3 EGCG decreases Ca21 sensitivity while
retaining coupling
EGCG decreased Ca2+ sensitivity of human cardiac thin filaments mea-
sured by IVMA and at saturating concentrations (100 mM) reduced the
maximum sliding speed up to 20% but had no significant effect on nH
(Table 1, Figure 3, see Supplementary material online, SB). Titration of
EGCG at 0.074 mM Ca2+ yielded a cooperative dose–response curve
with a calculated EC50 of 70+ 7 mM for phosphorylated and 60+ 1
for unphosphorylated (Figure 3C). Unlike EMD57033 and Bepridil,
100 mM EGCG had a similar effect on the EC50 of thin filaments with
phosphorylated and unphosphorylated troponin, (mean ratio EC50 +
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Effect of EMD57033, Bepridil, and EGCG on Ca21 regulation of motility
Treatment EC50 nH DVmax EC50, TPM1 E54K DCM mutation
Native
P 0.16+0.03 (4) 2.08+0.14 (4) 1.40+0.11 (4) 0.12+0.02 (3)
unP 0.091+0.014 (4)† 1.51+0.25 (4)† 1.30+0.04 (4) 0.11+0.008 (3)
+EMD57033
P 0.057+0.010 (4)** 1.26+0.07 (4)* 1.55+0.08 (4) 0.041+0.002 (3)*
unP 0.053+0.010 (4) 1.34+0.14 (4) 1.54+0.08 (4)* 0.041+0.002 (3)*
Native
P 0.13+0.007 (8) 2.89+0.48 (8) 2.09+0.14 (8) 0.13+0.014 (3)
unP 0.072+0.002 (6)†† 1.96+0.08 (6) 2.13+0.20 (6) 0.13+0.012 (3)
+Bepridil
P 0.045+0.001 (8)** 1.94+0.08 (8) 2.40+0.15 (8)** 0.060+0.009 (3)*
unP 0.045+0.001 (6)** 2.03+0.13 (6) 2.24+0.16 (6) 0.058+0.006 (3)**
Native
P 0.14+0.03 (7) 1.61+0.19 (7) 1.91+0.18 (7) 0.11+0.01 (5)
unP 0.059+0.011 (6)†† 1.50+0.21 (6) 1.92+0.22 (6) 0.11+0.02 (5)
+EGCG
P 0.26+0.02 (7)** 1.96+0.24 (7) 1.38+0.12 (7)** 0.23+0.03 (5)*
unP 0.15+0.02 (6)**,†† 1.79+0.30 (6) 1.52+0.13 (6)* 0.071+0.005 (5)††
Paired t-test was used for EC50, nH, and DVmax (the change in velocity due to Ca
2+). EC50 values rounded to two significant figures. The number of experiments is given in brackets.
*P, 0.05, **P, 0.01, for presence and absence of reagent.
†P, 0.05, ††P, 0.01, unphosphorylated compared with phosphorylated.
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EGCG/EC50 control ¼ 2.15+ 0.45-fold for phosphorylated and
2.80+ 0.48-fold for unphosphorylated thin filaments, see Supplemen-
tary material online, SB). Therefore, the coupling of TnI phosphoryl-
ation level to changes in Ca2+ sensitivity was retained (EC50 P/EC50
unP ¼ 2.24+ 0.10, P, 0.0001, n ¼ 6; EC50 P + EGCG/EC50 unP +
EGCG ¼ 1.73+0.16, P ¼ 0.006, n ¼ 6) (Table 1, Figure 3A, see Supple-
mentary material online, SB).
3.4 EGCG restores coupling to HCM and
DCM mutant thin filaments and myofibrils
EGCG also affected Ca2+ sensitivity in thin filaments containing
mutations associated with HCM or DCM in a phosphorylation-
dependent way. This was tested with five DCM-causing mutations and
three HCM-causing mutations. EGCG decreased the Ca2+ sensitivity
of phosphorylated mutant thin filaments in a similar way to wild-type
troponin (ratio EC50 with/without EGCG was 1.36–2.85). However,
with unphosphorylated troponin, EGCG tended to have no effect or,
in the case of the three tropomyosin mutations, increased Ca2+
sensitivity (Table 2). As a result, the dependence of Ca2+ sensitivity on
TnI phosphorylation level was restored. For example, thin filaments
containing the DCM-causing TPM1 mutation E54K were uncoupled
with EC50 of 0.106+ 0.013 mM for phosphorylated and 0.114+
0.019 mM for unphosphorylated giving a ratio of 0.95+0.03 compared
with a ratio of 2.24+0.10 for wild-type thin filaments (Table 1). In the
presence of 100 mM EGCG, the EC50 was 0.23+ 0.03 mM for phos-
phorylated and 0.071+0.005 mM for unphosphorylated giving a ratio
of 3.17+0.37 (P ¼ 0.004, n ¼ 5) (Table 1, Figure 3B). A dose–response
assay for recoupling yielded an EC50 of 58.8+ 13.3 mM (Figure 3D).
Similarly, EGCG was able to reversibly restore coupling of all the thin
filamentHCMandDCM-causingmutations in this study (Table 2, Figures 4
and 5, see Supplementary material online, SF).
3.5 The effect of EGCG on contraction of
myofibrils
We studied the effect of EGCG on mouse myofibril contractility
in basally phosphorylated and dephosphorylated states, obtained
Figure 2 Effect of Ca2+ sensitizers on Ca2+ control of motility. (A, B, D and E) Fraction of filaments motile, measured by IVMA is plotted against [Ca2+]
details as in Figure 1. (A and D) Effect of Ca2+ sensitizers on Ca2+ regulation of native thin filaments. Blue, native thin filaments; orange, the presence of
30 mMEMD57033; brown, the presence of 100 mMBepridil. (B and E) Effect of Ca2+ sensitizers on Ca2+ regulation of thin filaments containing the TPM1
E54K DCM-causing mutation. Red, E54K-containing thin filaments; orange, the presence of 30 mM EMD57033; brown, the presence of 100 mM Bepridil.
(C) EMD57033 dose–response curve: EC50 was determined at a range of EMD57033 concentrations. The change in EC50 (+SEM of four measurements
of motility in the same motility chamber) is plotted for three separate experiments. (F) Bepridil dose–response curve: motility was measured at a con-
stant of 0.037 mMCa2+with increasing concentrations of Bepridil. The increase in fraction of filaments motile (+SEM of four measurements of motility
in the same motility chamber) is plotted for three separate experiments and the curve represents the fit of the pooled data to the Hill equation. Values of
parameters obtained are shown.
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by treating mice with propranolol prior to sacrifice (Table 3 ,
Figure 6).
We found that 10 mM EGCG decreased Ca2+ sensitivity of isomet-
ric force for both phosphorylated and unphosphorylated mouse myo-
fibrils equally (EC50 P/EC50 P + EGCG ¼ 0.50+ 0.06, P, 0.001,
n ¼ 9, EC50 unP/EC50 unP + EGCG ¼ 0.45+ 0.07, P, 0.00, n ¼ 5).
Consequently, the effect of phosphorylation on Ca2+ sensitivity in
wild-type myofibrils was preserved in the presence of EGCG (EC50
P + EGCG/EC50 unP + EGCG ¼ 1.64+ 0.24, P, 0.001, n ¼ 5).
As previously shown,10 in myofibrils from ACTC E361G DCM mice,
the Ca2+ sensitivity of force is uncoupled (Table 3, Figure 6). EGCG de-
creased Ca2+ sensitivity in myofibrils from ACTC E361Gmice; however,
this effect was greater in phosphorylated myofibrils than unphosphory-
lated myofibrils. Thus, EGCG restored the phosphorylation-dependent
shift in Ca2+ sensitivity for ACTC E361G myofibrils to the same level as
in wild-typemyofibrils (EC50 P + EGCG/EC50 unP + EGCG ¼ 1.62+
0.20, P, 0.01, n ¼ 5 compared with 1.82+ 0.24 for wild-type in the
absence of EGCG). nH values were similar to those found in wild-type
Figure 3 Effect of EGCG on Ca2+ control of motility. (A and B) Fraction of filaments motile, measured by IVMA, is plotted against [Ca2+], details as in
Figure 1. Raw data from one experiment are shown here; the mean values of EC50 from replicate experiments are shown in Tables 1 and 2. (A) Effect of
EGCG on Ca2+ regulation of native thin filaments. Blue, native thin filaments; green, the presence of 100 mM EGCG. (B) Effect of EGCG on Ca2+ regu-
lation of thin filaments containing TPM1 E54KDCM-causing mutation. Red, E54K-containing thin filaments; green, the presence of 100 mM EGCG. (C and
D) Dose–response curves, the fraction motile was measured at a constant [Ca2+] with increasing concentrations of EGCG for a representative experi-
ment. (C) Effect of EGCG on donor thin filaments at 0.074 mMCa2+. The inset plots the change in fraction motility with increasing EGCG concentration,
and the curve represents the fit of the pooled data to the Hill equation. Values of parameters obtained are shown. (D) Effect of EGCG on thin filaments
containing TPM1 E180G tropomyosin at 0.037 mMCa2+. Initially, motility is the same (see Figure 1); the addition of EGCG reducedmotility of phosphory-
lated and increased motility of unphosphorylated thin filaments, indicating recoupling or the restoration of the phosphorylation-dependent Ca2+ sen-
sitivity difference (see Figure 3B). Details as in Figure 2F.
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Table 2 Effect of EGCG and TnI phosphorylation on the Ca21 sensitivity of thin filaments containing HCM and DCM mutations
Mutation EC50 of thin
filaments containing
phosphorylated
troponin mM+ SEM
EC50 of thin filaments
containing
unphosphorylated
troponin mM+ SEM
Ratio EC50 P/
unP+ SEM
EC50 of thin filaments
treated with EGCG
containing
phosphorylated
troponin mM+ SEM
EC50 of thin filaments
treated with EGCG
containing
unphosphorylated
troponin mM+ SEM
Ratio EC50 P 1 EGCG/
unP 1 EGCG+ SEM
Ratio EC50
P1 EGCG/
P+ SEM
Ratio EC50
unP1 EGCG/
unP+ SEM
WT 0.14+0.03 (7) 0.059+0.011 (6)†† 2.24+0.10 (6)†† 0.26+0.02 (7)** 0.15+0.02 (6)**,†† 1.73+0.16 (6)†† 2.15+0.45(7) 2.80+0.48(6)
DCM
TPM1
E54K
0.11+0.013 (5) 0.11+0.02 (5) 0.95+0.03 (5) 0.23+0.03 (5)* 0.071+0.005 (5)†† 3.17+0.37 (5)†† 2.33+0.53(5) 0.68+0.10(5)
TPM1
E40K
0.18+0.03 (8) 0.17+0.03 (8) 1.02+0.007 (8) 0.22+0.04 (5) 0.052+0.01 (5)*,† 4.63+0.96 (5)† 1.70+0.43(3) 0.34+0.05(3)
TNNC1
G159D
0.092+0.004 (5) 0.095+0.005 (5) 0.97+0.03 (5) 0.19+0.03 (5)* 0.088+0.005 (5)*,† 2.25+0.41 (5)† 2.13+0.36(5) 0.93+0.02(5)
TNNI3
K36Q
0.18+0.03 (10) 0.18+0.04 (10) 1.02+0.05 (10) 0.19+0.02 (5) 0.10+0.009 (5)*,† 1.97+0.12 (5)† 2.32+0.29(3) 1.28+0.04(3)
ACTC
E361G
0.087+0.002 (5) 0.080+0.002 (5) 1.08+0.02 (5) 0.20+0.02 (5)** 0.081+0.002 (5)†† 2.41+0.28 (5)†† 2.27+0.28(5) 1.01+0.02(5)
HCM
TPM1
E180G
0.086+0.013 (3) 0.087+0.011 (3) 0.98+0.02 (3) 0.11+0.01 (5)* 0.048+0.003 (5)*,† 2.41+0.32 (5)† 1.36+0.10(3) 0.51+0.06(3)
TNNT2
K280N
0.11+0.007 (5) 0.10+0.004 (5) 1.08+0.04 (5) 0.20+0.03 (5)* 0.10+0.004 (5)† 1.96+0.24 (5)† 2.15+0.18(3) 1.09+0.006(3)
ACTC
E99K
0.074+0.005 (5) 0.074+0.005 (5) 0.99+0.02 (5) 0.21+0.03 (5)** 0.10+0.007 (5)*,†† 2.03+0.21 (5)†† 2.85+0.28(5) 1.43+0.13(5)
Ratios: single value t-test compared with 1. ANOVA analysis of this data set is shown in Supplementary material online, SE. EC50 values rounded to two significant figures. The number of experiments is given in brackets.
*P, 0.05, **P, 0.01, for the presence and absence of EGCG using paired t-test.
†P, 0.05, ††P, 0.01, unphosphorylated compared with phosphorylated using paired t-test.
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myofibrils (Table 3). The duration of the initial, nearly isotonic, phase of
relaxation, tLIN, in phosphorylated and unphosphorylated ACTC E361G
myofibrils was restored to wild-type values (Table 3). EGCG decreased
the rate of force development (kACT) but did not affect maximum force.
kACT was decreased by EGCG in unphosphorylated wild-type myofi-
brils (decreased by 22.8%, P ¼ 0.059, n ¼ 15) as well as in phosphory-
lated and unphosphorylated ACTC E361G (decreased by 23%, P, 0.05,
n ¼ 10 and by 21%, P, 0.001, respectively, n ¼ 11).
4. Discussion
In previous studies, it was found that mutations in proteins of the car-
diac muscle thin filament that are associated with inherited cardiomy-
opathies (HCM and DCM) alter myofibrillar Ca2+ sensitivity. They also
cause the modulation of myofilament Ca2+ sensitivity to become inde-
pendent of the PKA-dependent phosphorylation of TnI. We have
named this phenomenon uncoupling. Moreover, this uncoupling effect
may be sufficient to generate the disease phenotype of familial
DCM.9,17 We have investigated whether small molecules might be
able to mimic or reverse the molecular effects of mutations.
The Ca2+ sensitizers EMD57033 and Bepridil, known to bind to
TnC, induce uncoupling in wild-type thin filaments, thus mimicking
the effects of HCMmutations. The Ca2+ desensitizer EGCG has an op-
posite effect. It preserves coupling in wild-type troponin and restores
coupling to thin filaments with HCM- and DCM-causing mutations in
TnI, TnC, TnT, tropomyosin, and actin, thus antagonizing the effect
of the HCM or DCM mutation. These findings suggest the potential
of EGCG for treating the symptoms of inherited cardiomyopathies.
4.1 Ca21 sensitizers mimic the effects of
HCM-causing mutations in thin filaments
Both EMD57033 and Bepridil increase Ca2+ sensitivity of phosphory-
lated thin filaments by 2.8- and 2.9-fold, measured by quantitative
Figure 4 Coupling is restored to HCM and DCM mutations by EGCG. Fraction of filaments motile, measured by IVMA in the presence of 100 mM
EGCG, is plotted against [Ca2+] for representative single experiments. Details as in Figure 1. Red lines, thin filaments containing DCM-causing mutations;
Purple lines, thin filaments containing HCM-causing mutations. The mean values of EC50 from replicate experiments are plotted in Figure 5 and summar-
ized in Table 2.
Figure 5 The re-coupling effect of EGCG. The ratio of EC50 phos-
phorylated/EC50 unphosphorylated (coupling constant) is plotted in
the absence (blue) and presence (green, red, and purple) of
100 mM EGCG. Green, control troponin; red, DCM-causing mutants;
purple, HCM-causing mutants, error bars are +SEM. All the mutant
samples are uncoupled, but the coupling constant is restored to con-
trol levels by EGCG. Data from Table 2.
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IVMA, in common with previous measurements.40,41 However, it has
not been shown before that they increase Ca2+ sensitivity of unpho-
sphorylated thin filaments considerably less than phosphorylated thin
filaments. As a consequence, Ca2+ sensitivity becomes independent
of the TnI phosphorylation level (uncoupled).
The effect of Ca2+ sensitizers is analogous to the effect of
HCM-causing mutations in vitro (Table 2) where both an increase in
the Ca2+ sensitivity and uncoupling of the Ca2+ sensitivity from the
TnI phosphorylation are observed. Uncoupling due to HCM mutations
was first reported in 200113 and several more thin filament mutations
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Effect of phosphorylation, ACTC E361G mutation, and EGCG on Ca21 regulation of myofibril contraction
Fmax (kN/m
2) EC50 (mM) nH kACT (s
21) tLIN (ms) kREL (s
21)
WTa
P 100.9+6.3 (14) 0.93+0.06 (11) 10.43+1.84 (10) 4.16+0.43 (11) 50.8+3.5 (12) 35.0+4.0 (10)
unP 87.1+6.0 (16) 0.51+0.06 (14)††† 4.74+0.66 (13)†† 4.50+0.24 (15) 67.0+4.2 (16)† 23.2+2.8 (11)†††
WT + EGCG
P 92.5+5.0 (15) 1.85+0.17 (9)*** 4.30+0.85 (8)** 4.44+0.24 (15) 46.7+3.9 (12) 41.0+4.0 (12)
unP 92.6+8.9 (8) 1.13+0.13 (5)††,*** 5.08+1.24 (5) 3.47+0.55 (6) 88.9+9.9 (7)†††,* 22.3+1.2 (7)††
E361Ga
P 93.5+8.9 (11) 0.38+0.05 (12)§§§ 5.39+1.26 (9)§ 4.51+0.32 (13) 75.4+6.5 (10)§§ 21.6+2.8 (10)§§§
unP 89.3+8.6 (10) 0.43+0.06 (10) 4.48+0.70 (8) 4.12+0.32 (11) 70.8+9.7 (11) 21.6+2.1 (10)
E361G + EGCG
P 89.1+4.5 (12) 2.07+0.20 (5)***,‡‡‡ 7.18+1.54 (5) 3.43+0.20 (13)*,§,‡‡ 49.7+3.3 (12)** 31.0+2.6 (12)*,§
unP 96.3+11.1 (11) 1.28+0.10 (8)††,***,‡‡‡ 4.14+0.42 (7)† 3.25+0.26 (11)***,‡‡ 63.0+4.7 (12)†,§ 31.0+2.0 (12)**,§§,‡‡
The number of experiments is given in brackets. Statistical analysis carried out by un-paired t-test (equal variance).
aVikhorev et al.11
*P, 0.05, **P, 0.01, ***P, 0.001, EGCG treated compared with no EGCG.
†P, 0.05, ††P, 0.01, †††P, 0.001, unphosphorylated compared with phosphorylated.
§P, 0.05, §§P, 0.01, §§§P, 0.001, ACTC E361G compared with wild type.
‡P, 0.05, ‡‡P, 0.01, ‡‡‡P, 0.001, ACTC E361G EGCG treated compared with no EGCG wild-type.
Figure 6 EGCG restores the relationship between Ca2+ sensitivity of force production and TnI phosphorylation in wild-type and ACTC E361Gmouse
myofibrils. Phosphorylation level was reduced by propranolol treatment and measured by phosphate affinity SDS–PAGE. Basally phosphorylated wild-
type was 1.02+0.03 and ACTC E361G was 1.08+0.01 mol Pi/mol TnI. For propranolol-treated (dephosphorylated) muscle, the phosphorylation level
was 0.30+0.04 in wild type and 0.34+0.07 mol Pi/mol TnI for ACTC E361G. (A) Ca2+ activation curves for ACTC E361G myofibrils in the presence
(green) and absence (red) of 10 mM EGCG. Solid lines and points, phosphorylated troponin (P); dotted lines and open points, unphosphorylated tropo-
nin (unP). The plot shows averaged isometric tension+ SEM from 11 to 14 myofibrils for experiments performed at SL ¼ 2.17 mm. EGCG shifts the
activation curve to the right and restores the difference between phosphorylated and unphosphorylated myofibrils. (B) Effects of the ACTC E361G mu-
tation, phosphorylation, and EGCG on the mean EC50 (+SEM) for myofibril isometric contraction. Significant differences, calculated by t-test, between
phosphorylated and unphosphorylated myofibrils are indicated: **P, 0.01; ***P, 0.001. Data from Table 3.
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have subsequently been demonstrated by in vitro assays,5,17 as the TPM1
E180G mutation, shown in Figure 1B, demonstrates.
4.2 Mechanistic considerations of Ca21
sensitizers
Since both EMD57033 and Bepridil appear to modulate Ca2+ sensitiv-
ity with a minimal effect on the sliding speed in IVMA or maximum iso-
metric force in muscle fibres,10,42 it is likely that they are acting on
troponin rather than the cross-bridge cycling mechanism in our
systems.
The Ca2+ sensitivity of cardiac troponin is modulated by the unique
N-terminal peptide of TnI (1–30) that contains the PKA phosphoryl-
ation sites, Ser22 and 23. When unphosphorylated, the peptide inter-
acts with the N-terminal domain of TnC, close to the regulatory
Ca2+-binding site and this interaction is lost or reduced when the
two serines are phosphorylated.43,44 The change in Ca2+ sensitivity
with TnI phosphorylation is a two- to three-fold reduction.
Bepridil is suggested to displace TnI 1–30 and/or the linker helix TnI
31–70.20,45 EMD57033 is believed to bind to the C-terminal domain of
TnC and also displaces the TnI 31–70 peptide.18,19,46 Thus, both these
compounds could act allosterically by interfering with the modulation
of Ca2+ sensitivity due to Ser22/23 phosphorylation, resulting in
uncoupling.
Interestingly, in experiments measuring isometric force in cardiac
muscle myofibrils, EMD57033 increased Ca2+ sensitivity but only
caused uncoupling at short sarcomere lengths. Thus, the uncoupling
phenomenon may be graded rather than all-or-none. One possibility
is that uncoupling may be related to Ca2+ sensitivity if the Ca2+ sensi-
tizer shifts the conformational equilibrium so far towards the
N-terminal bound conformation that it cannot be significantly influ-
enced by phosphorylation of the N-terminal peptide of TnI (see Sup-
plementary material online, SD). However, the Ca2+-sensitizing
property of these compounds does not necessarily involve the same
molecular mechanism as uncoupling.
The actions of small molecules that uncouple highlight the crucial
role of the allosteric coupling between the TnI 1–30 peptide and
ligand-binding sites that could be remotely located. Likewise, it is not-
able that DCM-causing mutations that uncouple are distributed in all
the proteins of the thin filament, also demonstrating long-range allo-
steric interactions.9,47 We have proposed that these mutations desta-
bilize the unphosphorylated state of the 1–30 peptide.9
4.3 The Ca21 desensitizer EGCG restores
coupling to thin filaments with HCM and
DCM mutations
Our observation that EGCG reduces Ca2+ sensitivity two- to three-
fold both in human thin filaments and in mouse myofibrils with only
small effects on maximum sliding speed, isometric force or Hill
coefficient, is in accord with previous measurements in skinned cardiac
muscle fibres.21,23 Moreover, we have demonstrated that the
phosphorylation-dependent shift in myofilament Ca2+ sensitivity is
unaffected by EGCG in both isolated filaments and intact myofibrils,
in contrast to the Ca2+ sensitizers (Figures 2, 3, and 6).
EGCG was also able to decrease the Ca2+ sensitivity of phosphory-
lated thin filaments containing HCM- and DCM-causing mutations;
however, it had different effects on phosphorylated and unphosphory-
lated thin filaments. With phosphorylated troponin, EGCG decreased
Ca2+ sensitivity similarly to wild-type troponin, but EGCG either had
no effect or increased Ca2+sensitivity with unphosphorylated troponin
(Table 2). This resulted in the restoration of the coupling of Ca2+ sen-
sitivity change to TnI phosphorylation (Figures 3, 4, and 5).
Several studies have located EGCG binding in the C-terminal domain
of TnC in the region of the hydrophobic cleft.21,22,46 Molecular dynam-
ics (MD) simulation suggests that it can bind in several interchangeable
orientations,46 and unlike EMD57033, EGCG can bind to the
C-terminal domain of cTnC even in the presence of TnI 34–71 helix.46
We suggest that it is possible that EGCG can re-stabilize the TnI–TnC
interaction, restoring the Ca2+ response to phosphorylation found in
DCM and HCM. MD calculations indicate that the uncoupling mutation
cTnC G159D strengthens TnI 34–71 helix binding to the hydrophobic
cleft while EGCGweakens this interaction,46 compatible with their op-
posite effects on coupling.
4.4 Effects of EGCG on myofibrillar
contractility
EGCG decreased Ca2+ sensitivity in phosphorylated and unpho-
sphorylated wild-type myofibrils by approximately two-fold but did
not change the relaxation parameters tLIN and kREL in phosphorylated
myofibrils (Table 3). The rate of force development (kACT), measured at
high Ca2+, was unchanged in myofibrils with phosphorylated TnI and
slightly decreased (P ¼ 0.059) in unphosphorylated myofibrils. As
kACT depends strongly on the Ca
2+ concentration,10 we conclude
that EGCG shifts the [Ca2+]–kACT relationship towards higher Ca
2+
concentration in agreement with IVMA data (Table 1). Thus, unlike
EMD57033, EGCG decreases cross-bridge activation kinetics.10
EGCG reduced Ca2+ sensitivity and kACT in both phosphorylated
and unphosphorylated ACTC E361G myofibrils. In addition, it restored
the lost difference in Ca2+ sensitivity between phosphorylated and un-
phosphorylated myofibrils and also the difference in the relaxation par-
ameter tLIN (Table 3). The observation that EGCG does not affect the
EC50 P/EC50 unP or tLIN in wild-type myofibrils but changes them in
ACTC E361G suggests that EGCG can restore coupling in ACTC
E361G myofibrils independently of its Ca2+-desensitizing function.
Although uncoupling can be clearly demonstrated at the level of
skinned muscle fibres or myocytes with thin filament mutations causing
DCM,35,48,49 this does not appear to be true for HCM-causing muta-
tions, despite being indistinguishable at the single filament level. A near-
normal response of Ca2+ sensitivity to TnI phosphorylation has been
reported for TNNC1 L29Q and TPM1 E180G in transgenic mice50,51
and TNNI3 R145W and TNNT2 K280N in human heart myectomy
samples.16 Despite this, both DCM- and HCM-linked mutations in
transgenic mice models are associated with an impaired response to
b1-adrenergic stimulation and reduced cardiac reserve as would be
expected if uncoupled15,35 (reviewed by Messer17). The physiological
manifestations of the uncoupling seen in unloaded filaments require
further investigation.
4.5 Clinical relevance of re-coupling
by EGCG
Ca2+ antagonists have been suggested as being potentially useful for
treatment of HCM.52 EGCG represents a new class of Ca2+ antago-
nists with a very favourable functional profile. EGCG acts directly on
the Ca2+ regulatory system of the thin filament that is also the main tar-
get of HCM-causing mutations in sarcomeric proteins.5 By binding to
troponin, it decreases the enhanced Ca2+ sensitivity characteristic of
HCM while also reversing the uncoupling effect we observed in
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HCM mutations. The ability to restore coupling to DCM mutant myo-
fibrils could be beneficial, since this was proposed to be the primary
cause of DCM, but the reduction in Ca2+ sensitivity in cases where
the mutation also reduces Ca2+ sensitivity may be deleterious.
EGCG has a wide range of pharmacological properties; indeed, it has
been cited as an example of a promiscuous molecule.53 Moreover, low
doses of EGCG have a positive inotropic effect in intact heart muscle,
due to effects on the ryanodine receptor type 2, Na+-K+ ATPase and
Na+-Ca2+ exchanger, that may override the Ca2+-desensitizing effect
in the contractile apparatus.54,55
Although EGCG is too non-specific to be a viable drug for treating
HCM, this study has demonstrated a significant proof of principle: it is
possible to directly reverse the molecular mechanism of HCM-causing
mutations pharmacologically. The coupling of Ca2+ sensitivity to cTnI
phosphorylation has been demonstrated to be a labile property of
troponin. HCM or DCMmutations and Ca2+ sensitizers can induce un-
coupling, indicating that small perturbations can destabilize tropo-
nin.9,17,32 It is very unusual to find a reagent that will give a gain of
function by apparently restoring the native conformational state in
the presence of mutations that destabilized this state.
Our findings provide a starting point for investigating molecules
related to EGCG that may be more efficacious and act specifically
on troponin.56
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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TPM3 Deletions Cause a Hypercontractile
Congenital Muscle Stiffness Phenotype
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Objective: Mutations in TPM3, encoding Tpm3.12, cause a clinically and histopathologically diverse group of myopa-
thies characterized by muscle weakness. We report two patients with novel de novo Tpm3.12 single glutamic acid
deletions at positions DE218 and DE224, resulting in a significant hypercontractile phenotype with congenital muscle
stiffness, rather than weakness, and respiratory failure in one patient.
Methods: The effect of the Tpm3.12 deletions on the contractile properties in dissected patient myofibers was meas-
ured. We used quantitative in vitro motility assay to measure Ca21 sensitivity of thin filaments reconstituted with
recombinant Tpm3.12 DE218 and DE224.
Results: Contractility studies on permeabilized myofibers demonstrated reduced maximal active tension from both
patients with increased Ca21 sensitivity and altered cross-bridge cycling kinetics in DE224 fibers. In vitro motility
studies showed a two-fold increase in Ca21 sensitivity of the fraction of filaments motile and the filament sliding
velocity concentrations for both mutations.
Interpretation: These data indicate that Tpm3.12 deletions DE218 and DE224 result in increased Ca21 sensitivity of
the troponin–tropomyosin complex, resulting in abnormally active interaction of the actin and myosin complex. Both
mutations are located in the charged motifs of the actin-binding residues of tropomyosin 3, thus disrupting the elec-
trostatic interactions that facilitate accurate tropomyosin binding with actin necessary to prevent the on-state. The
mutations destabilize the off-state and result in excessively sensitized excitation–contraction coupling of the contract-
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ile apparatus. This work expands the phenotypic spectrum of TPM3-related disease and provides insights into the
pathophysiological mechanisms of the actin–tropomyosin complex.
ANN NEUROL 2015;78:982–994
Tropomyosin 3 (Tpm3.12; a-tropomyosin slow),encoded by the TPM3 gene (Online Mendelian
Inheritance in Man database 191030), belongs to the
actin-binding tropomyosin family and is a component of
the sarcomeric thin filament troponin–tropomyosin com-
plex. Tpm3.12 is predominantly expressed in type 1
(slow twitch) fibers and forms dimers of linear coiled-coil
structures with Tpm2.2 (b-tropomyosin) encoded by
TPM2 and Tpm1.1 (a-tropomyosin) encoded by TPM1,
which then bind head-to-tail, providing structural stabil-
ity to actin filaments.1,2 This complex acts by regulating
Ca21 dependent binding of the myosin head to the actin
filament. It serves as an essential component in the regula-
tion of muscle contraction by preventing binding of the
myosin head when in the off-state and allowing it in the
on-state, in preparation for the force generating power
stroke. Mutations in TPM3 recognized thus far result in a
clinically and histopathologically heterogeneous group of
neuromuscular disorders, which are characterized by pro-
gressive weakness and include cap myopathy,3–5 congenital
fiber type disproportion (CFTD),6 and autosomal domi-
nant as well as recessive nemaline myopathy.7–10
Mutations in TPM2 also typically result in a phe-
notype of myopathy, manifesting with weakness. How-
ever, the deletion of a single lysine residue at position 7
in Tpm2.2 can manifest clinically with both muscle
weakness and moderate progressive muscle contractures.
Studies of this specific mutation suggest that the patho-
genic mechanism underlying some tropomyosin-related
disease may be due to elevated Ca21 sensitivity of the
contractile apparatus.11,12 Although such a mechanism
had been predicted on theoretical molecular grounds to
also be applicable for Tpm3.12,13 this phenomenon had
not yet been shown conclusively to be clinically
relevant.11,12
Here we report two unrelated patients with two dis-
tinct but closely spaced de novo Tpm3.12 single glutamic
acid deletions resulting in a marked generalized hyper-
contractile phenotype with very significant congenital
muscle stiffness, in the absence of detectable weakness,
and associated with respiratory failure in the more
severely affected patient. The effect of the Tpm3.12 glu-
tamic acid deletions was studied using in vitro motility
assays and mechanics on permeabilized myofibers. These
deletions appear to result in impaired maximum force
generation with altered cross-bridge cycling kinetics, and
increased Ca21 sensitivity of force. This study expands
the phenotypic, and pathophysiological spectrum of
TPM3 mutations, which now join a specific ACTA1
mutation as well as recessive ab-crystallin (CRYAB)
mutations as a myogenic cause for significant neonatal
muscle rigidity.14,15
Subjects and Methods
Patient Recruitment and Sample Collection
Two unrelated patients, one from the United States and one
from Germany, were identified through their local neurologists.
Medical history was obtained and clinical evaluations were per-
formed as part of the standard neurologic evaluation. This
study was approved by the institutional review board of the
National Institute of Neurological Disorders and Stroke,
National Institutes of Health (NIH). Written informed consent
was obtained from each family by a qualified investigator.
DNA was obtained from blood based on standard procedures.
Muscle biopsies were obtained as part of the regular clinical
diagnostic testing and were evaluated by standard light and
electron microscopy protocols. Banked muscle biopsy samples
were transferred to the NIH for further analysis.
Genetic Testing
Whole exome sequencing on blood samples obtained from
Patient 1 (P1) and his parents was performed at the NIH Intra-
mural Sequencing Center using the Illumina (San Diego, CA)
TruSeq Exome Enrichment Kit and Illumina HiSeq 2000
sequencing instruments. Mutations were analyzed using
GEM.app and xBrowse and searched for in dbSNP, NHLBI
EVS, ExAC Browser, or GEM.app.16 Polymerase chain reaction
amplification of exon 6 of TPM3 in P1, Patient 2 (P2), and
their parents, was followed by Sanger sequencing on an ABI
3130x1 capillary sequencer, in forward and reverse directions.
Synthesis of Tropomyosin in Sf9 Insect Cells
The wild-type (WT) human TPM3 cDNA sequence was ampli-
fied from reverse transcribed skeletal muscle RNA and then
cloned into the BacPak8 plasmid (Clontech Laboratories,
Mountain View, CA). The DE218 and DE224 mutations were
introduced into the TPM3 cDNA by site-directed mutagenesis.
The WT and two mutant tropomyosin proteins were expressed
in Sf9 insect cells using the flashBAC baculovirus system
(Oxford Expression Technologies, Oxford, UK). Recombinant
proteins were purified using protocols based on Akkari et al.17
Quantitative In Vitro Motility Assay
Thin filaments were reconstituted with 10nM rabbit skeletal
muscle a-actin (labeled with tetramethylrhodamine phalloi-
din),18 tropomyosin (40–60nM), and skeletal troponin (60nM)
to study Ca21 regulation of filament motility by the quantita-
tive in vitro motility assay previously described.19,20 Thin fila-
ment movement over a bed of immobilized rabbit fast skeletal
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muscle heavy meromyosin (100lg/ml) was then compared in
paired motility cells with WT or mutant tropomyosin. Filament
movement was recorded and analyzed as previously described,19
yielding 2 parameters, the fraction of filaments moving and the
speed of moving filaments. Fraction motile and sliding speed
was measured over a range of Ca21 concentrations to generate
Ca21 activation curves as shown previously.20–23 The tempera-
ture was set to 298C. Median effective concentration (EC50)
values from replicate experiments were analyzed by paired
t-test, because EC50 has been shown to be normally
distributed.20,24
Permeabilized Myofiber Contractile
Performance
The effect of the Tpm3.12 deletion on the contractile proper-
ties in myofibers derived from patients’ muscle biopsies was
measured. Myofiber bundles from frozen muscle biopsies from
P1 and P2 and age-matched controls were isolated as described
previously.13,25,26 In brief, smaller sections (2 3 2mm) of the
biopsies were isolated in liquid nitrogen. They were then placed
for 24 hours at 2208C in 4ml 50% glycerol/relaxing solution
containing high concentrations of protease inhibitors (phenyl-
methylsulfonyl fluoride [PMSF], 0.5mM; leupeptin, 0.04mM;
E64, 0.01mM). Subsequently, the sections were placed on a
roller band for 24 hours at 48C, followed by submersion in
skinning solution for 24 hours at 48C. Finally, the skinning
solution was substituted by a glycerol/relaxing solution with
lower concentrations of protease inhibitors and stored at
2208C until further use. On the day of an experiment, small
strips (cross-sectional area [CSA] 5 0.005!0.01mm2) were dis-
sected from the glycerinated sections and washed thoroughly
with relaxing solution. The strips were mounted using alumi-
num T-clips between a length motor (ASI 403A; Aurora Scien-
tific, Aurora, ON, Canada) and a force transducer element
(ASI 315C-I, Aurora Scientific) in a skinned fiber apparatus
(ASI 802D, Aurora Scientific) that was mounted on an inverted
microscope (Axio Observer A1; Zeiss, Oberkochen, Germany).
Sarcomere length (2.5lm) was set using a high-speed VSL cam-
era and ASI 900B software (Aurora Scientific). Six strips were
analyzed for P1 (average CSA 5 0.01mm2), P2 (average CSA
5 0.005mm2), and control (average CSA 5 0.006mm2). Fiber
width and diameter was measured at 3 points along the fiber
and the CSA was determined assuming an elliptical cross sec-
tion. Fiber dimensions were determined using an inverted
microscope (340 objective), a high-speed VSL camera with
calibrated ASI 900B software (Aurora Scientific), and a custom-
made prism that was mounted in the bath. Various types of
bathing solutions were used during the experimental protocols:
a relaxing solution (40mM balanced electrolyte solution [BES],
10mM ethyleneglycoltetraacetic acid [EGTA], 6.86mM MgCl2,
5.96mM Na–adenosine triphosphate [ATP], 3.28mM K-
propionate, 33mM creatine phosphate, 1mM dithiothreitol
[DTT], 0.5mM PMSF, 0.2mM leupeptin, 0.05mM E64), a
preactivating solution with low EGTA concentration (40mM
BES, 1mM EGTA, 6.66mM MgCl2, 5.98mM Na-ATP,
30.44mM K-propionate, 33mM creatine phosphate, 1mM
DTT, 0.5mM PMSF, 0.2mM leupeptin, 0.05mM E64), and
activating solutions with incremental Ca21 concentrations for
graded Ca21 response curves (40mM BES, 10mM CaCO3-
EGTA [for maximal activation]; 6.64mM MgCl2, 6.23mM Na-
ATP, 2.1mM K-propionate, 15mM creatine phosphate, 1mM
DTT, 0.5mM PMSF, 0.2mM leupeptin, 0.05mM E64). The
temperature of the bathing solutions was kept constant at 208C
using a temperature controller (ASI 825A, Aurora Scientific).
Absolute forces were normalized to the bundles’ CSA to
determine the maximal active tension. To determine the Ca21
sensitivity of force generation, permeabilized myofiber bundles
were sequentially bathed in a relaxing solution, a preactivation
solution, and solutions with pCa values ranging from 9.0 to
4.5. Steady-state forces were measured at all the Ca21 concen-
trations, and subsequently these steady-state values were nor-
malized to the maximal force obtained at pCa 5 4.5. The
obtained force-pCa data were fit to the Hill equation (Y 5 1/
[1 1 10nH(pCa 2 pCa50)]). Cross-bridge cycling kinetics were
determined by imposing a rapid release–restretch protocol on
an activated fiber based on previously reported methods.27 The
rate of tension redevelopment was obtained by fitting a biexpo-
nential through the force redevelopment curve. The resulting
first-order rate constant k1 reflects cross-bridge cycling kinetics
and thus was used in the analysis methods.28 A measure of
active stiffness was obtained by applying short-length perturba-
tions on the myofibers, while the myofibers were being maxi-
mally activated, and fit to a linear curve through the data
points. By dividing the maximal active tension by active stiff-
ness, the force generation per cross-bridge was estimated.29
Myosin Heavy Chain Isoform Composition of
Myofibers Used for Contractility Experiments
Because the contractile performance of muscle fibers is affected
by the composition of myosin heavy chain isoforms, we used
specialized sodium dodecyl sulfate (SDS)–polyacrylamide gel
electrophoresis to determine the myosin heavy chain isoforms
present in the muscle fibers used for contractile measure-
ments.25 In brief, muscles fibers were denatured by boiling for
2 minutes in SDS sample buffer. The stacking gel contained a
4% acrylamide concentration (pH 5 6.7), and the separating
gel contained 7% acrylamide (pH 5 8.7) with 30% glycerol
(vol/vol). The gels were run for 24 hours at 158C and a con-
stant voltage of 275V. Finally, the gels were silver-stained,
scanned, and analyzed with One-D scan EX (Scanalytics, Rock-
ville, MD) software (data not shown).
Results
Clinical Assessment Identified two Patients with
a Significant Hypercontractile Phenotype with
Marked Congenital Muscle Stiffness
We identified two patients with a history of marked con-
genital muscle stiffness, which was most significant at the
onset. Detailed clinical information is summarized in the
Table and Figure 1.
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TABLE 1. Clinical Details of Patients 1 and 2
Characteristic Patient 1 Patient 2
Sex/age, yr Male/4 Female/3
Tpm3.12 mutation DE224 DE218
Presentation Decreased fetal movements. At birth: stiff-
ness with arthrogryposis multiplex con-
genita, right clubfoot, bilateral hand
fisting, inguinal hernia, bilateral hip dys-
plasia, and knee contractures.
Decreased fetal movements and polyhy-
dramnios. At birth: pronounced general-
ized stiffness, limited-to-absent
movement, including the thoracic muscles
requiring ventilation, hip dysplasia,
umbilical hernia, left inguinal hernia. In
infancy: recurrent hypoxic crises.
Dysmorphic features Relative macrocephaly, short stature, and
thin habitus. Prominent forehead, small
mouth, short neck, and stiff face.
Retrognathia, micrognathia, and short
neck.
Cognition Normal Normal
Clinical features Kyphoscoliosis with lower spinal rigidity.
Mild head lag, no slip-through, and vari-
able tone distally. Multiple bilateral con-
tractures: shoulders, wrists with ulnar
deviation, finger flexors, jaw, hip flexion,
knee flexion, and heel cords. Prominent
paraspinous muscles. Fine tremor. Reflexes
present. Temperature dysregulation.
Kyphosis. Pronounced muscle hypertonia.
Limited passive range of motion. Thoracic
rigidity. Tracheostomy and ventilator
dependency. Feeding tube and bladder
catheter dependent. Profuse sweating
when excited.
Motor function
and strength
Stiff gait marked by exaggerated hip flex-
ion, thoracic kyphosis, and flexion at the
knees. Improvement over time. Strong
bilateral grip. No weakness.
Limited to absent movement. Unable to
sit or roll.
Respiration Neonatal transient hypoxemia. Increased
respiratory rate and occasional grunting.
Frequent respiratory infections. Hypoxe-
mia and obstructive sleep apnea requiring
supplemental oxygen.
Recurrent hypoxic crises in infancy. Tra-
cheostomy and ventilator dependency.
EMG Suggestive of a generalized myopathy with
denervating features. No myotonia or
myokymia observed.
No evidence of spontaneous activity or
myotonia.
NCS Sensory responses of the right median and
sural nerves were normal. Motor NCS of
the right median nerve showed normal
distal latency, moderate reduction in
response amplitude, and normal conduc-
tion velocity. Motor NCS of the right
peroneal nerve showed normal distal
latency, severe reduction in response
amplitude, and normal conduction
velocity.
Not performed.
Other CK: 205U/l. Normal: EEG, brain MRI,
and echocardiogram. Negative: ACTA1,
MYH3, TPM2, HSPG2, TNNT3,
TNNI2, FKRP, CRYAB, sequencing and
microarray.
CK between 200 and 1,000U/l. Osteope-
nia, shortened phalanges, and clinodactyly
on X-ray. Normal: brain MRI, EEG, and
metabolic screening. Negative ACTA1 and
CRYAB sequencing. Increased echogenic-
ity on muscle ultrasound.
CK 5 creatine kinase; EEG 5 electroencephalogram; EMG 5 electromyogram; MRI 5 magnetic resonance imaging; NCS 5
nerve conduction studies.
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P1 is a 5-year-old male (see Fig 1A, B). Pregnancy
was notable for decreased fetal movements but normal
amniotic fluid level. He was born with arthrogryposis
multiplex congenita with bilateral contractures of the
hips, knees, and wrists. He also had bilateral hand fisting,
right clubfoot deformity, unilateral hip dislocation, an
inguinal hernia, and generalized muscle stiffness. Neona-
tal course was complicated by transient respiratory dis-
tress, particularly during feeding, manifesting with an
increased respiratory rate. He also had a history of low
oxygen saturations and occasional grunting at rest as a
neonate. He rolled from his back to his side at 6 months
of age, could manipulate objects in his hands and bring
some objects to his mouth by 15 months of age, and
walked independently at 25 months of age. He had nota-
ble easy fatigability.
On examination at age 4 years, he had a “wooden
feel” to his muscles, which were noted to be very stiff,
particularity the hamstrings, the paraspinal muscles, and
the face muscles. He had well-defined biceps and promi-
nent thigh muscles. There was no muscle weakness
noted. Deep tendon reflexes were intact. He had good
fine motor control. Active and passive range of motion
was restricted at his shoulders, Achilles tendons, elbows,
knees, and jaw. He walked on his toes with a stiff, shuf-
fling gait with almost no flexion at the knees or hips
appreciated (Supplementary Video). Due to restricted
movement at these joints, he could not reach his arms
above his head. He had excessive thoracic kyphosis, with
a minimal scoliosis, and rigidity of the lower spine. He
had short stature with height below the 5th percentile,
weight along the 10th percentile, and head circumference
along the 50th percentile.
He had a history of inappropriate sweating and was
reported to be prone to “overheating” particularly at
night during sleep. His muscle stiffness was reported to
exacerbate with movement or fatigue and improve with
the application of warm water. He had a history of dys-
phagia and evidence of silent aspiration of liquids on vid-
eofluoroscopy. He also had a history of frequent episodes
of bronchiolitis. He had been diagnosed with restrictive
lung disease and uses a Cough Assist device to help
improve expiratory function. A sleep study revealed evi-
dence of hypoventilation. He has been advised to use
nighttime noninvasive ventilation in the form of bilevel
positive airway pressure (BiPAP), but he could not toler-
ate the BiPAP mask. After the time of our examination,
he received two courses of botulinum toxin injections to
the hamstrings and pectoral muscles in an effort to
improve his range of motion. He was then able to reach
his arms above his head and walk with more fluidity by
5 years of age. Diagnostic testing performed on P1
included electromyography (EMG) at age 6 months of
age, which was interpreted as being myopathic with
denervating features. Continuous motor unit activity in
the form of myotonia and myokymia were not observed.
P2 is a 3-year-old female (see Fig 1C). The preg-
nancy was notable for polyhydramnios and decreased
fetal movement. She was born at term and presented
with severe, generalized muscle stiffness immediately after
birth. Flexion muscle contractures were present in all
large joints, which resulted in an inability for active or
passive movements. Apparent involvement of the respira-
tory muscles contributed to recurrent episodes of apnea
that led to the need for invasive ventilation with high
inspiratory pressures (up to 40cm H2O). Treatment with
carbamazepine, benzodiazepines, and baclofen reportedly
provided no substantial benefit. Due to continuing venti-
latory dependency, a tracheostomy was placed. She also
had a percutaneous gastrostomy tube placed for feeding.
She was discharged from the hospital at the age of 5
months. At the current age of 3 years, she remains fully
ventilator-dependent with high inspiratory pressures (up
to 25cm H2O). On examination, she had normal eye
movements and appeared mentally alert. Muscle tone
was markedly increased, with absent deep tendon
reflexes. She demonstrated the ability to use a standing
FIGURE 1: (A, B) A 4-year-old male (Patient 1) with relative
macrocephaly compared to his short stature and thin habi-
tus. He has a prominent forehead, small mouth, short neck,
and stiff face. His shoulders are anteriorly rotated with
decreased lumbar lordosis and increased kyphosis, and he
has bilateral elbow and knee contractures. He has flat feet
that are turned outward, external hip rotation, and a barrel
chest with wide-spaced nipples. (C) A 3-year-old female
(Patient 2) with pronounced muscle stiffness. She has bilat-
eral contractures of elbows, knees, and ankles. She is venti-
lated with tracheostomy and has a feeding tube. [Color
figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com.]
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frame, but had difficulty sitting due to apparent hyperac-
tivity of her hip extensors.
Muscle tone reportedly reduced slightly after intra-
muscular injections of botulinum toxin, and some lim-
ited voluntary movements were appreciated. She has
started to use an assistive communication device. Exten-
sive diagnostic evaluations including brain magnetic reso-
nance imaging, electroencephalography, and metabolic
screening did not reveal any abnormalities. Serum crea-
tine kinase (CK) levels varied between 200 and 1,000U/
l. EMG did not show evidence of myotonia or myoky-
mia. Muscle ultrasound depicted markedly increased
echogenicity of all muscles imaged but no evidence of
muscle atrophy.
Exome Analysis Identified two Novel De Novo
Glutamic Acid Residue Deletions in Tpm3.12
Whole exome sequencing of P1 and both biological
parents followed by variant filtering for call quality and rar-
ity yielded a heterozygous c.673-675delGAA (p.Glu224-
del, DE224) TPM3 variant (reference NM_152263.3).
Due to phenotypic similarity noted between P1 and P2,
this region was Sanger sequenced in P2, revealing a hetero-
zygous 3 base pair deletion c.657_659delAGA (p.Glu218-
del, DE218), resulting in the deletion of glutamic acid at
amino acid 218 (Fig 2A, B). Parental segregation studies
for P1 and P2 were negative; the mutation was de novo in
both patients. Neither mutation had been previously
reported, and neither was present in dbSNP, NHLBI EVS,
ExAC Browser, or GEM.app.16 Both mutations are located
in highly conserved regions of TPM3 (see Fig 2C, D).
Tpm3.12 DE218 and DE224 Muscle Biopsies
Did Not Show Typical Tropomyosin Pathology
Muscle biopsy of P1 was performed at age 17 months
and was mildly myopathic in appearance without specific
features. There was mild variation in fiber size and a
mild type I fiber predominance (Fig 3). Nicotinamide
adenine dinucleotide (NADH) staining demonstrated
irregular staining in some fibers resulting in some areas
of clearing. Modified G€om€ori trichrome stain demon-
strated irregularities of the myofibrillar apparatus. There
was no evidence of clear nemaline rods or a pattern con-
sistent with CFTD. There was ultrastructural evidence of
accumulation of mitochondria, increased lipid storage,
and Z-line streaming and broadening, which was focal,
occurring in rare fibers, and spanning up to 6 to 7 sarco-
meres maximally, seen on electron microscopy (EM)
FIGURE 2: (A, B) Sequence chromatogram of Patients 1 and 2 (P1, P2) identifying a glutamic acid deletion in Tpm3.12. (C)
Schematic of known mutations in TPM3 along with their disease phenotypes. (D) Illustration of amino acid homology of TPM3
(P1, P2), as well as for TPM1, TPM2, and TPM4.
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along with some sarcolemmal folding as a result of fiber
atrophy.
Muscle biopsy of P2 was performed at age 3 weeks
and demonstrated mild myopathic features. Findings
included mild variation in fiber size and some rare baso-
philic fibers with centrally placed nuclei (see Fig 3).
There was mild type II fiber predominance seen on
ATPase and NADH staining but no fiber-type grouping.
Structures resembling minirods were identified on EM as
well as some Z-band broadening in atrophic fibers.
Whereas clearly formed nemaline rods were not seen on
modified G€om€ori trichrome stain or EM, mini “miliary”
rods were seen in small atrophic fibers both on modified
G€om€ori trichrome stain and on EM.
Increased Ca21 Sensitivity for Tpm3.12 DE218
and DE224 by In Vitro Motility Assay
Using the in vitro motility assay, the movement of syn-
thetic thin filaments containing recombinant WT or
mutant tropomyosin (Tpm3.12 DE218 and DE224) was
compared over a range of Ca21 concentrations. This assay
measures two parameters that are Ca21 regulated: fraction
of filaments motile and sliding speed of the filaments.
Ca21 increased the fraction motile from 2% to 90% and
the sliding speed from 1.3 to 4lm/s. The EC50 and Hill
coefficient (nH) were determined by fitting the Hill equa-
tion to the Ca21 activation curves. The mutations affected
both the fraction motile and the sliding speed of the fila-
ments in a similar way. Thin filaments reconstituted with
mutant tropomyosins showed a higher Ca21 sensitivity for
both the fraction motile and the sliding speed; representa-
tive Ca21 activation curves are shown in Figure 4. DE218
led to a 21=2 -fold increase in Ca
21 sensitivity (EC50 ratio
5 DE218/WT 5 0.40 6 0.07, p 5 0.004, n 5 4) for the
fraction motile and a 2-fold increase for the sliding speed
(EC50 ratio 5 DE218/WT 5 0.48 6 0.12, p 5 0.02, n
5 4). DE224 also showed an increase in Ca21 sensitivity
in the fraction motile and the sliding speed parameter by
2.2- and 3.0-fold, respectively (EC50 ratio 5 DE224/WT
for fraction motile 5 0.46 6 0.09, p 5 0.01, n 5 4;
EC50 ratio 5 DE224/WT for sliding speed 5 0.33 6
0.08, p 5 0.004, n 5 4), indicating that both mutations
cause a gain of function. There was no significant differ-
ence in the maximum fraction motile, maximum sliding
speed, or Hill coefficient between either of the mutants
and the WT thin filaments.
FIGURE 3: Muscle biopsy of Patient 1 (P1) at age 17
months (left) and Patient 2 (P2) at age 22 days (right).
Hematoxylin & eosin (original magnification, 320) shows
variability in fiber size with increased perimysial and endo-
mysial fibrosis in P1 (A) and P2 (B). There are some rare
basophilic fibers in P2 (B) with centrally placed nuclei
(green arrow). Trichrome staining (original magnification,
340) does not show inclusions suggestive of nemaline rods
or vacuoles in P1 (C), whereas P2 shows “miliary” rod-like
inclusions in some of the atrophic fibers (D). There is varia-
tion in fiber size of both fiber types on adenosine triphos-
phatase (ATPase) 9 (original magnification, 320) in P1 (E)
and ATPase 10.5 (original magnification, 320) in P2 (F).
There is mild type 1 predominance in P1 and mild type 2
fiber predominance in P2. Nicotinamide adenine dinucleo-
tide (original magnification, 340) in P1 (G) and P2 (H)
shows a increase in staining in the periphery of some of
the darker (type I) fibers, evidence of mitochondrial aggre-
gation and contracted fibers (green arrow). (I) Electron
microscopy (EM) of P1 shows Z-disk streaming (green
arrow) and sarcolemmal folds (blue arrow; bar 5 4lm). (J)
EM of P2 also shows Z-band broadening (red arrow; bar 5
1.7lm). There are some miliary rods (blue arrow). No clear
nemaline rods were seen.
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DE218 and DE224 Permeabilized Myofibers
Showed Decreased Maximum Force Generation
and DE218 Showed Increased Ca21 Sensitivity
with Reduced Cross-Bridge Cycling Kinetics
Contractile properties of permeabilized myofibers isolated
from biopsies from P1 and P2 (DE224 and DE218) were
measured. The maximal active tension in DE218 (31 6
5 mN/mm2) and DE224 (35 6 2 mN/mm2) permeabil-
ized myofibers showed a significant decrease in maxi-
mum force generation compared to controls (95 6
14 mN/mm2; Fig 5). The Ca21 sensitivity of force gen-
eration in DE224 (5.94 6 0.02) was increased compared
to control fibers (5.81 6 0.02). The maximum force a
muscle fiber can generate is dependent on the rate of
cross-bridge cycling kinetics. The rate constant of force
redevelopment (Ktr) is a widely used parameter of cross-
bridge cycling kinetics, reflecting both cross-bridge
attachment and detachment. Analysis showed that cross-
bridge cycling kinetics are reduced in Tpm3.12 DE224
(6.1 6 1) compared to control myofibers (9.8 6 1),
whereas maximal active tension over active stiffness, a
reflection of the force per cross-bridge, was not altered
between Tpm3.12 DE224 (2.2 6 0.1) and control fibers
(2.2 6 0.1). Unfortunately, due to technical limitations
caused by lower quality and quantity of the biopsy, we
could not measure cross-bridge cycling kinetics and force
per cross-bridge in Tpm3.12 DE218.
As the contractile performance of myofibers is
dependent on the myosin heavy chain (MHC) isoform
composition, the presence of MHC isoforms was deter-
mined. No significant changes between control myofibers
(27 6 6% slow MHC and 73 6 6% fast MHC) and
DE218 (30 6 5% slow MHC and 66 6 6% fast MHC)
or DE224 (20 6 7% slow MHC and 80 6 7% fast
MHC) were found. Therefore, the changes observed in
contractile performance between control and patient
FIGURE 4: Ca21 control of in vitro motility. Representative Ca21 activation curves are shown; DE218 on left and DE224 on right
are compared with wild-type control. Thin filaments were assembled using baculovirus expressed Tpm3.12, rabbit skeletal
muscle actin, and rabbit skeletal muscle troponin. Thin filament movement over immobilized heavy meromyosin (HMM) was
tracked and analyzed over a range of Ca21 concentrations. Solid lines 5 control; dotted lines 5 mutant tropomyosin. Error
bars are standard deviation for 4 measurements of motility in the same motility cell. The curves are the fits of the data to the
Hill equation: sliding speed (top) and fraction of filaments motile parameters (bottom). Four separate Ca21 curves were
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myofibers were not influenced by changes in myosin
heavy isoform composition, and are more likely due to
the specific mutations.
Discussion
Muscle fiber–based stiffness, in the absence of clinically
detectable weakness, is a rare manifestation of congenital
muscle disease. It was originally reported in Canadian
aboriginal patients with a fatal condition characterized by
progressive muscle stiffness and respiratory insufficiency15
due to recessive mutations in CRYAB. CRYAB codes for
the small chaperone ab-crystallin; however, the mecha-
nism responsible for the muscle stiffness remains unclear.
Additionally, a specific de novo mutation in ACTA1 was
found in a newborn with congenital episodic stiffness,
hypertrophic muscles, and nemaline rod muscle pathol-
ogy.14 Our report is the first to demonstrate specific
TPM3 deletions as the cause of a novel phenotypic mani-
festation of marked and generalized congenital muscle
stiffness. This phenotype is notable for an absence of
muscle weakness in combination with muscle stiffness,
which is so severe that it can result in early ventilatory
failure, likely due to an incapacity for respiratory muscle
relaxation, as evidenced by the high inspiratory pressures
required during mechanical ventilation in P2.
The muscle thin filament is a cooperative/allosteric
system. Its basic unit consists of a backbone of actin
monomers, the troponin–tropomyosin complex, and neb-
ulin.24 Muscle contraction is regulated by Ca21 via its
release and reuptake from the sarcoplasmic reticulum.
Ca21 binding to troponin C on the thin filaments of
muscle results in switching contraction from the “off” to
FIGURE 5: (A) A significant decrease in maximum force generation was seen in single fiber myofibers from Tpm3.12 DE224
and DE218 compared to controls. (B, C) The Ca21 sensitivity of force generation was increased in DE224 compared to controls
and DE218. Additionally, there is reduced cross-bridge cycling kinetics in Tpm3.12 DE224 (D), whereas the active stiffness was
not altered between Tpm3.12 DE224 and control (E). NS 5 not significant. * 5 P < 0.05. pCa 5 -log(10) of the calcium concen-
tration. pCa50 5 Ca21 concentration required to generate 50% of maximal force. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
ANNALS of Neurology
990 Volume 78, No. 6
the “on” state by causing a sideward shift of the actin-
binding tropomyosin dimer, exposing the myosin bind-
ing site on the actin filament.30–32 Tropomyosins thus
play a vital role in transmitting the Ca21 signal from the
troponin to the actin myosin binding site. Mutations in
TPM3 (coding for Tpm3.12) are an established molecu-
lar cause of a clinically and histopathologically heteroge-
neous group of myopathies, characterized by progressive
weakness and by variable but characteristic findings on
muscle pathology including nemaline rods, CFTD, or
cap-like structures. The phenotype associated with
Tpm3.12 DE218 and DE224, with its congenital stiffness
resulting from marked muscle hypercontractility, is signif-
icantly different from these known manifestation of
TPM3-related disease. Muscle biopsy analysis did not
reveal the typical muscle pathology seen in tropomyosin-
related disease, including clear nemaline rods, although
small rod-like structures (“miliary rods”) were seen in
atrophic fibers of P2. We also found evidence of myo-
fiber damage histologically, likely due to the permanently
hypercontracted state of the muscle fibers, consistent
with increased CK values. Six TPM2 and 1 TPM3 muta-
tion that result in increased Ca21 sensitivity have been
reported in patients with only moderately progressive
contractures and myopathic weakness.11,12,33 In contrast,
our patients presented with a distinctive and considerably
more severe congenital hypercontractile phenotype with
generalized muscle stiffness leading to severe respiratory
failure in the neonatal period in one patient which repre-
sents a novel phenotype for tropomyosin-related disease.
Mutations in tropomyosin or actin that produce a
hypercontractile phenotype may destabilize the “switched
off” state, shifting the equilibrium in favor of the
“switched on” state of actin–tropomyosin, which allows
for myosin binding, thereby increasing Ca21 sensitivity
and, in one case, increasing maximum force generated
and cross-bridge cycling rate.11,14,34,35 The finding that
the Tpm3.12 DE218 and DE224 mutations introduced
into recombinantly expressed tropomyosin resulted in
increased Ca21 sensitivity in the in vitro motility assay
(see Fig 4), and that the Tpm3.12 DE224 biopsy has
increased Ca21 sensitivity of force production (see Fig
5), is compatible with this mechanism as the basis of the
hypercontractile phenotype.
The hypercontractile phenotype associated with
these Tpm3.12 mutations also conforms to the predic-
tions made by Marston et al22 on biophysical grounds
(Fig 6), which we now confirm clinically as well as in
vitro. The atomic resolution structure of tropomyosin-
bound actin shows that tropomyosin makes contact with
actin at only two points: with actin Asp25 and with a
cluster of basic amino acids actin K326, K328, and
R147.36 Tropomyosin has a seven-fold repeated structure
corresponding to seven actin-binding interactions. Three
FIGURE 6: (A) Location of gain-of function mutations in tropomyosin isoforms Tpm2.2 and Tpm3.12. The amino acids predicted
to interact with actin are circled. (B) Structure of the F-actin–tropomyosin complex determined by Li et al.32 Surface rendering
was made using PyMol. Actin K326, K328, and R147 are shown in different shades of blue, and tropomyosin 218, 219, 223,
and 224 are shown in magenta. (C) The interface of tropomyosin period 6 with actin. Actin K326, K328, and R147 are shown
in different shades of blue, E218 and E224 are shown in red, and D219 and E223 are shown in pink. Actin is represented by
surface rendering; the secondary structure of tropomyosin backbone (coiled-coil alpha helix) is shown with the side chains in
line notation.
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Tpm2.2 mutations and the Tpm3.12 mutation K169E
were shown to destabilize the interaction with actin
Asp25, based on energy landscape calculations, and
increase Ca21 sensitivity in in vitro motility assay, con-
sistent with gain of contractile function.22,37 More
importantly, two Tpm2.2 mutations, DE139 and E181K,
destabilize the interaction with the actin K326, K328,
and R147 cluster. All of these mutations involve a charge
loss or reversal in a motif of two basic or acidic amino
acids. There are nine such motifs in all tropomyosin iso-
forms. Mutations have been described in myopathy
patients with increased in vitro Ca21 sensitivity for six of
the nine motifs (five in Tpm2.2 and one in Tpm3.12, 3
of which were associated with a phenotype of arthrogry-
posis or some signs of stiffness or contractures in addi-
tion to weakness). The remaining three motifs are at
218–219 (ED), 223–224 (EE), and 257–258 (ED) in
either tropomyosin.22 Thus, the “stiff” patients’ muta-
tions reported here are in the first two of these three
remaining domains, which were predicted to result in a
hypercontractile state. It is striking that the hypercontrac-
tile consequences in our cases are clinically more pro-
nounced compared to the manifestations of other
tropomyosin mutations previously reported. Notably,
most of the mutations tested in vitro and found to dis-
play increased Ca21 sensitivity are located adjacent to the
tropomyosin amino acid that interacts with actin rather
than at the site itself.22 This also applies to Tpm3.12
E218 and E224, which do not interact with actin,
whereas neighboring Tpm3.12 E219 and E223 interact
directly with the actin K326, K328, and R147 cluster
(see Fig 6). In light of the structural analysis modeling of
these physical interactions, it is significant that the actin
K326N mutation at the cognate site in actin itself was
the first “stiff” patient mutation reported in a thin fila-
ment protein.14,22,38 The degree of stiffness seen in that
patient appeared similar to our observation.14
The in vitro sliding data obtained with mutant pro-
tein provide the link crucial to understanding the clinical
hypercontractile phenotype; however, the consequences of
the mutation on the entire thin filament and contractile
fiber show additional complexities. Notably, the skinned
fiber preparation had decreased maximal active tension
resulting in a decrease in maximal force generation,
whereas the force per cross-bridge was not altered. This
raises the possibility that the cycling of cross-bridges back
into the “off” state is impaired. The observed reduction in
rate constant of force redevelopment, which indicates a
reduced effectiveness of cross-bridge cycling, could explain
the impaired force generation capacity of the muscle. Mus-
cle fibers from P1 (DE224) generated a higher relative
force at the same Ca21 concentration, which may there-
fore compensate for the loss of maximal force-generating
capacity. Because there was no evidence of weakness in the
patients (at the time of examination), we surmise that the
hypercontractility at submaximal calcium concentrations is
so overwhelming that any decrease in maximal force does
not come to bear on the phenotype. The continuous cellu-
lar stress of the hypercontractility of the muscle may cause
future muscle damage and breakdown in our patients, pos-
sibly resulting in weakness and findings of tropomyosin
muscle pathology over time. This assumption is supported
by the CK elevations and also by the markedly abnormal
muscle ultrasound findings in P2.
The question remains as to why the stiffness pheno-
type in our patients is significantly more severe and gen-
eralized compared to the best characterized gain of
function mutation in Tpm2.2, the DK7 deletion, identi-
fied in patients with progressive, early onset contractures
without clear muscle weakness in childhood but with
some stiffness noted in one 14-year-old boy.11 Tpm2.2 is
expressed in both fast- and slow-twitch fibers. Increased
Ca21 sensitivity of force generation has also been
observed in patients with distal arthrogryposis caused by
mutations in troponin I (TNNI2) and troponin T3
(TNNT3), encoding for contractile apparatus proteins
specific to fast-twitch fibers.39 Contractures due to distal
muscle involvement, which are predominantly fast-twitch
fibers, typically develop prenatally but have little to no
progression over time, with relatively normal proximal
muscle strength and histology.40 The generalized and
more severe congenital stiffness observed in the Tpm3.12
DE218 and DE224 patients may thus be partially related
to the expression pattern, with Tpm3.12 being the most
relevant tropomyosin for all slow-twitch fibers.
Finally, we considered how the molecular mecha-
nisms reported here could inform a rational therapeutic
approach to these patients. P1 showed improvement with
botulinum toxin injections, leading to increased range of
motion, improved gait, and increased jaw mobility with
enhanced speech production. Decreased neuromuscular
transmission from the botulinum application would lead
to less activation of excitation–contraction coupling,
likely taking the edge off the baseline hypercontractility
associated with the underlying TPM3 mutation. Given
the growing amount of literature supporting changed
Ca21 sensitivity of the actin–tropomyosin complex as a
mechanism for muscle disease, future therapeutic strat-
egies may involve reducing the release of Ca21 at the sar-
comere. An alternative approach would be to desensitize
the thin filament to Ca21. In cases of decreased Ca21
sensitivity, compounds that act as Ca21 sensitizers, which
are under active development in the neuromuscular and
heart failure field, may be utilized.39,40 The latter type of
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approach would likely be detrimental in the patients
reported here.
In conclusion, in this study we identified two
patients with a marked congenital hypercontractile phe-
notype caused by dominantly acting de novo mutations
in Tpm3.12, DE218 and DE224, representing the most
severe tropomyosin-related hypercontractile phenotype
recognized to date. Our experiments confirm a mecha-
nism of increased Ca21 sensitivity by which Tpm3.12
mutant muscle fibers contract at lower Ca21 concentra-
tions compared to WT fibers. Our data lend in vivo and
in vitro support to the conclusion that the increased
Ca21 sensitivity observed for both DE218 and DE224
results from a destabilization of the “off” state of the
thin filament, resulting in excessively sensitized excita-
tion–contraction coupling of the contractile apparatus, as
previously predicted for DE218 on theoretical biophysical
grounds. Mutations in tropomyosin, specifically in
TPM3, should therefore be considered when evaluating a
patient with congenital-onset muscle stiffness.
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Dr Hwang’s recent letter concerning our paper raises some very interesting 
points about the molecular mechanism of familial cardiomyopathy (HCM and 
DCM) due to mutations in the proteins of the thin filament and the key role of 
troponin. 
In principle such mutations could cause defects in force generation or force 
transmission but so far all the mutations in thin filament proteins that have 
been investigated in detail indicate abnormal force production linked to 
abnormal Ca2+-regulation.  Troponin, in concert with tropomyosin and actin 
comprises the Ca2+-dependent switch of muscle and the properties of this 
switch are modulated by PKA phosphorylating TnI, therefore troponin 
abnormalities are likely to play a central role in cardiomyopathies.  The case 
has been made that HCM-causing mutations increase myofilament Ca2+-
sensitivity and this is sufficient to trigger the symptoms of HCM. On the other 
hand DCM-causing mutations uncouple the normal relationship between 
Ca2+-sensitivity and PKA-dependent phosphorylation of troponin I (TnI) and 
this has been shown to blunt responses to adrenergic stimulation and 
predispose the heart to systolic dysfunction under stress 1, 2.   
Our recently published work highlights the importance of troponin still more, 
since we have demonstrated that small molecule Ca2+-sensitisers (EMD57033 
and Bepridil) can mimic the uncoupling effect of mutations, whilst the Ca2+-
desensitiser epigallocatechin-3-gallate (EGCG) can restore the modulation of 
Ca2+-sensitivity by TnI phosphorylation to thin filaments containing DCM or 
HCM mutations that uncouple this relationship 3.  All of these reagents act by 
binding to troponin; thus understanding how Ca2+ and phosphorylation control 
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contractility through troponin is the key to determining how thin filament 
cardiomyopathies are initiated 
There  are severe practical problems in linking troponin structure with function 
because the most important parts of the complex are intrinsically disordered 
and cannot be defined in terms of a static structure.  These include the 
cardiac-specific N-terminus of cTnI (amino acids 1-30) that contains the PKA 
phosphorylation sites (Serines 22 and 23), the so-called switch peptide of 
cTnI (148-164), that plays a key role in the Ca2+-dependent switching on and 
off of the thin filament, and the C-terminus of troponin T (cTnT3  280-298) 
whose function is not known although it is likely to be located close to the 
regulatory region of troponin and may interact with the other two peptides.  
Protein nuclear magnetic resonance has been used to determinethe structure 
of the missing peptides and their binary complexes with troponin C (TnC) in 
several states 4-9.  When TnI is unphosphorylated there is a weak ionic bond 
between the N terminal peptide and the regulatory Ca2+-binding EF hand of 
TnC.  When Ser 22 and 23 are phosphorylated the binding is further 
weakened.  We have proposed that the unphosphorylated state can also be 
disrupted by mutations or other alterations in any component of the thin 
filament or by small molecules resulting in uncoupling.  However, whilst it can 
account for all our experimental observations, we do not believe that this 
hypothesis can be tested until the structure and dynamics of the whole 
troponin structure is known.  This question is now being addressed by 
molecular dynamics simulations, but many practical and technical problems 
need to be solved before a believable structural and dynamic description of 
the regulatory elements of troponin becomes possible. 
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In his letter to the editors Dr Hwang presents  a model based on his extensive 
experience of investigating troponin by protein nuclear magnetic resonance 
protocols 6 that is proposed to be able to explain the structural basis of the 
results we obtained.  In this model an alternative mechanism of Ca2+-
dependent activation is proposed in addition to the current consensus 
mechanism that accounts for Ca2+-switching of muscle and its modulation by 
cTnI phosphorylation ( see for instance Solaro et al. 200810).  It is proposed 
that the helical segment of cTnI (39-60), downstream of the phosphorylatable 
peptide, that normally interacts strongly with the C-terminal domain of TnC  
can becomes dissociated, thus allowing a different interaction between the 
two domains of TnC  that would have a higher Ca2+-sensitivity and not involve 
cTnI 1-30, therefore it would be uncoupled.  The rationale for proposing this is 
the observation that we measure uncoupling and the effects of EMD57033 
and EGCG in the in vitro motility assay, where the Ca2+-sensitivity of filament 
activation is very high (EC50  0.1-0.3 µM)  whereas the Ca2+-sensitivity of 
contractility in skinned cardiac muscle in the phosphorylated and 
unphosphorylated states is about ten times lower. 
However, there seems no justification for a two-mechanism model.  As 
described in our papers, Ca2+-regulation of thin filaments occurs normally 
when measured by the in vitro motility assay and all the effects of 
phosphorylation, mutants, Ca2+ sensitisers and desensitisers and, especially 
uncoupling and re-coupling, on Ca2+-sensitivity  were consistently observed 
using the IVMA technique and, in the case of the small molecules, effects 
were shown to be fully reversible.  In these studies Ca2+-sensitivity ranged 
between 0.04 and 0.2 µM  so there is no reason to invoke  two mechanisms 
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based on different Ca2+-sensitivity ranges.   In fact it would be very hard 
indeed to explain how drugs such as EGCG could reverse uncoupling if they 
were acting through a mechanism separate from the one that modulates Ca2+-
sensitivity by phosphorylation or mutations.  The issue of absolute Ca2+-
sensitivity, and even the experimental system studied is irrelevant since we 
have clearly shown that exactly the same modulation of Ca2+-sensitivity of 
contraction by phosphorylation, drugs and mutations and the recoupling due 
to EGCG can be demonstrated in myofibrils, where the Ca2+- sensitivity is in 
the 0.4-2 µM range 3, 11 
What we undoubtedly agree upon is the central role of troponin abnormalities 
in cardiomyopathy and the need to know much more about the structure and 
dynamics of the intrinsically disordered regulatory segments of the molecule.  
Not only is this necessary to provide a molecular mechanism for the 
physiological effects of TnI phosphorylation and mutations in thin filaments 
that cause cardiomyopathy, it is also essential in order to understand how 
small molecules can interact with this system. 14  This is clinically relevant 
since Ca2+-sensitisers acting on TnC have been investigated as inotropic 
drugs and our discovery of the ability of EGCG and similar compounds to 
reverse the uncoupling effect of DCM-causing mutations (and some HCM-
causing mutations) points to potential therapies for familial cardiomyopathies. 
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